[{"title01":"Response to Comment on: “Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel”.","title02":"Response to Comment on: “Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel”.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300980. Online ahead of print","author":"Wang SA, Arenillas L, Buccisano F, Bruggemann M, Kern W, Menes M, Plesa A, Stone L, Wellnitz D, Westerman DA, Wood BL, Freeman SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988756"},{"title01":"Not guilty by association: myelodysplasia-related mutations in AML.","title02":"Not guilty by association: myelodysplasia-related mutations in AML.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02936-z. Online ahead of print","author":"Venugopal S, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020780"},{"title01":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","title02":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02966-7. Online ahead of print","author":"Ahmidouch M, Deshpande P, Salib C, Brunner P, Heller P, Abdel Azim D, Ball S, Tremblay D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045559"},{"title01":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","title02":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02939-w. Online ahead of print","author":"Montoro MJ, Acha P, Haferlach C, Chan O, Navarro V, Kubota Y, Schulz F, Briski R, Al Ali NH, Xicoy B, Palomo L, Lopez-Cadenas F, Bosch F, Meggendorfer M, Gonzalez T, Eder LN, Jerez A, Wang Y, Campagna A, Betz B, Santini V, Bernal T, Such E, Platzbecker AS, Kewan T, Gurnari C, Zindel C, Kulasekararaj A, Voso MT, Sekeres M, Diaz-Varela N, Al-Kali A, Polini A, Diral E, Memoli M, Platzbecker U, Haase D, Zeidan AM, Diez-Campelo M, Garcia-Manero G, Wiseman DH, Della Porta MG, Germing U, Maciejewski J, Komrokji RS, Sole F, Haferlach T, Fenaux P, Valcarcel D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42062555"},{"title01":"TP53 mutation analysis in myelodysplastic syndromes – long or short read sequencing?","title02":"TP53 mutation analysis in myelodysplastic syndromes – long or short read sequencing?","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300932. Online ahead of print","author":"Mittelman M, Shlush L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988775"},{"title01":"Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designs.","title02":"Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designs.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2026.300560. Online ahead of print","author":"Tauro S, Tefferi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021696"},{"title01":"Not all Tregs in MDS are created equal.","title02":"Not all Tregs in MDS are created equal.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70503. Online ahead of print","author":"Selig M, Penter L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42025585"},{"title01":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","title02":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2817-2828. doi: 10.1182\/bloodadvances.2025018431","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho V, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2743-2753. doi: 10.1182\/bloodadvances.2025018770","author":"DeZern AE, Gillis N, Otterstatter M, Abel G, Padron E, Deeg HJ, Al Baghdadi T, Liu J, Xie Z, Zhang L, Moscinski L, Kroft S, Harrington A, Foran J, Komrokji R, Starczynowski D, Gore S, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo N, Walter M, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","title02":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02966-7. Online ahead of print","author":"Ahmidouch M, Deshpande P, Salib C, Brunner P, Heller P, Abdel Azim D, Ball S, Tremblay D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045559"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study.","title02":"Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2025019349. Online ahead of print","author":"Pemmaraju N, Markova A, Masarova L, Reaven N, Funk SE, Ferguson TW, Bellamy LA, Dinh P, Oyuela P, Valone F, Molina A, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054546"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2767-2780. doi: 10.1182\/bloodadvances.2025018774","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","title02":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2634-2645. doi: 10.1182\/bloodadvances.2025016977","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli A, Apperley JF, Akhtar S, Bourhis JH, Maertens J, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola A, Schaap N, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak G, Peric Z, Penack O, Schoemans H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2648-2660. doi: 10.1182\/bloodadvances.2025018626","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Tobai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","title02":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2698-2710. doi: 10.1182\/bloodadvances.2025019065","author":"Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"HIV cure after HCT: seven horses seem to be on the mark.","title02":"HIV cure after HCT: seven horses seem to be on the mark.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2026019926. Online ahead of print","author":"Camargo JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054547"},{"title01":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","title02":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","journal":"Blood advances","issue":"2026 April 28. doi: 10.1182\/bloodadvances.2026019704. Online ahead of print","author":"De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Moreno-Castano AB, Charry P, Cid J, Lozano M, Arellano-Rodrigo E, Salas MQ, Rovira M, Martinez C, Escolar G, Carreras E, Alvarez-Larran A, Diaz-Ricart M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048573"},{"title01":"Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT.","title02":"Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT.","journal":"Blood advances","issue":"2026 April 28; 10(8):2786-2800. doi: 10.1182\/bloodadvances.2025015915","author":"de Gier M, Korzhenevich J, Schmidt FM, Janowska I, van Ostaijen-Ten Dam MM, Pico-Knijnenburg I, Cats D, Keller F, Hadlova P, Kunze M, Markfeld-Erol F, Reising K, Mei H, Bredius RGM, Lankester AC, van der Burg M, Rizzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544216"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2687-2697. doi: 10.1182\/bloodadvances.2025017945","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","title02":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","journal":"Blood advances","issue":"2026 April 28; 10(8):2854-2864. doi: 10.1182\/bloodadvances.2025019378","author":"Shimony S, Murdock HM, Keating J, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg D, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","title02":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","journal":"Blood","issue":"2026 April 30; 147(18):2064-2080. doi: 10.1182\/blood.2025031247","author":"Chen Y, Shen J, Lin Z, Ding Q, Zhang X, Zhang M, Yang H, Yao H, Liu S, Wan J, Liu S, Jia X, Wang X, Yu U, Hao S, Cao M, Jiang H, Guo B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671478"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Nuclear architecture: a mechanical lever for HSC fitness.","title02":"Nuclear architecture: a mechanical lever for HSC fitness.","journal":"Blood","issue":"2026 April 30; 147(18):2023-2024. doi: 10.1182\/blood.2026033532","author":"Rezk R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060330"},{"title01":"Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults.","title02":"Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02924-3. Online ahead of print","author":"Aleixo G, Cheon H, Zheng J, Soewito S, Lee J, Kaphan E, Kalakuntla N, Jen WY, Kotha S, Rupsee A, Djulbegovic M, Matthews JA, Kadia TM, Olson TS, Peffault de Latour R, Sicre De Fontbrune F, Bat T, DiNardo CD, Babushok DV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045556"},{"title01":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","title02":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","journal":"J Clin Oncol","issue":"2026 April 20; 44(12):1120-1129. doi: 10.1200\/JCO-25-01657","author":"Walter TP, Mazieres J, Otto J, Lena H, Lepage C, Smith D, Madelaine J, Geriniere L, Egenod T, El Hajbi F, Ferru A, Clement-Duchene C, Madroszyk A, Brotelle T, Bouhier-Leporrier K, Desrame J, Ghiringhelli F, Paleiron N, Khalil A, Milot L, Chevallier O, Couvelard A, Lantuejoul S, Langlais A, Morin F, Duruisseaux M, Michel P, Louvet C, Westeel V, Girard N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774886"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study.","title02":"Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300232. Online ahead of print","author":"Dayagi TW, Willis L, Arnold SD, Boklan J, Cada M, Coates TD, Corriveau-Bourque C, Gamper CJ, Geddis AE, Glader B, Kupfer GM, Nakano TA, Olson TS, Rogers ZR, Shimamura A, Takemoto C, Thompson AA, Williams DA, Dror Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988768"},{"title01":"A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.","title02":"A genetic risk score based on BCL11A and HBS1L-MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients.","journal":"Br J Haematol","issue":"2026 April 16. doi: 10.1111\/bjh.70489. Online ahead of print","author":"Arcanjo GS, Silva AP, Diniz MV, Domingos IF, Pereira-Martins DA, Araujo AB, Franca TSS, Anjos AC, Araujo AS, Belini-Junior E, Saad STO, Costa FF, Lucena-Araujo AR, Bezerra MAC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989145"},{"title01":"Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease.","title02":"Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70517. Online ahead of print","author":"Zhang X, Shah BN, Han J, Nouraie M, Zhang Y, Machado RF, Gladwin MT, Saraf SL, Gordeuk VR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42052798"},{"title01":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","title02":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","journal":"Blood advances","issue":"2026 April 28; 10(8):2661-2675. doi: 10.1182\/bloodadvances.2025018548","author":"Olivieri D, Othus M, Vo P, Walter RB, Manjappa S, Basom R, Storb R, Keel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrum.","title02":"Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrum.","journal":"Blood advances","issue":"2026 April 22. doi: 10.1182\/bloodadvances.2025019161. Online ahead of print","author":"D'Onofrio V, Esposito FM, Marra R, Rosato BE, Nostroso A, Perrotta A, Matsell E, Manno M Sr, Iscaro A, Dionisi M Sr, Martone S, Arcioni F, Barbato A, Chiariotti L, Della Monica R, van Oirschot BA, van Wijk R, Molday RS, Iolascon A, Russo R, Andolfo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018644"},{"title01":"Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis.","title02":"Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis.","journal":"Blood","issue":"2026 April 21. doi: 10.1182\/blood.2025030634. Online ahead of print","author":"Courbon G, Thomas JJ, Duque EJ, Kentrup D, Spindler J, Semancheck W, Tracey E, Vaughan DE, Chang W, Creemers JWM, Ji P, Isakova T, Martin A, David V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42013007"},{"title01":"Refined classification and phenotype-driven analysis of PIEZO1 variants in hereditary red cell and iron disorders.","title02":"Refined classification and phenotype-driven analysis of PIEZO1 variants in hereditary red cell and iron disorders.","journal":"Blood","issue":"2026 April 21. doi: 10.1182\/blood.2025031632. Online ahead of print","author":"Rosato BE, Marra R, Martone S, Manno M Sr, Dionisi M Sr, Ribersani M 2nd, Pinto VM, Forni GL, Balocco M, Carrara P, Lamagna M, Morisco F, Guarino M, Cossiga V, Barbato A, Arcioni F, Iolascon A, Russo R, Andolfo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42013021"},{"title01":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","title02":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","journal":"N Engl J Med","issue":"2026 April 16; 394(15):1503-1513. doi: 10.1056\/NEJMoa2515168","author":"Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Cervinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363800"},{"title01":"Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia.","title02":"Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 April 16. doi: 10.1111\/bjh.70482. Online ahead of print","author":"Soff SP, Ruder S, Bussel JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989015"},{"title01":"Anti-CD38 therapy in immune thrombocytopenia (ITP).","title02":"Anti-CD38 therapy in immune thrombocytopenia (ITP).","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70493. Online ahead of print","author":"Ghanima W, Hou Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021728"},{"title01":"The association of thrombocytopenia with haematological malignancy.","title02":"The association of thrombocytopenia with haematological malignancy.","journal":"Br J Haematol","issue":"2026 April 24. doi: 10.1111\/bjh.70498. Online ahead of print","author":"Vijenthira A, Frederiksen H, Sholzberg M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42031689"},{"title01":"HLA profile in paediatric ITP: Comparison with healthy controls and prognostic implications.","title02":"HLA profile in paediatric ITP: Comparison with healthy controls and prognostic implications.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70483. Online ahead of print","author":"Gonzalez de Pablo J, Molina YL, Vicario JL, Moreno Hidalgo MA, de la Cruz A, Galan A, Zubicaray J, Lopez de Hontanar G, Sanz A, Marin L, Verdejo de Antonio J, Sevilla J, Sebastian E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42051172"},{"title01":"Predicting development of pediatric chronic immune thrombocytopenia at disease onset using a statistical risk model.","title02":"Predicting development of pediatric chronic immune thrombocytopenia at disease onset using a statistical risk model.","journal":"Blood","issue":"2026 April 16; 147(16):1863-1872. doi: 10.1182\/blood.2025028563","author":"Hillier K, Zobeck M, MacMath D, Chumsky J, Kirk SE, O'Farrell C, Lucari B, Ngwerume F, Gaerlan S, Konde P, Wang K, Lambert MP, Grace RF, Grimes AB, Kim TO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632829"},{"title01":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","title02":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","journal":"Blood","issue":"2026 April 30; 147(18):2114-2131. doi: 10.1182\/blood.2025031332","author":"Wang YM, Zhou H, Leng SQ, Ma JJ, Li HY, Li GS, Sun T, Xu YT, Han SQ, Gu YF, Dong L, Yan ZY, Zhang L, Peng J, Liu XG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770851"},{"title01":"Chronic ITP prediction model.","title02":"Chronic ITP prediction model.","journal":"Blood","issue":"2026 April 16; 147(16):1887. doi: 10.1182\/blood.2026033691","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989799"},{"title01":"Cloudy with a chance of platelets: forecasting chronic ITP.","title02":"Cloudy with a chance of platelets: forecasting chronic ITP.","journal":"Blood","issue":"2026 April 16; 147(16):1788-1789. doi: 10.1182\/blood.2025033013","author":"Shimano KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989800"},{"title01":"Platelet-derived TGF-beta1 and Treg maintenance in a murine model of ITP.","title02":"Platelet-derived TGF-beta1 and Treg maintenance in a murine model of ITP.","journal":"Blood","issue":"2026 April 20. doi: 10.1182\/blood.2026034039. Online ahead of print","author":"Ahamed J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008373"},{"title01":"Toggling STAT to restore T-cell homeostasis in ITP.","title02":"Toggling STAT to restore T-cell homeostasis in ITP.","journal":"Blood","issue":"2026 April 30; 147(18):2028-2030. doi: 10.1182\/blood.2026033533","author":"Semple JW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060329"},{"title01":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","title02":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","journal":"Blood advances","issue":"2026 April 28; 10(8):2854-2864. doi: 10.1182\/bloodadvances.2025019378","author":"Shimony S, Murdock HM, Keating J, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg D, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70490. Online ahead of print","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","title02":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","journal":"Br J Haematol","issue":"2026 April 20. doi: 10.1111\/bjh.70500. Online ahead of print","author":"Ono T, Okada T, Ikeda R, Yamashita M, Koyauchi K, Takagi F, Adachi M, Takemura T, Mitsui K, Nagata Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42007689"},{"title01":"Reconsidering GVHD prophylaxis in cord blood transplantation.","title02":"Reconsidering GVHD prophylaxis in cord blood transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2727-2728. doi: 10.1182\/bloodadvances.2025019372","author":"Clara JA, Ballen K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41996199"},{"title01":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","title02":"Endothelial Activation and Damage associated with Steroid-Refractory aGVHD is counteracted by Ruxolitinib.","journal":"Blood advances","issue":"2026 April 28. doi: 10.1182\/bloodadvances.2026019704. Online ahead of print","author":"De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Moreno-Castano AB, Charry P, Cid J, Lozano M, Arellano-Rodrigo E, Salas MQ, Rovira M, Martinez C, Escolar G, Carreras E, Alvarez-Larran A, Diaz-Ricart M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048573"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2648-2660. doi: 10.1182\/bloodadvances.2025018626","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Tobai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 April 28; 10(8):2616-2625. doi: 10.1182\/bloodadvances.2025018537","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","title02":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","journal":"Blood advances","issue":"2026 April 28; 10(8):2661-2675. doi: 10.1182\/bloodadvances.2025018548","author":"Olivieri D, Othus M, Vo P, Walter RB, Manjappa S, Basom R, Storb R, Keel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","title02":"Pregnancy after hematopoietic stem cell transplant: an international multicenter study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2634-2645. doi: 10.1182\/bloodadvances.2025016977","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli A, Apperley JF, Akhtar S, Bourhis JH, Maertens J, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola A, Schaap N, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak G, Peric Z, Penack O, Schoemans H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","title02":"Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2817-2828. doi: 10.1182\/bloodadvances.2025018431","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho V, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al Ali N, Sallman D, Kuykendall A, Sweet K, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","title02":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","journal":"Blood","issue":"2026 April 23; 147(17):1903-1913. doi: 10.1182\/blood.2025030823","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1- and Th17-dependent GVHD within the gastrointestinal tract.","title02":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1- and Th17-dependent GVHD within the gastrointestinal tract.","journal":"Blood","issue":"2026 April 30; 147(18):2143-2155. doi: 10.1182\/blood.2025029431","author":"Takahashi S, Inoue T, Ensbey KS, Legg SRW, Sekiguchi T, Nelson E, Nemychenkov NS, Joshi T, Minnie SA, Yeh AC, Zhang P, Headley M, Paik J, Amory JK, Hill GR, Koyama M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662631"},{"title01":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","title02":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 30; 147(18):2041-2052. doi: 10.1182\/blood.2025029546","author":"Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 April 16; 147(16):1857-1862. doi: 10.1182\/blood.2025031952","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Dendritic cells team up to drive gut GVHD.","title02":"Dendritic cells team up to drive gut GVHD.","journal":"Blood","issue":"2026 April 30; 147(18):2032-2034. doi: 10.1182\/blood.2026033361","author":"Babiker L, Maillard I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060335"},{"title01":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","title02":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","journal":"Blood","issue":"2026 April 16; 147(16):1814-1827. doi: 10.1182\/blood.2025031455","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin I, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Ollila TA, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes JM, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Baidoun F, Monick SE, Trutzer IM, Can J, Ayers A, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","title02":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","journal":"Leukemia","issue":"2026 May; 40(5):906-917. doi: 10.1038\/s41375-026-02949-8","author":"Duong N, Khan DH, Thomas GE, Feng Y, Hurren R, Lee JB, St-Germain J, Drimmer L, Yan Y, Zhang LX, Fang KK, Ling D, Ma ML, MacLean N, Gronda M, Rondeau V, Brown BD, Matellan L, Jones CL, Chang H, Arruda A, Xie S, Pelletier L, Minden MD, Zhang L, Kornblau SM, Raught B, Jacobs K, Jacobs MG, Goede D, Spadavecchio V, Schimmer AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998300"},{"title01":"Imputing causality and clonal dynamics from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria.","title02":"Imputing causality and clonal dynamics from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02914-5. Online ahead of print","author":"Mizumaki H, Gao S, Wu Z, Gutierrez-Rodrigues F, Alemu L, Quinones Raffo D, Darden I, Rios O, Lotter J, Kajigaya S, Durrani J, Groarke EM, Patel BA, Young NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020783"},{"title01":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","title02":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","journal":"Leukemia","issue":"2026 April 29. doi: 10.1038\/s41375-026-02967-6. Online ahead of print","author":"Kamitori T, Saida S, Mitani K, Tsujimoto S, Goto H, Shibata H, Akazawa R, Isobe K, Ueno H, Kakiuchi N, Saito AM, Hiwatari M, Kudo K, Hirabayashi S, Fukuoka K, Koh K, Taga T, Kubota H, Kato I, Umeda K, Adachi S, Kawai T, Tomizawa D, Ikeda J, Shiba N, Hayashi Y, Ogawa S, Takita J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056531"},{"title01":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","title02":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300575. Online ahead of print","author":"Hannolainen L, Lang H, Pyoria L, Vepsalainen K, Vakkilainen S, Hedman K, Kekalainen E, Dickson Z, Ryhanen S, Perdomo MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988785"},{"title01":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia – a study on behalf of the Chronic Malignancies Working Party of the EBMT.","title02":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia – a study on behalf of the Chronic Malignancies Working Party of the EBMT.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.288819. Online ahead of print","author":"Drozd-Sokolowska J, Gras L, Baaij LGA, Koster L, Nicholson E, Dreger P, Gedde-Dahl T, Mielke S, Salmenniemi U, Basak G, Chevallier P, Wulf GG, Schetelig J, Johansson JE, Nagler A, Quoc SN, Potter V, Sala E, Sandstedt AB, Koc Y, Zeiser R, Van Gelder M, Jedrzejczak WW, Raj K, McLornan DP, Tournilhac O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021691"},{"title01":"SIRT3 deSUMOylation sustains hematopoietic stem cell activities under stressful conditions via the DHX58-IRF7 axis.","title02":"SIRT3 deSUMOylation sustains hematopoietic stem cell activities under stressful conditions via the DHX58-IRF7 axis.","journal":"Haematologica","issue":"2026 April 30. doi: 10.3324\/haematol.2025.300025. Online ahead of print","author":"He X, Yu J, Xu Y, Wang T, Lu Y, Wu J, Dan S, Xia Y, Mu X, Xie L, Chen C, Yu Z, Ye J, Gilson E, Zhang Y, Cheng J, Zheng J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42059296"},{"title01":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","title02":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70507. Online ahead of print","author":"Wang T, Ferreira AC, Hossain NM, Fu D, Hill EG, Jimenez Jimenez AM, Benjamin C, Komanduri KV, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047487"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70490. Online ahead of print","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","title02":"Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.","journal":"Br J Haematol","issue":"2026 April 20. doi: 10.1111\/bjh.70500. Online ahead of print","author":"Ono T, Okada T, Ikeda R, Yamashita M, Koyauchi K, Takagi F, Adachi M, Takemura T, Mitsui K, Nagata Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42007689"},{"title01":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","title02":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70505. Online ahead of print","author":"Cornago J, Baile M, Acera M, Fox L, Del Mar Perez-Artigas M, Santamaria A, Del Carmen Quintela M, Sanchez-Salinas A, Salmeron JM, Illana V, Abdallahi-Lefdil Z, Pardo L, Solan L, Lopez-Lorenzo JL, Fernandez-Luis S, Vega LP, Villar S, Beorlegui-Murillo P, Molina M, Esquirol A, Izquierdo I, Ribes J, Mussetti A, Lavilla E, Alda O, Lopez-Marin J, Bento L, Filaferro S, Balsalobre P, Sureda A, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056024"},{"title01":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","title02":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70497. Online ahead of print","author":"Zhang ZX, Zhang L, Lu AD, Zhang LP, Jia YP, Zeng HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047313"},{"title01":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","title02":"Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.","journal":"Blood advances","issue":"2026 April 28; 10(8):2661-2675. doi: 10.1182\/bloodadvances.2025018548","author":"Olivieri D, Othus M, Vo P, Walter RB, Manjappa S, Basom R, Storb R, Keel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","title02":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","journal":"Blood advances","issue":"2026 April 28; 10(8):2801-2816. doi: 10.1182\/bloodadvances.2025017559","author":"Lu B, Troyer J, Krause KJ, Lapite A, Aviles M, Della-Moretta S, Dobson D, Farrokhi K, Hasanali ZS, Pillai P, Taborda C, Villagomez L, Vo PT, Wang'ondu RW, Yui JC, Weyand AC, Fingrut WB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587417"},{"title01":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/–mediated clonal hematopoiesis.","title02":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/–mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 April 16; 147(16):1828-1841. doi: 10.1182\/blood.2024028031","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Extended HLA Haplotypes and Transplant Survival.","title02":"Extended HLA Haplotypes and Transplant Survival.","journal":"Blood","issue":"2026 April 22. doi: 10.1182\/blood.2025033031. Online ahead of print","author":"Petersdorf EW, McKallor C, Malkki M, He M, Spellman SR, Gooley TA, Stevenson PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018610"},{"title01":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","title02":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","journal":"Blood","issue":"2026 April 20. doi: 10.1182\/blood.2025030946. Online ahead of print","author":"Li X, Aguilar-Navarro AG, Nader M, Jahangiri S, Lee HS, Edun G, Gower M, Yang D, Fernandez M, Lin B, Oh D, Farhat S, Phillips DM, Bartman S, Murray DI, Kaszuba CM, Kossinna P, Kamath M, Whyne C, Schwartz G, Bajaj J, Kislinger T, Zhou BO, Coutu DL, Akens MK, Changoor A, Mallevaey T, Gaiti F, Jones CL, Naik S, Minden MD, Arruda A, Hitzler JK, Lee KJ, Kim YM, Adams RH, Sivaraj KK, Tikhonova AN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008378"},{"title01":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","title02":"How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide.","journal":"Blood","issue":"2026 April 23; 147(17):1903-1913. doi: 10.1182\/blood.2025030823","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival.","title02":"DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival.","journal":"Blood","issue":"2026 April 30; 147(18):2089-2097. doi: 10.1182\/blood.2025030049","author":"Chiodin G, Tatterton DJ, Rock P, Del Rio L, Snook E, James S, Duriez PJ, Di Re M, Verdoes M, Lanham S, Hodson DJ, Burack R, Forconi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557914"},{"title01":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","title02":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","journal":"Blood","issue":"2026 April 16; 147(16):1793-1803. doi: 10.1182\/blood.2025032357","author":"Stevenson FK, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557911"},{"title01":"SIGN of the times: DC-SIGN and the follicular lymphoma niche.","title02":"SIGN of the times: DC-SIGN and the follicular lymphoma niche.","journal":"Blood","issue":"2026 April 30; 147(18):2025-2026. doi: 10.1182\/blood.2025032939","author":"Tobin JWD, Gandhi MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060334"},{"title01":"Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma.","title02":"Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myeloma.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02931-4. Online ahead of print","author":"Bohra A, Dasari S, Zanwar S, Gonsalves WI, Kapoor P, Binder M, Dispenzieri A, Timm MM, Buadi F, Jevremovic D, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020784"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.","title02":"Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300333. Online ahead of print","author":"Alibert L, Ovejero S, Devin J, Thomas M, Kassambara A, Angles M, Requirand G, Robert N, Vincent L, Cartron G, Martinez AM, Herbaux C, Cavalli G, Moreaux J, Bret C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988779"},{"title01":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","title02":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300233. Online ahead of print","author":"DuMontier C, Cronin AM, Hshieh TT, Sanyal A, Mozessohn L, Abdallah MM, DeAngelo DJ, Munshi NC, Stone RM, Soiffer RJ, Driver JA, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021681"},{"title01":"Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.","title02":"Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300157. Online ahead of print","author":"Cumerlato M, Maccagno M, Labrador M, Luciano B, Mereu E, Porro M, Bandini C, Furlan M, Maisano D, D'Agostino M, Larocca A, Gay F, Tamburrini A, Anselmi F, Porporato PE, Oliviero S, Bruno B, Morelli E, Munshi N, Piva R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021688"},{"title01":"Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab.","title02":"Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.289215. Online ahead of print","author":"Lancman G, Sastow D, Aslanova M, Moshier E, Cho HJ, Jagannath S, Parekh S, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Thibaud S, Chari A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021698"},{"title01":"Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.","title02":"Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70510. Online ahead of print","author":"Marron G, Warrier N, Chan K, Augustson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42051159"},{"title01":"A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.","title02":"A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.","journal":"Br J Haematol","issue":"2026 April 24. doi: 10.1111\/bjh.70516. Online ahead of print","author":"Schnog JB, Erjavec Z, Van Dijck R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42032249"},{"title01":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","title02":"Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.","journal":"Br J Haematol","issue":"2026 April 23. doi: 10.1111\/bjh.70490. Online ahead of print","author":"Goel U, Dragomirescu C, Zanwar S, Cassano RC, Cicero KI, Cowan AJ, Banerjee R, Anwer F, Khouri J, Dima D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42023513"},{"title01":"Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.","title02":"Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2626-2628. doi: 10.1182\/bloodadvances.2025018974","author":"Di Palma-Grisi J, Biran N, Phull P, Vesole D, Siegel D, Parmar H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701974"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 April 28; 10(8):2616-2625. doi: 10.1182\/bloodadvances.2025018537","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Improving Control Arms in 2026 U.S. Myeloma Trials.","title02":"Improving Control Arms in 2026 U.S. Myeloma Trials.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2026020329. Online ahead of print","author":"Ding K, Kunesh J, Neupane K, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995759"},{"title01":"A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.","title02":"A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.","journal":"Blood advances","issue":"2026 April 22. doi: 10.1182\/bloodadvances.2025019136. Online ahead of print","author":"Lim KJ, Steinhardt MJ, Rees MJ, Greipp PT, Kelemen K, Dispenzieri A, Jevremovic D, Baughn LB, Buadi FK, Dingli D, Hayman SR, Kapoor P, Muchtar E, Leung N, Fonder AL, Hobbs MA, Hwa YL, Warsame R, Kourelis TV, Cook J, Binder M, Abdallah N, Zanwar SS, Lin Y, Go RS, Siddiqui M, Parrondo RD, Ailawadhi S, Roy V, Cooke RE, Dun K, Zordan AC Mr, Ninkovic S, Best S, Alatorre G, Wiedmeier-Nutor JE, Kortum KM, Einsele H, Chhabra S, Bergsagel PL, Kyle RA, Gertz MA, Kumar SK, Rajkumar SV, Fonseca R, Gonsalves WI, Yadav U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018661"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 April 16; 147(16):1857-1862. doi: 10.1182\/blood.2025031952","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Immune biomarkers of increased infection risk in multiple myeloma.","title02":"Immune biomarkers of increased infection risk in multiple myeloma.","journal":"Blood","issue":"2026 April 30; 147(18):2081-2088. doi: 10.1182\/blood.2025031744","author":"Zabaleta A, Tamariz-Amador LE, Kostopoulos IV, Sklavenitis-Pistofidis R, Smits F, Rodriguez-Otero P, Roncal C, Aranha MP, Zihala D, Machu M, Tsakirakis N, Bakouros P, Tsitsilonis O, Solia I, Moreno C, Maia C, Martin-Sanchez E, Perez JJ, Encinas C, Rios-Tamayo R, Oriol A, Blanchard MJ, de Arriba F, Gonzalez ME, Lakhwani S, Sureda A, Cabanas V, Escalante F, Carrillo-Cruz E, Perez-Montana A, Ocio EM, Bargay J, Orfao A, Jelinek T, Ghobrial IM, Mutis T, Zweegman S, Terpos E, Kastritis E, Martinez-Lopez J, Lahuerta JJ, Fernandez de Larrea C, Rosinol L, Blade J, Mateos MV, San-Miguel J, Cedena MT, Puig N, Paiva B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610428"},{"title01":"Does minimal residual disease matter in t(11;14) myeloma?","title02":"Does minimal residual disease matter in t(11;14) myeloma?","journal":"Blood","issue":"2026 April 16; 147(16):1787-1788. doi: 10.1182\/blood.2025032941","author":"Touzeau C, Corre J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989805"},{"title01":"Immune clues to infection risk in myeloma.","title02":"Immune clues to infection risk in myeloma.","journal":"Blood","issue":"2026 April 30; 147(18):2024-2025. doi: 10.1182\/blood.2026033248","author":"Ainley L, Yong K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060327"},{"title01":"CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.","title02":"CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.","journal":"N Engl J Med","issue":"2026 April 30; 394(17):1759-1762. doi: 10.1056\/NEJMc2517629","author":"Sandhu KS, Cheng J, Mellors PW, Dainton-Smith H, Lao-Sirieix P, Brugger W, Clark MC, Budde E, Ritz J, Gill S, Forman SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054687"},{"title01":"A velocity-informed framework for resolving functional stratification in rare human stem cells.","title02":"A velocity-informed framework for resolving functional stratification in rare human stem cells.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02956-9. Online ahead of print","author":"Jarczak J, Ratajczak MZ, Kucia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014860"},{"title01":"Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.","title02":"Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.","journal":"J Clin Oncol","issue":"2026 April 30; JCO2503104. doi: 10.1200\/JCO-25-03104. Online ahead of print","author":"Cutler C, Kim HT, El Banna H, Halloran E, Matozel E, Ho VT, Koreth J, Gooptu M, Shapiro R, Kelkar A, Gibson C, Nikiforow S, Nageshwar P, Reynolds C, Ansuinelli M, Tamada R, Au C, Panaro K, Gervais C, DeFilipp Z, El-Jawahri A, Chen YB, El Jurdi N, Weisdorf D, Couriel D, Lee C, Arai S, Sahaf B, Bacigalupi J, Ji K, Soiffer R, Miklos D, Antin JH, Ritz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42060875"},{"title01":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","title02":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2503051. doi: 10.1200\/JCO-25-03051. Online ahead of print","author":"Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044466"},{"title01":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","title02":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2502510. doi: 10.1200\/JCO-25-02510. Online ahead of print","author":"Milano F, Dahlberg A, Pedersen J, Roberts L, Azure A, Martin L, Mazziotta F, Hadland B, Chapuis AG, Delaney C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044462"},{"title01":"Favorable safety and efficacy profiles of alpha-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-versus-host disease of the gastrointestinal tract: a retrospective, single center study.","title02":"Favorable safety and efficacy profiles of alpha-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-versus-host disease of the gastrointestinal tract: a retrospective, single center study.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2026.300541. Online ahead of print","author":"Yehudai-Ofir D, Khatib H, Beyar-Katz O, Frisch A, Krayem B, Zuckerman T, Henig I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021699"},{"title01":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","title02":"Inherited HHV-6A reactivation linked to impaired immune reconstitution following hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300575. Online ahead of print","author":"Hannolainen L, Lang H, Pyoria L, Vepsalainen K, Vakkilainen S, Hedman K, Kekalainen E, Dickson Z, Ryhanen S, Perdomo MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988785"},{"title01":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","title02":"Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70505. Online ahead of print","author":"Cornago J, Baile M, Acera M, Fox L, Del Mar Perez-Artigas M, Santamaria A, Del Carmen Quintela M, Sanchez-Salinas A, Salmeron JM, Illana V, Abdallahi-Lefdil Z, Pardo L, Solan L, Lopez-Lorenzo JL, Fernandez-Luis S, Vega LP, Villar S, Beorlegui-Murillo P, Molina M, Esquirol A, Izquierdo I, Ribes J, Mussetti A, Lavilla E, Alda O, Lopez-Marin J, Bento L, Filaferro S, Balsalobre P, Sureda A, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056024"},{"title01":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","title02":"Day-30 IL1RL1, CXCL9 and REG3alpha are prognostic for survival after mismatched unrelated donor transplantation.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70507. Online ahead of print","author":"Wang T, Ferreira AC, Hossain NM, Fu D, Hill EG, Jimenez Jimenez AM, Benjamin C, Komanduri KV, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047487"},{"title01":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","title02":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70497. Online ahead of print","author":"Zhang ZX, Zhang L, Lu AD, Zhang LP, Jia YP, Zeng HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047313"},{"title01":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","title02":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70506. Online ahead of print","author":"Toda Y, Jo T, Arai Y, Harada K, Yanada M, Fukuda T, Yoshihara S, Doki N, Uchida N, Mori Y, Hasegawa Y, Kondo Y, Kawakita T, Eto T, Nishida T, Tanaka M, Onizuka M, Shono K, Hino M, Ichinohe T, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42046860"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2767-2780. doi: 10.1182\/bloodadvances.2025018774","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","title02":"Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2698-2710. doi: 10.1182\/bloodadvances.2025019065","author":"Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 28; 10(8):2687-2697. doi: 10.1182\/bloodadvances.2025017945","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"B-lymphoblastic leukemia with synchronous KMT2A::TXNRD1 and IGH::CEBPD rearrangements.","title02":"B-lymphoblastic leukemia with synchronous KMT2A::TXNRD1 and IGH::CEBPD rearrangements.","journal":"Blood","issue":"2026 April 23; 147(17):2018. doi: 10.1182\/blood.2025032543","author":"Li Y, Shao H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024392"},{"title01":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","title02":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2503051. doi: 10.1200\/JCO-25-03051. Online ahead of print","author":"Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044466"},{"title01":"Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.","title02":"Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.289111. Online ahead of print","author":"Lutterbeck C, Kaufman D, Bolen CR, Shin M, Akbari V, Mirebrahim H, Davies A, Knapp A, Nielsen T, Weigert O, Penuel E, Bogard PE, Bottos A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021704"},{"title01":"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.","title02":"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300289. Online ahead of print","author":"Basile G, Neuville A, Martineau D, Delapierre B, Dubois S, Noel R, Durot E, Caillet A, Laboure G, Laribi K, Gros FX, Bernard S, Mineur A, Borel C, Chartier L, Damaj G, Bouabdallah K, Galtier J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021687"},{"title01":"Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy.","title02":"Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300015. Online ahead of print","author":"Pages-Geli C, Medina-Gil D, Fernandez-Guzman P, Hernandez C, Carabia J, Pujadas G, Weiskopf K, Bosch F, Crespo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021682"},{"title01":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","title02":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300233. Online ahead of print","author":"DuMontier C, Cronin AM, Hshieh TT, Sanyal A, Mozessohn L, Abdallah MM, DeAngelo DJ, Munshi NC, Stone RM, Soiffer RJ, Driver JA, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021681"},{"title01":"Myeloid neoplasms after follicular helper T-cell lymphomas: a real, but limited risk.","title02":"Myeloid neoplasms after follicular helper T-cell lymphomas: a real, but limited risk.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300464. Online ahead of print","author":"Messeant O, Lemonnier F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988765"},{"title01":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","title02":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.289270. Online ahead of print","author":"Miyagi S, Mori K, Miyawaki K, Shimo M, Tamaki T, Sakihama S, Takatori M, Akashi K, Karube K, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988767"},{"title01":"Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed\/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110\/ReBeL study.","title02":"Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed\/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110\/ReBeL study.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300152. Online ahead of print","author":"Kersten MJ, Dreyling M, Linton KM, Chitu D, Zwezerijnen GJC, Tonino SH, Kap M, Liu R, Van Hooije C, Chamuleau MED, Visser HPJ, De Jongh E, Marijt EAF, Leys MBL, Bilgin YM, Durig J, McKay P, Snijders T, Pettitt A, Minnema MC, Prange-Krex G, Cuijpers MLH, Bohmer LH, Tick LW, Florschutz A, Silbermann M, Fijnheer R, Beeker A, Tolboom N, Mitea C, Arens AIJ, Wiegers SE, Heymans MW, Klapper W, Coupland SE, De Jong D, Doorduijn JK, Zijlstra JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988778"},{"title01":"Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.","title02":"Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.","journal":"Br J Haematol","issue":"2026 April 21. doi: 10.1111\/bjh.70502. Online ahead of print","author":"Dingli S, Rothweiler P, Corraes AMS, Atallah-Yunes A, Ansell SM, Bennani NN, Durani U, Johnston PB, Khurana A, Paludo J, Bisneto JCV, Wang Y, Lin Y, Erdman AG, Dingli D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42011548"},{"title01":"Real-world comparison of peripheral neuropathy and treatment delivery between Pola-R-CHP and R-CHOP in DLBCL.","title02":"Real-world comparison of peripheral neuropathy and treatment delivery between Pola-R-CHP and R-CHOP in DLBCL.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70524. Online ahead of print","author":"Nakamura N, Ohata K, Aizaki T, Kaneda Y, Ikoma Y, Matsumoto T, Nakamura H, Matsuoka SB, Sadaka SH, Suzuki A, Kanemura N, Shimizu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42052919"},{"title01":"Glofitamab in refractory Burkitt lymphoma-type post-transplant lymphoproliferative disorder.","title02":"Glofitamab in refractory Burkitt lymphoma-type post-transplant lymphoproliferative disorder.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70519. Online ahead of print","author":"Lam HPJ, Arulogun S, Mikhaeel NG, Brady JL, Stanley K, Yuen L, Lennie C, Chowdhury P, Warbey V, Gleeson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42049201"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"Aging cells, young patients: senescence in Hodgkin lymphoma.","title02":"Aging cells, young patients: senescence in Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2765-2766. doi: 10.1182\/bloodadvances.2025019439","author":"Kong IY, Giulino-Roth L, Steidl C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41996198"},{"title01":"TCRVbeta-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers.","title02":"TCRVbeta-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2026020282. Online ahead of print","author":"Vadivel CK, Norregaard KS, Perlado AM, Sorrosal LP, Zeng Z, Yan L, Namini MRJ, Gluud M, Buus TB, Engelholm LH, Behrendt N, Odum N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054548"},{"title01":"Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry Analysis.","title02":"Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry Analysis.","journal":"Blood advances","issue":"2026 April 22. doi: 10.1182\/bloodadvances.2025019510. Online ahead of print","author":"Yagi Y, Kanemasa Y, Terao T, Kato M, Jo T, Shimoyama T, Kitawaki T, Hanajiri R, Doki N, Yoshihara S, Fujii N, Iwaki N, Yamamoto G, Sakurai M, Matsukawa T, Sakaida E, Nakashima Y, Umezawa Y, Kim H, Kataoka K, Goto H, Atsuta Y, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018609"},{"title01":"Exploring the role of blinatumomab in pediatric B-lymphoblastic lymphoma (B-LLy).","title02":"Exploring the role of blinatumomab in pediatric B-lymphoblastic lymphoma (B-LLy).","journal":"Blood advances","issue":"2026 April 28; 10(8):2579-2581. doi: 10.1182\/bloodadvances.2025019473","author":"Devine KJ, Fries C, Wistinghausen B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643198"},{"title01":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","title02":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","journal":"Blood advances","issue":"2026 April 28; 10(8):2754-2764. doi: 10.1182\/bloodadvances.2025018515","author":"Godtfredsen SJ, Bergstrom F, Harrysson S, Kragholm K, El-Galaly TC, Smedby KE, Eloranta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637561"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 April 28; 10(8):2767-2780. doi: 10.1182\/bloodadvances.2025018774","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","title02":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","journal":"Blood advances","issue":"2026 April 28; 10(8):2599-2607. doi: 10.1182\/bloodadvances.2025018536","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","title02":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","journal":"Blood advances","issue":"2026 April 28; 10(8):2711-2726. doi: 10.1182\/bloodadvances.2025016953","author":"Agrusa JE, Abdel Fattah E, Lin H, Velazquez J, Salinas SA, Abhyankar HA, Scull BP, Fleischmann R, Elghetany MT, Marcogliese AN, Curry CV, Punia JN, Ozuah NW, Eckstein OS, El-Mallawany NK, Gulati N, Lubega J, Horton TM, Kamdar KY, McClain KL, Man TK, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538304"},{"title01":"Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.","title02":"Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.","journal":"Blood","issue":"2026 April 23. doi: 10.1182\/blood.2026033320. Online ahead of print","author":"Bariboloka KT, Serrano-Saenz S, Savcigil DP, Spoeck S, Poss RE, Schreurs LD, Lober J, Serin N, Valiulis J, Nugraha K, Gangarossa G, Lutz A, Reese M, Klein S, Enssle JC, Buttner R, Kashkar H, Peifer M, Chapuy B, Knittel G, Labi V, Villunger A, Nguyen PH, Scheich S, Oellerich T, Walczak H, Flumann R, Jachimowicz RD, Hallek MJ, Reinhardt HC, Annibaldi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024475"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 April 16; 147(16):1842-1856. doi: 10.1182\/blood.2025031409","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee A, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang A, Barsouk A, Cho JH, Shaw CE, Singh E, Ugwuanyi O, Paruzzo L, Stella F, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey A, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","title02":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","journal":"Blood","issue":"2026 April 22. doi: 10.1182\/blood.2025032393. Online ahead of print","author":"Wu CJ, Caligaris-Cappio F, Chiorazzi N, Gribben JG, Hallek MJ, Wierda WG, Kipps TJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018659"},{"title01":"Mosunetuzumab plus polatuzumab vedotin in relapsed\/refractory MCL after BTK inhibitor therapy: a phase 2 study.","title02":"Mosunetuzumab plus polatuzumab vedotin in relapsed\/refractory MCL after BTK inhibitor therapy: a phase 2 study.","journal":"Blood","issue":"2026 April 21. doi: 10.1182\/blood.2025032422. Online ahead of print","author":"Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Batlevi CL MD, PhD, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42013019"},{"title01":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","title02":"Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma.","journal":"Blood","issue":"2026 April 16; 147(16):1814-1827. doi: 10.1182\/blood.2025031455","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin I, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Ollila TA, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes JM, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Baidoun F, Monick SE, Trutzer IM, Can J, Ayers A, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","title02":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","journal":"Blood","issue":"2026 April 16. doi: 10.1182\/blood.2026033460. Online ahead of print","author":"Durgin JS, Seo SH, Kazmi S, Valentic B, Leff C, Markovska M, Jin X, Shen F, Berjis A, Mukherjee N, Sannecy A, Plesa G, Gabunia K, Scholler J, Gill SI, O'Connor RS, June CH, Ghassemi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41990270"},{"title01":"Mapping risk and therapy in secondary CNS lymphoma.","title02":"Mapping risk and therapy in secondary CNS lymphoma.","journal":"Blood","issue":"2026 April 16; 147(16):1783-1784. doi: 10.1182\/blood.2025032674","author":"Schorb E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41989802"},{"title01":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","title02":"A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 30; 147(18):2041-2052. doi: 10.1182\/blood.2025029546","author":"Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","title02":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 April 28; 10(8):2676-2686. doi: 10.1182\/bloodadvances.2025018600","author":"Xu J, McCoy M, Martinez Z, Sussman JH, Gao D, Vincent T, Wang H, Ma C, Elghawy O, Chen GM, Yang AG, Polonen P, Natan K, Shraim R, Newman H, Hofmann TJ, Scoma S, DiNofia AM, Hunger SP, Yang JJ, Mullighan CG, Bernt KM, Hexner EO, Grupp SA, Watanabe K, June CH, Tan K, Teachey DT, Diorio C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671457"},{"title01":"Hypertension and CLL: a common and hazardous relationship.","title02":"Hypertension and CLL: a common and hazardous relationship.","journal":"Blood advances","issue":"2026 April 28; 10(8):2833-2835. doi: 10.1182\/bloodadvances.2026019633","author":"Mulligan SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008321"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 April 28; 10(8):2648-2660. doi: 10.1182\/bloodadvances.2025018626","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Tobai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","title02":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.","journal":"Blood advances","issue":"2026 April 28; 10(8):2854-2864. doi: 10.1182\/bloodadvances.2025019378","author":"Shimony S, Murdock HM, Keating J, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg D, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","title02":"IFNgamma Drives Long-Term Bone Marrow Niche Dysfunction Following Doxorubicin-Based Chemotherapy.","journal":"Blood","issue":"2026 April 20. doi: 10.1182\/blood.2025030946. Online ahead of print","author":"Li X, Aguilar-Navarro AG, Nader M, Jahangiri S, Lee HS, Edun G, Gower M, Yang D, Fernandez M, Lin B, Oh D, Farhat S, Phillips DM, Bartman S, Murray DI, Kaszuba CM, Kossinna P, Kamath M, Whyne C, Schwartz G, Bajaj J, Kislinger T, Zhou BO, Coutu DL, Akens MK, Changoor A, Mallevaey T, Gaiti F, Jones CL, Naik S, Minden MD, Arruda A, Hitzler JK, Lee KJ, Kim YM, Adams RH, Sivaraj KK, Tikhonova AN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008378"},{"title01":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","title02":"The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.","journal":"Blood","issue":"2026 April 16; 147(16):1793-1803. doi: 10.1182\/blood.2025032357","author":"Stevenson FK, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557911"},{"title01":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","title02":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","journal":"Blood","issue":"2026 April 23; 147(17):1941-1957. doi: 10.1182\/blood.2025029972","author":"Sekrecki M, Sekrecka A, Lattupally RR, Le K, Jin X, Mozes C, Dwyer BG, Zhuang Z, Romero BA, Pineda JMB, Cao X, Nguyen L, Chen V, Zhou CM, Wallace JA, Tanaka K, Tiwari C, Gabel A, Kim WJ, Stanley RF, Benbarche S, Thind J, Muruganandham A, Zhang TY, Greenberg PL, Gotlib JR, Mannis G, Shomali WE, Salmasi G, Kuo C, Shanafelt T, Singh I, Inoue D, Hansen FK, Gray NS, van Rechem C, Fakhri B, Zhang X, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587094"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 April 23; 147(17):1914-1927. doi: 10.1182\/blood.2025031053","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron J, Magenau J, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam M, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez M, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Donor T cells on double duty: VCAR33 for AML after transplant.","title02":"Donor T cells on double duty: VCAR33 for AML after transplant.","journal":"Blood","issue":"2026 April 23; 147(17):1889-1891. doi: 10.1182\/blood.2026033164","author":"Geyer MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024396"},{"title01":"NPM1-mutated acute myeloid leukemia with a hybrid granulocytic and monocytic phenotype.","title02":"NPM1-mutated acute myeloid leukemia with a hybrid granulocytic and monocytic phenotype.","journal":"Blood","issue":"2026 April 23; 147(17):2019. doi: 10.1182\/blood.2025032818","author":"Wang W, Fang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024393"},{"title01":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","title02":"Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.","journal":"Blood","issue":"2026 April 16. doi: 10.1182\/blood.2026033460. Online ahead of print","author":"Durgin JS, Seo SH, Kazmi S, Valentic B, Leff C, Markovska M, Jin X, Shen F, Berjis A, Mukherjee N, Sannecy A, Plesa G, Gabunia K, Scholler J, Gill SI, O'Connor RS, June CH, Ghassemi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41990270"},{"title01":"Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.","title02":"Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.","journal":"Blood","issue":"2026 April 23; 147(17):2011-2017. doi: 10.1182\/blood.2025031734","author":"Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643192"},{"title01":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","title02":"Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.","journal":"Blood","issue":"2026 April 22. doi: 10.1182\/blood.2025032393. Online ahead of print","author":"Wu CJ, Caligaris-Cappio F, Chiorazzi N, Gribben JG, Hallek MJ, Wierda WG, Kipps TJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018659"},{"title01":"The transposable element-PARP axis underpins synthetic lethality and immunogenic vulnerability in blood cancer.","title02":"The transposable element-PARP axis underpins synthetic lethality and immunogenic vulnerability in blood cancer.","journal":"Blood","issue":"2026 April 30; 147(18):2035-2040. doi: 10.1182\/blood.2025032216","author":"Zeisig BB, Karimi MM, So CWE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812189"},{"title01":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/–mediated clonal hematopoiesis.","title02":"A compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/–mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 April 16; 147(16):1828-1841. doi: 10.1182\/blood.2024028031","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 April 16; 147(16):1842-1856. doi: 10.1182\/blood.2025031409","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee A, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang A, Barsouk A, Cho JH, Shaw CE, Singh E, Ugwuanyi O, Paruzzo L, Stella F, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey A, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.","title02":"A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02955-w. Online ahead of print","author":"Arffman M, Meriranta L, Jorgensen J, Karjalainen-Lindsberg ML, Beiske K, Pedersen M, Drott K, Fluge O, Jyrkkio S, Brown P, Holte H, Leppa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020781"},{"title01":"Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study.","title02":"Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study.","journal":"Leukemia","issue":"2026 April 23. doi: 10.1038\/s41375-026-02929-y. Online ahead of print","author":"Migaud P, Dalla Pria A, Drauz D, Dayalan N, Fulgenzi CA, Hosmann K, Leone AG, Muller M, Stocker H, Temple A, Hentrich M, Bower M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026178"},{"title01":"PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.","title02":"PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.","journal":"Leukemia","issue":"2026 April 17. doi: 10.1038\/s41375-026-02932-3. Online ahead of print","author":"Liu Y, Chen R, Gao X, Zhu F, Ni Q, Bates PD, Wu S, Zai Z, Obernberger VA, Weerawardhene K, Tourdot TK, Petta S, Conyers MJ, Capitini CM, Rui L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998301"},{"title01":"Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","title02":"Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.","journal":"J Clin Oncol","issue":"2026 April 16; JCO2501770. doi: 10.1200\/JCO-25-01770. Online ahead of print","author":"Leonard JP, Trneny M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, Thieblemont C, Zinzani PL, Gkasiamis A, Ahn JR, Gribben JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41990300"},{"title01":"Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.","title02":"Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 April 29; JCO2501928. doi: 10.1200\/JCO-25-01928. Online ahead of print","author":"Uppal M, Bhinder B, Marderstein AR, Lee Batlevi C, Falchi L, Hamlin P, Horwitz S, Kumar A, Noy A, Zelenetz AD, Lue JK, Torka P, Epstein-Peterson ZD, Arcila M, Dogan A, Imber B, Yahalom J, Vardhana SA, Intlekofer A, Raj S, Shouval R, Hodkinson B, Stokes ME, Kittai AS, Brody JD, Elemento O, Salles G, Joffe E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054619"},{"title01":"Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed\/Refractory Peripheral T-Cell Lymphoma.","title02":"Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed\/Refractory Peripheral T-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 April 22; 101200JCO2503120. doi: 10.1200\/JCO-25-03120. Online ahead of print","author":"Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, Gritti G, Pinter-Brown L, Izutsu K, Sidransky D, Bentur OS, Pro B, Fox CP, Brammer JE, Horwitz SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42018969"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","title02":"Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.","journal":"J Clin Oncol","issue":"2026 April 24; JCO2502351. doi: 10.1200\/JCO-25-02351. Online ahead of print","author":"Dierickx D, Heimovaara JH, Bellido M, Van Calsteren K, Cardonick E, Garcia AC, Baten A, Evens AM, Ferber A, Fumagalli M, Lampka E, Specht L, Vandecaveye V, Vogelius IR, Alber M, Amant F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42030539"},{"title01":"Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","title02":"Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 April 20; JCO2600304. doi: 10.1200\/JCO-26-00304. Online ahead of print","author":"Wierda WG, Leow CC, Ruppert AS, Bian Y, Woyach JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008785"},{"title01":"RBM15 and ZMYND8 shape acute myeloid leukemia response to BCL2 inhibitors.","title02":"RBM15 and ZMYND8 shape acute myeloid leukemia response to BCL2 inhibitors.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.288972. Online ahead of print","author":"Cruz-Rodriguez N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988758"},{"title01":"RNA modification, leukemia stem cell, selective vulnerability.","title02":"RNA modification, leukemia stem cell, selective vulnerability.","journal":"Haematologica","issue":"2026 April 30. doi: 10.3324\/haematol.2026.301076. Online ahead of print","author":"Zhou F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42059285"},{"title01":"Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12)(p15;q13)\/NUP98::HOXC12: a novel NUP98 fusion partner.","title02":"Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12)(p15;q13)\/NUP98::HOXC12: a novel NUP98 fusion partner.","journal":"Haematologica","issue":"2026 April 30. doi: 10.3324\/haematol.2025.300433. Online ahead of print","author":"Khan A, Xu J, Thakral B, Toruner GA, Medeiros LJ, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42059282"},{"title01":"Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.","title02":"Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300350. Online ahead of print","author":"Voss RK, Qi W, Browne L, Wang'ondu RW, Khanlari M, Ma J, Ma X, Lott J, Barajas JM, Thomas Iii M, Loyola VBP, Cao H, Furtado LV, Naik S, Bami S, Karol SE, Rubnitz JE, Klco JM, Liu YC, Wang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021697"},{"title01":"Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patients.","title02":"Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patients.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300521. Online ahead of print","author":"Zhang A, Gong B, Liu Y, Zhang G, Zhou C, Li S, Guo C, Yang H, Li Y, Wang L, Zhang B, Wei H, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988760"},{"title01":"Timing of microbial exposure and risk of infectionpromoted acute lymphoblastic leukemia.","title02":"Timing of microbial exposure and risk of infectionpromoted acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.289280. Online ahead of print","author":"Cazzaniga V, Shamsaei E, Procter J, John-Baptiste P, Ford AM, Greaves M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988764"},{"title01":"Efficacy of the kinase inhibitor CHZ868 against JAK2 rearrangements in pediatric acute lymphoblastic leukemia.","title02":"Efficacy of the kinase inhibitor CHZ868 against JAK2 rearrangements in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.287840. Online ahead of print","author":"Quadri M, Saitta C, Palamini S, Rebellato S, Watrin T, Tu JW, Bhatia S, Borkhardt A, Palmi C, Biondi A, Cazzaniga G, Fazio G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988773"},{"title01":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","title02":"Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70506. Online ahead of print","author":"Toda Y, Jo T, Arai Y, Harada K, Yanada M, Fukuda T, Yoshihara S, Doki N, Uchida N, Mori Y, Hasegawa Y, Kondo Y, Kawakita T, Eto T, Nishida T, Tanaka M, Onizuka M, Shono K, Hino M, Ichinohe T, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42046860"},{"title01":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","title02":"Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.","journal":"Br J Haematol","issue":"2026 April 28. doi: 10.1111\/bjh.70497. Online ahead of print","author":"Zhang ZX, Zhang L, Lu AD, Zhang LP, Jia YP, Zeng HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047313"},{"title01":"Deacetylase inhibitors CM-444 and CM-1758 enhance chemotherapy response in AML via ALOX5.","title02":"Deacetylase inhibitors CM-444 and CM-1758 enhance chemotherapy response in AML via ALOX5.","journal":"Br J Haematol","issue":"2026 April 29. doi: 10.1111\/bjh.70520. Online ahead of print","author":"Gimenez-Camino N, San Jose-Eneriz E, Garate L, Miranda E, Saez E, Pineda-Lucena A, Prosper F, Agirre X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42052754"},{"title01":"A rare chain of events: Post-follicular therapy-related t(8;21) acute myeloid leukaemia with KIT D816Y mutation revealing systemic mastocytosis.","title02":"A rare chain of events: Post-follicular therapy-related t(8;21) acute myeloid leukaemia with KIT D816Y mutation revealing systemic mastocytosis.","journal":"Br J Haematol","issue":"2026 April 16. doi: 10.1111\/bjh.70442. Online ahead of print","author":"Assadi-Gazvini C, Amiot Q, Menier L, Bugier S, Li C, Konopacki J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41992504"},{"title01":"Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.","title02":"Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.","journal":"Br J Haematol","issue":"2026 April 17. doi: 10.1111\/bjh.70491. Online ahead of print","author":"Christensen LM, Simonsen MR, Jensen JF, Kristensen DT, Dybkaer K, Gronbaek K, El-Galaly TC, Ettrup MS, Ommen HB, Sorensen ALT, Hansen DL, Severinsen MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41992976"},{"title01":"Flow cytometry-guided ex vivo drug sensitivity testing informs venetoclax-based therapy in acute undifferentiated leukaemia.","title02":"Flow cytometry-guided ex vivo drug sensitivity testing informs venetoclax-based therapy in acute undifferentiated leukaemia.","journal":"Br J Haematol","issue":"2026 April 17. doi: 10.1111\/bjh.70499. Online ahead of print","author":"Xu L, Wang J, Zhao W, Wang Y, Hu Y, Li Y, Lai W, Yong J, Gao C, Liu D, Gao X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995597"},{"title01":"Hypertension affects survival and treatment in chronic lymphocytic leukemia.","title02":"Hypertension affects survival and treatment in chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2026 April 28; 10(8):2729-2742. doi: 10.1182\/bloodadvances.2025018771","author":"Vainer N, Brieghel C, Rostgaard K, Daviethsson OB, Dietz JB, Frederiksen CM, da Cunha-Bang C, Hjalgrim H, Niemann CU, Rotbain EC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604617"},{"title01":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","title02":"Long-read KIR genotyping reveals donor KIR\/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.","journal":"Blood advances","issue":"2026 April 17. doi: 10.1182\/bloodadvances.2025019066. Online ahead of print","author":"Morita-Fujita M, Kawaguchi S, Shindo T, Izumi K, Shimizu M, Inadomi Y, Kanda J, Watanabe M, Takahashi M, Tsujimura T, Tarumoto S, Yamamoto T, Kato K, Tanaka H, Morishima S, Morishima Y, Nakano N, Hayashi M, Miyazaki Y, Imada K, Higuchi Y, Yonezawa A, Suehiro Y, Yoshimitsu M, Doki N, Katayama Y, Hasegawa Y, Serizawa K, Ichinohe T, Fukuda T, Onizuka M, Atsuta Y, Takaori-Kondo A, Matsuda F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41995743"},{"title01":"Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.","title02":"Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.","journal":"Blood advances","issue":"2026 April 29. doi: 10.1182\/bloodadvances.2026019978. Online ahead of print","author":"Eyre TA, Martinez-Calle N, Paneesha S, Norouzi M, Tucker DL, Walter HS, Boden A, Kilner M, Phillips N, Patten PE, Shah N, Ruparelia M, Oddy S, Tsawayo T, Forconi F, Wardle H, Gbemre T, Gregory C, Cook LBM, Allsup DJ, Morris A, Knechtli CJC, Davies J, Galani J, Marr H, Hutchinson C, Williams S, Hickey J, Harding H, Hunjan S, Blak BT, Walewska R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42054544"},{"title01":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","title02":"An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.","journal":"Blood advances","issue":"2026 April 28; 10(8):2599-2607. doi: 10.1182\/bloodadvances.2025018536","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"ENO1 promotes acute myeloid leukemia progression through SCD1-mediated lipid metabolism reprogramming.","title02":"ENO1 promotes acute myeloid leukemia progression through SCD1-mediated lipid metabolism reprogramming.","journal":"Blood advances","issue":"2026 April 28. doi: 10.1182\/bloodadvances.2025017973. Online ahead of print","author":"Wu Y, Gao L, Fang F, Li Z, Hu Y, Zhang Y, Yang C, Wei Z, Liu X, Yang Y, Zhang F, Zhang W, Sun K, Li Y, Yang C, Pan J, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42048629"},{"title01":"Common variants, rare disease: new insights into AML risk.","title02":"Common variants, rare disease: new insights into AML risk.","journal":"Blood","issue":"2026 April 23; 147(17):1894-1896. doi: 10.1182\/blood.2025032945","author":"Wen S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42024400"},{"title01":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.","title02":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.","journal":"Blood","issue":"2026 April 23; 147(17):1958-1969. doi: 10.1182\/blood.2025031266","author":"Ranasinghe D, Lin WY, Fordham SE, Alharbi A, Sunter NJ, Elstob C, Nahari MH, Xu Y, Park C, Hungate E, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Enshaei A, Gunasinghe D, Hawking ZL, Heslop H, Nandana D, Di B, Plokhuta A, Brown IT, Allsup DJ, Houlston RS, Collins A, Milne P, Norden J, Dickinson AM, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhauser M, Rollig C, Altmann H, Ruhnke L, Kunadt D, Wagenfuhr L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gomez-Segui I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Weisinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Wang J, Meggendorfer M, Haferlach T, Krizsan S, Bodor C, Parkin B, Malek SN, Stolzel F, Onel K, Allan JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610418"},{"title01":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","title02":"Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.","journal":"Leukemia","issue":"2026 April 29. doi: 10.1038\/s41375-026-02967-6. Online ahead of print","author":"Kamitori T, Saida S, Mitani K, Tsujimoto S, Goto H, Shibata H, Akazawa R, Isobe K, Ueno H, Kakiuchi N, Saito AM, Hiwatari M, Kudo K, Hirabayashi S, Fukuoka K, Koh K, Taga T, Kubota H, Kato I, Umeda K, Adachi S, Kawai T, Tomizawa D, Ikeda J, Shiba N, Hayashi Y, Ogawa S, Takita J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056531"},{"title01":"Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.","title02":"Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02923-4. Online ahead of print","author":"Hodder A, Mishra A, Enshaei A, Baird S, Bhuller K, Castleton A, Clesham K, Connor P, Elbeshlawi I, Gattens M, George L, Heaney N, Ingham D, Jigoulina G, Lindsay K, Madni M, Malone A, Mitchell B, Motwani J, Nicholson E, Patrick K, Ramanathan S, Taylor G, Tewari S, Thakur I, Samrin L, McLelland V, Osborne C, Hogan LE, Cooper S, Ji L, Bhojwani D, Brown PA, Hunger SP, Loh ML, Bonney D, Cummins M, van Delft F, Ghorashian S, Halsey C, Hough R, Moorman A, Moppett J, Samarasinghe S, Vora A, O'Connor D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42056530"},{"title01":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","title02":"Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02966-7. Online ahead of print","author":"Ahmidouch M, Deshpande P, Salib C, Brunner P, Heller P, Abdel Azim D, Ball S, Tremblay D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045559"},{"title01":"Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use.","title02":"Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use.","journal":"Leukemia","issue":"2026 April 27. doi: 10.1038\/s41375-026-02962-x. Online ahead of print","author":"Lertvivatpong N, Inaba H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42045557"},{"title01":"Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia.","title02":"Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 April 24. doi: 10.1038\/s41375-026-02952-z. Online ahead of print","author":"Ghete T, Gaschler L, Krumbholz M, Sembill S, Behrens YL, Karow A, Wolfl M, Auer F, Hauer J, Carta MG, Ferrazzi F, Hutter S, Horn AHC, Sticht H, Schlegel PG, Metzler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42032322"},{"title01":"ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.","title02":"ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.","journal":"Leukemia","issue":"2026 April 23. doi: 10.1038\/s41375-026-02965-8. Online ahead of print","author":"Hochhaus A, le Coutre P, Milojkovic D, Kim DDH, Lim SM, Pavlovsky C, Nguyen T, Nicolini FE, Moiraghi B, Grosicki S, Phu CD, Etienne G, Marco de Lucas F, Ayala Diaz RM, Breccia M, Chuah C, Abi Rached R, Pokhriyal H, Ic A, Schuld P, Pilipovic V, Alisch F, Boquimpani CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026180"},{"title01":"The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.","title02":"The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.","journal":"Leukemia","issue":"2026 April 23. doi: 10.1038\/s41375-026-02902-9. Online ahead of print","author":"Drewes C, Lopez C, Okeke N, Jebaraj B, Wiegreffe C, Kraus I, Hillebrecht S, Awada A, Bens S, Chteinberg E, Eichhorst B, Datismann S, Dyer MJS, Fischer A, Fischer K, Glaser S, Hallek M, Kretzmer H, Mottok A, Pfaff D, Schnitzler K, Meier-Kolthoff JP, Schlesner M, Schneider C, Britsch S, Ammerpohl O, Stilgenbauer S, Tausch E, Siebert R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026179"},{"title01":"A transgenic zebrafish leukemia model driven by KMT2A::MLLT3 (MLL-AF9).","title02":"A transgenic zebrafish leukemia model driven by KMT2A::MLLT3 (MLL-AF9).","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02953-y. Online ahead of print","author":"Saberi M, Delfi O, Hall CJ, Madola DWKK, Browett PJ, Kakadia PM, Bohlander SK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020782"},{"title01":"Not guilty by association: myelodysplasia-related mutations in AML.","title02":"Not guilty by association: myelodysplasia-related mutations in AML.","journal":"Leukemia","issue":"2026 April 22. doi: 10.1038\/s41375-026-02936-z. Online ahead of print","author":"Venugopal S, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42020780"},{"title01":"Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.","title02":"Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02958-7. Online ahead of print","author":"Houtman AH, Arfeuille C, Strullu M, Baruchel A, Cave H, Caye-Eude A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014859"},{"title01":"Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML.","title02":"Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02963-w. Online ahead of print","author":"Shastri VM, Dai R, Zhang Y, Loken MR, Lamba JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014857"},{"title01":"Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.","title02":"Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02970-x. Online ahead of print","author":"Wang Y, Li C, Gale RP, Liang Q, Kay NE, Huang Q, Song Y, Wang W, Liang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42062556"},{"title01":"How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","title02":"How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 April 20; JCO2503114. doi: 10.1200\/JCO-25-03114. Online ahead of print","author":"Levy V, Chevret S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42008784"},{"title01":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","title02":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.","journal":"J Clin Oncol","issue":"2026 April 27; JCO2502510. doi: 10.1200\/JCO-25-02510. Online ahead of print","author":"Milano F, Dahlberg A, Pedersen J, Roberts L, Azure A, Martin L, Mazziotta F, Hadland B, Chapuis AG, Delaney C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42044462"},{"title01":"Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration.","title02":"Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300027. Online ahead of print","author":"Chen AL, Hu HY, Alamoudi D, Zhang JY, Yao SJ, Zhao BH, Song HY, Zhu HH, Wang QF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021693"},{"title01":"An unusual case of basophilic meningitis revealing a chronicphase chronic myeloid leukemia: a report after almost three years of follow-up.","title02":"An unusual case of basophilic meningitis revealing a chronicphase chronic myeloid leukemia: a report after almost three years of follow-up.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.300120. Online ahead of print","author":"Rahme R, Dragani M, Fleury C, Tueur G, Bamba PM, Torres-Villaros H, Giocanti-Auregan A, Bangbotche R, Lazarian G, Baran-Marszak F, Gardin C, Braun T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988759"},{"title01":"Phase Ib\/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results.","title02":"Phase Ib\/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2026.300627. Online ahead of print","author":"Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat Y, Stein E, Deininger MW, Schiller G, Pollyea DA, Foran JM, Olin R, Lin T, Boyiadzis MM, Handa S, Rueter B, Gana TJ, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker B, Levine R, Burd A, Yocum AO, Byrd JC, Blum W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021690"},{"title01":"SQSTM1::RARA fusion in acute promyelocytic leukemia: the first case report and literature review.","title02":"SQSTM1::RARA fusion in acute promyelocytic leukemia: the first case report and literature review.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300329. Online ahead of print","author":"Yin X, Li N, Cheng Z, Ai J, Liang H, Sun S, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021686"},{"title01":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","title02":"Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.300233. Online ahead of print","author":"DuMontier C, Cronin AM, Hshieh TT, Sanyal A, Mozessohn L, Abdallah MM, DeAngelo DJ, Munshi NC, Stone RM, Soiffer RJ, Driver JA, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021681"},{"title01":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia – a study on behalf of the Chronic Malignancies Working Party of the EBMT.","title02":"Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia – a study on behalf of the Chronic Malignancies Working Party of the EBMT.","journal":"Haematologica","issue":"2026 April 23. doi: 10.3324\/haematol.2025.288819. Online ahead of print","author":"Drozd-Sokolowska J, Gras L, Baaij LGA, Koster L, Nicholson E, Dreger P, Gedde-Dahl T, Mielke S, Salmenniemi U, Basak G, Chevallier P, Wulf GG, Schetelig J, Johansson JE, Nagler A, Quoc SN, Potter V, Sala E, Sandstedt AB, Koc Y, Zeiser R, Van Gelder M, Jedrzejczak WW, Raj K, McLornan DP, Tournilhac O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42021691"},{"title01":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","title02":"Gene expression profile of adult T-cell leukemia\/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia\/lymphoma.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2025.289270. Online ahead of print","author":"Miyagi S, Mori K, Miyawaki K, Shimo M, Tamaki T, Sakihama S, Takatori M, Akashi K, Karube K, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988767"},{"title01":"Origins of iAMP21 in children who later developed paediatric acute lymphoblastic leukemia: an investigation of neonatal blood spots.","title02":"Origins of iAMP21 in children who later developed paediatric acute lymphoblastic leukemia: an investigation of neonatal blood spots.","journal":"Haematologica","issue":"2026 April 16. doi: 10.3324\/haematol.2026.300813. Online ahead of print","author":"Leijonhufvud G, Ljungstrom V, Amini RM, Saft I, Ford AM, Gustafsson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41988772"},{"title01":"HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.","title02":"HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April 21. doi: 10.1038\/s41375-026-02950-1. Online ahead of print","author":"Zhang L, Guo W, Fu YH, Wu D, Li M, Chen YC, Tseng CY, Hua WK, Nguyen LXT, He X, Dong H, Zhang L, Zhang B, Li L, Marcucci G, Kuo YH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42014858"},{"title01":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","title02":"Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.","journal":"Leukemia","issue":"2026 May; 40(5):906-917. doi: 10.1038\/s41375-026-02949-8","author":"Duong N, Khan DH, Thomas GE, Feng Y, Hurren R, Lee JB, St-Germain J, Drimmer L, Yan Y, Zhang LX, Fang KK, Ling D, Ma ML, MacLean N, Gronda M, Rondeau V, Brown BD, Matellan L, Jones CL, Chang H, Arruda A, Xie S, Pelletier L, Minden MD, Zhang L, Kornblau SM, Raught B, Jacobs K, Jacobs MG, Goede D, Spadavecchio V, Schimmer AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41998300"},{"title01":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","title02":"How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?","journal":"Leukemia","issue":"2026 April 30. doi: 10.1038\/s41375-026-02939-w. Online ahead of print","author":"Montoro MJ, Acha P, Haferlach C, Chan O, Navarro V, Kubota Y, Schulz F, Briski R, Al Ali NH, Xicoy B, Palomo L, Lopez-Cadenas F, Bosch F, Meggendorfer M, Gonzalez T, Eder LN, Jerez A, Wang Y, Campagna A, Betz B, Santini V, Bernal T, Such E, Platzbecker AS, Kewan T, Gurnari C, Zindel C, Kulasekararaj A, Voso MT, Sekeres M, Diaz-Varela N, Al-Kali A, Polini A, Diral E, Memoli M, Platzbecker U, Haase D, Zeidan AM, Diez-Campelo M, Garcia-Manero G, Wiseman DH, Della Porta MG, Germing U, Maciejewski J, Komrokji RS, Sole F, Haferlach T, Fenaux P, Valcarcel D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/42062555"},{"title01":"Response to Comment on: “Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies”.","title02":"Response to Comment on: “Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies”.","journal":"Haematologica","issue":"2026 April 1; 111(4):1507-1508. doi: 10.3324\/haematol.2025.289053","author":"Rees MJ, Quach H, Jardine D, Thompson A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931863"},{"title01":"HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: “Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies”.","title02":"HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: “Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies”.","journal":"Haematologica","issue":"2026 April 1; 111(4):1505-1506. doi: 10.3324\/haematol.2025.288942","author":"Rago A, Ridola L, Di Toritto TC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905098"},{"title01":"Erratum to: “Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial”.","title02":"Erratum to: “Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial”.","journal":"Haematologica","issue":"2026 April 1; 111(4):1509-1510. doi: 10.3324\/haematol.2025.289379","author":"Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Zak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919560"},{"title01":"Response to Comment on: “Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","title02":"Response to Comment on: “Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300922. Online ahead of print","author":"Chang YS, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924903"},{"title01":"Response to Comment on: “Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","title02":"Response to Comment on: “Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300922. Online ahead of print","author":"Chang YS, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924903"},{"title01":"The “Sweet” crosstalk between refractory leukemia cells and vascular niche.","title02":"The “Sweet” crosstalk between refractory leukemia cells and vascular niche.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300820. Online ahead of print","author":"Cheng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924906"},{"title01":"Implications of the EHA\/ELN guidelines for reporting blast percentage. Comment on: “Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel”.","title02":"Implications of the EHA\/ELN guidelines for reporting blast percentage. Comment on: “Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel”.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300842. Online ahead of print","author":"Przepiorka D, Jen EY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924912"},{"title01":"Erratum to: “Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial”.","title02":"Erratum to: “Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial”.","journal":"Haematologica","issue":"2026 April 1; 111(4):1509-1510. doi: 10.3324\/haematol.2025.289379","author":"Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Zak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919560"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","journal":"Br J Haematol","issue":"2026 April; 208(4):1472-1476. doi: 10.1111\/bjh.70324","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 April; 208(4):1306-1313. doi: 10.1111\/bjh.70365","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 April; 208(4):1207-1210. doi: 10.1111\/bjh.70392","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 April; 208(4):1369-1379. doi: 10.1111\/bjh.70381","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy.","title02":"Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy.","journal":"Blood advances","issue":"2026 April 6. doi: 10.1182\/bloodadvances.2026019614. Online ahead of print","author":"Einarsdottir S, Fei T, Singh KH, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead PM, Westervelt P, McCarty J, McGuirk JP, Hamadani M, Sharon E, Spahn A, Toor AA, Waldvogel SL, Greenberger LM, Auletta JJ, Horowitz MM, Riches M, Hosszu K, Hill JA, DeWolf S, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941698"},{"title01":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","title02":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019655. Online ahead of print","author":"MacKenzie TC, Lianoglou BR, Gonzalez J MD, Dvorak CC, Kharbanda S, Herzeg A, Canepa E, Kreger EM, Frascoli M, Sper R, Gupta A, Leung J, Tang Q, Sinha R, Worthington AK, Gano D, Coco Bakkour S, Chafets D, Keller RL, Shimotake J, Lal A, Glenn OA, Moon-Grady A, Vichinsky EP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41984996"},{"title01":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025017738. Online ahead of print","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes JE, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","title02":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025019567. Online ahead of print","author":"Nickel RS, Abraham AA, Chiang KY, Ali M, Rangarajan HG, Chaudhury S, Kent M, Odinakachukwu MC, Kukadiya D, Malloy J, Zhang A, Hardy SJ, Guilcher GMT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945757"},{"title01":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","title02":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025018918. Online ahead of print","author":"Amonoo HL, Keane EP, Guo M, Gudenkauf LM, Boardman AC, Larizza IS, Wolfe ED, Mate-Kole MN, Healy BC, Cutler CS, Jim HS, Lee SJ, Greer JA, Huffman JC, El-Jawahri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945755"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 April 14; 10(7):2431-2440. doi: 10.1182\/bloodadvances.2025017189","author":"Utrero-Rico A, Kapoor U, Berrios B, Morales G, Levine JE, Prado-Acosta M, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","title02":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","journal":"Blood advances","issue":"2026 April 14; 10(7):2452-2469. doi: 10.1182\/bloodadvances.2025017065","author":"Hagen MW, Setiawan NJ, Dexter S, Woodruff KA, Gaerlan FK, Billings TM, Orozco JJ, Termini CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671449"},{"title01":"HCT Pre-App program: a telemedicine-based prehabilitation for allogeneic hematopoietic cell transplant candidates.","title02":"HCT Pre-App program: a telemedicine-based prehabilitation for allogeneic hematopoietic cell transplant candidates.","journal":"Blood advances","issue":"2026 April 14; 10(7):2232-2243. doi: 10.1182\/bloodadvances.2025018378","author":"Salinas Gonzalez RS, Guardia L, Sole B, Moreno C, de Llobet N, Cascos E, Martinez-Sanchez J, Diaz-Ricart M, Carreras E, Antonio M, Suarez-Lledo M, Rosinol L, Closa C, Sebio R, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544211"},{"title01":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","title02":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2026019724. Online ahead of print","author":"Schaefer DA, Guo M, Keane EP, Song MT, Larizza IS, Adri F, Wolfe ED, Saadeh N, Boardman AC, Acharya NB, Waldman LP, Monahan JA, Ramirez-Gamero AF, Diaz Gonzalez-Colmenero F, Watson J, Cronin AE, Celano CM, Brown L, Lee SJ, Stoto MA, Gudenkauf LM, Amonoo HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925563"},{"title01":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Reply.","title02":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Reply.","journal":"N Engl J Med","issue":"2026 April 9; 394(14):1455. doi: 10.1056\/NEJMc2602059","author":"Xiong H, Li R, Shi J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950486"},{"title01":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","title02":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","journal":"N Engl J Med","issue":"2026 April 9; 394(14):1455. doi: 10.1056\/NEJMc2602059","author":"Yang S, Lu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950485"},{"title01":"[(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b\/2 study.","title02":"[(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b\/2 study.","journal":"Lancet Oncol","issue":"2026 April; 27(4):470-479. doi: 10.1016\/S1470-2045(26)00017-3","author":"Sandhu S, Joshua AM, Emmett L, Bressel M, Anton A, Spain L, Horvath LG, Pasam A, Tolmeijer SH, Akhurst TJ, Alipour R, Banks P, Buteau JP, Cassidy E, Crumbaker M, Dhiantravan N, Xu W, Chan J, Hitchen N, Scalzo M, Ravi Kumar AS, Kong G, Wallace R, Williams N, Williams S, Haynes NM, Neeson P, Wyatt AW, Hicks RJ, Hofman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926961"},{"title01":"Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.","title02":"Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 April 9. doi: 10.1016\/S1470-2045(26)00014-8. Online ahead of print","author":"Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41969015"},{"title01":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial.","title02":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial.","journal":"Lancet Oncol","issue":"2026 April; 27(4):491-501. doi: 10.1016\/S1470-2045(25)00733-8","author":"Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, Piha-Paul SA, Friedman CF, Satoh T, Okamoto N, Singh J, Yoshizuka N, Windish HP, Qian M, Tran BP, Doi T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926962"},{"title01":"Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990-2023: a population-based modelling study.","title02":"Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990-2023: a population-based modelling study.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e227-e240. doi: 10.1016\/S2352-3026(26)00013-X","author":"Teply CJ, Gardner WM, Noyes TS, McHugh TA, Tandiono HA, Gusti Ayu Nanditha N, Harris AA, Perumal N, Markt-Maloney J, Howatt BC, Taylor HJ, Humphrey K, Bhutta ZA, Girelli D, Hay SI, Murray CJL, Musallam KM, Nnodu O, Suchdev PS, Kassebaum NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41934993"},{"title01":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.","title02":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.","journal":"Lancet","issue":"2026 April 10. doi: 10.1016\/S0140-6736(26)00462-9. Online ahead of print","author":"Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagameri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41974149"},{"title01":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","title02":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","journal":"J Clin Oncol","issue":"2026 April; 44(10):893-902. doi: 10.1200\/JCO-25-01929","author":"Zhou H, Zhao H, Hou X, Wang Y, He Z, Li Y, Ma Y, Zhao Y, Huang Y, Chen L, Xiao S, Zhu H, Zhu Y, Fang W, Zhang L, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779981"},{"title01":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","title02":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300746. Online ahead of print","author":"Olivieri DJ, Gooley T, Manjappa S, Walter RB, Keel S, Flowers M, Storb R, Vo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952636"},{"title01":"Clinical features and maternal-fetal outcome of pregnancy with aplastic anaemia: A single-centre retrospective study.","title02":"Clinical features and maternal-fetal outcome of pregnancy with aplastic anaemia: A single-centre retrospective study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70464. Online ahead of print","author":"Wu X, Yang Z, Zhang X, Lu S, Sun A, Wu D, Zhou H, Miao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937249"},{"title01":"Short-course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease.","title02":"Short-course blood transfusion therapy with hydroxyurea, a functional strategy in the management of stroke in children with sickle cell disease.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70399. Online ahead of print","author":"Temiye E, Akinsete A, Joacquim A, Fakile U, Ashefor O, Ogamba C, Ogbenna A, Adeyemo N, Okodugha O, Edokpolo E, Elemo O, Salako A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937419"},{"title01":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","title02":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1389-1397. doi: 10.1111\/bjh.70348","author":"Alam AU, Kaul P, Jain V, Wu C, Sun HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41589617"},{"title01":"Transthyretin V122I Variant and Protein Affects Cardiac Severity and Mortality in Sickle Cell Disease.","title02":"Transthyretin V122I Variant and Protein Affects Cardiac Severity and Mortality in Sickle Cell Disease.","journal":"Blood advances","issue":"2026 April 1. doi: 10.1182\/bloodadvances.2026019698. Online ahead of print","author":"Li H, Gao S, Wang X, Asomaning N, Conrey A, Kruah B, Joo J, Wu CO, Sachdev V, Thein SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921073"},{"title01":"Lipid metabolism transcriptomic signature of defective erythropoiesis in Diamond Blackfan anemia syndrome.","title02":"Lipid metabolism transcriptomic signature of defective erythropoiesis in Diamond Blackfan anemia syndrome.","journal":"Blood advances","issue":"2026 April 14; 10(7):2272-2285. doi: 10.1182\/bloodadvances.2025017318","author":"Deng K, Wang Y, Min JC, Liu X, Ueharu H, Myers G, Yu L, Hammoud S, Adam A, Saba R, Natogi V, Drysdale C, Chen B, Yee J, Kitzman JO, Lyssiotis CA, Mishina Y, Jones M, Kaartinen V, Guan Y, Khoriaty R, Engel JD, Singh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576344"},{"title01":"Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.","title02":"Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.","journal":"Blood advances","issue":"2026 April 9. doi: 10.1182\/bloodadvances.2025019511. Online ahead of print","author":"Backeljauw P, Tomlinson G, Smart LR, Tshilolo LMM, Williams TN, Santos B, Olupot-Olupot P, Stuber SE, Lane A, Latham TS, Ware RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954645"},{"title01":"Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study.","title02":"Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study.","journal":"Blood advances","issue":"2026 April 14; 10(7):2291-2301. doi: 10.1182\/bloodadvances.2025017577","author":"Di Stefano V, Gianesin B, Orecchia V, Longo F, Barella S, Barone A, Culcasi M, Denotti AR, Costantini S, Ferrara F, Foggetti I, Gigante A, Manca MR, Mazzi F, Pasanisi A, Pisaniello M, Ricchi P, Serra M, Origa R, Bertini M, Motta I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569798"},{"title01":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","title02":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","journal":"Blood advances","issue":"2026 April 14; 10(7):2257-2271. doi: 10.1182\/bloodadvances.2025017907","author":"Winward A, Lalonde L, Nair D, Socolovsky M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441873"},{"title01":"A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.","title02":"A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.","journal":"N Engl J Med","issue":"2026 April 9; 394(14):1388-1398. doi: 10.1056\/NEJMoa2513120","author":"Kuter DJ, Miura K, Patriarca A, Pulanic D, Radinoff A, Sapunarova K, Syrigou A, Yang R, Nguyen VA, Skelton E, Wang S, Yee DL, Patwari P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950473"},{"title01":"Thrombosis in immune thrombocytopenia.","title02":"Thrombosis in immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 April 9. doi: 10.1111\/bjh.70474. Online ahead of print","author":"Garabet L, Ghanima W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952648"},{"title01":"MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.","title02":"MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70485. Online ahead of print","author":"Liu Z, Rebetz J, Garabet L, Ghanima W, Xu P, Wadenvik H, Provan D, Kapur R, Semple JW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983341"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 April 14. doi: 10.1038\/s41375-026-02946-x. Online ahead of print","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):717-729. doi: 10.1038\/s41375-026-02883-9","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 April; 40(4):783-793. doi: 10.1038\/s41375-026-02892-8","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"TGFbeta-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.","title02":"TGFbeta-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.","journal":"Haematologica","issue":"2026 April 1; 111(4):1355-1367. doi: 10.3324\/haematol.2025.287951","author":"Zhang L, Li W, Thalla R, Ma R, Mack R, Kini AR, Runde A, Hagen PA, Barton K, Kosti-Schwartz J, Breslin P, Ji HL, Zhang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163575"},{"title01":"Clinical outcomes of WHO2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M.","title02":"Clinical outcomes of WHO2022 and ICC MDS entities with risk stratification by IPSS-R and IPSS-M.","journal":"Haematologica","issue":"2026 April 1; 111(4):1422-1426. doi: 10.3324\/haematol.2025.288090","author":"Kwag D, Bae B, Jung J, Kim HS, Lee JM, Ahn A, Yoon JS, Park SY, Park S, Kim M, Kim YJ, Kim Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163580"},{"title01":"Azacitidine for MDS and CMML.","title02":"Azacitidine for MDS and CMML.","journal":"Haematologica","issue":"2026 April 1; 111(4):1147-1148. doi: 10.3324\/haematol.2026.289398","author":"Martin ES, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919559"},{"title01":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","title02":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300534. Online ahead of print","author":"Goldfinger M, Mantzaris I, Shastri A, Rockwell B, Saunthararajah Y, Yin S, Levitz D, Gritsman K, Sica AR, Kornblum N, Shapiro LC, Gupta R, Peeke S, Shah N, Pradhan K, Munoz A, Dhawan A, Verceles JA, Fehn K, Comas M, Shah L, Shi Y, Jonas BA, Cooper DL, Konopleva M, Feldman EJ, Verma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924907"},{"title01":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","title02":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","journal":"Br J Haematol","issue":"2026 April; 208(4):1443-1447. doi: 10.1111\/bjh.70345","author":"Furumoto T, Ando K, Toriyama E, Hata T, Sakamoto H, Chiwata M, Kitanosono H, Nakashima J, Kato T, Taguchi M, Horai M, Itonaga H, Sato S, Sawayama Y, Imanishi D, Imaizumi Y, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582419"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70477. Online ahead of print","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","title02":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","journal":"Blood","issue":"2026 April 6. doi: 10.1182\/blood.2025032031. Online ahead of print","author":"Lu C, Matt GY, Paul R, Wang J, Sioson E, Gangwani K, Acic A, Willems A, Zaldivar Peraza A, Reilly C, Polonen P, Gao Q, Li Q, Pounds SB, Zeng AGX, Li S, Nadarajah N, Brady SW, Iacobucci I, Haferlach T, Rose MC, Mullighan CG, Zhou X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41940951"},{"title01":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","title02":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 April; 40(4):773-782. doi: 10.1038\/s41375-026-02885-7","author":"Rolles B, Filho CMO, Fergusson N, Bewersdorf JP, Keating J, Perkins C, Schwede M, England J, Luskin MR, DeAngelo DJ, Shimony S, Faiz M, Hillerbrand AC, Kim C, Weeks LD, Waldman L, Wazir M, How J, Marneth AE, Liu Y, Aryee MJ, Rampal R, Tsai HK, Gotlib J, Gupta V, Stahl M, Mullally A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735484"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 April; 40(4):783-793. doi: 10.1038\/s41375-026-02892-8","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.","title02":"New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 April 1. doi: 10.1038\/s41375-026-02937-y. Online ahead of print","author":"Nishimura K, Ono R, Nagaharu K, Ohya E, Tsuji T, Ikejiri M, Nakamura A, Nosaka T, Tawara I, Sugimoto Y, Ohishi K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41922799"},{"title01":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.","title02":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.","journal":"Leukemia","issue":"2026 April 8. doi: 10.1038\/s41375-026-02882-w. Online ahead of print","author":"Silver RT, Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41951941"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 April 14. doi: 10.1038\/s41375-026-02946-x. Online ahead of print","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","title02":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","journal":"Haematologica","issue":"2026 April 1; 111(4):1368-1379. doi: 10.3324\/haematol.2025.287585","author":"Masubuchi N, Yang Y, Imai M, Kihara Y, Morishita S, Edahiro Y, Komatsu N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195513"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2026 April 1; 111(4):1179-1197. doi: 10.3324\/haematol.2025.288654","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","title02":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","journal":"Haematologica","issue":"2026 April 1; 111(4):1380-1388. doi: 10.3324\/haematol.2025.288681","author":"Barosi G, Rosti V, Campanelli R, Massa M, Abba C, Carolei A, Catarsi P, Inzoli A, Pergola L, Barbui T, Tatarelli C, Finazzi MC, Condorelli A, Salmoiraghi S, Rambaldi A, Gianatti A, De Stefano V, Galli A, Gandossini M, Bardelli M, Gale RP, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262049"},{"title01":"Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency.","title02":"Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300245. Online ahead of print","author":"Guglielmelli P, Paoli C, Borgi G, Fagiolo L, Bianchini S, Loscocco GG, Gesullo F, Di Vaio F, Matteoli C, Pancani F, Danesi S, Pestelli S, Barbui T, Vannucchi AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952646"},{"title01":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","title02":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","journal":"Br J Haematol","issue":"2026 April; 208(4):1211-1222. doi: 10.1111\/bjh.70404","author":"Speight B, Hamblin A, Talley P, Tsoulaki O, Robinson R, Dean P, Khorashad J, Kulasekararaj A, Godfrey AL, Mead AJ, McVeigh TP, Snape K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773566"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","title02":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 April 14; 10(7):2142-2152. doi: 10.1182\/bloodadvances.2025018682","author":"Ouellet M, Rizzolo A, Venne C, Moussa H, Bilodeau K, Mollica L, Chabot-Roy G, Huynh-Trudeau G, Lesage S, Harnois M, Busque L, Sirhan S, Szuber N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499761"},{"title01":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN.","title02":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN.","journal":"Blood advances","issue":"2026 April 14; 10(7):2168-2172. doi: 10.1182\/bloodadvances.2025018811","author":"Tashi T, Shih LY, Yo YT, Sullivan AE, Chueh HY, Kuo MC, Smith A, Kim SJ, Parsegov B, Reeves BN, Song J, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587484"},{"title01":"Thrombosis in primary myelofibrosis: the influence of cohort composition and disease biology.","title02":"Thrombosis in primary myelofibrosis: the influence of cohort composition and disease biology.","journal":"Blood advances","issue":"2026 April 14; 10(7):2521-2524. doi: 10.1182\/bloodadvances.2026019668","author":"Barbui T, De Stefano V, Tefferi A, Vannucchi AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678834"},{"title01":"Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.","title02":"Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity.","journal":"Blood","issue":"2026 April 2; 147(14):1611-1623. doi: 10.1182\/blood.2024027897","author":"Thompson-Peach CAL, Thomas D, Dottore M, Lim K, Stomski F, Panagopoulos RA, Fosselteder J, Reinisch A, Chandrakanthan V, Jenkner S, Bland L, Paton S, Gronthos S, Hercus TR, Wardill HR, Kan WL, Kamel MM, Moretti PA, Pitson SM, Burbury K, Ross DM, Nair PC, Lopez AF, Tvorogov D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481383"},{"title01":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","title02":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70453. Online ahead of print","author":"Lum SH, Greener S, Memon IL, Amrolia P, Nademi Z, Chiesa R, Silva J, Young H, Owens S, Williams E, Ng KF, Flood T, Gennery AR, Hambleton S, Rao K, Slatter M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958357"},{"title01":"Endothelial activation and stress index score as a predictor of transplant-associated thrombotic microangiopathy in patients with sickle cell disease.","title02":"Endothelial activation and stress index score as a predictor of transplant-associated thrombotic microangiopathy in patients with sickle cell disease.","journal":"Br J Haematol","issue":"2026 April 2. doi: 10.1111\/bjh.70465. Online ahead of print","author":"Krishnan R, Sankaran H, Jacobsohn D, Nickel R, Snelling K, Vatsayan A, Dreyzin A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924942"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70477. Online ahead of print","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","title02":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70486. Online ahead of print","author":"McComb C, Pai V, Stanek J, Rankin AW, Lamb M, Bhunia N, Bajwa R, Abu-Arja R, Rangarajan HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983326"},{"title01":"Serotherapy in transplant: Getting it right!","title02":"Serotherapy in transplant: Getting it right!","journal":"Br J Haematol","issue":"2026 April 6. doi: 10.1111\/bjh.70456. Online ahead of print","author":"Wynn R, Admiraal R, Lindemans C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937680"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1359-1368. doi: 10.1111\/bjh.70380","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 April; 208(4):1306-1313. doi: 10.1111\/bjh.70365","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 April; 208(4):1369-1379. doi: 10.1111\/bjh.70381","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1331-1338. doi: 10.1111\/bjh.70379","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","journal":"Br J Haematol","issue":"2026 April; 208(4):1472-1476. doi: 10.1111\/bjh.70324","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 April; 208(4):1477-1481. doi: 10.1111\/bjh.70318","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","title02":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: A multicenter prospective study.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025019567. Online ahead of print","author":"Nickel RS, Abraham AA, Chiang KY, Ali M, Rangarajan HG, Chaudhury S, Kent M, Odinakachukwu MC, Kukadiya D, Malloy J, Zhang A, Hardy SJ, Guilcher GMT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945757"},{"title01":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","title02":"A Pilot Randomized Clinical Trial of a Peer Support Intervention for Hematopoietic Stem Cell Transplantation.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025018918. Online ahead of print","author":"Amonoo HL, Keane EP, Guo M, Gudenkauf LM, Boardman AC, Larizza IS, Wolfe ED, Mate-Kole MN, Healy BC, Cutler CS, Jim HS, Lee SJ, Greer JA, Huffman JC, El-Jawahri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945755"},{"title01":"Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.","title02":"Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.","journal":"Blood advances","issue":"2026 April 14; 10(7):2202-2217. doi: 10.1182\/bloodadvances.2025017413","author":"Goldenberg M, Varadhan R, Gamper CJ, Cooke KR, Ambinder AJ, Symons HJ, Pecker LH, Jones RJ, Brodsky RA, Bolanos-Meade J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569644"},{"title01":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","title02":"Supportive Care Interventions in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2026019724. Online ahead of print","author":"Schaefer DA, Guo M, Keane EP, Song MT, Larizza IS, Adri F, Wolfe ED, Saadeh N, Boardman AC, Acharya NB, Waldman LP, Monahan JA, Ramirez-Gamero AF, Diaz Gonzalez-Colmenero F, Watson J, Cronin AE, Celano CM, Brown L, Lee SJ, Stoto MA, Gudenkauf LM, Amonoo HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925563"},{"title01":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","title02":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 14; 10(7):2190-2201. doi: 10.1182\/bloodadvances.2025017360","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis S, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","title02":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","journal":"Blood advances","issue":"2026 April 14; 10(7):2525-2537. doi: 10.1182\/bloodadvances.2025018349","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas S, Dalle JH, Risitano AM, Kulasekararaj A, Alsultan A, Cutler C, Ho VT, Hellstrom-Lindberg E, Mielke S, Myhre AE, Rihani R, Shanap MA, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough R, Ali Jafri SR, Ayas M, Jardine L, Mellid EF, Corrales I, Richardson D, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen S, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 April 14; 10(7):2431-2440. doi: 10.1182\/bloodadvances.2025017189","author":"Utrero-Rico A, Kapoor U, Berrios B, Morales G, Levine JE, Prado-Acosta M, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","title02":"In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019655. Online ahead of print","author":"MacKenzie TC, Lianoglou BR, Gonzalez J MD, Dvorak CC, Kharbanda S, Herzeg A, Canepa E, Kreger EM, Frascoli M, Sper R, Gupta A, Leung J, Tang Q, Sinha R, Worthington AK, Gano D, Coco Bakkour S, Chafets D, Keller RL, Shimotake J, Lal A, Glenn OA, Moon-Grady A, Vichinsky EP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41984996"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 April 9; 147(15):1763-1778. doi: 10.1182\/blood.2025031080","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk F, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"GVHD fails the acid test.","title02":"GVHD fails the acid test.","journal":"Blood","issue":"2026 April 9; 147(15):1660-1662. doi: 10.1182\/blood.2025032810","author":"Chakraverty R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954963"},{"title01":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","title02":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032587. Online ahead of print","author":"Pan Z, Deng Y, Huang J, Bian H, Chen Y, Huang A, Jiang C, Wang L, Zhang Z, Lu H, Li S, Yin T, Yu S, Zhu J, Zhao WL, Wang J, Ji J, Xu Y, Cheng H, Chen J, Hu H, Hu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980031"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat beta-Thalassemia.","title02":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat beta-Thalassemia.","journal":"N Engl J Med","issue":"2026 April 2; 394(13):1292-1301. doi: 10.1056\/NEJMoa2501277","author":"Frangoul H, Hanna R, Walters MC, Kao RL, Carroll C, McManus M, Chang KH, Jaskolka MC, Kim K, Yu Q, Badamosi N, Mei B, Afonja O, Thompson A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931048"},{"title01":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","title02":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 April 2; 394(13):1281-1291. doi: 10.1056\/NEJMoa2415550","author":"Hanna R, Frangoul H, Pineiro L, McKinney C, Mapara M, Dalal J, Rangarajan HG, Atkins H, Sharma A, Chang KH, Jaskolka MC, Kim K, Yu Q, Mei B, Afonja O, Walters MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931047"},{"title01":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","title02":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02903-8. Online ahead of print","author":"Mehta RS, Kanakry CG, Nawas M, Lazaryan A, Kanakry JA, Holtan S, Al-Juhaishi T, Rimando JC, Singh A, Saultz J, Mccurdy SR, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986623"},{"title01":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","title02":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02957-8. Online ahead of print","author":"Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986621"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e241-e253. doi: 10.1016\/S2352-3026(26)00011-6","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Maintenance intensification after autologous HSCT: refining selection.","title02":"Maintenance intensification after autologous HSCT: refining selection.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e189-e191. doi: 10.1016\/S2352-3026(26)00064-5","author":"Perrot A, Frenzel L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831470"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):1003-1015. doi: 10.1200\/JCO-25-01591","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 April 6; JCO2501966. doi: 10.1200\/JCO-25-01966. Online ahead of print","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","title02":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300403. Online ahead of print","author":"Olson TS, Ericson K, Antin JH, Babbitt L, Babich M, Deuitch NT, DiNardo C, Ford PJ, Obeng EA, Stewart BL, Xiao W, Shimamura A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924923"},{"title01":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2026 April 1; 111(4):1254-1264. doi: 10.3324\/haematol.2025.288721","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","title02":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.287767. Online ahead of print","author":"Krishnan V, Shyamsunder P, Ong TS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952641"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2026 April 1; 111(4):1179-1197. doi: 10.3324\/haematol.2025.288654","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era – emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era – emerging humoral and cellular players.","journal":"Haematologica","issue":"2026 April 1; 111(4):1265-1279. doi: 10.3324\/haematol.2025.288237","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"Role of donor regulatory T-cell adoptive immunotherapy in B-cell immunity after hematopoietic cell transplantation.","title02":"Role of donor regulatory T-cell adoptive immunotherapy in B-cell immunity after hematopoietic cell transplantation.","journal":"Haematologica","issue":"2026 April 1; 111(4):1404-1410. doi: 10.3324\/haematol.2024.286905","author":"Piccinelli S, Limongello R, Viglione V, Hohxa E, Zei T, Ostini RI, Bigerna B, Tabarrini A, Sembenico R, Tricarico S, Zorutti F, Martelli MP, Carotti A, Martelli MF, Velardi A, Ruggeri L, Mancusi A, Pierini A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195519"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 April 1; 111(4):1484-1489. doi: 10.3324\/haematol.2025.289076","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","title02":"Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70486. Online ahead of print","author":"McComb C, Pai V, Stanek J, Rankin AW, Lamb M, Bhunia N, Bajwa R, Abu-Arja R, Rangarajan HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41983326"},{"title01":"Serotherapy in transplant: Getting it right!","title02":"Serotherapy in transplant: Getting it right!","journal":"Br J Haematol","issue":"2026 April 6. doi: 10.1111\/bjh.70456. Online ahead of print","author":"Wynn R, Admiraal R, Lindemans C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937680"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 April; 208(4):1482-1485. doi: 10.1111\/bjh.70327","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 April; 208(4):1477-1481. doi: 10.1111\/bjh.70318","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","title02":"Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70453. Online ahead of print","author":"Lum SH, Greener S, Memon IL, Amrolia P, Nademi Z, Chiesa R, Silva J, Young H, Owens S, Williams E, Ng KF, Flood T, Gennery AR, Hambleton S, Rao K, Slatter M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958357"},{"title01":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","title02":"Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.","journal":"Br J Haematol","issue":"2026 April 10. doi: 10.1111\/bjh.70477. Online ahead of print","author":"Chen Y, Zhang X, Shen N, Zhang J, Guo R, Xing H, Han L, Liu Y, Tian W, Wang M, Xie X, Jiang Z, Wan D, Zhou X, Xu H, Qin L, Shi W, Cao W, Bian Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41960892"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 April; 208(4):1462-1466. doi: 10.1111\/bjh.70350","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","title02":"Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 April 14; 10(7):2190-2201. doi: 10.1182\/bloodadvances.2025017360","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis S, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","title02":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","journal":"Blood advances","issue":"2026 April 14; 10(7):2525-2537. doi: 10.1182\/bloodadvances.2025018349","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas S, Dalle JH, Risitano AM, Kulasekararaj A, Alsultan A, Cutler C, Ho VT, Hellstrom-Lindberg E, Mielke S, Myhre AE, Rihani R, Shanap MA, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough R, Ali Jafri SR, Ayas M, Jardine L, Mellid EF, Corrales I, Richardson D, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen S, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 April 9; 147(15):1763-1778. doi: 10.1182\/blood.2025031080","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk F, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"Turning off SP140 to turn on HSCs.","title02":"Turning off SP140 to turn on HSCs.","journal":"Blood","issue":"2026 April 2; 147(14):1511-1513. doi: 10.1182\/blood.2025032459","author":"Juster S, Gottgens B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926141"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","title02":"CD28(+) CD8(+) Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032587. Online ahead of print","author":"Pan Z, Deng Y, Huang J, Bian H, Chen Y, Huang A, Jiang C, Wang L, Zhang Z, Lu H, Li S, Yin T, Yu S, Zhu J, Zhao WL, Wang J, Ji J, Xu Y, Cheng H, Chen J, Hu H, Hu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980031"},{"title01":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","title02":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","journal":"Blood","issue":"2026 April 2; 147(14):1584-1597. doi: 10.1182\/blood.2025032084","author":"Liu X, Zhang Z, Cui X, Guo R, Ding X, Ma L, Liu P, Yu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397285"},{"title01":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","title02":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","journal":"Blood","issue":"2026 April 9; 147(15):1680-1692. doi: 10.1182\/blood.2024028063","author":"Castiglioni C, Piussi R, Ditadi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481376"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 April; 40(4):783-793. doi: 10.1038\/s41375-026-02892-8","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.","title02":"Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 April 1. doi: 10.1056\/NEJMoa2504835. Online ahead of print","author":"Gupta AO, Sharma A, Frangoul H, Kanter J, Mapara MY, Dalal J, Alavi A, Jaroscak JJ, Ayala E, DiPersio JF, Ziga ED, Eapen M, Rifkin-Zenenberg S, Minella AC, Chen Y, Chesler S, Ambati S, Bowman TS, Habtemariam B, Joseney-Antoine M, Chockalingam PS, Lin L, Goyal S, Simon A, Thompson AA, Heeney MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931046"},{"title01":"Updated anaemia estimates: implications for global monitoring.","title02":"Updated anaemia estimates: implications for global monitoring.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e188-e189. doi: 10.1016\/S2352-3026(26)00040-2","author":"Leung S, Pasricha SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41934986"},{"title01":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","title02":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","journal":"Lancet","issue":"2026 April 4; 407(10536):1383-1396. doi: 10.1016\/S0140-6736(26)00150-9","author":"Doeven T, Glenthoj A, Grace RF, van Beers EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41833294"},{"title01":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","title02":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032757. Online ahead of print","author":"Zent CS, Tiacci E, Kreitman RJ, Tadmor T, Tallman MS, Wormann BJ, Andritsos LA, Arons E, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call TG, Dearden C, Demeter J, Dietrich S, El-Sharkawi D, Fagarasanu A, Falini B, Forconi F, Gerrie AS, Gladstone DE, Gozzetti A, Hampel PJ, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kipps TJ, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Rai KR, Ravandi F, Robak T Prof, Rogers KA, Saven A, Seymour JF, Tam CS, Troussard X, Zenz T, Zinzani PL, Grever MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980020"},{"title01":"Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma.","title02":"Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1723-1734. doi: 10.1182\/blood.2025030489","author":"Wiegand L, Silva P, Noerenberg D, Christen F, Kopp K, Locher BN, Lowe P, Tilgner M, Altwasser R, Storzer V, Stein CM, Briest F, Arends CM, Frick M, Ihlow J, Dolnik A, Ishaque N, Keller U, Na IK, Penter L, Bullinger L, Hablesreiter R, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490454"},{"title01":"Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.","title02":"Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1713-1722. doi: 10.1182\/blood.2025030190","author":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460964"},{"title01":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","title02":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","journal":"Leukemia","issue":"2026 April; 40(4):730-738. doi: 10.1038\/s41375-026-02889-3","author":"Riedhammer C, Truger M, Lee H, Leypoldt LB, Meggendorfer M, Hutter S, Muller H, Mersi J, Kadel SK, Buchwald T, Kosch R, Helal M, Afrin N, Rosenwald A, Gerhard-Hartmann E, Brioli A, Kronke J, Haferlach T, Haferlach C, Weisel KC, Neri P, Einsele H, Kortum KM, Waldschmidt JM, Bahlis N, Weinhold N, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703032"},{"title01":"An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.","title02":"An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass.","journal":"Lancet Haematol","issue":"2026 April 2. doi: 10.1016\/S2352-3026(26)00015-3. Online ahead of print","author":"Piperidou A, Rondogianni P, Zorbala A, Korkolopoulou P, Kontogeorgakos V, Vassilakopoulos TP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41936370"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e241-e253. doi: 10.1016\/S2352-3026(26)00011-6","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):992-1002. doi: 10.1200\/JCO-25-01969","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","title02":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","journal":"J Clin Oncol","issue":"2026 April; 44(10):914-941. doi: 10.1200\/JCO-25-02587","author":"Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, Wildes TM, Bal S, Bhella S, Chmielewski C, Costello C, Dabney R, Hartley-Brown M, Langerak A, Lipe B, Martin T, McCurdy A, Mian H, Riva E, Seth R, Subramanian L, Mikhael J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41494138"},{"title01":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","title02":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","journal":"J Clin Oncol","issue":"2026 April; 44(10):903-913. doi: 10.1200\/JCO-25-01713","author":"Banerjee R, King T, Faiman B, Harding S, Rosenberg AS, Sanchorawala V, Mikhael JR, Cowan AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592262"},{"title01":"The genetic landscape of extramedullary plasmacytoma: a comparative analysis with extramedullary disease of multiple myeloma.","title02":"The genetic landscape of extramedullary plasmacytoma: a comparative analysis with extramedullary disease of multiple myeloma.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300201. Online ahead of print","author":"Vogelsberg A, Salmeron-Villalobos J, Wilhelmi AL, Otto F, Schneider A, Mankel B, Bag E, Colmenero A, Dettmer MS, Narbaitz M, Tzankov A, Salaverria I, Bonzheim I, Fend F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952616"},{"title01":"Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myeloma.","title02":"Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myeloma.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300383. Online ahead of print","author":"Williams CMD, Noll JE, Harnas D, Parkinson HB, Hewett DR, Zannettino ACW, Vandyke K, Cox TR, Panagopoulos V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924905"},{"title01":"Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.","title02":"Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300105. Online ahead of print","author":"Pietzsch M, Beer SA, Kimmich LM, Windsor C, Gekeler S, Besemer B, Stanger AMP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924901"},{"title01":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","title02":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","journal":"Haematologica","issue":"2026 April 1; 111(4):1474-1477. doi: 10.3324\/haematol.2025.288692","author":"Cheng SS, Jiang JG, Lin SC, Yu YH, Chang TW, Lim C, Yu YB, Chu HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195521"},{"title01":"Single-cell analysis unveils distinct transcriptional alterations and cellular origins in IgD multiple myeloma.","title02":"Single-cell analysis unveils distinct transcriptional alterations and cellular origins in IgD multiple myeloma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1449-1454. doi: 10.3324\/haematol.2025.288418","author":"Luo T, Zhou X, Chen X, Liu J, Yang Y, Hu X, Li J, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163585"},{"title01":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers.","title02":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers.","journal":"Haematologica","issue":"2026 April 1; 111(4):1432-1435. doi: 10.3324\/haematol.2025.288320","author":"May P, Rassner M, Hoegner M, Shahbaz W, Wasch R, Martinez AMG, Schmidt B, Theurich S, Engelhardt M, Bassermann F, Jung J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098101"},{"title01":"Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.","title02":"Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.","journal":"Br J Haematol","issue":"2026 April 14. doi: 10.1111\/bjh.70479. Online ahead of print","author":"Delimpasi S, Spicka I, Butler JP, Stevens DA, Mesa MG, Bygrave C, Merlo GM, la Porte C, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41978554"},{"title01":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","title02":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","journal":"Br J Haematol","issue":"2026 April; 208(4):1454-1457. doi: 10.1111\/bjh.70356","author":"Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622574"},{"title01":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","title02":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2026 April; 208(4):1314-1323. doi: 10.1111\/bjh.70373","author":"Jamroziak K, Dytfeld D, Kubicki T, Dutka M, Wrobel T, Giannopoulos K, Konska A, Druzd-Sitek A, Tyczynska A, Olszewska-Szopa M, Morawska M, Szeremet A, Kopinska A, Wisniewski K, Czyz J, Helbig G, Gil L, Zaucha JM, Kruk-Kwapisz D, Walewski J, Gorecki T, Pula B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704058"},{"title01":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","title02":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","journal":"Br J Haematol","issue":"2026 April; 208(4):1324-1330. doi: 10.1111\/bjh.70395","author":"Su M, Khan AM, Cowan AJ, Anderson LD Jr, Kaur G, Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733330"},{"title01":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","title02":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","journal":"Br J Haematol","issue":"2026 April; 208(4):1179-1180. doi: 10.1111\/bjh.70376","author":"Amiot Q, Assadi-Gazvini C, Bugier S, Arnautou P, Maillot J, Malfuson JV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797264"},{"title01":"Biochemical bone biomarkers in plasma cell dyscrasias for the British Journal of Haematology.","title02":"Biochemical bone biomarkers in plasma cell dyscrasias for the British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 April 8. doi: 10.1111\/bjh.70467. Online ahead of print","author":"Nador G, Vijjhalwar R, Javaid MK, Edwards CM, Ramasamy K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41948808"},{"title01":"HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.","title02":"HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.","journal":"Br J Haematol","issue":"2026 April 8. doi: 10.1111\/bjh.70478. Online ahead of print","author":"Hughes E, Blombery P, Kannan S, Khong T, Spencer A, Morley A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41947647"},{"title01":"Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies.","title02":"Cytomegalovirus reactivation in multiple myeloma patients receiving bispecific antibodies.","journal":"Blood advances","issue":"2026 April 6. doi: 10.1182\/bloodadvances.2025019563. Online ahead of print","author":"Sastre-Escola E, Reynolds GK, Yong MK, Zhu V, Harrison SJ, Khot AS, Slavin MA, Teh BW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941693"},{"title01":"Point: CAR-T therapy is the preferred option in relapsed\/refractory multiple myeloma.","title02":"Point: CAR-T therapy is the preferred option in relapsed\/refractory multiple myeloma.","journal":"Blood advances","issue":"2026 April 13. doi: 10.1182\/bloodadvances.2026019898. Online ahead of print","author":"Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41973829"},{"title01":"IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.","title02":"IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2025018710. Online ahead of print","author":"Ohguchi Y, Ajiro M, Ogiya D, Masuda T, Kawano Y, Usuki S, Koga T, Hino S Dr, Harada T, Takahashi S, Okada S, Yasunaga JI, Sashida G, Ohtsuki S, Nakao M, Minami T, Yoshimi A, Ohguchi H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925579"},{"title01":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.","title02":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.","journal":"Blood advances","issue":"2026 April 14; 10(7):2244-2248. doi: 10.1182\/bloodadvances.2025017889","author":"Mersi J, Burow L, Zhou X, Eisele F, Fante M, Riedhammer C, Stich A, Isberner N, Afrin N, Duell J, Topp MS, Einsele H, Waldschmidt J, Kortum KM, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610311"},{"title01":"BCMA\/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: a phase I study.","title02":"BCMA\/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: a phase I study.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2025019036. Online ahead of print","author":"Liu J, Fan X, Peng L, Liu J, He H, Qiang W, Jin L, Shi L, Lu J, Guo P, Shah N, Zhang Q, Shen L, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925575"},{"title01":"Breaking new ground with antibody-drug conjugates in myeloma.","title02":"Breaking new ground with antibody-drug conjugates in myeloma.","journal":"Blood","issue":"2026 April 2; 147(14):1510-1511. doi: 10.1182\/blood.2025032443","author":"Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926146"},{"title01":"Venetoclax in myeloma: t(11;14) and what else?","title02":"Venetoclax in myeloma: t(11;14) and what else?","journal":"Blood","issue":"2026 April 2; 147(14):1513-1515. doi: 10.1182\/blood.2025032670","author":"Pellat-Deceunynck C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926144"},{"title01":"Tunneling Nanotube-Mediated Filamin A Transport Mechanosensitively Programs Osteoclastogenesis in Myeloma Bone Disease.","title02":"Tunneling Nanotube-Mediated Filamin A Transport Mechanosensitively Programs Osteoclastogenesis in Myeloma Bone Disease.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025031627. Online ahead of print","author":"Guo J, Wang J, Xie Y, Wang Y, Peng Z, Wang M, Cheng H, Li T, Jia L, Xu H, Su D, Qiao M, Liu H, Li X, Li W, Wu D, Huang J, Bergsagel PL, Li F, Zhao Z, Liu Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950002"},{"title01":"Phase 1\/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed\/refractory multiple myeloma.","title02":"Phase 1\/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed\/refractory multiple myeloma.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025032044. Online ahead of print","author":"Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A, Niesvizky R, Trudel S, Mollee P, Vij R, Minnema MC, Rasche L, Upreti VV, Zhou D, Xia Q, Talpes M, Eggert T, Kapoor P, Ailawadhi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950113"},{"title01":"Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.","title02":"Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.","journal":"Blood","issue":"2026 April 2; 147(14):1574-1583. doi: 10.1182\/blood.2025031629","author":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, Migkou M, Theodorakakou F, Spiliopoulou V, Solia E, Eleutherakis-Papaiakovou E, Psarros G, Kastritis E, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346230"},{"title01":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","title02":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","journal":"Blood","issue":"2026 April 2; 147(14):1598-1610. doi: 10.1182\/blood.2025029996","author":"Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante M, Diamond B, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren O, Usmani S, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar S, Maura F, Baughn LB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481388"},{"title01":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","title02":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.","journal":"N Engl J Med","issue":"2026 April 2; 394(13):1281-1291. doi: 10.1056\/NEJMoa2415550","author":"Hanna R, Frangoul H, Pineiro L, McKinney C, Mapara M, Dalal J, Rangarajan HG, Atkins H, Sharma A, Chang KH, Jaskolka MC, Kim K, Yu Q, Mei B, Afonja O, Walters MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41931047"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e241-e253. doi: 10.1016\/S2352-3026(26)00011-6","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 April 6; JCO2501966. doi: 10.1200\/JCO-25-01966. Online ahead of print","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):992-1002. doi: 10.1200\/JCO-25-01969","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","title02":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","journal":"J Clin Oncol","issue":"2026 April; 44(10):861-873. doi: 10.1200\/JCO-25-02083","author":"Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671533"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 April 10; 44(11):1003-1015. doi: 10.1200\/JCO-25-01591","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","title02":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","journal":"Haematologica","issue":"2026 April 1; 111(4):1246-1253. doi: 10.3324\/haematol.2025.288553","author":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035402"},{"title01":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO.","title02":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300574. Online ahead of print","author":"Abeyakoon C, Kuruvilla J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924908"},{"title01":"Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? – the CON.","title02":"Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? – the CON.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300566. Online ahead of print","author":"Moskowitz AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924918"},{"title01":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","title02":"Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300403. Online ahead of print","author":"Olson TS, Ericson K, Antin JH, Babbitt L, Babich M, Deuitch NT, DiNardo C, Ford PJ, Obeng EA, Stewart BL, Xiao W, Shimamura A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924923"},{"title01":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","title02":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","journal":"Haematologica","issue":"2026 April 1; 111(4):1389-1395. doi: 10.3324\/haematol.2025.288232","author":"Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163564"},{"title01":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","title02":"Impact of horse anti-thymocyte globulin on graft-versus-host disease after human leukocyte antigen-matched related bone marrow transplantation for severe aplastic anemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300746. Online ahead of print","author":"Olivieri DJ, Gooley T, Manjappa S, Walter RB, Keel S, Flowers M, Storb R, Vo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952636"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era – emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era – emerging humoral and cellular players.","journal":"Haematologica","issue":"2026 April 1; 111(4):1265-1279. doi: 10.3324\/haematol.2025.288237","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2026 April 1; 111(4):1179-1197. doi: 10.3324\/haematol.2025.288654","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2026 April 1; 111(4):1254-1264. doi: 10.3324\/haematol.2025.288721","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 April 1; 111(4):1484-1489. doi: 10.3324\/haematol.2025.289076","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1467-1471. doi: 10.1111\/bjh.70347","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 April; 208(4):1462-1466. doi: 10.1111\/bjh.70350","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 April; 208(4):1482-1485. doi: 10.1111\/bjh.70327","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 April; 208(4):1207-1210. doi: 10.1111\/bjh.70392","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attack.","title02":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attack.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025016927. Online ahead of print","author":"Apodaca K, Xu C, Stanton KL, Baroja ML, Alfaro Doblado AR, Engel NW, Wellhauusen N, Cox A, Berjis A, Ji MQ, Bushara O, Melendez D, Welch C, Banerjee E, Assenmacher CA, Sheppard NC, Scholler J, June CH, Carreno BM, Linette GP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945756"},{"title01":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","title02":"Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.","journal":"Blood advances","issue":"2026 April 14; 10(7):2525-2537. doi: 10.1182\/bloodadvances.2025018349","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas S, Dalle JH, Risitano AM, Kulasekararaj A, Alsultan A, Cutler C, Ho VT, Hellstrom-Lindberg E, Mielke S, Myhre AE, Rihani R, Shanap MA, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough R, Ali Jafri SR, Ayas M, Jardine L, Mellid EF, Corrales I, Richardson D, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen S, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel.","title02":"Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel.","journal":"Blood advances","issue":"2026 April 10. doi: 10.1182\/bloodadvances.2025018853. Online ahead of print","author":"Lim KJ, Lee HE, Chen ZE, Bledsoe A, Parrondo RD, Chhabra S, Dooley K, De Menezes Silva Corraes A, Gertz MA, Hwa YL, Stephens H, Kapoor P, Tan MS, Kourelis TV, Warsame R, Cook J, Binder M, Bergsagel PL, Yadav U, Wiedmeier-Nutor JE, Geyer S, Ailawadhi S, Fonseca R, Kumar SK, Chowla N, Lin Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41961998"},{"title01":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025017738. Online ahead of print","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes JE, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","title02":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","journal":"Leukemia","issue":"2026 April; 40(4):845-850. doi: 10.1038\/s41375-026-02869-7","author":"Grunenberg A, Schmelzle B, Gokeler J, Mund H, Viardot A, Dreyhaupt J, Nagel G, Reiser M, Gabrysiak T, Braulke F, Dunst J, Schlag R, Gaska T, Runde V, Kraemer D, Weber T, Mueller L, Johansson P, Ziske C, Hess G, Liersch R, Buske C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792439"},{"title01":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","title02":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","journal":"Leukemia","issue":"2026 April; 40(4):759-772. doi: 10.1038\/s41375-026-02868-8","author":"Filip D, Litzmanova K, Michaelou A, Kledus F, Devan J, Boudny M, Hoferkova E, Sharma S, Seda V, Zeni PF, Borsky M, Matulova K, Kren L, Oppelt J, Blavet N, Hejret V, Urik M, Mareckova A, Rimsza LM, Kamaradova K, Belada D, Sykorova A, Mocikova H, Trneny M, Prouzova Z, Evans AG, Danilov A, Horn H, Ott G, Staber P, Mayer J, Friedberg JW, Janikova A, Mraz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714403"},{"title01":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","title02":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers.","journal":"Leukemia","issue":"2026 April 14. doi: 10.1038\/s41375-026-02946-x. Online ahead of print","author":"Liu X, Adami HO, Boberg E, Smedby KE, Wei H, Fang F, Liu Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41981103"},{"title01":"Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL.","title02":"Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL.","journal":"Leukemia","issue":"2026 April 8. doi: 10.1038\/s41375-026-02948-9. Online ahead of print","author":"Alvarez-Corrales E, Moreno-Palomares R, Gomez-Escolar C, Martinez M, Moral-Perez U, Laguna-Herrero M, Fuertes T, Estrada BS, Mur S, de Bonis A, Leiva M, Martinez-Martin N, Somoza A, Ramiro AR, de Yebenes VG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41951939"},{"title01":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","title02":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","journal":"Leukemia","issue":"2026 April; 40(4):739-750. doi: 10.1038\/s41375-026-02894-6","author":"Madiot C, Bellanger C, Dousset C, Decombis S, Thirouard L, Papin A, Baron E, Barc J, Le Bris Y, Gomez-Bougie P, Moreau-Aubry A, Tessoulin B, Pellat-Deceunynck C, Chiron D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714404"},{"title01":"Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.","title02":"Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02942-1. Online ahead of print","author":"Tavarozzi R, Maher N, Catania G, Zacchi G, D'Andrea F, Sofia A, Zanni M, Ladetto M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986622"},{"title01":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO.","title02":"Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300574. Online ahead of print","author":"Abeyakoon C, Kuruvilla J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924908"},{"title01":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","title02":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1176-1178. doi: 10.3324\/haematol.2025.289294","author":"Lee D, Dahiya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437826"},{"title01":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","title02":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","journal":"Haematologica","issue":"2026 April 1; 111(4):1198-1214. doi: 10.3324\/haematol.2025.288185","author":"Loh Z, Yeh P, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195522"},{"title01":"Relapse as a return, not a reinvention – genomic stability and pre-existing resistance in mantle cell lymphoma.","title02":"Relapse as a return, not a reinvention – genomic stability and pre-existing resistance in mantle cell lymphoma.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.289129. Online ahead of print","author":"Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952644"},{"title01":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","title02":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300118. Online ahead of print","author":"Suurenbroek LC, Van der Ham CG, Boer JM, Derks LLM, Hagelaar R, Van Roosmalen MJ, Klamer P, Sonneveld E, Den Boer ML, Van Boxtel R, Van Leeuwen FN, Loeffen JLC, Kuiper RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952634"},{"title01":"Anti-CD19 CAR T-cell therapy in relapsed\/refractory T-cell\/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.","title02":"Anti-CD19 CAR T-cell therapy in relapsed\/refractory T-cell\/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.289196. Online ahead of print","author":"Andre A, Bourbon E, Cartron G, Morschhauser F, Fayard A, Ricard L, Di Blasi R, Chauchet A, Guidez S, Castilla-Llorente C, Brisou G, Bories P, Houot R, Cuozzo A, Gat E, Lemonnier F, Laurent C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952624"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 April; 208(4):1287-1295. doi: 10.1111\/bjh.70383","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","title02":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","journal":"Br J Haematol","issue":"2026 April; 208(4):1429-1432. doi: 10.1111\/bjh.70361","author":"Poh C, Zain J, Godfrey J, Querfeld C, Puverel S, Chen L, Allen P, Herrera AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693089"},{"title01":"Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II ‘FLUORO’ study.","title02":"Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II ‘FLUORO’ study.","journal":"Br J Haematol","issue":"2026 April 8. doi: 10.1111\/bjh.70468. Online ahead of print","author":"Martynchyk A, Chong G, Khor R, Lee D, Lee ST, Scott AM, Grobler AC, Campbell BA, Thachil T, Manos K, Douglas G, Romano A, Palmer JB, Burgess M, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949430"},{"title01":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","title02":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","journal":"Br J Haematol","issue":"2026 April; 208(4):1424-1428. doi: 10.1111\/bjh.70335","author":"Song J, Jiang H, Ding K, Liu H, Wang Y, Gao S, Ren Y, Liu Z, Zhuo J, Li B, Wang G, Jiao Z, Gao D, Fu R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582824"},{"title01":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","title02":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","journal":"Br J Haematol","issue":"2026 April; 208(4):1185-1195. doi: 10.1111\/bjh.70329","author":"Gowdy SC, Flerlage JE, Seelisch J, Palese M, Bradshaw T, Castellino SM, Cho S, Dieckmann K, Hoppe BS, Howard S, Kelly KM, Kurch L, Lai HA, Lopci E, Lucas JT Jr, Mauz-Korholz C, McCarten KM, Pandit-Taskar N, Schoder H, Steglich J, Stoevesandt D, Voss SD, Milgrom SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535222"},{"title01":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","title02":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","journal":"Br J Haematol","issue":"2026 April; 208(4):1419-1423. doi: 10.1111\/bjh.70326","author":"Fu YC, Liu LP, Zhou YP, Yang MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787912"},{"title01":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","title02":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","journal":"Br J Haematol","issue":"2026 April; 208(4):1347-1358. doi: 10.1111\/bjh.70357","author":"O'Reilly MA, Wilson W, Maybury B, Kuhnl A, Roddie C, Uttenthal B, Johnson R, Alajangi R, Creasey T, Abdulgawad A, Arias CG, Iyengar S, Ferguson G, Panopoulou K, Delaney A, Pryce A, Rubio L, Jones C, Lambert J, Gupta S, Mathew A, Kasivisvanathan S, Awofisayo O, Hanmantgad S, Collins GP, Besley C, Seymour F, Sanderson R, Chaganti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796018"},{"title01":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","title02":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1296-1305. doi: 10.1111\/bjh.70390","author":"Ligia S, Assanto GM, Soriano T, Cappelli LV, Passucci M, Annechini G, D'Elia GM, Pulsoni A, Martelli M, Del Giudice I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721535"},{"title01":"Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.","title02":"Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70488. Online ahead of print","author":"Arai Y, Jo T, Sato T, Sakurai M, Kaji D, Kitawaki T, Shimada K, Shimoyama T, Yoshihara S, Makita S, Fujii N, Yamamoto G, Kataoka K, Sakaida E, Goto H, Nakashima Y, Yoshida A, Umezawa Y, Kim H, Kato M, Atsuta Y, Kato K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986280"},{"title01":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","title02":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70494. Online ahead of print","author":"Valcarcel B, Utsunomiya A, Otsuka M, Miyahara M, Ishitsuka K, Takamatsu Y, Suzumiya J, Tamura K, Vasquez JF, Enriquez-Vera D, Beltran BE, Castro D, Runciman T, Idrobo H, Arrieta E, Arias O, Gotuzzo E, Garrido-Pinzas G, Rivera V, Rosa D, Pena C, Fiad L, Ramos JC, Sandoval-Sus J, Sica A, Bell BN, Cook LB, Leataud V, Miranda ECM, Chiattone C, Katsuya H, Malpica L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986288"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 April; 208(4):1207-1210. doi: 10.1111\/bjh.70392","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1331-1338. doi: 10.1111\/bjh.70379","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.","title02":"Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2025018126. Online ahead of print","author":"Pizzarella D, Kofides A, Hatcher JM, Liu X, Guijosa A, Tsakmaklis N, Peachey A, Wang J, Guerrera ML, Patterson CJ, Hunter ZR, Sun H, Sarosiek S, Castillo JJ, Buhrlage S, Dhe-Paganon S, Branagan AR, Treon SP, Liu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985014"},{"title01":"LySeqST: A targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.","title02":"LySeqST: A targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026020105. Online ahead of print","author":"Hilton LK, Gillis S, Yahyaei-Moayyed F, Bridgers J, Alduaij W, Jiang A, Ben-Neriah S, Collinge B, Wong JCH, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Villa D, Savage KJ, Sehn LH, Karsan A, Wright G, Staudt LM, Morin RD, Steidl C, Scott DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985007"},{"title01":"Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.","title02":"Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2025019553. Online ahead of print","author":"Meyer-Wentrup F, Jonas SF, Knorr F, Auperin A, Alexander S, Andres M, Attarbaschi A, Burke GAA, Burkhardt B, Ceppi F, Gross TG, Kabickova E, Klapper W, Miles RR, Taj MM, Zimmermann M, Minard-Colin V, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979343"},{"title01":"Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.","title02":"Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2026020012. Online ahead of print","author":"Flerlage JE, Eichenauer DA, Fuchs M, Hartmann S, Eich HT, Savage KJ, Lo AC, Skinnider B, Akhtar S, Rauf MS, Maghfoor I, Pinnix CC, Steiner RE, Milgrom SA, Vega F, Alomari M, Zhang XY, Collins GP, Advani RH, Kumar P, Dickinson MJ, Wirth A, Tsang R, Prica A, Major A, Smith SM, Hendrickson PG, Kelsey CR, Hopkins D, McKay P, Ng AK, Koenig JL, Constine LS, Casulo C, Sakthivel G, Baron JA, Plastaras JP, Roberts KB, Gao S, Al Kendi J, Al Rahbi N, Balogh AG Jr, Levis M, Ricardi U, Sridhar A, Torka P, Specht L, De Silva R, Shah N, Pickard K, Osborne W, Blazin LJ, Henry M, Chang I, Smith CM, Halperin D, Miall F, Brady JL, Mikhaeel NG, Brennan B, Penn A, Senchenko M, Volchkov EV, Reeves M, Hoppe BS, Terezakis SA, Talaulikar D, Della Pepa R, Picardi M, Kirova Y, Fergusson P, Northend M, Hawkes EA, Lee D, Wong Doo N, Barraclough A, Opat S, Cheah CY, Salvaris R, Ku M, Hamad N, Mutsando H, Tedjaseputra A, Gilbertson M, Marconi T, Viiala N, Palese M, Shankar AG, Maurer MJ, Natkunam Y, Kelly KM, Borchmann P, Hoppe RT, Binkley MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979337"},{"title01":"Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.","title02":"Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2025019108. Online ahead of print","author":"Camus V, Krzisch D, Bruscaggin A, Leveque E, Viennot M, Fornecker LM, Cheminant M, Bailly S, Morschhauser F, Feugier P, Choquet S, Durot E, Carras S, Delette C, Damaj G, Waultier Rascalou A, Lebreton P, Le Du K, Galtier J, Houot R, Morineau N, Laribi K, Lebras L, Oberic L, Amorim S, Bocchetta S, Viailly PJ, Rainville V, Ruminy P, Caillot M, Terzi di Bergamo L, Piffaretti D, Pirosa MC, Salehi M, Forestieri G, Drieux F, Veresezan EL, Traverse-Glehen A, Donzel M, Burel L, Bohers E, Lanic MD, Penther D, Becker S, Decazes P, Tonnelet D, Draye-Carbonnier S, Tilly H, Jardin F, Rossi D, Sesques P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979332"},{"title01":"Invasive Fungal Infections Following Bruton Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-analysis.","title02":"Invasive Fungal Infections Following Bruton Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-analysis.","journal":"Blood advances","issue":"2026 April 9. doi: 10.1182\/bloodadvances.2025019221. Online ahead of print","author":"Srisurapanont K, Meejun T, Manothummetha K, Li LX, Baddley JW, Schulz CA, Dioverti MV, Zhang SX, Avery RK, Kates OS, Permpalung N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954633"},{"title01":"POD24 is a novel determinant of prognosis in patients with Waldenstrom macroglobulinemia.","title02":"POD24 is a novel determinant of prognosis in patients with Waldenstrom macroglobulinemia.","journal":"Blood advances","issue":"2026 April 14; 10(7):2322-2327. doi: 10.1182\/bloodadvances.2025017751","author":"Zanwar S, Abeykoon J, D'Sa S, Roos-Weil D, Larson DR, Colby CL, Durot E, Kastritis E, Uppal E, Tomkins O, Morel P, Mondello P, Montes L, Paludo J, Ailawadhi S, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Rajkumar SV, Quinquenel A, Dispenzieri A, Fonseca R, Gertz MA, Kumar S, Dimopoulos MA, Ansell SM, Treon S, Castillo JJ, Kapoor P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499755"},{"title01":"Zamtocabtagene autoleucel in relapsed\/refractory B-NHL: 5-year follow-up of a CD20\/19 tandem CAR T-cell phase 1 trial.","title02":"Zamtocabtagene autoleucel in relapsed\/refractory B-NHL: 5-year follow-up of a CD20\/19 tandem CAR T-cell phase 1 trial.","journal":"Blood advances","issue":"2026 April 14; 10(7):2395-2405. doi: 10.1182\/bloodadvances.2025018073","author":"Balke-Want H, Godel P, Schmid C, Ayuk F, Friedrichs B, van Heteren P, Holtkamp S, Zadoyan G, Brillant C, Costa J, Hanssens L, Holzer T, Wohle C, Biedermann S, Burger I, Orentas R, Overstijns T, Scheid C, Holtick U, Miltenyi S, Hallek M, Borchmann P, Kutsch N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512222"},{"title01":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","title02":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025019415. Online ahead of print","author":"Betensky M, Azzam M, Bercovitz RS, Bhat R, Biss TT, Branchford BR, Brandao LR, Chan AK, Faustino EVS, Hamarsha Q, Jaffray J, Jones SE, Kawtharany H, Kerlin BA, Khawandi J, Krider G, Kucine N, Kumar R, Male C, Monagle P, Pelland-Marcotte MC, Raffini L, Raulji CM, Sartain SE, Takemoto CM, Tarango C, van Ommen CH, Velez MC, Vesely SK, Wiernikowski JT, Williams S, Wilson HP, Woods G, Mustafa RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949461"},{"title01":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R marginal zone lymphoma: phase 1\/2 BRUIN study.","title02":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R marginal zone lymphoma: phase 1\/2 BRUIN study.","journal":"Blood advances","issue":"2026 April 14; 10(7):2441-2451. doi: 10.1182\/bloodadvances.2025017489","author":"Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfo L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544219"},{"title01":"Improved survival and health care use with CAR-T vs historical care in relapsed\/refractory large B-cell lymphoma.","title02":"Improved survival and health care use with CAR-T vs historical care in relapsed\/refractory large B-cell lymphoma.","journal":"Blood advances","issue":"2026 April 14; 10(7):2304-2313. doi: 10.1182\/bloodadvances.2025017401","author":"Kordbacheh T, Chan KKW, Crump M, Ante Z, Liu N, Aminilari M, Gong IY, Bhella S, Vijenthira A, Kuruvilla J, Kridel R, Chen C, Kukreti V, Yang C, Hodgson D, Prica A, Rodin D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544221"},{"title01":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","title02":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","journal":"Blood advances","issue":"2026 April 14; 10(7):2125-2141. doi: 10.1182\/bloodadvances.2025017682","author":"Qin Y, Xia PH, Huang YH, Cheng S, Liu JY, Gao X, Cai MC, Wang C, Qiu YR, Hu S, Shi Q, Yang HX, Zhao JY, Wang L, Xiong J, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564436"},{"title01":"AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.","title02":"AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 April 1. doi: 10.1182\/bloodadvances.2025018954. Online ahead of print","author":"Overgaard N, Lia K, Collin J, Asdahl PH, Wikman P, Glimelius I, Lagerlof I, Johansson AS, Hansson L, Enblad G, Linderoth J, Goldkuhl C, Jerlstrom U, Fossa A, Kamper P, Molin D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921203"},{"title01":"Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.","title02":"Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2026 April 14; 10(7):2495-2505. doi: 10.1182\/bloodadvances.2025018474","author":"Shen J, Zhang J, Zhu Z, Ma H, Zhang J, Zhou F, Tian H, Liu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587420"},{"title01":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","title02":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","journal":"Blood advances","issue":"2026 April 14; 10(7):2186-2189. doi: 10.1182\/bloodadvances.2025018353","author":"Zeremski V, Aydilek E, Behringer A, Brunner F, Haage TR, Haenel M, Kos I, Krueger W, Lenz G, Lesan V, Schneider J, Schultze-Florey C, Shumilov E, Weber T, Wulf G, Vucinic V, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411524"},{"title01":"Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","title02":"Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","journal":"Blood advances","issue":"2026 April 14; 10(7):2249-2253. doi: 10.1182\/bloodadvances.2025018491","author":"Gong IY, Kuruvilla J, Prica A, Olney H, Fraser G, Buckstein R, Skrabek P, Keating MM, Hay A, Shepherd L, Chen BE, Crump M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587423"},{"title01":"Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.","title02":"Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial.","journal":"Blood","issue":"2026 April 2. doi: 10.1182\/blood.2025031809. Online ahead of print","author":"Robertz AS, Buhnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth T, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Jaworek CP, Fuchs M, Kobe C, Baues C, Borchmann P, von Tresckow B, Behringer K, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926569"},{"title01":"Digging deep for the roots of lymphoma.","title02":"Digging deep for the roots of lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1657-1658. doi: 10.1182\/blood.2025032718","author":"Schroers-Martin JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954960"},{"title01":"Targeted therapy in early-stage classical Hodgkin lymphoma.","title02":"Targeted therapy in early-stage classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 April 9; 147(15):1655-1657. doi: 10.1182\/blood.2025032560","author":"Aoki T, Kuruvilla J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954961"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.","title02":"Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2026033090. Online ahead of print","author":"Vodicka P, El-Galaly TC, Prochazka V, Flowers CR, Villa D, Dietrich CE, Jakobsen LH, Ghesquieres H, Clausen MR, Kridel R, Cheah CY, Hawkes EA, Wahlin BE, Gandhi MK, Larson MC, Cahn EJ, Friedberg JW, Martin P, Chihara D, Cohen JB, Habermann TM, Casulo C, Wang Y, Brown PN, Mou E, Belada D, Janikova A, Mocikova H, Burack R, Lossos IS, Kahl BS, Smedby KE, Sehn LH, Trneny M, Cerhan JR, Maurer MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980013"},{"title01":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study.","title02":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study.","journal":"Haematologica","issue":"2026 April 1; 111(4):1443-1448. doi: 10.3324\/haematol.2025.288411","author":"Valentini CG, Pellegrino C, Chiusolo P, Rossi E, Ladiana R, Za T, Sica S, Pagano L, De Stefano V, Teofili L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126731"},{"title01":"Clinical and genomic features of macrofocal multiple myeloma: a distinct profile.","title02":"Clinical and genomic features of macrofocal multiple myeloma: a distinct profile.","journal":"Haematologica","issue":"2026 April 1; 111(4):1462-1468. doi: 10.3324\/haematol.2025.288535","author":"Liu J, Fan J, Zhou X, Chen X, Hu X, He H, Jin L, Fu W, Hou J, Du J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126728"},{"title01":"From myeloma to POEMS: extending the potential of T-cell redirecting therapies.","title02":"From myeloma to POEMS: extending the potential of T-cell redirecting therapies.","journal":"Haematologica","issue":"2026 April 1; 111(4):1173-1175. doi: 10.3324\/haematol.2025.288466","author":"Cook J, Dispenzieri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963394"},{"title01":"Talquetamab, a GPRC5DxCD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study.","title02":"Talquetamab, a GPRC5DxCD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study.","journal":"Haematologica","issue":"2026 April 1; 111(4):1411-1416. doi: 10.3324\/haematol.2025.287334","author":"An G, Jin J, Cai Z, Jing H, Fu C, He P, Xia Z, Liu R, Li L, Gai X, Zhang H, Zhu D, Luo X, Sun B, Xu H, Zhou L, Campagna M, Masterson TJ, Lau BW, Renaud T, Heuck C, Singh I, Vishwamitra D, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063704"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 April; 208(4):1287-1295. doi: 10.1111\/bjh.70383","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","title02":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1240-1251. doi: 10.1111\/bjh.70351","author":"Monaghan L, Bunschoten RP, Bittencourt-Silvestre J, Park T, Gannon S, Pirvan PA, Hoose A, Wheadon H, Liskamp RMJ, Huang X, Jorgensen HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622589"},{"title01":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","title02":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1437-1442. doi: 10.1111\/bjh.70339","author":"Crespo-Garcia E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, Martinez-Verbo L, Esteller M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41606290"},{"title01":"Short and complex-Telomeres and genomes in CLL.","title02":"Short and complex-Telomeres and genomes in CLL.","journal":"Br J Haematol","issue":"2026 April; 208(4):1503-1504. doi: 10.1111\/bjh.70430","author":"Jebaraj BMC, Stilgenbauer S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814451"},{"title01":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","title02":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","journal":"Br J Haematol","issue":"2026 April; 208(4):1232-1239. doi: 10.1111\/bjh.70349","author":"Bidet A, Laharanne E, Dos Santos M, De Grande AC, Leguay T, Pigneux A, Frison E, Achard S, Dupont-Moufakkir S, Klein E, Dumas PY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622767"},{"title01":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","title02":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","journal":"Blood advances","issue":"2026 April 14; 10(7):2425-2428. doi: 10.1182\/bloodadvances.2025018688","author":"Chiu SK, Furlong E, Fox A, McKinnon EJ, Ovando SS, McLean-Tooke A, Oommen J, Yeoh DK, Cheung LC, Gottardo NG, Kotecha RS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628313"},{"title01":"Prospective feasibility study of peripheral blood for MRD detection in acute myeloid leukemia by flow cytometry.","title02":"Prospective feasibility study of peripheral blood for MRD detection in acute myeloid leukemia by flow cytometry.","journal":"Blood advances","issue":"2026 April 14; 10(7):2470-2478. doi: 10.1182\/bloodadvances.2025018607","author":"Li S, Short NJ, Wang W, Ling J, Qiu L, Xu J, Wang WJ, Jia F, Tang G, Karrar O, Maroun M, Medeiros LJ, Ravandi F, Wang SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41649796"},{"title01":"Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.","title02":"Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.","journal":"Blood advances","issue":"2026 April 14; 10(7):2565-2577. doi: 10.1182\/bloodadvances.2025018345","author":"Batatinha H, Valenzuela AM, Filioglou D, Wilde P, Leite G, Kistner TM, Baker FL, Katsanis E, Simpson RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538301"},{"title01":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","title02":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","journal":"Blood advances","issue":"2026 April 14; 10(7):2506-2520. doi: 10.1182\/bloodadvances.2025018369","author":"Baeten JT, Agashe S, Tabet I, Wooldridge JT, Carter A, Butler JN, Miller CA, Helton N, Quinet A, Johansson KB, Yang Y, Uy GL, Vindigni A, Link DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610325"},{"title01":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","title02":"ASH ISTH 2026 guidelines for Anticoagulant Prophylaxis of Pediatric Patients at Risk of Venous Thromboembolism.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025019415. Online ahead of print","author":"Betensky M, Azzam M, Bercovitz RS, Bhat R, Biss TT, Branchford BR, Brandao LR, Chan AK, Faustino EVS, Hamarsha Q, Jaffray J, Jones SE, Kawtharany H, Kerlin BA, Khawandi J, Krider G, Kucine N, Kumar R, Male C, Monagle P, Pelland-Marcotte MC, Raffini L, Raulji CM, Sartain SE, Takemoto CM, Tarango C, van Ommen CH, Velez MC, Vesely SK, Wiernikowski JT, Williams S, Wilson HP, Woods G, Mustafa RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949461"},{"title01":"No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.","title02":"No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.","journal":"Blood advances","issue":"2026 April 2. doi: 10.1182\/bloodadvances.2025018640. Online ahead of print","author":"Laurenti L, Guglielmi F, Mosca A, Vitale C, Montalbano MC, Favrin G, Ferrarini I, Galitzia A, Pasquale R, Moratti M, Catania G, Murru R, Giannarelli D, Martino EA, Moia R, Zucchetto A, Tissino E, Autore F, Tomasso A, Stirparo L, Quaranta T, Abbate PL, Gattei V, Gaidano G, Gentile M, Krampera M, Farina G, Visentin A, Innao V, Varettoni M, Coscia M, Innocenti I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41925576"},{"title01":"Similar androgen receptor expression in male and female AML.","title02":"Similar androgen receptor expression in male and female AML.","journal":"Blood advances","issue":"2026 April 1. doi: 10.1182\/bloodadvances.2026020008. Online ahead of print","author":"Prabhu KS, Qian F, Sarkar D, Zheng H, Paulson RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41921074"},{"title01":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","title02":"Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.","journal":"Blood advances","issue":"2026 April 8. doi: 10.1182\/bloodadvances.2025017738. Online ahead of print","author":"Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes JE, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949390"},{"title01":"DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia.","title02":"DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia.","journal":"Blood advances","issue":"2026 April 7. doi: 10.1182\/bloodadvances.2025018830. Online ahead of print","author":"Verboon L, Barwe SP, Tavenner M, Faust JR, Issa H, Goncalves-Dias J, Schuschel K, Bhayadia R, van Berkel PH, Sebastian A, Ries RE, Paczesny S, Meshinchi S, Hitzler JK, Pikman Y, Kolb EA, Heckl D, Klusmann JH, Gopalakrishnapillai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41945753"},{"title01":"Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.","title02":"Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025030772. Online ahead of print","author":"Drucker M, Lee D, Bowman MS, Zhang X, Kain BN, Nicolet D, Bandopadhyay R, Singh V, Wang Z, Stone RM, Saygin C, Mrozek K, Carroll AJ, Starczynowski DT, Levine RL, Byrd JC, Salomonis N, Skuli SJ, Grimes HL, Eisfeld AK, Bowman RL, Miles LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41950000"},{"title01":"A tumor suppressor role of the miR-15b\/16-2 cluster in T-cell acute lymphoblastic leukemia.","title02":"A tumor suppressor role of the miR-15b\/16-2 cluster in T-cell acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025030670. Online ahead of print","author":"Toribio ML, Garcia-Leon MJ, Garcia-Peydro M, Fuentes P, Alcain J, Martin-Gayo E, Croce CM, Garzon R, Gonzalez-Garcia S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949997"},{"title01":"Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.","title02":"Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.","journal":"Blood","issue":"2026 April 8. doi: 10.1182\/blood.2025032083. Online ahead of print","author":"Suzuki Y, Nakajima-Takagi Y, Oshima M, Ochi Y, Tsuchiya A, Koide S, Yokomizo-Nakano T, Kurosawa S, Rizq O, Kon A, Miyano S, Rahmutulla B, Kaneda A, Nakayama M, Koseki H, Yu E, Toki T, Ito E, Ogawa S, Iwama A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41949996"},{"title01":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","title02":"Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.","journal":"Blood","issue":"2026 April 2; 147(14):1562-1573. doi: 10.1182\/blood.2025032277","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.","title02":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.","journal":"Blood","issue":"2026 April 2; 147(14):1532-1561. doi: 10.1182\/blood.2024027904","author":"Zwaan CM, Tasian SK, Aplenc R, Brodersen LE, Buldini B, De Moerloose B, Dworzak MN, Fogelstrand L, Gibson BES, Goemans BF, Hasle H, Hirsch BA, Kaspers GJL, Klusmann JH, Kutny MA, Lehrnbecher T, Locatelli F, Meshinchi S, Petit A, Pigazzi M, Tierens A, Kolb EA, Reinhardt D, Tomizawa D, Cooper TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105890"},{"title01":"A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.","title02":"A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.","journal":"Blood","issue":"2026 April 9; 147(15):1702-1712. doi: 10.1182\/blood.2025029971","author":"Itsara A, Rogness VM, Samples L, Yuan CM, Wang HW, Ahn IE, Farooqui MZH, Tian X, Sun C, Tomasulo E, Soto S, Superata J, Bezkorovaynaya L, Hughes TE, Nierman P, Wiestner A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405491"},{"title01":"Das not enough in CBF AML.","title02":"Das not enough in CBF AML.","journal":"Blood","issue":"2026 April 9; 147(15):1658-1659. doi: 10.1182\/blood.2025032734","author":"Stone RM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954958"},{"title01":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","title02":"Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032757. Online ahead of print","author":"Zent CS, Tiacci E, Kreitman RJ, Tadmor T, Tallman MS, Wormann BJ, Andritsos LA, Arons E, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call TG, Dearden C, Demeter J, Dietrich S, El-Sharkawi D, Fagarasanu A, Falini B, Forconi F, Gerrie AS, Gladstone DE, Gozzetti A, Hampel PJ, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kipps TJ, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Rai KR, Ravandi F, Robak T Prof, Rogers KA, Saven A, Seymour JF, Tam CS, Troussard X, Zenz T, Zinzani PL, Grever MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980020"},{"title01":"Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.","title02":"Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025032033. Online ahead of print","author":"Ceran E, Jaramillo S, Merbach AK, Rohde C, Wass M, Schaffrath J, Durruthy-Durruthy R, Arribas-Layton M, Sciambi A, Rieger K, Nogai A, Hanel M, Herbst RT, Stolzel F, Rollig C, Jost E, Schlenk R, Lotze M, Noppeney R, Brandts CH, Krug U, Gotze KS, Buske S, Florschutz A, Schubert JEA, Opitz B, Esseling E, von Witzendorff S, Subklewe M, Kaufmann M, Frickhofen N, Scholz CW, Schafer-Eckart K, Kunzmann V, Schmidt-Hieber M, Sayer HG, Rank A, Hemmati PG, Schuler F, Scheller M, Kowoll S, Steighardt J, Edemir B, Ludwig-Kraus B, Mueller LP, Edemir S, Vainstein-Haras A, Sorani E, Gliko-Kabir I Mrs, Kadosh S, Tavor S, Gromann C, Wienke A, Bauer M, Wickenhauser C, Baldus CD, Platzbecker U, Cerwenka A, Serve H, Bornhauser M, Junghanss C, Muller-Tidow C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980027"},{"title01":"T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.","title02":"T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.","journal":"Blood","issue":"2026 April 14. doi: 10.1182\/blood.2025030579. Online ahead of print","author":"Marzuttini F, Potenza A, Celli L, Simioni A, Conte L, Camisa B, Magnani ZI, Sergi Sergi L, Mohammadi N, Scaramuzza S, El Khoury R, Improta CM, Ugolini A, Spiga M, Remiddi E, Grometto A, Carnevale E, Cavallaro V, Veronese S, Scola A, Toffalori C, Abbati D, Sanvito F, Ponzoni M, Lupo Stanghellini MT, Themeli M, Casucci M, Degano M, Vago L, Merelli I, Ciceri F, Bonini C, Ruggiero E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41980033"},{"title01":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease.","title02":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease.","journal":"Blood","issue":"2026 April 9; 147(15):1663-1679. doi: 10.1182\/blood.2025030230","author":"Schimmer RR, Klemm N, Fullin J, Topcu E, Treacy M, Zielinska KA, Doerdelmann C, Devesa-Serrano D, Lock M, Caiado F, Koch C, Dietliker N, Schwotzer R, Buhler M, Myllymaki M, Kurppa KJ, Manz MG, Lopes M, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490322"},{"title01":"A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","title02":"A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","journal":"Blood","issue":"2026 April 9; 147(15):1735-1748. doi: 10.1182\/blood.2025030722","author":"Dohner H, Spath D, Saadati M, Fiedler W, Gotze K, Koller E, Westermann J, Vogel W, Heuser M, Lubbert M, Tischler HJ, Germing U, Teichmann LL, Fransecky L, Wolfler A, Nachbaur D, Hertenstein B, Schroers R, Martens U, von Harsdorf S, Radsak M, Aschauer G, Weisshaar S, Corbacioglu A, Schrade A, Gaidzik VI, Thol F, Paschka P, Bullinger L, Benner A, Dohner K, Ganser A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490515"},{"title01":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","title02":"The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.","journal":"Blood","issue":"2026 April 6. doi: 10.1182\/blood.2025032031. Online ahead of print","author":"Lu C, Matt GY, Paul R, Wang J, Sioson E, Gangwani K, Acic A, Willems A, Zaldivar Peraza A, Reilly C, Polonen P, Gao Q, Li Q, Pounds SB, Zeng AGX, Li S, Nadarajah N, Brady SW, Iacobucci I, Haferlach T, Rose MC, Mullighan CG, Zhou X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41940951"},{"title01":"Breast hairy cell leukemia mimicking lobular breast carcinoma.","title02":"Breast hairy cell leukemia mimicking lobular breast carcinoma.","journal":"Blood","issue":"2026 April 2; 147(14):1648. doi: 10.1182\/blood.2025032411","author":"Tsvetnov IV, Lyapichev KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41926137"},{"title01":"CML mimicker: a myeloid neoplasm with BCR::FGFR1 fusion without peripheral blood eosinophilia or basophilia.","title02":"CML mimicker: a myeloid neoplasm with BCR::FGFR1 fusion without peripheral blood eosinophilia or basophilia.","journal":"Blood","issue":"2026 April 9; 147(15):1780. doi: 10.1182\/blood.2025032576","author":"Wang HY, Mangan JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41954956"},{"title01":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","title02":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1171-1172. doi: 10.3324\/haematol.2025.289153","author":"Ringelstein-Harlev S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230691"},{"title01":"Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed\/refractory large B-cell lymphoma.","title02":"Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed\/refractory large B-cell lymphoma.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300063. Online ahead of print","author":"Shumilov E, Wurm-Kuczera R, Kauer J, Wang M, Mazzeo P, Boyadzhiev H, Gebauer N, Holtick U, Holscher A, Teichert M, Nierychlewska PM, Kimmich C, Berning P, Melchardt T, Zeremski V, Wirths C, Nakov P, Schultze-Florey C, Velazquez GF, Lesan V, Kramer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Godel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hanel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow BV, Pabst T, Muller F, Lenz G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924925"},{"title01":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","title02":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300154. Online ahead of print","author":"Ilan U, Boer JM, Luesink M, Bautista F, Hofmans M, Vedi A, Egyed B, Geoerger B, Tuckuviene R, Als-Nielsen B, Velasco P, Fuster JL, Rubio A, Tasian SK, Delft FV, Irving JAE, Erdely DJ, Schmiegelow K, De Moerloose B, Baruchel A, Den Boer ML, Zwaan MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924922"},{"title01":"Azacitidine-induced remission enables allogeneic transplantation in TET2\/BCOR-mutant relapsed extranodal natural killer\/T-cell lymphoma: a case report.","title02":"Azacitidine-induced remission enables allogeneic transplantation in TET2\/BCOR-mutant relapsed extranodal natural killer\/T-cell lymphoma: a case report.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300314. Online ahead of print","author":"Ortiz CR, Abouzeid H, De Bernardi C, Durham A, Mathoux G, Masouridi S, Mckee TA, Sibon D, Hermine O, Weinstock DM, Egervari K, Tamburini J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924921"},{"title01":"CAR-T therapy for relapsed\/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.","title02":"CAR-T therapy for relapsed\/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300151. Online ahead of print","author":"Hwang A, Kirkwood AA, Hardefeldt P, Amrith M, O'Reilly M, Kuhnl A, Northend M, Maciocia P, Chaganti S, Cwynarski K, Sanderson R, Roddie C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924913"},{"title01":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","title02":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","journal":"Haematologica","issue":"2026 April 1; 111(4):1389-1395. doi: 10.3324\/haematol.2025.288232","author":"Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163564"},{"title01":"CNS infiltration by zamtocabtagene autoleucel tandem CD20\/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.","title02":"CNS infiltration by zamtocabtagene autoleucel tandem CD20\/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.","journal":"Haematologica","issue":"2026 April 1; 111(4):1494-1499. doi: 10.3324\/haematol.2025.288856","author":"Hardy NM, Yared JA, Luetkens T, Ahmad H, Mulatu R, Yamoah D, Fan X, Weeks S, Bredar SA, Gelin A, Baker JM, Dietze KA, Matsangos A, Fromowitz A, Theruvath J, Wirthlin L, Kaleta R, Wijatyk A, Koka R, Kallen ME, Hankey KG, Rapoport AP, Atanackovic D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098100"},{"title01":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","title02":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","journal":"Br J Haematol","issue":"2026 April; 208(4):1223-1231. doi: 10.1111\/bjh.70363","author":"Wei C, Zhang Y, Zhao D, Zhang W, Zhou D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41668589"},{"title01":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","title02":"UV-induced mutations accumulate during early clonal expansion in aneuploid subtypes of pediatric B-cell precursor acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300118. Online ahead of print","author":"Suurenbroek LC, Van der Ham CG, Boer JM, Derks LLM, Hagelaar R, Van Roosmalen MJ, Klamer P, Sonneveld E, Den Boer ML, Van Boxtel R, Van Leeuwen FN, Loeffen JLC, Kuiper RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952634"},{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300202. Online ahead of print","author":"Berton G, Bewersdorf JP, Gilhodes J, Iat A, Soua A, DeAngelo DJ, Boussi L, Shallis RM, Zucenka A, Bystrom RP, Ling K, Aguirre LE, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Mendez L, Podoltsev N, Tauveron-Jalenques U, Lanino L, Stein E, Zeidan AM, Forcade E, Cluzeau T, Dumas PY, Heiblig M, Devillier R, Shimony S, Goldberg AD, Stahl M, Garciaz S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924924"},{"title01":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia.","title02":"SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1220-1234. doi: 10.3324\/haematol.2024.287269","author":"Chen M, Li W, Tao Y, Hu C, Ge R, Kang S, Yue P, Man CH, Wang L, Yan X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905075"},{"title01":"Clinical and germline risk factors for multiple treatmentrelated toxicities in pediatric acute lymphoblastic leukemia.","title02":"Clinical and germline risk factors for multiple treatmentrelated toxicities in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1478-1483. doi: 10.3324\/haematol.2025.288939","author":"Mateos MK, Mayoh C, Sullivan P, Barbaro PM, Quinn MCJ, George C, Sutton R, Revesz T, Giles JE, Barbaric D, Alvaro F, Conyers R, Catchpoole D, MacGregor S, Kotecha RS, Dalla-Pozza L, Trahair TN, Marshall GM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163570"},{"title01":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","title02":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1500-1504. doi: 10.3324\/haematol.2025.289085","author":"Cheng F, Li W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376545"},{"title01":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","title02":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1427-1431. doi: 10.3324\/haematol.2025.288255","author":"Shah B, Francis R, Pei J, Neumann-Domer R, Mackrides N, Testa JR, Nejati R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262051"},{"title01":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusiondriven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2026 April 1; 111(4):1254-1264. doi: 10.3324\/haematol.2025.288721","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","title02":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1162-1164. doi: 10.3324\/haematol.2025.289066","author":"Boussi L, Goldberg AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230690"},{"title01":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO.","title02":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO.","journal":"Haematologica","issue":"2026 April 1; 111(4):1149-1152. doi: 10.3324\/haematol.2025.288785","author":"Kayser S, Schlenk RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537334"},{"title01":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the CON.","title02":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the CON.","journal":"Haematologica","issue":"2026 April 1; 111(4):1153-1158. doi: 10.3324\/haematol.2025.288786","author":"Russell NH, Lewis KD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537333"},{"title01":"Patient-centered care strategies for Jehovah’s Witnesses with acute leukemia and high-grade myeloid neoplasms.","title02":"Patient-centered care strategies for Jehovah’s Witnesses with acute leukemia and high-grade myeloid neoplasms.","journal":"Haematologica","issue":"2026 April 1; 111(4):1469-1473. doi: 10.3324\/haematol.2025.288622","author":"Zarka J, Al-Kali A, Alkhateeb HB, Matin A, Gangat N, Hogan WJ, Foran J, Murthy H, Yi CA, Prasad DK, Mina S, Litzow MR, Begna KH, Saliba AN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41163567"},{"title01":"Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.","title02":"Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML.","journal":"Haematologica","issue":"2026 April 1; 111(4):1280-1288. doi: 10.3324\/haematol.2025.288283","author":"Millot F, De Keizer J, Metzler M, Kalwak K, Gunes AM, De Moerloose B, Luesink M, Honrubia AM, Sedlacek P, Yajima J, Ampatzidou M, Dworzak M, Lausen B, Borisevich M, Li CK, Kolenova A, Jakovljevic G, Farah R, Durocher L, Baruchel A, Suttorp M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126742"},{"title01":"Age-specific mutation profiles and their prognostic implications in pediatric KMT2A-rearranged acute myeloid leukemia.","title02":"Age-specific mutation profiles and their prognostic implications in pediatric KMT2A-rearranged acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1235-1245. doi: 10.3324\/haematol.2025.288481","author":"Shoji K, Yoshida K, Iyoda S, Ishikawa M, Tanaka M, Nobe M, Saito N, Shino Y, Nannya Y, Yamato G, Tsujimoto S, Shiba N, Hayashi Y, Shiozawa Y, Shiraishi Y, Chiba K, Okada A, Tanaka H, Miyano S, Koga Y, Goto H, Terui K, Ito E, Kiyokawa N, Tomizawa D, Taga T, Moritake H, Tawa A, Takita J, Nishikori M, Adachi S, Ogawa S, Matsuo H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41126738"},{"title01":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","title02":"Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.","journal":"Haematologica","issue":"2026 April 1; 111(4):1246-1253. doi: 10.3324\/haematol.2025.288553","author":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035402"},{"title01":"Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations.","title02":"Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutations.","journal":"Br J Haematol","issue":"2026 April 14. doi: 10.1111\/bjh.70484. Online ahead of print","author":"Huber S, Kornauth C, Hutter S, Meggendorfer M, Summerer I, Kern W, Haferlach T, Pohlkamp C, Hoermann G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979368"},{"title01":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","title02":"Distribution of adult T-cell leukaemia\/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.","journal":"Br J Haematol","issue":"2026 April 15. doi: 10.1111\/bjh.70494. Online ahead of print","author":"Valcarcel B, Utsunomiya A, Otsuka M, Miyahara M, Ishitsuka K, Takamatsu Y, Suzumiya J, Tamura K, Vasquez JF, Enriquez-Vera D, Beltran BE, Castro D, Runciman T, Idrobo H, Arrieta E, Arias O, Gotuzzo E, Garrido-Pinzas G, Rivera V, Rosa D, Pena C, Fiad L, Ramos JC, Sandoval-Sus J, Sica A, Bell BN, Cook LB, Leataud V, Miranda ECM, Chiattone C, Katsuya H, Malpica L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986288"},{"title01":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","title02":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","journal":"Br J Haematol","issue":"2026 April; 208(4):1339-1346. doi: 10.1111\/bjh.70393","author":"Eriksen JVN, de Pietri S, Rathe M, Hasle H, Enevold C, Nielsen CH, Schmigelow K, Moser C, Muller K, Weischendorff S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733102"},{"title01":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","title02":"Trends in survival outcomes after allogeneic transplantation for MDS and MDS\/MPN in a real-world experience: A 25-year nationwide study.","journal":"Br J Haematol","issue":"2026 April 5. doi: 10.1111\/bjh.70463. Online ahead of print","author":"Itonaga H, Miyazaki Y, Tachi N, Kurosawa S, Marumo A, Konuma T, Ebina T, Doki N, Uchida N, Fukuda T, Nishida T, Katayama Y, Asada N, Sakurai M, Maeda T, Eto T, Tanaka M, Nakamae H, Onizuka M, Kawamura K, Kanda Y, Atsuta Y, Tachibana T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41937388"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive ‘real-world routine’.","journal":"Br J Haematol","issue":"2026 April; 208(4):1472-1476. doi: 10.1111\/bjh.70324","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.","title02":"BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.","journal":"Br J Haematol","issue":"2026 April 9. doi: 10.1111\/bjh.70476. Online ahead of print","author":"Tauveron-Jalenques U, Inchiappa L, Paillassa J, Maitre E, Willems L, Stocker N, Merabet F, Lok A, Lara D, Bijou F, Herbaux C, Ramos I, Guieze R, Tomowiak C, Troussard X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41958072"},{"title01":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","title02":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","journal":"Br J Haematol","issue":"2026 April; 208(4):1501-1502. doi: 10.1111\/bjh.70420","author":"Poirot M, de Medina P, Silvente-Poirot S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41804099"},{"title01":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children’s Cancer Group trial (JCCG AML-12).","title02":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children’s Cancer Group trial (JCCG AML-12).","journal":"Br J Haematol","issue":"2026 April; 208(4):1252-1262. doi: 10.1111\/bjh.70355","author":"Komori T, Kawai T, Okuno Y, Tsujimoto S, Kato S, Kamitori T, Saida S, Ikeda J, Ohki K, Kato M, Tomizawa D, Taga T, Takita J, Horibe K, Adachi S, Hayashi Y, Ito S, Shiba N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41631723"},{"title01":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","title02":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","journal":"Br J Haematol","issue":"2026 April; 208(4):1263-1277. doi: 10.1111\/bjh.70346","author":"Dai X, Wu Z, Zhang W, Chen S, Zhao X, Lu Y, Ma Y, Zheng W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608869"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1467-1471. doi: 10.1111\/bjh.70347","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 April; 208(4):1359-1368. doi: 10.1111\/bjh.70380","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 April; 208(4):1462-1466. doi: 10.1111\/bjh.70350","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","title02":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","journal":"Br J Haematol","issue":"2026 April; 208(4):1278-1286. doi: 10.1111\/bjh.70353","author":"Lee YW, Chiang CJ, Lin YC, Tzeng HE, Chuang YT, Yang YW, Lee WC, Wu SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608915"},{"title01":"PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating Cells.","title02":"PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating Cells.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2025018908. Online ahead of print","author":"Xiao S, Kopbayashi M, Bai Y, Cai W, Barajas S, Amin MA, Vemula S, Yao C, Yang Y, Borchers C, Mays TM, Sotelo M, Pan H, Jia Y, Shen J, Hu SKK, Ali M, Veranga S, Ogino J, Eggleston SG, Liu H, Perlman H, Li L, Altman JK, Abaza Y, Eklund EA, Ji P, Zhang CR, Khan I, Mayo LD, Mulloy JC, Sukhanova M, Dou Y, Platanias LC, Zhang ZY, Chen H, Liu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985006"},{"title01":"Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic Leukemia.","title02":"Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic Leukemia.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019599. Online ahead of print","author":"Wang'ondu RW, Kairalla JA, Shago M, Angiolillo A, Breidenbach HM, Burke MJ, Carroll AJ, Rabin KR, Salzer W, Schore RJ, Wang C, Hunger SP, Teachey DT, Raetz EA, Loh ML, Davis KL, Rau RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41985005"},{"title01":"Adding Induction Intrathecal Cytarabine in Newly Diagnosed CNS2 B-Acute Lymphoblastic Leukemia Does Not Improve Outcomes.","title02":"Adding Induction Intrathecal Cytarabine in Newly Diagnosed CNS2 B-Acute Lymphoblastic Leukemia Does Not Improve Outcomes.","journal":"Blood advances","issue":"2026 April 15. doi: 10.1182\/bloodadvances.2026019660. Online ahead of print","author":"Lee-Miller CA, Kairalla JA, Hibbitts E, Winick NJ, Rabin KR, Angiolillo A, Schore RJ, Salzer W, Burke MJ, Loh ML, Raetz EA, Hunger SP, Devidas M, Teachey DT, Gupta S, McNeer J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41984995"},{"title01":"Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.","title02":"Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.","journal":"Blood advances","issue":"2026 April 14; 10(7):2153-2167. doi: 10.1182\/bloodadvances.2025018002","author":"Da Ros A, Peloso A, Longo G, Benetton M, Indio V, Cairo S, Sandri M, Buldini B, Bresolin S, Rosato A, Pession A, Tregnago C, Locatelli F, Pigazzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576348"},{"title01":"Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.","title02":"Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.","journal":"Blood advances","issue":"2026 April 14; 10(7):2328-2332. doi: 10.1182\/bloodadvances.2025019153","author":"Zeidner JF, Jain J, Welkie RL, Huang Y, Swords RT, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Handa S, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632633"},{"title01":"Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis.","title02":"Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis.","journal":"Blood advances","issue":"2026 April 14. doi: 10.1182\/bloodadvances.2025019565. Online ahead of print","author":"Tian L, Gottschalk S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41979357"},{"title01":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","title02":"Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02903-8. Online ahead of print","author":"Mehta RS, Kanakry CG, Nawas M, Lazaryan A, Kanakry JA, Holtan S, Al-Juhaishi T, Rimando JC, Singh A, Saultz J, Mccurdy SR, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986623"},{"title01":"Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.","title02":"Error-corrected next-generation sequencing for profiling the subclonal genetic architecture of juvenile myelomonocytic leukemia.","journal":"Leukemia","issue":"2026 April 7. doi: 10.1038\/s41375-026-02922-5. Online ahead of print","author":"Sajiki D, Muramatsu H, Wakamatsu M, Tsumura Y, Yamashita D, Yamamori A, Narita K, Kataoka S, Takahashi Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41942652"},{"title01":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","title02":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):854. doi: 10.1038\/s41375-026-02897-3","author":"Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41741799"},{"title01":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2026 April; 40(4):855. doi: 10.1038\/s41375-026-02909-2","author":"Setiawan T, Muhammad JA, Julianto NM, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787068"},{"title01":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","title02":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):794-805. doi: 10.1038\/s41375-026-02898-2","author":"Zhang L, Han Q, Xiang H, Lapalombella R, Eisfeld AK, Hanel WG, Brammer JE, Mims AS, Woyach JA, Song C, Ge Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792440"},{"title01":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","title02":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","journal":"Leukemia","issue":"2026 April; 40(4):806-815. doi: 10.1038\/s41375-026-02901-w","author":"Selimoglu-Buet D, Chevret S, Santini V, Thepot S, Morabito M, Ades L, Laplane L, Giagounidis A, Droin N, Lubbert M, Sapena R, Nimubona S, Torregrosa-Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Paul F, Patriarca A, Stamatoullas A, Gotze K, Chermat F, Platzbecker U, Fenaux P, Solary E, Itzykson R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803403"},{"title01":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","title02":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","journal":"Leukemia","issue":"2026 April; 40(4):816-826. doi: 10.1038\/s41375-026-02906-5","author":"Parker H, Carr L, Norris K, Nilsson-Takeuchi A, Stevens B, Amarasinghe H, Kadalayil L, Else M, Clifford R, Pettitt A, Munir T, Schuh A, Walewska R, Baird DM, Oscier DG, Pepper C, Bryant D, Gibson J, Strefford JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814015"},{"title01":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2026 April; 40(4):856. doi: 10.1038\/s41375-026-02911-8","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814016"},{"title01":"Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?","title02":"Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?","journal":"Leukemia","issue":"2026 April; 40(4):713-716. doi: 10.1038\/s41375-026-02910-9","author":"Turcsanyi L, Zhang XS, Kudelka M, Kubikova K, Radvansky M, Yang S, Kriegova E, Juranova J, Mayer J, Klamova H, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Othus M, Gale RP, Jiang Q, Faber E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41840226"},{"title01":"Testicular organoids formation from leukaemia-infiltrated prepubertal testicular tissue: implications for fertility preservation.","title02":"Testicular organoids formation from leukaemia-infiltrated prepubertal testicular tissue: implications for fertility preservation.","journal":"Leukemia","issue":"2026 April 1. doi: 10.1038\/s41375-026-02938-x. Online ahead of print","author":"Cui Y, Lohi J, Lindskog C, Jahnukainen K, Stukenborg JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41922798"},{"title01":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","title02":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","journal":"Leukemia","issue":"2026 April; 40(4):751-758. doi: 10.1038\/s41375-026-02875-9","author":"Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, Fabisch C, Nicolini FE, Olsson-Stromberg U, Zackova D, Lewandowski K, Ernst P, Castagnetti F, Hirschbuhl K, Zupan I, Voskanyan A, Golos A, Frietsch JJ, Gil J, Faber E, Krause SW, Parry A, Saussele S, Heibl S, Franke GN, Casado LF, Paczkowska E, Hebart H, Eder M, Anhut P, Trautmann-Grill K, Szczepanek E, Sudhoff T, Patkowska E, Kiani A, Ernst T, Apperley J, Mayer J, Hochhaus A, Pfirrmann M, Brioli A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714405"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April; 40(4):717-729. doi: 10.1038\/s41375-026-02883-9","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","title02":"Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.","journal":"Leukemia","issue":"2026 April 15. doi: 10.1038\/s41375-026-02957-8. Online ahead of print","author":"Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41986621"},{"title01":"Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.","title02":"Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.","journal":"Leukemia","issue":"2026 April 13. doi: 10.1038\/s41375-026-02954-x. Online ahead of print","author":"Neelamraju Y, Rapaport F, Gandara JA, Paudel BB, DeWolf S, Dunham N, Fan H, Lee T, Mayo MW, Othman J, Sheridan C, Sol-Church K, Solga MD, Wang L, Cripe LD, Dillon R, Kleppe M, Carroll M, Mason CE, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Paietta E, Levine R, Melnick AM, Bekiranov S, Garrett-Bakelman FE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41975002"},{"title01":"Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children’s Oncology Group randomized trial ACCL1033.","title02":"Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children’s Oncology Group randomized trial ACCL1033.","journal":"Leukemia","issue":"2026 April 13. doi: 10.1038\/s41375-026-02951-0. Online ahead of print","author":"Bhatia S, Hageman L, Chen Y, Wadhwa A, Wong FL, McQuaid EL, Freyer DR, Mba N, Aristizabal P, Raetz E, Landier W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41975001"},{"title01":"mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.","title02":"mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.","journal":"Leukemia","issue":"2026 April 10. doi: 10.1038\/s41375-026-02940-3. Online ahead of print","author":"Zhou C, Bian S, Pang J, Bian H, Cheng T, Koyama H, Liu B, Li B, Tse W, Liu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41963593"},{"title01":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.","title02":"Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 April 10. doi: 10.1038\/s41375-026-02959-6. Online ahead of print","author":"Chin KK, Abdul-Hay M, Shukla M, Geyer MB, Tamari R, Ko KH, Xiao W, Stein EM, Cai SF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41963592"},{"title01":"Concomitant or sequential lower intensity triplet therapy in AML.","title02":"Concomitant or sequential lower intensity triplet therapy in AML.","journal":"Lancet Haematol","issue":"2026 April; 13(4):e197-e198. doi: 10.1016\/S2352-3026(26)00031-1","author":"Senapati J, Daver NG, Jain J, Mims AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41934991"},{"title01":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.","title02":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.","journal":"Lancet","issue":"2026 April 10. doi: 10.1016\/S0140-6736(26)00602-1. Online ahead of print","author":"Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41974150"},{"title01":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","title02":"First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.","journal":"J Clin Oncol","issue":"2026 April 6; JCO2501966. doi: 10.1200\/JCO-25-01966. Online ahead of print","author":"Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Gungor T, Klusmann JH, Klingebiel T, Bader P, Bonig H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41941697"},{"title01":"Conditioning for acute myeloid leukemia: looking beyond intensity.","title02":"Conditioning for acute myeloid leukemia: looking beyond intensity.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300787. Online ahead of print","author":"Gilbert JS, Milano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952631"},{"title01":"Gatekeepers of mitochondrial metabolism: the emerging role of the SLC25 family in leukemia.","title02":"Gatekeepers of mitochondrial metabolism: the emerging role of the SLC25 family in leukemia.","journal":"Haematologica","issue":"2026 April 1; 111(4):1159-1161. doi: 10.3324\/haematol.2025.288787","author":"Haran A, Nachmias B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994341"},{"title01":"Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia.","title02":"Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300631. Online ahead of print","author":"Dong K, An Z, Dong C, Jin Z, Wang X, Qiao B, Ning Y, Sun Z, Qianni J, Ren F, Zhang Y, Chang J, Guo L, Zhou X, Liu H, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952642"},{"title01":"Azacitidine for MDS and CMML.","title02":"Azacitidine for MDS and CMML.","journal":"Haematologica","issue":"2026 April 1; 111(4):1147-1148. doi: 10.3324\/haematol.2026.289398","author":"Martin ES, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41919559"},{"title01":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","title02":"Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.287767. Online ahead of print","author":"Krishnan V, Shyamsunder P, Ong TS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952641"},{"title01":"Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.","title02":"Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2026.300540. Online ahead of print","author":"Angotzi F, Borlenghi E, Sartor C, Giannini MB, Marconi G, Tamellini E, Turrini M, Loscocco F, Audisio E, Federico V, Vetro C, Grimaldi F, Visentin A, Ferrara F, Trentin L, Gurrieri C, Lessi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952620"},{"title01":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","title02":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2026.300534. Online ahead of print","author":"Goldfinger M, Mantzaris I, Shastri A, Rockwell B, Saunthararajah Y, Yin S, Levitz D, Gritsman K, Sica AR, Kornblum N, Shapiro LC, Gupta R, Peeke S, Shah N, Pradhan K, Munoz A, Dhawan A, Verceles JA, Fehn K, Comas M, Shah L, Shi Y, Jonas BA, Cooper DL, Konopleva M, Feldman EJ, Verma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924907"},{"title01":"Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.","title02":"Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.289041. Online ahead of print","author":"Golla U, Bhalodia R, Annageldiyev C, Patel S, Bollu VS, Tan SF, Cabot MC, Feith DJ, Loughran TP Jr, Levine RL, Mineishi S, Zheng H, Minagawa K, Hengst J, Sholler GLS, Desai D, Dovat S, Fisher-Wellman KH, Claxton DF, Sharma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924919"},{"title01":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","title02":"First-year results of the International Leukemia\/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.","journal":"Haematologica","issue":"2026 April 2. doi: 10.3324\/haematol.2025.300154. Online ahead of print","author":"Ilan U, Boer JM, Luesink M, Bautista F, Hofmans M, Vedi A, Egyed B, Geoerger B, Tuckuviene R, Als-Nielsen B, Velasco P, Fuster JL, Rubio A, Tasian SK, Delft FV, Irving JAE, Erdely DJ, Schmiegelow K, De Moerloose B, Baruchel A, Den Boer ML, Zwaan MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41924922"},{"title01":"Bipartite NUP98::RARA-E412* fusion with a cis-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia.","title02":"Bipartite NUP98::RARA-E412* fusion with a cis-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 April 9. doi: 10.3324\/haematol.2025.300368. Online ahead of print","author":"Liu Q, Chen J, Zhou X, Teng Q, Chen X, Cao P, Fang J, Wang X, Zhang C, Ma X, Wang Z, Wang F, Zhang Y, Xin L, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41952639"},{"title01":"Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.","title02":"Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.","journal":"Br J Haematol","issue":"2026 April 7. doi: 10.1111\/bjh.70475. Online ahead of print","author":"Yamashita N, Kawakami T, Matsuzawa S, Miyairi S, Maruyama M, Kawakami F, Kojima S, Yanagisawa R, Higuchi Y, Makishima H, Nakazawa H, Ishida F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41943918"},{"title01":"Do myelodysplasia-related gene mutations alter transplant decisions in NPM1-mutated acute myeloid leukemia? Comment on: “Prognostic implications of myelodysplasiarelated gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","title02":"Do myelodysplasia-related gene mutations alter transplant decisions in NPM1-mutated acute myeloid leukemia? Comment on: “Prognostic implications of myelodysplasiarelated gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2026.300857. Online ahead of print","author":"Desai N, Mattsson J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885021"},{"title01":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","title02":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","journal":"Blood advances","issue":"2026 March 24; 10(6):1979-1991. doi: 10.1182\/bloodadvances.2025016780","author":"Fan C, Hayase T, Chang CC, Glover IK, Flores II, McDaniel LK, Ortega MR, Sanchez CA, El-Himri RK, Brown AN, Karmouch JL, Jamal MA, Ahmed SS, Halsey TM, Jin Y, Tsai WB, Prasad R, Enkhbayar A, Mohammed A, Schmiester M, Damania A, Ajami NJ, Wargo JA, Peterson CB, Rondon G, Al-Juhaishi T, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Martens E, Arias CA, Jenq RR, Hayase E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558030"},{"title01":"A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.","title02":"A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.","journal":"Br J Haematol","issue":"2026 March 17. doi: 10.1111\/bjh.70434. Online ahead of print","author":"Ruiz Lopez JN, Shao L, Jiang D, Bailey LS, Bikkani T, Boothby A, Moore DC, Murakhovskaya I, Piatek CI, Pineda-Roman M, Jin P, Poston JN, Stolla M, Stroncek DF, Hudson KE, Bussel JB, Panch SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41846299"},{"title01":"In-depth analysis of osmotic gradient ektacytometry parameters across different genotypes in hereditary spherocytosis.","title02":"In-depth analysis of osmotic gradient ektacytometry parameters across different genotypes in hereditary spherocytosis.","journal":"Br J Haematol","issue":"2026 March 31. doi: 10.1111\/bjh.70457. Online ahead of print","author":"de Wilde JRA, Kuppens GZL, Boesveld ME, van Vuren AJ, van Solinge WW, Waanders E, van Beers EJ, Rab MAE, Bartels M, van Wijk R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41914049"},{"title01":"Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.","title02":"Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.","journal":"Blood advances","issue":"2026 March 24; 10(6):1967-1976. doi: 10.1182\/bloodadvances.2025016338","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz LG, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing JJ, Loughran TP Jr, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 March 24; 10(6):1992-2005. doi: 10.1182\/bloodadvances.2025018285","author":"Andresen F, Yoshimi A, Bader P, Bierings M, Bod'ova I, Bordon V, Buechner J, Burkhardt B, Dworzak M, Erlacher M, Kallay K, Labarque V, Locatelli F, Malone A, Masmas T, Muller I, Nollke P, Schmugge M, Pawelec K, Sedlacek P, Sevilla J, Smith O, Stary J, Niemeyer C, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Clinical Spectrum of Hereditary Hemorrhagic Telangiectasia: Data from the Comprehensive HHT Outcomes Registry of the US (CHORUS).","title02":"Clinical Spectrum of Hereditary Hemorrhagic Telangiectasia: Data from the Comprehensive HHT Outcomes Registry of the US (CHORUS).","journal":"Blood","issue":"2026 March 17. doi: 10.1182\/blood.2026033112. Online ahead of print","author":"Al-Samkari H, Friday C, Kasthuri RS, Gossage J Jr, Murphy CG, Hountras P, Smith KL, Kirkland KJ, Iyer V, Prasad V, Ahluwalia V, Rodriguez-Lopez J, Witkin AS, Conrad M, Hetts S, Ohliger M, Chakinala M, Sisk BA, Beasley MA, Kirkpatrick P, Lindquist J, Battaile JT, Lu A, Parambil J, McCrae KR, Sheynzon V, Whitehead K, Sion C, McWilliams JP, Cusumano LR, Trerotola S, Drivas TG, Chesnutt M, Kaufman C, Dickey MA, Boyce D, Krock N, Cottrill C, Competiello T, Levy H, Clancy MS, Henderson K, Pollak J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843464"},{"title01":"Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia.","title02":"Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia.","journal":"Blood","issue":"2026 March 18. doi: 10.1182\/blood.2025031806. Online ahead of print","author":"Wagner SA, Panzer M, Pertler E, Redl S, Saretto M, Schaefer B, Pammer LM, Obholzer L, Troppmair MR, Hess MW, Salvenmoser W, Degenhart G, Grossgut M, Talasz H, Faserl K, Sarg B, Haubner R, Hartmann MA, Blouin S, Petzer V, Gronich-Wondrak P, Kronbichler A, Manzl C, Glodny B, Tilg H, Franke A, Wolf M, Hadjihannas MV, Zoller H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849242"},{"title01":"Sutimlimab vs B-Cell-Targeted Therapy in Cold Agglutinin Disease: Which Is the Optimal Approach?","title02":"Sutimlimab vs B-Cell-Targeted Therapy in Cold Agglutinin Disease: Which Is the Optimal Approach?","journal":"Blood","issue":"2026 March 30. doi: 10.1182\/blood.2026033150. Online ahead of print","author":"Fattizzo B, Miyakawa Y, Broome C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41911068"},{"title01":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.","title02":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.","journal":"Blood","issue":"2026 March 19; 147(12):1351-1364. doi: 10.1182\/blood.2025031449","author":"Leaf RK, Mones JV, Shenoy T, Warsame M, Beltrami-Moreira M, Panch S, Leavitt AD, Zon RL, Kendall EK, Shahamatdar S, Lim TL, Cui C, Jiang D, Kaunfer SA, Durai L, Hoge ST, Dias JA, Sha C, Holmes AN, Easton N, Corley EM, Zhao E, Li X, Spelman A, Amos CB, Soebbing D, Shabih M, Jamison T, Liu B, Hussein G, Yadav S, Elsaid MI, Owen DH, Meara A, Juras PK, Suresh A, Heskel M, Huang JJ, Glezerman IG, Go RS, Reynolds KL, Al-Samkari H, Kroll MH, Leaf DE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359796"},{"title01":"Myelodysplastic CMML-1 mimicking ITP, unmasked by corticosteroids: evolution from clonal monocytosis.","title02":"Myelodysplastic CMML-1 mimicking ITP, unmasked by corticosteroids: evolution from clonal monocytosis.","journal":"Blood","issue":"2026 March 26; 147(13):1503. doi: 10.1182\/blood.2025032170","author":"Xu Z, Hudoba M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885848"},{"title01":"Complement activation profile in adult primary immune thrombocytopenia.","title02":"Complement activation profile in adult primary immune thrombocytopenia.","journal":"Blood","issue":"2026 March 31. doi: 10.1182\/blood.2025032255. Online ahead of print","author":"Nakata K, Onami I, Kato H, Kosugi S, Tomiyama Y, Matsushita H, Kurata A, Sato K, Takahashi K, Sawamura F, Ohmine K, Ohtomo S, Hosen N, Kashiwagi H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915761"},{"title01":"Do myelodysplasia-related gene mutations alter transplant decisions in NPM1-mutated acute myeloid leukemia? Comment on: “Prognostic implications of myelodysplasiarelated gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","title02":"Do myelodysplasia-related gene mutations alter transplant decisions in NPM1-mutated acute myeloid leukemia? Comment on: “Prognostic implications of myelodysplasiarelated gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis”.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2026.300857. Online ahead of print","author":"Desai N, Mattsson J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885021"},{"title01":"Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.","title02":"Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.300065. Online ahead of print","author":"Kotsos D, Gradowska P, Hermans SJF, Pabst T, Maertens J, Manz M, Breems DA, Gertsen BT, Lehmann S, Biemond BJ, Beverloo BH, Valk PJM, Janssen JJWM, Ossenkoppele G, Lowenberg B, Huls G, Raaijmakers MHGP, Versluis J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885025"},{"title01":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","title02":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","journal":"Br J Haematol","issue":"2026 March 23. doi: 10.1111\/bjh.70411. Online ahead of print","author":"George A, Rolf E, Domeradzka M, Ribeiro S, Mills B, Hallett A, Macmahon S, Proszek P, Shaikh R, Yuan L, Hubank M, Petrizan MV, McVeigh TP, Khorashad JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41873058"},{"title01":"IDH1 and IDH2 mutated myeloid neoplasms: mutational pattern, clonal hierarchy and the role in AML transformation.","title02":"IDH1 and IDH2 mutated myeloid neoplasms: mutational pattern, clonal hierarchy and the role in AML transformation.","journal":"Blood advances","issue":"2026 March 20. doi: 10.1182\/bloodadvances.2025019387. Online ahead of print","author":"Huber S, Goessweiner F, Walter W, Summerer I, Meggendorfer M, Ordemann R, Pohlkamp C, Kneisel N, Haferlach C, Kern W, Haferlach T, Delic S, Hoermann G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860384"},{"title01":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","title02":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","journal":"Blood","issue":"2026 March 18. doi: 10.1182\/blood.2025032569. Online ahead of print","author":"Yang J Sr, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","title02":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","journal":"Leukemia","issue":"2026 March 27. doi: 10.1038\/s41375-026-02928-z. Online ahead of print","author":"Gagnon LL, Duminuco A, Stagno F, Sobas M, Fominykh M, Virchis A, Nicolini FE, Hildt J, Bentley H, Godfrey AL, Shih LY, Chee A, Mead A, Lewandowski K, Sobieralski P, Hannah G, Reyal Y, Cummin T, Piszcz J, Yip K, Frewin R, Narayanan S, Rahman D, Ajayi A, Cervi P, Byrne J, Taylor T, Lebowa W, Pavlu J, Arami S, Ceesay M, Chraniuk D, Delage R, Condorelli A, Santana C, Radia DH, de Lavallade H, Milojkovic D, Harrison C, Harrington P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41896663"},{"title01":"Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.","title02":"Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.","journal":"Blood advances","issue":"2026 March 24. doi: 10.1182\/bloodadvances.2026019612. Online ahead of print","author":"Gill H, Au L, Yim RLH, Lee P, Li VWK, Chin L, Zhang Q, Chan PY, Lee CYY, Wu TKY, Leung GMK, Kwong YL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41875235"},{"title01":"Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.","title02":"Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.","journal":"Blood advances","issue":"2026 March 17. doi: 10.1182\/bloodadvances.2025018695. Online ahead of print","author":"Mascarenhas JO, Fogliatto LM, Green SD, Corvalan I, Traer E, Kirito K, Chuah HS, Sakatoku K, Hoeg RT, Khawandanah M, Lavie D, Hunter Z, Quinn D, Wang Y, Harb JG, Zha J, Malyankar UM, Ritchie EK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843794"},{"title01":"Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.","title02":"Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.","journal":"Blood","issue":"2026 March 19; 147(12):1267-1277. doi: 10.1182\/blood.2025028642","author":"Salzman GS, Mullally A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857671"},{"title01":"Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis.","title02":"Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis.","journal":"Blood","issue":"2026 March 19; 147(12):1278-1288. doi: 10.1182\/blood.2025028643","author":"Kremyanskaya M, Ginzburg YZ, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100735"},{"title01":"Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.","title02":"Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.","journal":"Blood","issue":"2026 March 19; 147(12):1255-1266. doi: 10.1182\/blood.2025028645","author":"Constantinescu SN, Vainchenker W, Pecquet C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511882"},{"title01":"CD19\/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.","title02":"CD19\/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.287983. Online ahead of print","author":"Yang L, Wan X, Luo C, Huang X, Su M, Qin X, Zhang J, An K, Qian J, Wang T, Shi W, Yang J, Jia R, Fei C, Wang X, Tang Y, Chen J, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852345"},{"title01":"A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.","title02":"A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300238. Online ahead of print","author":"Liberatore C, Piciocchi A, Vincelli D, Mancuso K, Musso M, Buda G, Derudas D, Pavan L, Belotti A, Rago A, Paris L, Mina R, Conticello C, Rossi E, Skert C, Accardi F, Clissa C, Antonioli E, Farina F, Furlan A, Franceschini L, Mangiacavalli S, Cellini C, Aquino S, De Paoli L, Giuliani N, Vassallo F, Sargentini V, Soddu S, Bringhen S, Gentile M, Mele G, Patriarca F, More S, Fazio F, Musto P, Di Raimondo F, Cavo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852332"},{"title01":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","title02":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","journal":"Br J Haematol","issue":"2026 March 29. doi: 10.1111\/bjh.70454. Online ahead of print","author":"Zhang Q, Zhao YZ, Wang D, Ma HH, Cui L, Li WJ, Wang CJ, Li ZG, Zhang R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905747"},{"title01":"Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 March 24; 10(6):1992-2005. doi: 10.1182\/bloodadvances.2025018285","author":"Andresen F, Yoshimi A, Bader P, Bierings M, Bod'ova I, Bordon V, Buechner J, Burkhardt B, Dworzak M, Erlacher M, Kallay K, Labarque V, Locatelli F, Malone A, Masmas T, Muller I, Nollke P, Schmugge M, Pawelec K, Sedlacek P, Sevilla J, Smith O, Stary J, Niemeyer C, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","title02":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","journal":"Blood advances","issue":"2026 March 24; 10(6):1979-1991. doi: 10.1182\/bloodadvances.2025016780","author":"Fan C, Hayase T, Chang CC, Glover IK, Flores II, McDaniel LK, Ortega MR, Sanchez CA, El-Himri RK, Brown AN, Karmouch JL, Jamal MA, Ahmed SS, Halsey TM, Jin Y, Tsai WB, Prasad R, Enkhbayar A, Mohammed A, Schmiester M, Damania A, Ajami NJ, Wargo JA, Peterson CB, Rondon G, Al-Juhaishi T, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Martens E, Arias CA, Jenq RR, Hayase E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558030"},{"title01":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","title02":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","journal":"Blood advances","issue":"2026 March 24; 10(6):2054-2064. doi: 10.1182\/bloodadvances.2025017621","author":"Tan JLC, Khong T, Kim YJ, Reynolds J, Barmanray RD, Gardiner B, Morrissey CO, Mithraprabhu S, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538294"},{"title01":"Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.","title02":"Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.","journal":"Blood advances","issue":"2026 March 24; 10(6):1843-1853. doi: 10.1182\/bloodadvances.2025018152","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YIM, Balaguer-Rossello A, Van Der Poel MWM, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients.","title02":"Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients.","journal":"Blood advances","issue":"2026 March 24; 10(6):2108-2121. doi: 10.1182\/bloodadvances.2025017393","author":"Nishitani M, Graham RA, Wang T, Devos J, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385339"},{"title01":"Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.","title02":"Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.","journal":"Blood advances","issue":"2026 March 24; 10(6):1967-1976. doi: 10.1182\/bloodadvances.2025016338","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz LG, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing JJ, Loughran TP Jr, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","title02":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","journal":"Blood","issue":"2026 March 18. doi: 10.1182\/blood.2025032569. Online ahead of print","author":"Yang J Sr, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.","title02":"Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.","journal":"Blood","issue":"2026 March 19; 147(12):1255-1266. doi: 10.1182\/blood.2025028645","author":"Constantinescu SN, Vainchenker W, Pecquet C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511882"},{"title01":"IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.","title02":"IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.","journal":"Blood","issue":"2026 March 27. doi: 10.1182\/blood.2025031102. Online ahead of print","author":"Bendig S, Hartmann AM, Wessels W, Beder T, Kim R, Passet M, Gao Q, Wolgast N, Horns JM, Alves Santos L, Iben K, Steffen FD, Cantoni L, Kehden B, Chitadze G, Kunstner A, Busch H, Bornhauser B, Bourquin JP, Leguay TT, Boissel N, Gokbuget N, Iacobucci I, Mullighan CG, Clappier E, Baldus CD, Bruggemann M, Bastian L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894249"},{"title01":"Enterococcus faecalis induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","title02":"Enterococcus faecalis induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","journal":"Blood","issue":"2026 March 26; 147(13):1485-1497. doi: 10.1182\/blood.2024028248","author":"Nguyen CL, Funes J, Ghale R, Duong N, Victor K, Gipson B, Zhang ZJ, Dai A, Li R, Armijo G, Huang A, Martinez M, Chen Y, Ghazarian D, Docampo M, Pathak K, Pirrotte P, Markey KA, Peled JU, Paredes J, Burgos da Silva M, van den Brink MRM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460962"},{"title01":"Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.","title02":"Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.","journal":"Blood","issue":"2026 March 19; 147(12):1365-1379. doi: 10.1182\/blood.2025030951","author":"Buechner J, Poetschger U, Bader P, Yesilipek A, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard M, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi A, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease.","title02":"Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease.","journal":"N Engl J Med","issue":"2026 March 26; 394(12):1195-1203. doi: 10.1056\/NEJMoa2509807","author":"Gori JL, Haddad E, Frangoul H, Kohn DB, Morris EC, Martin BN, Deary BA, Nickerson M, Scholz RL, Fernandez I, Leveille K, De Ravin SS, Kang EM, Pierzynski M, Estwick T, Littel P, Kuhns DB, Long Priel DA, Teira P, Turvey S, Arnold J, Evans MD, McManus M, Carpenter B, Waterman DP, Anzalone AV, Petrusich A, Osuna CE, O'Malley TT, Stewart-Ornstein J, Heath JM, Nehilla BJ, Asmal M, Malech HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358590"},{"title01":"WBC Growth Factors: ASCO Guideline Update.","title02":"WBC Growth Factors: ASCO Guideline Update.","journal":"J Clin Oncol","issue":"2026 March 20; 44(9):812-824. doi: 10.1200\/JCO-25-02938","author":"Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740078"},{"title01":"CD19\/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.","title02":"CD19\/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.287983. Online ahead of print","author":"Yang L, Wan X, Luo C, Huang X, Su M, Qin X, Zhang J, An K, Qian J, Wang T, Shi W, Yang J, Jia R, Fei C, Wang X, Tang Y, Chen J, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852345"},{"title01":"Preservation of adaptive immunity after nonmyeloablative hematopoietic cell transplantation in adults with sickle cell disease (PROTECT study).","title02":"Preservation of adaptive immunity after nonmyeloablative hematopoietic cell transplantation in adults with sickle cell disease (PROTECT study).","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2026.300480. Online ahead of print","author":"Dovern E, Zwolsman M, Goorhuis A, Biemond BJ, Wolthers KC, Nur E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885033"},{"title01":"HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group.","title02":"HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.288751. Online ahead of print","author":"Chinnabhandar V, Verneris MR, Schultz KR, Gamis AS, Aplenc R, Hudson CA, Alonzo TA, Gerbing RB, Horan JT, Chewning JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885017"},{"title01":"Monitoring of haematopoietic stem cell mobilization by targeted DNA methylation analysis for the British Journal of Haematology.","title02":"Monitoring of haematopoietic stem cell mobilization by targeted DNA methylation analysis for the British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 March 17. doi: 10.1111\/bjh.70446. Online ahead of print","author":"Hubens WHG, Diehlmann A, Wuchter P, Wagner W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41844549"},{"title01":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","title02":"Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort.","journal":"Br J Haematol","issue":"2026 March 29. doi: 10.1111\/bjh.70454. Online ahead of print","author":"Zhang Q, Zhao YZ, Wang D, Ma HH, Cui L, Li WJ, Wang CJ, Li ZG, Zhang R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905747"},{"title01":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","title02":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 March 22. doi: 10.1111\/bjh.70450. Online ahead of print","author":"Fuji S, Ohmoto A, Najima Y, Yoshimura K, Uchida N, Tanaka M, Hasegawa Y, Fukuda T, Asada N, Sawa M, Sakata-Yanagimoto M, Ishimura M, Onizuka M, Nishida T, Doki N, Kawamura K, Hino M, Kanda Y, Atsuta Y, Yakushijin K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41866833"},{"title01":"Advances in Diagnosis and Classification of B-ALL: Comparative Insights from Updated Guidelines.","title02":"Advances in Diagnosis and Classification of B-ALL: Comparative Insights from Updated Guidelines.","journal":"Blood advances","issue":"2026 March 26. doi: 10.1182\/bloodadvances.2025017301. Online ahead of print","author":"Chen X, Yuan L, Ma X, Wang F, Zhang Y, Fang J, Cao P, Wang T, Chen J, Zhou X, Long J, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886641"},{"title01":"Real-world experience with Tabelecleucel within and beyond the approval label.","title02":"Real-world experience with Tabelecleucel within and beyond the approval label.","journal":"Blood advances","issue":"2026 March 25. doi: 10.1182\/bloodadvances.2025019207. Online ahead of print","author":"Farid KMN, Kocher F, Arnold T, Fauser J, Henze E, Schultze-Florey CR, Herling CD, Vucinic V, Reicherts C, Stelljes M, Stadelmann R, Scheid C, Holtick U, Masouridi-Levrat S, Wehrli M, Novak U, Schnitzler P, Ben-Salah C, Kramer I, Schmitt A, Muller-Tidow C, Luft T, Dreger P, Schmitt M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41879713"},{"title01":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","title02":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 March 20. doi: 10.1182\/bloodadvances.2025018279. Online ahead of print","author":"Tobin J, Stelmach P, Richter S, Xu D, Sauer S, Raab MS, Gu M, Dunn WG, Fabre MA, Muller-Tidow C, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860374"},{"title01":"BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","title02":"BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","journal":"Blood advances","issue":"2026 March 31. doi: 10.1182\/bloodadvances.2025017700. Online ahead of print","author":"Bejarano-Garcia JA, Nufer M, Palacios-Barea MJ, Guijarro-Albaladejo B, Sierro-Martinez B, Bella A, Robles-Benitez C, Garcia-Guerrero E, Carrasco-Brocal I, Lara-Chica M, Sanoja-Flores L, Valerdiz N, Caballero-Velazquez T, Rodriguez-Gil A, Perez-Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915889"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2026 March 24; 10(6):1897-1928. doi: 10.1182\/bloodadvances.2025017934","author":"Sekeres MA, Mattison R, Artz A, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar C, Garcia JS, Gilberto L, Gomez de Leon A, Lancet J, Loh KP, Malcovati L, Marini B, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt G, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 March 24; 10(6):1992-2005. doi: 10.1182\/bloodadvances.2025018285","author":"Andresen F, Yoshimi A, Bader P, Bierings M, Bod'ova I, Bordon V, Buechner J, Burkhardt B, Dworzak M, Erlacher M, Kallay K, Labarque V, Locatelli F, Malone A, Masmas T, Muller I, Nollke P, Schmugge M, Pawelec K, Sedlacek P, Sevilla J, Smith O, Stary J, Niemeyer C, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","title02":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","journal":"Blood advances","issue":"2026 March 24; 10(6):2054-2064. doi: 10.1182\/bloodadvances.2025017621","author":"Tan JLC, Khong T, Kim YJ, Reynolds J, Barmanray RD, Gardiner B, Morrissey CO, Mithraprabhu S, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538294"},{"title01":"Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.","title02":"Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.","journal":"Blood advances","issue":"2026 March 24; 10(6):1843-1853. doi: 10.1182\/bloodadvances.2025018152","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YIM, Balaguer-Rossello A, Van Der Poel MWM, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients.","title02":"Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients.","journal":"Blood advances","issue":"2026 March 24; 10(6):2108-2121. doi: 10.1182\/bloodadvances.2025017393","author":"Nishitani M, Graham RA, Wang T, Devos J, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385339"},{"title01":"Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.","title02":"Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.","journal":"Blood advances","issue":"2026 March 24; 10(6):1967-1976. doi: 10.1182\/bloodadvances.2025016338","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz LG, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing JJ, Loughran TP Jr, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","title02":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","journal":"Blood","issue":"2026 March 18. doi: 10.1182\/blood.2025032569. Online ahead of print","author":"Yang J Sr, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells towards glycolysis.","title02":"Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells towards glycolysis.","journal":"Blood","issue":"2026 March 24. doi: 10.1182\/blood.2025031552. Online ahead of print","author":"Sighinolfi S, Cassina L, Lidonnici MR, Beretta S, Stefanoni D, Storto M, Mayerhofer C, Kristiansen TA, Scadden DT, Merelli I, Boletta A, Aprile A, Ferrari G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41878806"},{"title01":"Enterococcus faecalis induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","title02":"Enterococcus faecalis induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","journal":"Blood","issue":"2026 March 26; 147(13):1485-1497. doi: 10.1182\/blood.2024028248","author":"Nguyen CL, Funes J, Ghale R, Duong N, Victor K, Gipson B, Zhang ZJ, Dai A, Li R, Armijo G, Huang A, Martinez M, Chen Y, Ghazarian D, Docampo M, Pathak K, Pirrotte P, Markey KA, Peled JU, Paredes J, Burgos da Silva M, van den Brink MRM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460962"},{"title01":"Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.","title02":"Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.","journal":"Blood","issue":"2026 March 19; 147(12):1365-1379. doi: 10.1182\/blood.2025030951","author":"Buechner J, Poetschger U, Bader P, Yesilipek A, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard M, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi A, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Final Efficacy and Safety Data From the Phase I\/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.","title02":"Final Efficacy and Safety Data From the Phase I\/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.","journal":"J Clin Oncol","issue":"2026 March 26; JCO2501489. doi: 10.1200\/JCO-25-01489. Online ahead of print","author":"Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazieres J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886723"},{"title01":"Variations in mitochondrial genome as potential prognostic markers in sickle cell disease.","title02":"Variations in mitochondrial genome as potential prognostic markers in sickle cell disease.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300253. Online ahead of print","author":"Ray R, Li H, Gao S, Asomaning N, Le K, Ahmad MM, Wang X, Li Y, Kamimura S, Dalgard CL, Liu C, Quezado ZMN, Lack J, Tumburu L, Thein SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852318"},{"title01":"Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia.","title02":"Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300088. Online ahead of print","author":"Biemond BJ, Kesse-Adu R, Wahab E, Azbell RCG, Boucher AA, Eleftheriou P, De Castro LM, Bergmann S, Hedrich WD, Wilson FR, Jung K, Araco M, Wang R, Shore PM, Kato GJ, Gordeuk VR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852326"},{"title01":"CD19\/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.","title02":"CD19\/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.287983. Online ahead of print","author":"Yang L, Wan X, Luo C, Huang X, Su M, Qin X, Zhang J, An K, Qian J, Wang T, Shi W, Yang J, Jia R, Fei C, Wang X, Tang Y, Chen J, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852345"},{"title01":"Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.","title02":"Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.","journal":"Blood advances","issue":"2026 March 19. doi: 10.1182\/bloodadvances.2025016688. Online ahead of print","author":"Xu R, Wu G, Rice S, Booker M, Weekes JC, Bell HL, Gao Y, Nirmal AJ, Liu H, Ciantra Z, Luo Q, Fortune AL, Whalen K, Guanci TM, Wan Y, Louissaint A Jr, Nordberg JJ, Lin JR, Hemann MT, Manalis SR, Armand P, Smith EL, Jacobson CA, Tolstorukov M, Murakami MA, Sorger PK, Weinstock DM, Song L, Lane AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41855504"},{"title01":"Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.","title02":"Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.","journal":"Blood advances","issue":"2026 March 19. doi: 10.1182\/bloodadvances.2025018267. Online ahead of print","author":"Baek G, Varma G, Yamshon S, van Besien HJ, Bartlett NL, Watkins MP, Shah HR, Baron K, Merryman RW, Falade AS, Svoboda J, Prischak S, D'Angelo CR, Lukowski JD, Advani RH, Yeung AH, Rosenberg MC, Voutsinas JM, Di M, Lynch RC, Poh C, Raghunathan V, Shadman M, Smith SD, Till BG, Ujjani CS, Diefenbach C, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41855500"},{"title01":"Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed\/refractory follicular lymphoma.","title02":"Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed\/refractory follicular lymphoma.","journal":"Blood advances","issue":"2026 March 24; 10(6):1947-1951. doi: 10.1182\/bloodadvances.2025018546","author":"Iacoboni G, Kyvsgaard ER, Navarro Garces V, Russler-Germain DA, Lewis K, Martin Garcia-Sancho A, Carro I, Thompson PA, Therwhanger D, Quintela D, Ku M, Gomez P, Valencia E, Vega G, Jimenez-Ubieto A, Bastos-Oreiro M, Serna A, Husby S, De La Cruz B, Luan J, Camarillas S, Medina L, Cabero A, Cordoba R, Canales M, Sancho JM, Bosch F, Sureda A, Schuster S, Cheah CY, Hutchings M, Barba P, Abrisqueta P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499758"},{"title01":"Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.","title02":"Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.","journal":"Blood advances","issue":"2026 March 24; 10(6):1843-1853. doi: 10.1182\/bloodadvances.2025018152","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YIM, Balaguer-Rossello A, Van Der Poel MWM, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"Infections after bispecific antibodies in B-cell lymphomas.","title02":"Infections after bispecific antibodies in B-cell lymphomas.","journal":"Blood advances","issue":"2026 March 24; 10(6):2006-2015. doi: 10.1182\/bloodadvances.2025017366","author":"Kim DH, Lee N, Koh Y, Jo HJ, Kang CK, Choe PG, Park WB, Lee CM, Byun JM, Kim NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538299"},{"title01":"Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.","title02":"Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.","journal":"Blood advances","issue":"2026 March 24; 10(6):1929-1942. doi: 10.1182\/bloodadvances.2025017049","author":"Yim J, Lee S, Kim S, Han B, Lim S, Song YK, Youk J, Bae JM, Koh J, Lee C, Kim YA, Paik JH, Kim TM, Yun H, Jeon YK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544233"},{"title01":"Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.","title02":"Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.","journal":"Blood","issue":"2026 March 31. doi: 10.1182\/blood.2026033126. Online ahead of print","author":"Gower N, Feugier P, Westin JR, Schiano de Colella JS, Tilly H, Palomba ML, Julia E, Damaj GL, Durand A, Flinn IW, Lemonnier F, Morineau N, Ysebaert L, Bartlett N, Thieblemont C, Ribrag V, Gastinne T, Arthur D, Fouillet L, Guidez S, Houot R, da Silva MG, Barnes J, Bijou F, Cartron G, Martin Garcia-Sancho AM, Eradat HA, Cheminant M, Lopez-Guillermo AL, Abrisqueta P, Abraham J, Sarkozy C, Izutsu K, Crochet G, Sehn LH, Gkasiamis A, Yge ML, Chartier L, Fowler NH, Xerri L, Salles GA, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915772"},{"title01":"Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08.","title02":"Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08.","journal":"Blood","issue":"2026 March 19; 147(12):1289-1301. doi: 10.1182\/blood.2025029535","author":"Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT Jr, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529162"},{"title01":"A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.","title02":"A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300238. Online ahead of print","author":"Liberatore C, Piciocchi A, Vincelli D, Mancuso K, Musso M, Buda G, Derudas D, Pavan L, Belotti A, Rago A, Paris L, Mina R, Conticello C, Rossi E, Skert C, Accardi F, Clissa C, Antonioli E, Farina F, Furlan A, Franceschini L, Mangiacavalli S, Cellini C, Aquino S, De Paoli L, Giuliani N, Vassallo F, Sargentini V, Soddu S, Bringhen S, Gentile M, Mele G, Patriarca F, More S, Fazio F, Musto P, Di Raimondo F, Cavo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852332"},{"title01":"Tumor flare pain reaction following bispecific T-Cell engagers in multiple myeloma: a unique and underrecognized toxicity.","title02":"Tumor flare pain reaction following bispecific T-Cell engagers in multiple myeloma: a unique and underrecognized toxicity.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.289122. Online ahead of print","author":"Jadot G, Sabouret A, Couture A, Laflamme L, Larose F, Ahmad I, Benkirane K, Delisle JS, Fleury I, Lachance S, LeBlanc R, Roy J, Thiant S, Veilleux O, Claveau JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885028"},{"title01":"Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.","title02":"Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.","journal":"Br J Haematol","issue":"2026 March 26. doi: 10.1111\/bjh.70427. Online ahead of print","author":"Singh G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41889201"},{"title01":"MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in >\/=VGPR\/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.","title02":"MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in >\/=VGPR\/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.","journal":"Br J Haematol","issue":"2026 March 26. doi: 10.1111\/bjh.70448. Online ahead of print","author":"Gozzetti A, Pacelli P, Caroni F, Raspadori D, Bestoso E, Antonioli E, Buda G, Ciofini S, Santoni A, Puccetti L, Bacchiarri F, Pengue L, Tocci D, Attucci I, Del Giudice ML, Ruggieri M, Lombardo A, Liberati AM, Candi V, Sammartano V, Cartocci A, Sicuranza A, Galimberti S, Vannucchi AM, Bocchia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888038"},{"title01":"Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists\/oncologists.","title02":"Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists\/oncologists.","journal":"Br J Haematol","issue":"2026 March 17. doi: 10.1111\/bjh.70435. Online ahead of print","author":"Banerjee R, Dong S, McCaughan G, Mehra N, Wang B, Sperling AS, Cowan AJ, Anderson LD Jr, Rajkumar SV, Kaur G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41841734"},{"title01":"Daratumumab, bortezomib and dexamethasone for previously treated myeloma-Real-world outcomes for 2545 patients treated in England.","title02":"Daratumumab, bortezomib and dexamethasone for previously treated myeloma-Real-world outcomes for 2545 patients treated in England.","journal":"Br J Haematol","issue":"2026 March 17. doi: 10.1111\/bjh.70425. Online ahead of print","author":"Lawton SL, Bishton M, Thackray KE, Kipps E, Smith D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41846296"},{"title01":"Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study.","title02":"Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study.","journal":"Br J Haematol","issue":"2026 March 23. doi: 10.1111\/bjh.70444. Online ahead of print","author":"Benavente Y, Hermosa S, Papadimitriou N, Clay-Gilmour A, Brown EE, Hofmann JN, Rothman N, Lan Q, Berndt SI, Albanes D, Purdue M, Machiela MJ, Chanock SJ, Bhatti P, Cozen W, Norman A, Slager SL, Cerhan JR, Rajkumar V, Kumar SK, Vachon CM, Novak AJ, Habermann TM, Link BK, Salles G, Ghesquieres H, Bracci PM, Holly E, Griffin RG, Hildebrandt MAT, Vermeulen RCH, Kolijn PM, Hjalgrim H, Smedby KE, Jayasekara H, Cheah S, Monnereau A, Chen Y, Arslan A, Zhang Y, Camp NJ, Sborov DW, Osman AEG, Ziv E, De Vivo I, Joseph V, Teras LR, Patel AV, Kane E, Vajdic CM, Guilloteau A, Cocco P, Alemany L, Sainz J, McKay J, Birmann BM, Casabonne D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41873017"},{"title01":"Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients.","title02":"Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients.","journal":"Blood advances","issue":"2026 March 26. doi: 10.1182\/bloodadvances.2026019617. Online ahead of print","author":"van Besien HJ, Ozkan G, Easton N, Tix T, Alhomoud M, Shouval R, Rejeski K, Yamshon S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886632"},{"title01":"Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.","title02":"Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.","journal":"Blood advances","issue":"2026 March 24; 10(6):1959-1963. doi: 10.1182\/bloodadvances.2025018951","author":"Oswald LB, Li X, Ferraris CE, De Avila G, Scheiber-Camoretti D, Gudenkauf LM, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker N, Carson TL, Vinci CE, Baz RC, Shain KH, Blue B, Grajales-Cruz AF, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini O, Nishihori T, Liu H, Locke FL, Jim HSL, Hansen DK, Peres LC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564433"},{"title01":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","title02":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 March 20. doi: 10.1182\/bloodadvances.2025018279. Online ahead of print","author":"Tobin J, Stelmach P, Richter S, Xu D, Sauer S, Raab MS, Gu M, Dunn WG, Fabre MA, Muller-Tidow C, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860374"},{"title01":"FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial.","title02":"FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial.","journal":"Blood advances","issue":"2026 March 27. doi: 10.1182\/bloodadvances.2025019465. Online ahead of print","author":"Jamet B, Ahrari S, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin MD, Minnema MC, Bodet-Milin C, de Keizer B, Corre J, Sonneveld P, Mateus D, Moreau P, Touzeau C, Kraeber-Bodere F, Carlier T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894685"},{"title01":"Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.","title02":"Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.","journal":"Blood advances","issue":"2026 March 27. doi: 10.1182\/bloodadvances.2025018639. Online ahead of print","author":"Forsberg PA, Turner JA, Meyer M, Abbott D, Nicholson S, Schade H, Matous JV, Gregory T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894686"},{"title01":"Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MM.","title02":"Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MM.","journal":"Blood advances","issue":"2026 March 27. doi: 10.1182\/bloodadvances.2025017186. Online ahead of print","author":"Sidana S, Lin Y, Cowan AJ, Rodriguez-Otero P, Scheid C, Mueller PJ, Broussard C, Krengel PW, Li Y, Piault R, Corrao A, Ho C, Patel KK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894689"},{"title01":"Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.","title02":"Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.","journal":"Blood advances","issue":"2026 March 24; 10(6):2016-2022. doi: 10.1182\/bloodadvances.2025018945","author":"Jin Y, Cheng X, Zhang X, Shi Q, Zhu Y, Li J, Fan L, Chen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564431"},{"title01":"Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of >\/=100.","title02":"Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of >\/=100.","journal":"Blood","issue":"2026 March 26; 147(13):1412-1415. doi: 10.1182\/blood.2025031907","author":"Chakraborty R, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557896"},{"title01":"Evolution of multiple myeloma from a genomic perspective.","title02":"Evolution of multiple myeloma from a genomic perspective.","journal":"Blood","issue":"2026 March 26; 147(13):1423-1432. doi: 10.1182\/blood.2024026313","author":"Maura F, Samur M, Munshi N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359792"},{"title01":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","title02":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March 26. doi: 10.1038\/s41375-026-02930-5. Online ahead of print","author":"Li YR, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, Yang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888396"},{"title01":"Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphoma.","title02":"Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphoma.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300402. Online ahead of print","author":"Ramdial J, Agbadiba E, Hawkins M, Ayers A, Maadani F, Kaur I, Strati P, Chihara D, Bashir Q, Hosing C, Pinnix C, Neelapu S, Shpall EJ, Nieto Y, Ahmed S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852340"},{"title01":"HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group.","title02":"HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.288751. Online ahead of print","author":"Chinnabhandar V, Verneris MR, Schultz KR, Gamis AS, Aplenc R, Hudson CA, Alonzo TA, Gerbing RB, Horan JT, Chewning JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885017"},{"title01":"Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia.","title02":"Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.289318. Online ahead of print","author":"Nguyen D, Jabbour E, Kantarjian HM, Macaron W, Jain N, Nasnas C, Kebriaei P, Shpall EJ, Khouri I, Haddad F, Karrar O, Maroun M, Garris R, Ravandi F, Short NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885010"},{"title01":"Front-line systemic treatment outcomes in POEMS syndrome.","title02":"Front-line systemic treatment outcomes in POEMS syndrome.","journal":"Br J Haematol","issue":"2026 March 23. doi: 10.1111\/bjh.70436. Online ahead of print","author":"Tomkins O, Khwaja J, Koay S, Japzon N, Keh R, Keddie S, Wechalekar A, Kirkwood A, Carr A, Lunn M, D'Sa S, Sive J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871552"},{"title01":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","title02":"Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 March 22. doi: 10.1111\/bjh.70450. Online ahead of print","author":"Fuji S, Ohmoto A, Najima Y, Yoshimura K, Uchida N, Tanaka M, Hasegawa Y, Fukuda T, Asada N, Sawa M, Sakata-Yanagimoto M, Ishimura M, Onizuka M, Nishida T, Doki N, Kawamura K, Hino M, Kanda Y, Atsuta Y, Yakushijin K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41866833"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2026 March 24; 10(6):1897-1928. doi: 10.1182\/bloodadvances.2025017934","author":"Sekeres MA, Mattison R, Artz A, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar C, Garcia JS, Gilberto L, Gomez de Leon A, Lancet J, Loh KP, Malcovati L, Marini B, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt G, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.","title02":"Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.","journal":"Blood advances","issue":"2026 March 27. doi: 10.1182\/bloodadvances.2025018683. Online ahead of print","author":"Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah HR, Geyer S, Ganesan N, Chang T, Othman T, Shah GL, Nedved AN, Durani U, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Iyengar S, Micallef IN, Stuver RN, Herrera AF, Mei M, Armand P, Merryman RW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894690"},{"title01":"Management of relapsed\/ refractory AL amyloidosis.","title02":"Management of relapsed\/ refractory AL amyloidosis.","journal":"Blood advances","issue":"2026 March 27. doi: 10.1182\/bloodadvances.2025019223. Online ahead of print","author":"Ling J, Sidiqi MH, Gertz MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894688"},{"title01":"Advances in Diagnosis and Classification of B-ALL: Comparative Insights from Updated Guidelines.","title02":"Advances in Diagnosis and Classification of B-ALL: Comparative Insights from Updated Guidelines.","journal":"Blood advances","issue":"2026 March 26. doi: 10.1182\/bloodadvances.2025017301. Online ahead of print","author":"Chen X, Yuan L, Ma X, Wang F, Zhang Y, Fang J, Cao P, Wang T, Chen J, Zhou X, Long J, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886641"},{"title01":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","title02":"Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation.","journal":"Blood advances","issue":"2026 March 20. doi: 10.1182\/bloodadvances.2025018279. Online ahead of print","author":"Tobin J, Stelmach P, Richter S, Xu D, Sauer S, Raab MS, Gu M, Dunn WG, Fabre MA, Muller-Tidow C, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860374"},{"title01":"BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","title02":"BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.","journal":"Blood advances","issue":"2026 March 31. doi: 10.1182\/bloodadvances.2025017700. Online ahead of print","author":"Bejarano-Garcia JA, Nufer M, Palacios-Barea MJ, Guijarro-Albaladejo B, Sierro-Martinez B, Bella A, Robles-Benitez C, Garcia-Guerrero E, Carrasco-Brocal I, Lara-Chica M, Sanoja-Flores L, Valerdiz N, Caballero-Velazquez T, Rodriguez-Gil A, Perez-Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915889"},{"title01":"Total Body Irradiation and Smoking Interact to Increase Lung Cancer Risk after Blood or Marrow Transplantation.","title02":"Total Body Irradiation and Smoking Interact to Increase Lung Cancer Risk after Blood or Marrow Transplantation.","journal":"Blood advances","issue":"2026 March 17. doi: 10.1182\/bloodadvances.2025019391. Online ahead of print","author":"Balas N, Chen Y, Meng Q, Hageman L, Landier W, Richman J, Bosworth AK, Wong FL, Bhatia R, Weisdorf DJ, Armenian SH, Bhatia S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843797"},{"title01":"Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.","title02":"Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.","journal":"Blood advances","issue":"2026 March 24; 10(6):2016-2022. doi: 10.1182\/bloodadvances.2025018945","author":"Jin Y, Cheng X, Zhang X, Shi Q, Zhu Y, Li J, Fan L, Chen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564431"},{"title01":"Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.","title02":"Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.","journal":"Blood","issue":"2026 March 18. doi: 10.1182\/blood.2025031201. Online ahead of print","author":"Miao H, Wu T, Purohit T, Chen D, Klossowski S, Borkin D, Clegg B, Ray JM, Park S, Stevens R, Kim E, Kempinska K, Wang Y, He M, Wen B, Goldman JW, Agrusa JE, Ding C, Sulis ML, Sun D, Mody R, Kim AS, Ren P, Li LS, Liu Y, Burrows F, Kessler L, Cierpicki T, Grembecka J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849234"},{"title01":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","title02":"Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.","journal":"Blood","issue":"2026 March 18. doi: 10.1182\/blood.2025032569. Online ahead of print","author":"Yang J Sr, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849227"},{"title01":"FLT3-ITD scaffolds PKCiota-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML.","title02":"FLT3-ITD scaffolds PKCiota-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML.","journal":"Blood","issue":"2026 March 24. doi: 10.1182\/blood.2025032254. Online ahead of print","author":"Wang Y, Chen S, Liu S, Liang Z, Zheng H, Li C, Huang Q, Liang Q, Zhu Z, Wang W, Liang Y, Huang XJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41878790"},{"title01":"IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.","title02":"IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.","journal":"Blood","issue":"2026 March 27. doi: 10.1182\/blood.2025031102. Online ahead of print","author":"Bendig S, Hartmann AM, Wessels W, Beder T, Kim R, Passet M, Gao Q, Wolgast N, Horns JM, Alves Santos L, Iben K, Steffen FD, Cantoni L, Kehden B, Chitadze G, Kunstner A, Busch H, Bornhauser B, Bourquin JP, Leguay TT, Boissel N, Gokbuget N, Iacobucci I, Mullighan CG, Clappier E, Baldus CD, Bruggemann M, Bastian L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894249"},{"title01":"Inhibition of p300\/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.","title02":"Inhibition of p300\/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.","journal":"Blood","issue":"2026 March 18. doi: 10.1182\/blood.2025031924. Online ahead of print","author":"Meyerhofer M, Zhou Y, Gallego-Crespo A, Shah V, Behrendt MA, Saura-Panella M, Haupl B, Todoriuk O, Hartmann M, Klein M, Wolfel C, Hahnel PS, Michel CS, Muth S, Kindler T, Bopp T, Schild H, Horton SJ, Radsak MP, Theobald M, Vassiliou GS, Huntly BJ, Kuhn MW, Butter F, Oellerich T, Sasca D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41849237"},{"title01":"Clonal dynamics of CH in CLL.","title02":"Clonal dynamics of CH in CLL.","journal":"Blood","issue":"2026 March 19; 147(12):1247-1249. doi: 10.1182\/blood.2025032522","author":"Hanache S, Takahashi K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41854658"},{"title01":"Cracking the nut of NUTM1 rearrangements in infant leukemia.","title02":"Cracking the nut of NUTM1 rearrangements in infant leukemia.","journal":"Blood","issue":"2026 March 26; 147(13):1383-1384. doi: 10.1182\/blood.2025032530","author":"Shiloh R, Izraeli S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885855"},{"title01":"Beyond ATP: asciminib and the allosteric path in CML.","title02":"Beyond ATP: asciminib and the allosteric path in CML.","journal":"Blood","issue":"2026 March 26; 147(13):1384-1386. doi: 10.1182\/blood.2025032327","author":"Abruzzese E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885854"},{"title01":"Myelodysplastic CMML-1 mimicking ITP, unmasked by corticosteroids: evolution from clonal monocytosis.","title02":"Myelodysplastic CMML-1 mimicking ITP, unmasked by corticosteroids: evolution from clonal monocytosis.","journal":"Blood","issue":"2026 March 26; 147(13):1503. doi: 10.1182\/blood.2025032170","author":"Xu Z, Hudoba M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885848"},{"title01":"Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphoma.","title02":"Salvage high-dose chemotherapy and autologous stem cell transplant consolidation following relapse after CAR-T cell for large B-cell lymphoma.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300402. Online ahead of print","author":"Ramdial J, Agbadiba E, Hawkins M, Ayers A, Maadani F, Kaur I, Strati P, Chihara D, Bashir Q, Hosing C, Pinnix C, Neelapu S, Shpall EJ, Nieto Y, Ahmed S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852340"},{"title01":"Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process.","title02":"Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.288239. Online ahead of print","author":"Tzioni MM, Watanabe N, Stelloo E, Chen Z, Ghosh A, Wu F, Sugino K, Ito K, Feitsma H, Fujisawa M, Sakata-Yanagimoto M, Raso-Barnett L, Marafioti T, Attygalle AD, Wotherspoon A, Du MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852323"},{"title01":"Histological response dynamics in gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue after helicobacter-pylori eradication: a singlecenter longitudinal analysis.","title02":"Histological response dynamics in gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue after helicobacter-pylori eradication: a singlecenter longitudinal analysis.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300054. Online ahead of print","author":"Sunder-Plassmann V, Kiesewetter B, Simonitsch-Klupp I, Brand R, Dolak W, Mayerhoefer ME, Raderer M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852321"},{"title01":"Early prediction of adult lymphoma-associated haemophagocytic lymphohistiocytosis using an interpretable machine learning model.","title02":"Early prediction of adult lymphoma-associated haemophagocytic lymphohistiocytosis using an interpretable machine learning model.","journal":"Br J Haematol","issue":"2026 March 23. doi: 10.1111\/bjh.70447. Online ahead of print","author":"Luan M, Jia R, Wang D, Zhang F, Han X, Sheng X, Li S, Zhou Q, Li B, Ning C, Ji C, Ye J, Zang S, Lu F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871894"},{"title01":"Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma’s new era.","title02":"Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma’s new era.","journal":"Br J Haematol","issue":"2026 March 23. doi: 10.1111\/bjh.70451. Online ahead of print","author":"Cliff ERS, McKeague S, Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871830"},{"title01":"Mediastinal grey zone lymphomas: Results of the expert pathological review analysis of a case series enrolled in the multicentre BIOGZL-2020 study in Italy.","title02":"Mediastinal grey zone lymphomas: Results of the expert pathological review analysis of a case series enrolled in the multicentre BIOGZL-2020 study in Italy.","journal":"Br J Haematol","issue":"2026 March 17. doi: 10.1111\/bjh.70432. Online ahead of print","author":"Sabattini E, Ascani S, Ciavarella S, Di Napoli A, Facchetti F, Lazzi S, Leoncini L, Lorenzi L, Lucioni M, Motta G, Nassi L, Parisi A, Paulli M, Pileri S, Ponzoni M, Tripodo C, Righi S, Agostinelli C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41844512"},{"title01":"Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphoma.","title02":"Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphoma.","journal":"Br J Haematol","issue":"2026 March 17. doi: 10.1111\/bjh.70440. Online ahead of print","author":"Solow M, Owen C, Stewart C, Cao JQ, Balogh A, Perry S, Shafey M, Street L, Puckrin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41841763"},{"title01":"Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.","title02":"Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.","journal":"Br J Haematol","issue":"2026 March 29. doi: 10.1111\/bjh.70458. Online ahead of print","author":"Caserta S, Martino EA, Skafi M, Alvaro ME, Bruzzese A, Amodio N, Fiorillo M, Lucia E, Olivito V, Labanca C, Mendicino F, Vigna E, Morabito F, Gentile M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905770"},{"title01":"Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.","title02":"Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.","journal":"Br J Haematol","issue":"2026 March 29. doi: 10.1111\/bjh.70439. Online ahead of print","author":"Arcaini L, Merli M, Rattotti S, Nizzoli ME, Tarantino V, Consoli C, Talami A, Murru R, Deodato M, Cencini E, Re F, Visco C, Duffles G, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano C, Pennese E, Varettoni M, Cappello E, Favrin G, La Fauci M, Marcheselli L, Paulli M, Luminari S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41905881"},{"title01":"Digital Spatial Profiling Uncovers Transcriptomic Features of Distinct Plasma Cell-like Phenotypes in Diffuse Large B-cell Lymphoma.","title02":"Digital Spatial Profiling Uncovers Transcriptomic Features of Distinct Plasma Cell-like Phenotypes in Diffuse Large B-cell Lymphoma.","journal":"Blood advances","issue":"2026 March 26. doi: 10.1182\/bloodadvances.2025018014. Online ahead of print","author":"Xie Z, Qin Y, Xue X, Chen X, Xie T, Zhu H, Huang L, Yang S, Yang J, Liu P, Gui L, Tang L, Feng X, Shi Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886633"},{"title01":"A phase I\/II Study of Duvelisib plus Venetoclax in Patients with Relapsed\/Refractory CLL\/SLL or Richter Transformation.","title02":"A phase I\/II Study of Duvelisib plus Venetoclax in Patients with Relapsed\/Refractory CLL\/SLL or Richter Transformation.","journal":"Blood advances","issue":"2026 March 26. doi: 10.1182\/bloodadvances.2025018878. Online ahead of print","author":"Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar AJ, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886642"},{"title01":"Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.","title02":"Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.","journal":"Blood advances","issue":"2026 March 27. doi: 10.1182\/bloodadvances.2026019802. Online ahead of print","author":"Kuhnl A, Kirkwood AA, Northend M, Alajangi R, Uttenthal BJ, Norman J, Hiew HJ, Seymour F, Maybury BD, Osborne W, Sillito F, Abdulgawad A, Jones CH, Delaney A, Townsend W, Panopoulou A, Gribben JG, Bataillard EJ, Mathew A, Martinez-Calle N, Gajendran L, Davies AJ, Chavda ND, Kumar EA, Sanderson R, Kamat S, Petrides G, Roddie C, Menne T, Chaganti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894687"},{"title01":"Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.","title02":"Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.","journal":"Blood advances","issue":"2026 March 27. doi: 10.1182\/bloodadvances.2025018683. Online ahead of print","author":"Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah HR, Geyer S, Ganesan N, Chang T, Othman T, Shah GL, Nedved AN, Durani U, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Iyengar S, Micallef IN, Stuver RN, Herrera AF, Mei M, Armand P, Merryman RW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894690"},{"title01":"Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.","title02":"Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.","journal":"Blood advances","issue":"2026 March 19. doi: 10.1182\/bloodadvances.2025019031. Online ahead of print","author":"Wang WL, Lee D, Cheung E, Jensen A, Rana MS, Goyal A, Hamilton MP, Ghalehsari N, Latchford T, Scott BJ, Mallampet J, Heng E, Khan H, Zarak MS, Lohman C, Sahaf B, Sidana S, Weng WK, Smith M, Bharadwaj S, Frank MJ, Miklos DB, Dahiya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41855506"},{"title01":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","title02":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2026 March 31. doi: 10.1182\/bloodadvances.2025018310. Online ahead of print","author":"Furman RR, Wierda WG, Patten PE, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM MD, Byrd JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915892"},{"title01":"Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.","title02":"Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.","journal":"Blood advances","issue":"2026 March 24; 10(6):2065-2069. doi: 10.1182\/bloodadvances.2025018719","author":"Heger JM, Mattlener J, Herhaus P, Meissner J, Trautmann-Grill K, Voltin CA, Schneider J, Schleifenbaum JK, Heidenreich S, Kobe C, Kaul H, Klapper W, von Tresckow B, Borchmann P, Brockelmann PJ, Borchmann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592288"},{"title01":"From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma.","title02":"From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma.","journal":"Blood","issue":"2026 March 23. doi: 10.1182\/blood.2025030859. Online ahead of print","author":"Kamdar M, Bartlett NL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41871044"},{"title01":"Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma.","title02":"Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma.","journal":"Blood","issue":"2026 March 19; 147(12):1315-1322. doi: 10.1182\/blood.2025031476","author":"Luan D, Ben Valid O, Beyar-Katz O, Tix T, Accav NG, Alhomoud M, Avigdor A, Bucklein VL, Cohen L, Dahi PB, Einarsdottir S, Elimelech J, Escribano-Serrat S, Falchi L, Fei T, Giralt S, Gomez-Llobell M, Goy A, Horesh N, Israeli S, Kruk L, Leslie L, Lue JK, Marcus R, Nagler A, Palomba ML, Park JH, Raj S, Reddy S, Romancik J, Rosenbaum E, Salles G, Scordo M, Shah GL, Shimoni A, von Bergwelt-Baildon M, Perales MA, Subklewe M, Greenbaum U, Ip A, Ram R, Rejeski K, Shouval R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41489404"},{"title01":"Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.","title02":"Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.","journal":"Blood","issue":"2026 March 17. doi: 10.1182\/blood.2025031869. Online ahead of print","author":"Kaulen LD, Nayak L, Karschnia P, Kraai I, Galluzzo DR, de Groot FA, Witterholt M, Donovan L, Bhella S, Kuschel LP, Fox CP, Seidel S, Paterson J, Richter B, Dixit KS, Zeyen T, Alderuccio JP, Montoto S, Kuittinen O, Traub BL, Doubrovinskaia S, Rohdjess H, Mueller K, Enting R, de Bresser J, Kuitunen H, Iwamoto FM, Alencar AJ, Herrlinger U, Platten M, Cwynarski K, Mendez JS, Roth P, von Baumgarten L, Prica A, Bhagat G, Lurain K, Schiff D, Vermaat JS, Baehring J, Nijland M, Dietrich J, Batchelor TT, Wick W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843467"},{"title01":"Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.","title02":"Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.","journal":"Leukemia","issue":"2026 March 24. doi: 10.1038\/s41375-026-02941-2. Online ahead of print","author":"Waldschmidt J, Fandrei D, Hecker JS, Meggendorfer M, Truger M, Reinhard F, Shibru B, Hogner M, Gebauer A, Koppel M, Muller H, Jung J, Teschner D, Topp MS, Purcarea A, Vucinic V, Haferlach T, Bassermann F, Platzbecker U, Einsele H, Haferlach C, Kortum KM, Metzeler KH, Merz M, Gotze KS, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876727"},{"title01":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","title02":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","journal":"Leukemia","issue":"2026 March 18. doi: 10.1038\/s41375-026-02918-1. Online ahead of print","author":"Wobst J, Ruge H, Senk S, Muller H, Truger M, Ecker V, Tsamadou C, Baldi A, Hoermann G, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41851472"},{"title01":"Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.","title02":"Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.","journal":"Leukemia","issue":"2026 March 31. doi: 10.1038\/s41375-026-02920-7. Online ahead of print","author":"Munawar U, Thurner J, Nerreter S, Nerreter T, Leipold AM, Han S, Verbruggen C, Gerhard-Hartmann E, Vogt C, Grams B, Kurian S, Besant E, Roth S, Weingart J, Eiring P, Truger M, Afrin N, Steinbrunn T, Tamamushi Y, Zhou X, Rein N, Lehmann J, Koppel M, Rosenwald A, Haferlach C, Hudecek M, Saliba AE, Rasche L, Sauer M, Einsele H, Kuster B, Waldschmidt J, Kortum KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41917280"},{"title01":"CD70\/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.","title02":"CD70\/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.","journal":"Leukemia","issue":"2026 March 23. doi: 10.1038\/s41375-026-02899-1. Online ahead of print","author":"Forster S, Reinhardt C, Boy M, Wegmuller A, Hinrichsen A, Schurch CM, Bruhl FK, Fend F, Tzankov A, Kronig MN, Rommele M, Gluck A, Luscher B, Legros M, Bacher U, Seipel K, Pabst T, Radpour R, Riether C, Ochsenbein AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41872502"},{"title01":"Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly.","title02":"Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly.","journal":"Leukemia","issue":"2026 March 31. doi: 10.1038\/s41375-026-02933-2. Online ahead of print","author":"Merz M, Jurgens E, Fandrei D, Usmani SZ, Mailankody S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41917281"},{"title01":"Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma.","title02":"Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.289317. Online ahead of print","author":"Raimondi V, Vescovini R, Storti P, Franceschi V, Pozzi G, Sitzia C, Iannozzi NT, Toscani D, Dalla Palma B, Scita M, Dessena M, Minesso S, Ricci S, Mohammadi F, Lungu O, Mirandola P, Donofrio G, Giuliani N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885031"},{"title01":"Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience.","title02":"Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.289143. Online ahead of print","author":"Liberatore C, Ferretti VV, Tacchetti P, Conticello C, Barila G, Antonioli E, Belotti A, Cafro AM, Paris L, Bongarzoni V, Gentile M, Da Via M, Gamberi B, Pezzatti S, Ciambelli F, Garzia M, Annibali O, Fazio F, Antolino G, More S, Sgherza N, Farina F, Citro A, Steffanoni P, Del Fabro V, Cartia CS, Fioritoni F, Mancuso K, Attucci I, Pioltelli ML, Puppi M, Terlizzi S, Lisi C, Palumbo M, Offidani M, Petrucci MT, Mangiacavalli S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885018"},{"title01":"Reply to: Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.","title02":"Reply to: Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.","journal":"J Clin Oncol","issue":"2026 March 27; JCO2600338. doi: 10.1200\/JCO-26-00338. Online ahead of print","author":"Montesinos P, Labrador J, Lloret-Madrid P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894642"},{"title01":"Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.","title02":"Quizartinib for Newly Diagnosed FLT3-ITD-Negative AML.","journal":"J Clin Oncol","issue":"2026 March 27; JCO2502702. doi: 10.1200\/JCO-25-02702. Online ahead of print","author":"Shibusawa M, Tanimoto T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894645"},{"title01":"Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.","title02":"Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 March 27; JCO2502116. doi: 10.1200\/JCO-25-02116. Online ahead of print","author":"Lanino L, Hunter AM, Gagelmann N, Robin M, Dall'Olio D, Flamigni A, Sala C, Gurnari C, Wang YH, Pleyer L, Xicoy B, Montalban-Bravo G, Shih LY, Alsugair A, Fathima S, Gregorio C, Rollo C, Palomo L, Platzbecker AS, Asti G, Itzykson R, Sallman DA, Fariselli P, Kern W, Garcia-Manero G, Platzbecker U, Sole F, Diez-Campelo M, Maciejewski J, Bejar R, Thol F, Kroger N, Savona M, Fenaux P, Sanz G, Kordasti S, Santini V, Fontenay M, Zeidan AM, Komrokji RS, Haferlach T, Germing U, Castellani G, D'Amico S, Patnaik M, Ieva F, Solary E, Tefferi A, Padron E, Della Porta MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41894646"},{"title01":"Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.","title02":"Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.300065. Online ahead of print","author":"Kotsos D, Gradowska P, Hermans SJF, Pabst T, Maertens J, Manz M, Breems DA, Gertsen BT, Lehmann S, Biemond BJ, Beverloo BH, Valk PJM, Janssen JJWM, Ossenkoppele G, Lowenberg B, Huls G, Raaijmakers MHGP, Versluis J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885025"},{"title01":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","title02":"Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.","journal":"Br J Haematol","issue":"2026 March 23. doi: 10.1111\/bjh.70411. Online ahead of print","author":"George A, Rolf E, Domeradzka M, Ribeiro S, Mills B, Hallett A, Macmahon S, Proszek P, Shaikh R, Yuan L, Hubank M, Petrizan MV, McVeigh TP, Khorashad JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41873058"},{"title01":"Single-cell transcriptional consequences of leukaemogenic SETBP1 mutations.","title02":"Single-cell transcriptional consequences of leukaemogenic SETBP1 mutations.","journal":"Br J Haematol","issue":"2026 March 25. doi: 10.1111\/bjh.70452. Online ahead of print","author":"Trinh MK, Anderson ND, Young MD, Whitfield HJ, Parks C, Ogbonnah T, Oszlanczi A, Zhou D, Robertson ER, Hodder A, Thomas R, Straathof K, Adams S, Bartram J, Summerfield N, Behjati S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41881778"},{"title01":"Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.","title02":"Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 March 17. doi: 10.1111\/bjh.70431. Online ahead of print","author":"Kalampalika F, Jimenez-Pompa A, Sanchez-Lanzas R, Patel B, Ganuza M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41841727"},{"title01":"Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.","title02":"Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.","journal":"Br J Haematol","issue":"2026 March 30. doi: 10.1111\/bjh.70416. Online ahead of print","author":"Allsup DJ, Cairns DA, Samy EF, Duley L, Bloor A, Varghese A, Meads D, Dawkins B, Girvan S, Howard DR, Hockaday A, Brown JM, Jackson S, Greatorex N, Templeton P, Tupper M, Phillips D, Yaqub S, Mortimer D, Stones D, Patten PEM, Rawstron A, Hillmen P, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912408"},{"title01":"Advances in Diagnosis and Classification of B-ALL: Comparative Insights from Updated Guidelines.","title02":"Advances in Diagnosis and Classification of B-ALL: Comparative Insights from Updated Guidelines.","journal":"Blood advances","issue":"2026 March 26. doi: 10.1182\/bloodadvances.2025017301. Online ahead of print","author":"Chen X, Yuan L, Ma X, Wang F, Zhang Y, Fang J, Cao P, Wang T, Chen J, Zhou X, Long J, Liu H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886641"},{"title01":"A phase I\/II Study of Duvelisib plus Venetoclax in Patients with Relapsed\/Refractory CLL\/SLL or Richter Transformation.","title02":"A phase I\/II Study of Duvelisib plus Venetoclax in Patients with Relapsed\/Refractory CLL\/SLL or Richter Transformation.","journal":"Blood advances","issue":"2026 March 26. doi: 10.1182\/bloodadvances.2025018878. Online ahead of print","author":"Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar AJ, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41886642"},{"title01":"NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.","title02":"NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.","journal":"Blood advances","issue":"2026 March 25. doi: 10.1182\/bloodadvances.2026020243. Online ahead of print","author":"Bazinet A, Ferrajoli A, Jain N, Burger JA, Yilmaz M, Swaminathan M, Kantarjian HM, Keating M, Thompson PA, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41879712"},{"title01":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","title02":"Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2026 March 31. doi: 10.1182\/bloodadvances.2025018310. Online ahead of print","author":"Furman RR, Wierda WG, Patten PE, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM MD, Byrd JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41915892"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2026 March 24; 10(6):1897-1928. doi: 10.1182\/bloodadvances.2025017934","author":"Sekeres MA, Mattison R, Artz A, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar C, Garcia JS, Gilberto L, Gomez de Leon A, Lancet J, Loh KP, Malcovati L, Marini B, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt G, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia.","title02":"Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia.","journal":"Blood advances","issue":"2026 March 20. doi: 10.1182\/bloodadvances.2025019519. Online ahead of print","author":"Goulart H, Short NJ, Borthakur G, Jain N, DiNardo CD, Loghavi S, Khouri R, Hachem MCR, Ravandi F, Daver NG, Kadia TM, Yilmaz M, Issa GC, Bazinet A, Swaminathan M, Montalban-Bravo G, Haddad FG, Garris R, Kantarjian HM, Jabbour E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860396"},{"title01":"IDH1 and IDH2 mutated myeloid neoplasms: mutational pattern, clonal hierarchy and the role in AML transformation.","title02":"IDH1 and IDH2 mutated myeloid neoplasms: mutational pattern, clonal hierarchy and the role in AML transformation.","journal":"Blood advances","issue":"2026 March 20. doi: 10.1182\/bloodadvances.2025019387. Online ahead of print","author":"Huber S, Goessweiner F, Walter W, Summerer I, Meggendorfer M, Ordemann R, Pohlkamp C, Kneisel N, Haferlach C, Kern W, Haferlach T, Delic S, Hoermann G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41860384"},{"title01":"Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria.","title02":"Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria.","journal":"Blood advances","issue":"2026 March 24; 10(6):1879-1882. doi: 10.1182\/bloodadvances.2025018032","author":"Shimony S, Wang Y, Cronin A, Walsh TP, Charles A, Slopen N, Cho HL, Stahl M, Bystrom RP, Luskin MR, Abel GA, DeAngelo DJ, Stone RM, Lindsley RC, Hantel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538295"},{"title01":"Does age matter? Optimizing AML treatment in older adults.","title02":"Does age matter? Optimizing AML treatment in older adults.","journal":"Blood advances","issue":"2026 March 24; 10(6):1952-1953. doi: 10.1182\/bloodadvances.2025018866","author":"Lai C, Lin TL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41823952"},{"title01":"Venetoclax Retreatment in Chronic Lymphocytic Leukemia is biologically rational and clinically effective.","title02":"Venetoclax Retreatment in Chronic Lymphocytic Leukemia is biologically rational and clinically effective.","journal":"Blood advances","issue":"2026 March 17. doi: 10.1182\/bloodadvances.2026019871. Online ahead of print","author":"Castonguay M, Anderson MA, Thompson PA, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41843779"},{"title01":"Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.","title02":"Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.","journal":"Blood","issue":"2026 March 26; 147(13):1433-1446. doi: 10.1182\/blood.2025029210","author":"Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky DJ, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397287"},{"title01":"Comprehensive molecular and functional analysis of NUTM1-rearranged leukemia.","title02":"Comprehensive molecular and functional analysis of NUTM1-rearranged leukemia.","journal":"Blood","issue":"2026 March 26; 147(13):1395-1411. doi: 10.1182\/blood.2024026928","author":"Nishimura K, Isobe T, Shigehiro T, Nomura M, Zang W, Xiao M, Liao W, Koike Y, Nishimura A, Sato-Otsubo A, Yamazaki H, Ito H, Okada S, Matsumoto N, Saika W, Zhang Y, Aoyama Y, Hasegawa C, Yamasaki T, Kubota Y, Ohki K, Kiyokawa N, Nagae G, Yoshida K, Nannya Y, Ueno H, Fukuda S, Tatsuno K, Tsutsumi S, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Eguchi M, Arakawa Y, Koh K, Deguchi T, Tomizawa D, Miyamura T, Ishii E, Mizutani S, Miyano S, Aburatani H, Ogawa S, Takaori-Kondo A, Yokoyama A, Abdel-Wahab O, Ernst P, Takita J, Ikawa T, Takagi M, Inoue D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460961"},{"title01":"The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.","title02":"The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.","journal":"Blood","issue":"2026 March 19; 147(12):1323-1337. doi: 10.1182\/blood.2025029905","author":"Al-Sawaf O, Locher BN, Christen F, Hablesreiter R, Rajamani A, Robrecht S, Zhang C, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Kopp K, Mertz ME, Fustero-Torre C, Kleo K, Seymour J, Blombery P, Bullinger L, Chyla B, Jin HY, Jiang Y, Stilgenbauer S, Hallek M, Eichhorst B, Langerbeins P, Fischer K, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528026"},{"title01":"Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13\/GAIA trial.","title02":"Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13\/GAIA trial.","journal":"Blood","issue":"2026 March 30. doi: 10.1182\/blood.2025032160. Online ahead of print","author":"Furstenau M, Niemann CU, Robrecht S, Rotbain EC, Eurelings LEM, Giza A, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstrom V, Juliusson G, Janssens A, da Cunha-Bang C, Schneider C, Herishanu Y, O'Shea D, Baumann M, Widmer AA, Nosslinger T, Bjorn Poulsen C, Frederiksen H, Lotfi K, Ranti J, Enggaard L, Velders GA, Vekemans MM, de Heer K, Snijders TJF, Siemes C, Wendtner CM, Knauf WU, Kroeber A, Zahn MO, Illmer T, Schottker B, Simon F, Fink AM, Fischer K, D'Brot R, Holmes EE, Kreuzer KA, Ritgen M, Bruggemann M, Tausch E, Stilgenbauer S, Levin MD, Hallek MJ, Kater AP, Eichhorst BF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41911073"},{"title01":"Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.","title02":"Outcomes of BCP-ALL with hypodiploidy or BCR::ABL1 fusion in children undergoing allogeneic HSCT: results from the FORUM study.","journal":"Blood","issue":"2026 March 19; 147(12):1365-1379. doi: 10.1182\/blood.2025030951","author":"Buechner J, Poetschger U, Bader P, Yesilipek A, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard M, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi A, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Targeting UHRF1 induces regression of aggressive mantle cell lymphoma.","title02":"Targeting UHRF1 induces regression of aggressive mantle cell lymphoma.","journal":"Leukemia","issue":"2026 March 24. doi: 10.1038\/s41375-026-02915-4. Online ahead of print","author":"Yang Y, Tang Z, Hu Q, Yang P, Zhang W, Wang J, Jing H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876725"},{"title01":"Prognostic significance of clinical risk models and genomic alterations in Waldenstrom macroglobulinemia before or after the BTK inhibitor era.","title02":"Prognostic significance of clinical risk models and genomic alterations in Waldenstrom macroglobulinemia before or after the BTK inhibitor era.","journal":"Leukemia","issue":"2026 March 30. doi: 10.1038\/s41375-026-02919-0. Online ahead of print","author":"Yan Y, Chen W, Yu Y, Li Y, Xiong W, Zhang X, Wang T, Liu W, Sui W, Yu Z, Hao M, An G, Zou D, Qiu L, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912911"},{"title01":"KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.","title02":"KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.","journal":"Leukemia","issue":"2026 March 23. doi: 10.1038\/s41375-026-02943-0. Online ahead of print","author":"Iaccarino I, Hartmann AM, Yalcin F, Mondal M, Bozzetti C, Wolgast N, Loeffen JLC, Boer JM, Bruggemann M, Baldus CD, Cario G, Klapper W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41872503"},{"title01":"Validation of Prospective Cutaneous Lymphoma International Prognostic Index for advanced cutaneous lymphoma in a multicenter Chinese cohort.","title02":"Validation of Prospective Cutaneous Lymphoma International Prognostic Index for advanced cutaneous lymphoma in a multicenter Chinese cohort.","journal":"Leukemia","issue":"2026 March 20. doi: 10.1038\/s41375-026-02927-0. Online ahead of print","author":"Chen Z, Ruan Y, Wang Y, Liu F, Sun J, Xiao Y, Wen Y, Lai P, Jiang Y, Li M, Yang C, Cui Z, Hong Z, Deng R, Ye C, Tong Z, Zhu Z, Shen X, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41862596"},{"title01":"Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.","title02":"Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300064. Online ahead of print","author":"Stuver R, Tang H, Dogan A, Epstein-Peterson ZD, Geller S, Ghione P, Johnson WT, Moskowitz A, Moy A, Virgen CA, Horwitz SM, Pulitzer M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852317"},{"title01":"Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous LRBA mutation.","title02":"Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous LRBA mutation.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2026.300514. Online ahead of print","author":"Tembrink M, Haverkamp T, Reinhardt HC, Hanoun M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852350"},{"title01":"Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader.","title02":"Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader.","journal":"Leukemia","issue":"2026 March 20. doi: 10.1038\/s41375-026-02926-1. Online ahead of print","author":"Sherpa MG, Sinha S, Han W, Darby HC, Parikh SA, Kay NE, Wang Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41862595"},{"title01":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","title02":"Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.","journal":"Leukemia","issue":"2026 March 27. doi: 10.1038\/s41375-026-02928-z. Online ahead of print","author":"Gagnon LL, Duminuco A, Stagno F, Sobas M, Fominykh M, Virchis A, Nicolini FE, Hildt J, Bentley H, Godfrey AL, Shih LY, Chee A, Mead A, Lewandowski K, Sobieralski P, Hannah G, Reyal Y, Cummin T, Piszcz J, Yip K, Frewin R, Narayanan S, Rahman D, Ajayi A, Cervi P, Byrne J, Taylor T, Lebowa W, Pavlu J, Arami S, Ceesay M, Chraniuk D, Delage R, Condorelli A, Santana C, Radia DH, de Lavallade H, Milojkovic D, Harrison C, Harrington P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41896663"},{"title01":"Targeting BMP and TAZ\/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.","title02":"Targeting BMP and TAZ\/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.","journal":"Leukemia","issue":"2026 March 18. doi: 10.1038\/s41375-026-02904-7. Online ahead of print","author":"Barral L, Lespinasse N, Martin Cardozo C, Jeanpierre S, Bourgeois A, Rosel K, Beillard E, Laurent D, Peyrouze P, Belhabri A, Guillermin Y, Mazurier F, Cheok M, Audry-Deschamps MC, Faivre M, Maguer-Satta V, Lefort S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41851473"},{"title01":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","title02":"Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.","journal":"Leukemia","issue":"2026 March 18. doi: 10.1038\/s41375-026-02918-1. Online ahead of print","author":"Wobst J, Ruge H, Senk S, Muller H, Truger M, Ecker V, Tsamadou C, Baldi A, Hoermann G, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41851472"},{"title01":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","title02":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March 26. doi: 10.1038\/s41375-026-02930-5. Online ahead of print","author":"Li YR, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, Yang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888396"},{"title01":"Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia.","title02":"Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia.","journal":"Leukemia","issue":"2026 March 23. doi: 10.1038\/s41375-026-02912-7. Online ahead of print","author":"Fasci A, Vallone FE, Nabelsi N, Viry E, Sana I, Morabito A, Seghezzi S, Pesce NA, Rovere M, Bertola N, Duculty C, Ravera S, Mouhssine S, Muzio M, Ghia P, Vitale C, Coscia M, Moussay E, Gaidano G, Allan J, Furman RR, Paggetti J, Vaisitti T, Deaglio S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41872504"},{"title01":"Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.","title02":"Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March 26. doi: 10.1038\/s41375-026-02900-x. Online ahead of print","author":"Vasseur L, Duchmann M, Duployez N, Raffoux E, Berthon C, Heiblig M, Genthon A, Braun T, Leclerc M, Lebon D, Chantepie S, Micol JB, Lambert J, Recher C, Chretien ML, Iat A, Vaidie J, Malfuson JV, Uzunov M, Pigneux A, Peterlin P, Tarfi S, Hirsch P, Penther D, Jourdan E, Celli-Lebras K, Preudhomme C, Dombret H, Lambert J, Boissel N, Itzykson R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41888395"},{"title01":"The impact of periconceptional folate on the DNA methylome of acute lymphoblastic leukemia.","title02":"The impact of periconceptional folate on the DNA methylome of acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 March 24. doi: 10.1038\/s41375-026-02866-w. Online ahead of print","author":"Nickels EM, Morimoto LM, Kang AY, Metayer C, Wiemels JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876728"},{"title01":"Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.","title02":"Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity.","journal":"Leukemia","issue":"2026 March 25. doi: 10.1038\/s41375-026-02925-2. Online ahead of print","author":"Tu Y, Cai X, Tao Z, Zhang R, Li X, Chen B, Zhang H, Hu X, Ke J, Chen X, Bai X, Li J, Xu T, Zhou Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41882098"},{"title01":"Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?","title02":"Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?","journal":"Leukemia","issue":"2026 March 16. doi: 10.1038\/s41375-026-02910-9. Online ahead of print","author":"Turcsanyi L, Zhang XS, Kudelka M, Kubikova K, Radvansky M, Yang S, Kriegova E, Juranova J, Mayer J, Klamova H, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Othus M, Gale RP, Jiang Q, Faber E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41840226"},{"title01":"Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.","title02":"Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.","journal":"Leukemia","issue":"2026 March 24. doi: 10.1038\/s41375-026-02945-y. Online ahead of print","author":"Mauro FR, Allsup D, Molica S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41876726"},{"title01":"Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.","title02":"Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 March 30. doi: 10.1038\/s41375-026-02944-z. Online ahead of print","author":"Kirchhoff H, Schoenherr C, Fleischer L, Talbot SR, Heidel FH, Bergmann AK, Eder M, Scherr M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912910"},{"title01":"The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.","title02":"The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 March 30. doi: 10.1038\/s41375-026-02921-6. Online ahead of print","author":"Perusini MA, Pagnano K, Pavlovsky C, Zackova D, Mayer J, Moiraghi B, Varela AI, Bianchini M, Pascoal Lopes AB, Duarte G, de Souza CA, Jeziskova I, Kvetkova A, Jurcek T, Won Lee H, Chang MH, Medeiros JJF, Abelson S, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912912"},{"title01":"BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.","title02":"BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.","journal":"Leukemia","issue":"2026 March 30. doi: 10.1038\/s41375-026-02916-3. Online ahead of print","author":"Park J, Kim SH, Park J, Park H, Kim H, Kim DW, Lim C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912913"},{"title01":"A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia.","title02":"A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March 25. doi: 10.1038\/s41375-026-02917-2. Online ahead of print","author":"Aryal S, Curtiss BM, Zhou X, Lu R, Cheng C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41882099"},{"title01":"Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia.","title02":"Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.289318. Online ahead of print","author":"Nguyen D, Jabbour E, Kantarjian HM, Macaron W, Jain N, Nasnas C, Kebriaei P, Shpall EJ, Khouri I, Haddad F, Karrar O, Maroun M, Garris R, Ravandi F, Short NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885010"},{"title01":"Bedside treatment algorithm for safe administration of 24-hour high-dose methotrexate in adult acute lymphoblastic leukemia.","title02":"Bedside treatment algorithm for safe administration of 24-hour high-dose methotrexate in adult acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.300203. Online ahead of print","author":"Hamberg AK, Schubert J, Lennmyr E, Hallbook H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885012"},{"title01":"Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia.","title02":"Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2026.000001. Online ahead of print","author":"Hu C, Qi N, Wang W, Gale RP, Zhu F, Li H, Cheng H, Cao J, Yan Z, Qi K, Sang W, Zhao K, Chen W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852346"},{"title01":"Monitoring relapse in post-transplant acute myeloid leukemia requires integrated assessment, with flow cytometry showing the highest efficacy.","title02":"Monitoring relapse in post-transplant acute myeloid leukemia requires integrated assessment, with flow cytometry showing the highest efficacy.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.289192. Online ahead of print","author":"Wang WJ, Wang SA, Fang H, Wei Q, Hu S, Loghavi S, Al-Atrash G, Zang C, Wei P, Medeiros JL, Wang W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885014"},{"title01":"Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies.","title02":"Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.300215. Online ahead of print","author":"Radich JP, Chaturvedi S, Sadek I, Obourn V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885027"},{"title01":"HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group.","title02":"HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group.","journal":"Haematologica","issue":"2026 March 26. doi: 10.3324\/haematol.2025.288751. Online ahead of print","author":"Chinnabhandar V, Verneris MR, Schultz KR, Gamis AS, Aplenc R, Hudson CA, Alonzo TA, Gerbing RB, Horan JT, Chewning JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41885017"},{"title01":"B-cell precursor acute lymphoblastic leukaemia with IGH::CEBP rearrangement: what have we learnt over the years?","title02":"B-cell precursor acute lymphoblastic leukaemia with IGH::CEBP rearrangement: what have we learnt over the years?","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300431. Online ahead of print","author":"Alqahtani A, Fung KTM, Marchetti L, Enshaei A, Bashton M, Heidenreich O, Harrison CJ, Moorman AV, Russell LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852344"},{"title01":"The prognostic role of myeloid-related gene mutations in adult acute lymphoblastic leukemia.","title02":"The prognostic role of myeloid-related gene mutations in adult acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300044. Online ahead of print","author":"Wang W, Chen J, Li Y, Zhang G, Zhou C, Fang Q, Li S, Liu K, Lin D, Gong B, Liu Y, Guo C, Hui Y, Wang Y, Qiu S, Liu B, Wang Y, Mi Y, Gong X, Wang J, Wei H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852325"},{"title01":"Decoding the actionable potential of ribosome biogenesis in acute myeloid leukemia.","title02":"Decoding the actionable potential of ribosome biogenesis in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 19. doi: 10.3324\/haematol.2025.300149. Online ahead of print","author":"Miliara S, Zhong X, Papadaki S, Devesa-Serrano D, Farrants AO, Lehmann S, Bartek J, Kanellis DC, Lennartsson A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41852324"},{"title01":"Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.","title02":"Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.","journal":"N Engl J Med","issue":"2026 March 26; 394(12):1238-1240. doi: 10.1056\/NEJMc2518028","author":"Annamalay A, Garcia Gonzalez I, Forsyth C, Jenkins I, Arteaga M, Othieno-Abinya NA, Desai C, Duarte F, Gangadharan VP, Gundeti S, Malhotra H, Malhotra P, Meliksetyan K, Mojica R, Zarza J, Sabonge JM, Santana AL, Gebremedhin A, Orellana Martinez R, Martinez Miranda M, Lima Valencia MG, Garcia-Gonzalez P, Radich J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41880621"},{"title01":"PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.","title02":"PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.","journal":"Leukemia","issue":"2026 March 30. doi: 10.1038\/s41375-026-02935-0. Online ahead of print","author":"Tian Z, Gao P, Zhang Y, Ma J, Hu X, Wang H, Lu L, Zhang Y, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41912914"},{"title01":"Comment on “Acute Promyelocytic Leukemia with other RARA rearrangements”.","title02":"Comment on “Acute Promyelocytic Leukemia with other RARA rearrangements”.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300363. Online ahead of print","author":"Su Z, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816827"},{"title01":"Erratum to: “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation”.","title02":"Erratum to: “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation”.","journal":"Haematologica","issue":"2026 March 1; 111(3):1136-1137. doi: 10.3324\/haematol.2025.289363","author":"Lastovytska I, Heidenreich S, Klyuchnikov E, Niederwieser C, Gagelmann N, Richter J, Massoud R, Rathje K, Perekhrestenko T, Zeck G, Luck C, Janson D, Wolschke C, Ayuk F, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773030"},{"title01":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","title02":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 March; 40(3):609-621. doi: 10.1038\/s41375-025-02843-9","author":"Kealy D, Ellerington R, Bansal S, Medeiros JJF, Hawley CA, Zeng AGX, Lukaszonek J, West KA, Sinha AD, Caalim G, Gawne RT, Pope J, Ferreira BL, Blacknell NM, Drylie B, Chatzigerou J, Khoo HM, Wilkinson AC, Fielding AK, Wang G, Psaila B, Kent DG, Hitchcock IS, Holding AN, Mason AS, Gupta V, Dick JE, Bridge KS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41629621"},{"title01":"Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.","title02":"Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.","journal":"Haematologica","issue":"2026 March 1; 111(3):990-996. doi: 10.3324\/haematol.2024.286697","author":"Leontyeva Y, Landtblom AR, Hultcrantz M, Lambe M, Bower H, Lambert PC, Andersson TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994348"},{"title01":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","title02":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 March 1; 111(3):1070-1074. doi: 10.3324\/haematol.2025.288166","author":"Boasman K, Walker CL, Simmonds MJ, Rinaldi CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994357"},{"title01":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","title02":"Somatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.","journal":"Br J Haematol","issue":"2026 March 3. doi: 10.1111\/bjh.70404. Online ahead of print","author":"Speight B, Hamblin A, Talley P, Tsoulaki O, Robinson R, Dean P, Khorashad J, Kulasekararaj A, Godfrey AL, Mead AJ, McVeigh TP, Snape K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773566"},{"title01":"Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.","title02":"Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.","journal":"Blood advances","issue":"2026 March 10; 10(5):1473-1480. doi: 10.1182\/bloodadvances.2025018011","author":"Barbui T, Scandura JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370203"},{"title01":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.","title02":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 March 10; 10(5):1603-1613. doi: 10.1182\/bloodadvances.2025018724","author":"Leiva O, Soo S, Liu OC, You V, Palmer A, Kahla J, Murtaza Y, Odenike O, Patel AA, DeCara JM, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499780"},{"title01":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","title02":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019152. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779966"},{"title01":"Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.","title02":"Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031366. Online ahead of print","author":"Mora B, Palandri F, Guglielmelli P, Kuykendall AT, Maffioli M, Iurlo A, De Stefano V, Salmoiraghi S, Devos T, Itri F, Cervantes F, Kiladjian JJ, Della Porta MG, Albano F, Gotlib J, Benevolo G, Caramella M, Ruggeri M, Rumi E, Ross DM, Pessina C, Colugnat I, Orsini F, Micucci G, Rotunno G, Komrokji RS, Cattaneo D, Chiusolo P, Bortolotti M, Barbui T, Cilloni D, Breccia M, Palumbo GA, Branzanti F, Margotto L, Franchi M, Vannucchi AM, Passamonti F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785373"},{"title01":"A niche for every stem cell in myeloproliferative neoplasms.","title02":"A niche for every stem cell in myeloproliferative neoplasms.","journal":"Blood","issue":"2026 March 12; 147(11):1143-1144. doi: 10.1182\/blood.2025032458","author":"Mendez-Ferrer S, Fleischman AG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817558"},{"title01":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","title02":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","journal":"Blood","issue":"2026 March 11. doi: 10.1182\/blood.2025030972. Online ahead of print","author":"Gao L, Zhai X, Wang N, Liao N, Xiao P, Xu F, Yang M, Xu X, An Q, Luo J, Yang L, Yuan X, He Y, Zhuang Y, Wang H, Yang L, Zhang W, Liu YL, Li J, He H, Wang Y, Cheng C, Lu J, Jiang H, Ju X, Wang Q, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812214"},{"title01":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","title02":"Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.","journal":"J Clin Oncol","issue":"2026 March 4; JCO2501929. doi: 10.1200\/JCO-25-01929. Online ahead of print","author":"Zhou H, Zhao H, Hou X, Wang Y, He Z, Li Y, Ma Y, Zhao Y, Huang Y, Chen L, Xiao S, Zhu H, Zhu Y, Fang W, Zhang L, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779981"},{"title01":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","title02":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","journal":"Haematologica","issue":"2026 March 1; 111(3):955-970. doi: 10.3324\/haematol.2025.287676","author":"Jiang S, Qi J, Pan T, Yao Z, Lu S, Han Y, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820810"},{"title01":"Romiplostim for aplastic anemia: beyond an eltrombopag alternative.","title02":"Romiplostim for aplastic anemia: beyond an eltrombopag alternative.","journal":"Haematologica","issue":"2026 March 1; 111(3):794-796. doi: 10.3324\/haematol.2025.288632","author":"Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905092"},{"title01":"Safety and efficacy of romiplostim in children with acquired aplastic anemia who are naive to immunosuppressive therapy.","title02":"Safety and efficacy of romiplostim in children with acquired aplastic anemia who are naive to immunosuppressive therapy.","journal":"Haematologica","issue":"2026 March 1; 111(3):1061-1064. doi: 10.3324\/haematol.2025.288078","author":"Bordbar M, Faghihi A, Zekavat OR, Shahriari M, Bordbar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702901"},{"title01":"Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding.","title02":"Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding.","journal":"Blood advances","issue":"2026 March 10; 10(5):1508-1517. doi: 10.1182\/bloodadvances.2025018315","author":"Wang D, Sra M, Ito S, Ng DQ, Glaeser-Khan S, Wang DY, Hirniak S, Lee AI, Cuker A, Goshua G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504430"},{"title01":"Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS).","title02":"Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS).","journal":"Blood advances","issue":"2026 March 10; 10(5):1799-1808. doi: 10.1182\/bloodadvances.2025018382","author":"Zhang E, Kasthuri RS, Parambil J, Prasad V, Iyer VN, Whitehead KJ, Hodges PG, Pishko AM, Conrad MB, Phelan D, Rodriguez-Lopez J, McCrae KR, Al-Samkari H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512167"},{"title01":"Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming.","title02":"Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming.","journal":"Blood advances","issue":"2026 March 10; 10(5):1444-1456. doi: 10.1182\/bloodadvances.2025017625","author":"Carminita E, Camacho V, Branfield S, Walsey E, Barrachina MN, Tabang DN, Lee DH, Becker IC, Brodsky SV, Issa SM, Gendron N, Machado S, Wolberg AS, Steen H, Kerlin B, Machlus KR, Zarjou A, Italiano JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411491"},{"title01":"Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study.","title02":"Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018706. Online ahead of print","author":"Ali H, Mohan SR, Kishtagari A, Prchal JT, Maher KR, Chai Y, Gudi G, Taverna P, Mark TM, Tantravahi SK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785311"},{"title01":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","title02":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025031135. Online ahead of print","author":"Liu Y, Zhang W, Cai J, Zhou D, Zhao H, Dong W, Zhao B, Lu Y, Hao S, Ding Y, Jiang N, Qiao T, Li K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824385"},{"title01":"Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.","title02":"Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.","journal":"N Engl J Med","issue":"2026 March 5; 394(10):1030-1033. doi: 10.1056\/NEJMc2516228","author":"Gottschlich A, Bucklein V, El-Marouk K, Kaiser R, Schmid M, Janert TA, Winkelmann M, Ziemann F, Hanel G, Handtke S, Thiele T, Wichmann C, Kobold S, Zugmaier G, Rausch C, Schulze-Koops H, Lindner LH, Spiekermann K, von Bergwelt-Baildon M, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41780009"},{"title01":"Sustained response off-treatment and thrombotic events in patients with immune thrombocytopenia treated with fostamatinib: a systematic review and meta-analysis.","title02":"Sustained response off-treatment and thrombotic events in patients with immune thrombocytopenia treated with fostamatinib: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2026.288458. Online ahead of print","author":"Clerici B, Mondini C, Pontisso E, Sala S, Tarasconi E, Pisetta C, Birocchi S, Podda GM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784025"},{"title01":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","title02":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300199. Online ahead of print","author":"Zadro Y, Lafaurie M, Sommet A, Lapeyre-Mestre M, Moulis G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816826"},{"title01":"Lack of association between vaccine-induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort.","title02":"Lack of association between vaccine-induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70419. Online ahead of print","author":"Schonborn L, Tzvetkova A, Thiele T, Volker U, Ameling S, Franzenburg S, Kaderali L, Greinacher A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797449"},{"title01":"Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety.","title02":"Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70414. Online ahead of print","author":"Shah SD, Vibhakar A, Shah RP, Rathod N, Modi G, Patel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802829"},{"title01":"Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.","title02":"Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70403. Online ahead of print","author":"Sorin B, Azzouguen B, Loustau V, Boutin E, Henique H, Graveleau J, Souchaud-Debouverie O, Pascal L, Gilardin L, Costedoat-Chalumeau N, Reynaud Q, Pan-Petesch B, Cheze S, Terriou L, Comont T, Sauvetre G, Royer B, Mahevas M, Michel M, Canoui-Poitrine F, Godeau B, Guillet S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814575"},{"title01":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","title02":"CDK8\/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025031332. Online ahead of print","author":"Wang YM, Zhou H, Leng S, Ma JJ, Li H, Li G, Sun T, Xu Y, Han S, Gu Y, Dong L, Yan Z, Zhang L, Peng J, Liu XG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770851"},{"title01":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","title02":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","journal":"Leukemia","issue":"2026 March; 40(3):661-665. doi: 10.1038\/s41375-025-02858-2","author":"Zhao LP, Kosmider O, Heiblig M, Moulinet T, Lacombe V, Comont T, Lobbes H, Karam JD, Terriou L, Ardois S, Le Guenno G, Jachiet V, Wolff L, Vertenoeil G, Hadjadj J, Bouaziz JD, Lemaire P, Fain O, Terrier B, Georgin-Lavialle S, Larcher L, Clappier E, Sebert M, Ades L, Mekinian A, Fenaux P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545701"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):622-629. doi: 10.1038\/s41375-026-02874-w","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 March; 40(3):649-660. doi: 10.1038\/s41375-026-02886-6","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","title02":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","journal":"Leukemia","issue":"2026 March; 40(3):468-480. doi: 10.1038\/s41375-026-02865-x","author":"Lee NC, Miao R, Young NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703030"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 March; 13(3):e181-e185. doi: 10.1016\/S2352-3026(25)00359-X","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","title02":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 March 1; 111(3):1070-1074. doi: 10.3324\/haematol.2025.288166","author":"Boasman K, Walker CL, Simmonds MJ, Rinaldi CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994357"},{"title01":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","title02":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.288146. Online ahead of print","author":"Feng J, Wang K, Gou J, Wang Y, Hu B, Wei W, Ge J, Feng Y, Feng S, Solary E, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784036"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","journal":"Blood advances","issue":"2026 March 10; 10(5):1548-1558. doi: 10.1182\/bloodadvances.2025018631","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Validation of ICC hierarchical classification in secondary AML.","title02":"Validation of ICC hierarchical classification in secondary AML.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018188. Online ahead of print","author":"Attardi E, Cipriani M, Guarnera L, Savi A, Fabiani E, Mallegni F, Moretti F, Silvestrini G, Awada H, Durmaz A, Ferrari I, Maggioni G, Memoli M, Visconte V, Venditti A, Della Porta MG, Gurnari C, Piciocchi A, Maciejewski JP, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785326"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1098-1110. doi: 10.1182\/blood.2025030816","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 March; 40(3):698-701. doi: 10.1038\/s41375-026-02860-2","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","title02":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","journal":"Blood","issue":"2026 March 12; 147(11):1215-1228. doi: 10.1182\/blood.2025031454","author":"Lu M, Mia MB, Xia L, Mosoyan G, Hayat M, Schaniel C, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397284"},{"title01":"Focal MPN-associated JAK2-mutated skeletal lesion with normal blood counts and bone marrow.","title02":"Focal MPN-associated JAK2-mutated skeletal lesion with normal blood counts and bone marrow.","journal":"Blood","issue":"2026 March 5; 147(10):1135. doi: 10.1182\/blood.2025032152","author":"Eren OC, Konoplev S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785000"},{"title01":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):981-989. doi: 10.3324\/haematol.2025.287750","author":"Sanz J, Ferhat AT, Kulagin A, Kroger N, Rovira M, Lazzari L, Arat M, Montoro J, Versluis J, Remenyi P, Sica S, Blaise D, Saif MA, Vydra J, Fagioli F, Nur E, Giebel S, Peric Z, Brissot E, Nagler A, Piemontese S, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820728"},{"title01":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","title02":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300176. Online ahead of print","author":"Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stolzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784041"},{"title01":"Proteostasis meets signaling: UBE2G1 in hematopoietic stem cell aging.","title02":"Proteostasis meets signaling: UBE2G1 in hematopoietic stem cell aging.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2026.300724. Online ahead of print","author":"Miller V, Nachmias B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784031"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70421. Online ahead of print","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","title02":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025015971. Online ahead of print","author":"Nademi Z, Lum SH, Gilbert P, Sirait T, Karakukcu M, Locatelli F, Schulz AS, Gozdzik J, Ikinciogullari A, Kalwak K, Alsaedi H, Bierings MB, Bader P, Diaz-de-Heredia C, Winiarski JH, Masmas TNN, Lankester AC, Gabriel M, Biffi A, Mitchell R, Ryhanen SJ, Kuskonmaz B, Corbacioglu S, Faraci M, Buechner J, Kerre TCC, Slatter MA, Albert MH, Neven B, Gennery AR, Kulagin AD, Lewalle P, Ghosh S, Schlegel PG, Eyrich M, Schwinger W, Wynn R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774850"},{"title01":"A CHARMed life after HCT: health span beyond life span.","title02":"A CHARMed life after HCT: health span beyond life span.","journal":"Blood advances","issue":"2026 March 10; 10(5):1743-1745. doi: 10.1182\/bloodadvances.2025018938","author":"Hamilton BK, Ragon BK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759034"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","title02":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","journal":"Blood advances","issue":"2026 March 10; 10(5):1657-1669. doi: 10.1182\/bloodadvances.2025018340","author":"Artz AS, Logan B, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris L, Imus P, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall S, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","title02":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025018720. Online ahead of print","author":"Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774854"},{"title01":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.","title02":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.","journal":"Blood advances","issue":"2026 March 10; 10(5):1783-1798. doi: 10.1182\/bloodadvances.2025017662","author":"Alexander JL, Davila Saldana BJ, Brazauskas R, Dammalapati SG, Griffith LM, Shah AJ, Shimano KA, Ochs HD, Bleesing JJ, Ebens CL, Kapadia M, Bauchat A, Kapoor N, Oved JH, Eissa H, Lust H, Keller MD, Haines H, Chandrakasan S, Talano JA, Rayes A, Madden L, Shereck E, Miller HK, Satter LF, Martinez C, Rozmus J, Bednarski JJ, Yu LC, Chellapandian D, Aquino VM, Knutsen A, Chong H, Chopek A, Gillio AP, Joshi A, Rangarajan H, Moore TB, Andolina JR, DeSantes KB, Vander Lugt M, Prockop SE, Shyr DC, Sullivan KE, Parikh S, Weinacht KG, Torgerson TR, Marsh R, Dvorak CC, Chan AY, Haddad E, Heimall JR, Pulsipher MA, Leiding JW, Kohn DB, Puck JM, Notarangelo LD, Rawlings DJ, Cowan MJ, Petrovic A, Pai SY, Burroughs LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346295"},{"title01":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","title02":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","journal":"Blood advances","issue":"2026 March 10; 10(5):1746-1755. doi: 10.1182\/bloodadvances.2025018031","author":"Badar T, Marando L, Latorre E, Lasho T, Olivia FD, Lin C, McCormick BJ, El Kettani M, Shah KJ, Kusne Y, Jamy O, Diebold K, Coltoff A, Finke C, Foran J, Kharfan-Dabaja M, Fan YS, Jiang L, He R, Thomas M, Patel A, Viswanatha D, Shah MV, Saliba A, Mangaonkar A, Kirschner K, Al-Kali A, Gangat N, Litzow M, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499760"},{"title01":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","title02":"Low Serum Cholesterol Is a Biomarker of Advanced Disease and Poor Outcomes in Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019152. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779966"},{"title01":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","title02":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019142. Online ahead of print","author":"Ben Hassine K, Gloor YS, Dupanloup I, Uppugunduri Satyanarayana CR, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi AC, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","title02":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2026 March 12; 147(11):1147-1167. doi: 10.1182\/blood.2025031480","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang S, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw D, Kern W, Kim DDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein V, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon R, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","title02":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","journal":"Blood","issue":"2026 March 5; 147(10):1019-1036. doi: 10.1182\/blood.2025028762","author":"Verkamp B, Jordan MB, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481377"},{"title01":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","title02":"TMEM187 is a novel modulator in the regulation of erythropoiesis.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025031135. Online ahead of print","author":"Liu Y, Zhang W, Cai J, Zhou D, Zhao H, Dong W, Zhao B, Lu Y, Hao S, Ding Y, Jiang N, Qiao T, Li K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824385"},{"title01":"Immune-mediated side effects of cancer immunotherapies.","title02":"Immune-mediated side effects of cancer immunotherapies.","journal":"Blood","issue":"2026 March 9. doi: 10.1182\/blood.2025030059. Online ahead of print","author":"Braun LM, Naidoo J, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802111"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 March; 40(3):698-701. doi: 10.1038\/s41375-026-02860-2","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","title02":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","journal":"Lancet Oncol","issue":"2026 March; 27(3):349-360. doi: 10.1016\/S1470-2045(25)00707-7","author":"Louis FM, van der Voort A, van Ramshorst MS, Daletzakis A, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJM, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Egeler MD, van de Poll-Franse LV, Mann RM, Sonke GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713473"},{"title01":"Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.","title02":"Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.","journal":"Lancet Oncol","issue":"2026 March; 27(3):372-382. doi: 10.1016\/S1470-2045(25)00720-X","author":"van den Hoek L, Burgmans M, Tong T, Goeman J, Speetjens F, Zunder S, van Erkel A, van der Meer R, van Rijswijk C, Lutjeboer J, Koolhaas D, Jonker-Bos M, Roozen I, Kropff S, van Meerten EVP, Zoethout R, Sitsen E, Helmerhorst H, Tijl F, Blank C, Kapiteijn E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785896"},{"title01":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","title02":"Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.","journal":"Lancet","issue":"2026 March 12. doi: 10.1016\/S0140-6736(26)00150-9. Online ahead of print","author":"Doeven T, Glenthoj A, Grace RF, van Beers EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41833294"},{"title01":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","title02":"Nivolumab +\/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.","journal":"J Clin Oncol","issue":"2026 March 3; JCO2501657. doi: 10.1200\/JCO-25-01657. Online ahead of print","author":"Walter TP, Mazieres J, Otto J, Lena H, Lepage C, Smith D, Madelaine J, Geriniere L, Egenod T, El Hajbi F, Ferru A, Clement-Duchene C, Madroszyk A, Brotelle T, Bouhier-Leporrier K, Desrame J, Ghiringhelli F, Paleiron N, Khalil A, Milot L, Chevallier O, Couvelard A, Lantuejoul S, Langlais A, Morin F, Duruisseaux M, Michel P, Louvet C, Westeel V, Girard N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774886"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1098-1110. doi: 10.1182\/blood.2025030816","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Immune-mediated side effects of cancer immunotherapies.","title02":"Immune-mediated side effects of cancer immunotherapies.","journal":"Blood","issue":"2026 March 9. doi: 10.1182\/blood.2025030059. Online ahead of print","author":"Braun LM, Naidoo J, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802111"},{"title01":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","title02":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031466. Online ahead of print","author":"Mimura K, Kaino A, Ochi Y, Chang YH, Seki M, Takeda J, Katayama S, Niizuma H, Sasahara Y, Mizoguchi Y, Shimomura M, Koyamada R, Ono R, Hasegawa D, Mitani K, Kubota H, Yoshihara S, Hiramoto N, Otsuki A, Okamura Y, Katsuoka F, Kinoshita K, Hasegawa M, Togo-Ohno M, Maeda H, Kakiuchi N, Takeuchi M, Sato-Otsubo A, Kato S, Watanabe K, Katayama K, Imoto S, Shiraishi Y, Koh K, Suenobu S, Hiyama E, Goyama S, Kikuchi A, Ogawa S, Kato M, Nannya Y, Takita J, Yoshida K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41790573"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","title02":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","journal":"Blood","issue":"2026 March 4. doi: 10.1182\/blood.2025031016. Online ahead of print","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","title02":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025030207. Online ahead of print","author":"Minnie S, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SR, Schmidt CR, Comstock ML, Lyons J, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770790"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 March; 40(3):491-501. doi: 10.1038\/s41375-025-02848-4","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 March; 40(3):594-608. doi: 10.1038\/s41375-025-02828-8","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","title02":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","journal":"Leukemia","issue":"2026 March; 40(3):502-510. doi: 10.1038\/s41375-025-02857-3","author":"Mehta RS, Aljawai YM, Kebriaei P, Rondon G, Fingrut W, Smallbone P, Oran B, Olson A, Champlin RE, Shpall EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526616"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","title02":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","journal":"Leukemia","issue":"2026 March; 40(3):511-521. doi: 10.1038\/s41375-025-02850-w","author":"Zhou J, Hu T, Li D, Li S, Li M, Shi X, Nakada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526615"},{"title01":"Tele-prehabilitation for allogeneic HCT.","title02":"Tele-prehabilitation for allogeneic HCT.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e131-e132. doi: 10.1016\/S2352-3026(26)00033-5","author":"Salas MQ, Salinas Gonzalez RS, Fernandez-Aviles F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791830"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 March; 13(3):e181-e185. doi: 10.1016\/S2352-3026(25)00359-X","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e133-e143. doi: 10.1016\/S2352-3026(25)00328-X","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","title02":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e157-e168. doi: 10.1016\/S2352-3026(25)00358-8","author":"Ruhnke L, Schliemann C, Mikesch JH, Stelljes M, Fransecky L, Steffen B, Kaufmann M, Burchert A, Rank A, Hanoun M, Hollein A, Kraus S, Schafer-Eckart K, Hanel M, Haake A, Fiebig F, Kramer M, Zukunft S, Kunadt D, Middeke JM, Sockel K, Schetelig J, Platzbecker U, von Bonin M, Rohnert MA, Oelschlagel U, Wagenfuhr L, Thiede C, Herold S, Poitz D, Stolzel F, Baldus CD, Serve H, Wermke M, Bornhauser M, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791831"},{"title01":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","title02":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e169-e180. doi: 10.1016\/S2352-3026(25)00361-8","author":"Oliva EN, Cottone F, Unni S, Correges A, Hansen JB, Marston XL, Cortes J, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791832"},{"title01":"Maintenance intensification after allogeneic HSCT: refining selection.","title02":"Maintenance intensification after allogeneic HSCT: refining selection.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00064-5. Online ahead of print","author":"Perrot A, Frenzel L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831470"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00011-6. Online ahead of print","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Sickle cell disease.","title02":"Sickle cell disease.","journal":"Lancet","issue":"2026 March 14; 407(10533):1095-1111. doi: 10.1016\/S0140-6736(25)02278-0","author":"Colombatti R, Jastaniah W, Makani J, Andemariam B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831848"},{"title01":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","title02":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289250. Online ahead of print","author":"Zhou B, Yuan Y, Cai Y, Zhou J, Shi L, Qin Y, Meng C, Zhang S, Yu S, Chen X, He X, Wu S, Li M, Yu X, Shi Y, Xing C, Chen C, Zhao M, Gao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816830"},{"title01":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","title02":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):971-980. doi: 10.3324\/haematol.2024.287061","author":"Schafer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, Kursteiner O, Nair G, Halter J, Gungor T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","title02":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","journal":"Haematologica","issue":"2026 March 1; 111(3):955-970. doi: 10.3324\/haematol.2025.287676","author":"Jiang S, Qi J, Pan T, Yao Z, Lu S, Han Y, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820810"},{"title01":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","title02":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","journal":"Haematologica","issue":"2026 March 1; 111(3):1081-1088. doi: 10.3324\/haematol.2025.288306","author":"Tassi E, Orofino G, Beretta V, Valtolina V, Bergonzi GM, Noviello M, Xue E, Doglio M, Acerbis A, Lazzari L, Giglio F, Piemontese S, Diral E, Bruno A, Farina F, Dell'Acqua R, Vago L, Assanelli A, Ruggeri A, Clerici D, Corti C, Lupo-Stanghellini MT, Ciceri F, Bonini C, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905077"},{"title01":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","title02":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","journal":"Haematologica","issue":"2026 March 1; 111(3):892-905. doi: 10.3324\/haematol.2025.288464","author":"Wu N, Ding W, Wu J, Ling M, Yue K, Cheng C, Jia M, Liu J, Huang XJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994352"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 March 14. doi: 10.1111\/bjh.70426. Online ahead of print","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00011-6. Online ahead of print","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Sickle cell disease.","title02":"Sickle cell disease.","journal":"Lancet","issue":"2026 March 14; 407(10533):1095-1111. doi: 10.1016\/S0140-6736(25)02278-0","author":"Colombatti R, Jastaniah W, Makani J, Andemariam B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831848"},{"title01":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","title02":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","journal":"J Clin Oncol","issue":"2026 March 10; 44(8):698-708. doi: 10.1200\/JCO-25-02087","author":"Faramand RG, Xie Z, Jain MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671523"},{"title01":"Thyroid hormones induce an acute platelet release mechanism via integrin alphaVbeta3.","title02":"Thyroid hormones induce an acute platelet release mechanism via integrin alphaVbeta3.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289252. Online ahead of print","author":"Foster HR, Herbert N, Di Buduo CA, Schmidt AP, Fang J, Biswas R, Taimoor M, Waller AK, Howard D, Vallance TM, Lawrence M, Mueller A, Moreau T, Evans AL, Turro E, Fischer R, Wilcox DA, Hoffmeister KM, Balduini A, Ghevaert C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816842"},{"title01":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","title02":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300176. Online ahead of print","author":"Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stolzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784041"},{"title01":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","title02":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):971-980. doi: 10.3324\/haematol.2024.287061","author":"Schafer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, Kursteiner O, Nair G, Halter J, Gungor T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","title02":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):843-851. doi: 10.3324\/haematol.2025.287777","author":"Murphy T, Zhang B, Zhang T, King I, Capo-Chichi JM, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee KWL, Arruda A, Lu Z, Khalaf D, Rockwell C, Leber B, Sabloff M, Tierens A, Stockley TL, Chan SM, Ng SWK, Wang JCY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637740"},{"title01":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","title02":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","journal":"Haematologica","issue":"2026 March 1; 111(3):997-1006. doi: 10.3324\/haematol.2025.288006","author":"Yousuf M, Faldu P, Abdelmagid M, Aperna F, Fathima S, Alsugair AKA, Csizmar CM, Lasho TL, Mangaonkar AA, Reichard KK, He R, Pardanani A, Gangat N, Patnaik MM, Tefferi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098096"},{"title01":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","title02":"Impact of letermovir on cytomegalovirus-specific T-cell reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era.","journal":"Haematologica","issue":"2026 March 1; 111(3):1081-1088. doi: 10.3324\/haematol.2025.288306","author":"Tassi E, Orofino G, Beretta V, Valtolina V, Bergonzi GM, Noviello M, Xue E, Doglio M, Acerbis A, Lazzari L, Giglio F, Piemontese S, Diral E, Bruno A, Farina F, Dell'Acqua R, Vago L, Assanelli A, Ruggeri A, Clerici D, Corti C, Lupo-Stanghellini MT, Ciceri F, Bonini C, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905077"},{"title01":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):981-989. doi: 10.3324\/haematol.2025.287750","author":"Sanz J, Ferhat AT, Kulagin A, Kroger N, Rovira M, Lazzari L, Arat M, Montoro J, Versluis J, Remenyi P, Sica S, Blaise D, Saif MA, Vydra J, Fagioli F, Nur E, Giebel S, Peric Z, Brissot E, Nagler A, Piemontese S, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820728"},{"title01":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","title02":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","journal":"Haematologica","issue":"2026 March 1; 111(3):1017-1028. doi: 10.3324\/haematol.2025.288381","author":"Al-Bazaz M, Pischke S, Alsdorf W, Sonnemann P, Cichutek S, Wiesch JSZ, Schaefers C, Artzenroth J, Leypoldt L, Kamili A, Bokemeyer C, Weisel K, Kosch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994343"},{"title01":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","title02":"MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-beta1 and LRP6 pathways.","journal":"Haematologica","issue":"2026 March 1; 111(3):892-905. doi: 10.3324\/haematol.2025.288464","author":"Wu N, Ding W, Wu J, Ling M, Yue K, Cheng C, Jia M, Liu J, Huang XJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994352"},{"title01":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","title02":"KLF4 overexpression protects against complementmediated endothelial injury in transplant-associated thrombotic microangiopathy.","journal":"Haematologica","issue":"2026 March 1; 111(3):955-970. doi: 10.3324\/haematol.2025.287676","author":"Jiang S, Qi J, Pan T, Yao Z, Lu S, Han Y, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820810"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70421. Online ahead of print","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","title02":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025018720. Online ahead of print","author":"Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774854"},{"title01":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","title02":"Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of Immunity.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025015971. Online ahead of print","author":"Nademi Z, Lum SH, Gilbert P, Sirait T, Karakukcu M, Locatelli F, Schulz AS, Gozdzik J, Ikinciogullari A, Kalwak K, Alsaedi H, Bierings MB, Bader P, Diaz-de-Heredia C, Winiarski JH, Masmas TNN, Lankester AC, Gabriel M, Biffi A, Mitchell R, Ryhanen SJ, Kuskonmaz B, Corbacioglu S, Faraci M, Buechner J, Kerre TCC, Slatter MA, Albert MH, Neven B, Gennery AR, Kulagin AD, Lewalle P, Ghosh S, Schlegel PG, Eyrich M, Schwinger W, Wynn R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774850"},{"title01":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","title02":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019142. Online ahead of print","author":"Ben Hassine K, Gloor YS, Dupanloup I, Uppugunduri Satyanarayana CR, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi AC, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","title02":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","journal":"Blood advances","issue":"2026 March 10; 10(5):1576-1586. doi: 10.1182\/bloodadvances.2025017837","author":"Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124669"},{"title01":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","title02":"CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.","journal":"Blood advances","issue":"2026 March 10; 10(5):1657-1669. doi: 10.1182\/bloodadvances.2025018340","author":"Artz AS, Logan B, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris L, Imus P, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall S, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1773-1782. doi: 10.1182\/bloodadvances.2025018057","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","journal":"Blood advances","issue":"2026 March 10; 10(5):1548-1558. doi: 10.1182\/bloodadvances.2025018631","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","title02":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","journal":"Blood advances","issue":"2026 March 10; 10(5):1469-1472. doi: 10.1182\/bloodadvances.2025017795","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"Graft manipulation and GVHD: what goes around comes around.","title02":"Graft manipulation and GVHD: what goes around comes around.","journal":"Blood","issue":"2026 March 12; 147(11):1137-1138. doi: 10.1182\/blood.2025032408","author":"Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817555"},{"title01":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","title02":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","journal":"Blood","issue":"2026 March 11. doi: 10.1182\/blood.2025030972. Online ahead of print","author":"Gao L, Zhai X, Wang N, Liao N, Xiao P, Xu F, Yang M, Xu X, An Q, Luo J, Yang L, Yuan X, He Y, Zhuang Y, Wang H, Yang L, Zhang W, Liu YL, Li J, He H, Wang Y, Cheng C, Lu J, Jiang H, Ju X, Wang Q, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812214"},{"title01":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","title02":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 March 5; 147(10):1125-1134. doi: 10.1182\/blood.2025030151","author":"Desai SH, Moskowitz AJ, Merryman RW, Shah H, Pederson LD, Geyer SM, Ganesan N, Chang T, Othman T, Falade AS, Shah GL, Durani U, Sumransub N, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Armand P, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405496"},{"title01":"BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.","title02":"BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025031983. Online ahead of print","author":"Kumar R, Neidemire-Colley L, Garfinkle EA, Steere C, Surana S, Murray A, Giordano G, Martin O, Woodbury ED, Rivaldi A, Singh S, Corps K, Lederer K, Karunasiri M, Gorr MW, Wold LE, Sehgal L, Oestreich KJ, Grieselhuber NR, de Lima MJ, Blazar BR, Maillard I, Miller KE, Choe HK, Ranganathan P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770848"},{"title01":"Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma.","title02":"Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma.","journal":"Blood advances","issue":"2026 March 13. doi: 10.1182\/bloodadvances.2025018482. Online ahead of print","author":"Song Z, Cheng Y, Yang H, Zhang L, Zou L, Guo Y, Cao J, Huang H, Wang Z, Huang S, Fang Y, Lyu J, Zhang Y, Liu Y, Zhou K, Zhang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824782"},{"title01":"From phase 1 to approval: lymphoma’s long road.","title02":"From phase 1 to approval: lymphoma’s long road.","journal":"Blood advances","issue":"2026 March 10; 10(5):1809-1810. doi: 10.1182\/bloodadvances.2025018860","author":"Hertzberg M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41771007"},{"title01":"Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer\/T-cell lymphoma.","title02":"Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer\/T-cell lymphoma.","journal":"Blood advances","issue":"2026 March 13. doi: 10.1182\/bloodadvances.2025018855. Online ahead of print","author":"Chen Z, Huang H, Fang X, Tian Y, Weng H, Gale RP, Zou L, Zhang W, Li Z, Guo H, Ge J, Huang Z, Chen N, Liang Y, Hong H, Lin T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824796"},{"title01":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","title02":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","journal":"Blood","issue":"2026 March 4. doi: 10.1182\/blood.2025031016. Online ahead of print","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine.","title02":"Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine.","journal":"Blood","issue":"2026 March 12; 147(11):1191-1198. doi: 10.1182\/blood.2025031423","author":"Hosoya H, Bastidas Torres AN, Fernandez-Pol S, Gubatan J, Najidh S, Duran GE, Dong F, Ehlinger ZJ, Lohman C, Wright C 3rd, Sahaf B, Mackall C, Miklos DB, Sidana S, Kurtz DM, Khodadoust MS, Mikkilineni L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41288531"},{"title01":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","title02":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","journal":"Blood","issue":"2026 March 12; 147(11):1199-1214. doi: 10.1182\/blood.2024027700","author":"Feldman AL, Dasari S, Rimsza LM, Scott DW, Oishi N, Hu G, Farinha P, Amador C, Campo E, Chan WC, Cook JR, Delabie J, Fu K, Greiner TC, Hilton LK, Inghirami G, Iqbal J, Jaffe ES, Morin RD, Ondrejka SL, Ott G, Pittaluga S, Raess PW, Rosenwald A, Savage KJ, Slack GW, Slager SL, Song JY, Wright GW, Wang HW, Zeng Y, Yoshino T, Wu X, Wilcox RA, Wang X, Shi M, Satou A, Perry AM, Miranda RN, Medeiros LJ, Maurer MJ, Mou E, Ko YH, Karube K, Kahl BS, Jiang L, Jaye DL, Gru AA, de Leval L, Chen W, Chapman JR, Cerhan JR, Barrionuevo C, Ansell SM, Aljudi AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329859"},{"title01":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","title02":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","journal":"Blood","issue":"2026 March 5; 147(10):1125-1134. doi: 10.1182\/blood.2025030151","author":"Desai SH, Moskowitz AJ, Merryman RW, Shah H, Pederson LD, Geyer SM, Ganesan N, Chang T, Othman T, Falade AS, Shah GL, Durani U, Sumransub N, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Armand P, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405496"},{"title01":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","title02":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","journal":"Blood","issue":"2026 March 6. doi: 10.1182\/blood.2025031402. Online ahead of print","author":"Di Giacomo D, Polonen P, Bardelli V, Kimura S, Pierini V, Pagliaro L, Arniani S, Chang Y, Gao Q, Montefiori LE, Wu Y, Park CS, Wright WC, Vento F, Wei H, Matteucci C, Lei S, Rosikiewicz W, Nardelli C, Lema Fernandez AG, Ostergaard A, Backhaus EA, Baviskar P, Cerrano M, Leoncin M, Manabe A, Hirabayashi S, Takita J, Hasegawa D, Miyamoto S, Macchiarulo A, Xu J, Teachey DT, Roti G, Iacobucci I, La Starza R, Mecucci C, Mullighan CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791840"},{"title01":"Pretransplant promise for PD-1 in Hodgkin lymphoma.","title02":"Pretransplant promise for PD-1 in Hodgkin lymphoma.","journal":"Blood","issue":"2026 March 5; 147(10):1015-1017. doi: 10.1182\/blood.2025032407","author":"Zammar G, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785003"},{"title01":"Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.","title02":"Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.","journal":"Blood","issue":"2026 March 3. doi: 10.1182\/blood.2025031733. Online ahead of print","author":"Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774517"},{"title01":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","title02":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","journal":"Leukemia","issue":"2026 March; 40(3):481-490. doi: 10.1038\/s41375-025-02841-x","author":"Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L, Namburi S, Ribas P, Santoro A, Rodriguez-Otero P, Creignou M, Chen J, Cao C, Kiesel B, Gaudy A, Thompson EG, Shen Y, Zarif S, Hsu K, Shelat SG, Burgess MR, Godwin C, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501501"},{"title01":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","title02":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March 11. doi: 10.1016\/S2352-3026(26)00011-6. Online ahead of print","author":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Pula A, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41831471"},{"title01":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","title02":"Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches.","journal":"Haematologica","issue":"2026 March 1; 111(3):1017-1028. doi: 10.3324\/haematol.2025.288381","author":"Al-Bazaz M, Pischke S, Alsdorf W, Sonnemann P, Cichutek S, Wiesch JSZ, Schaefers C, Artzenroth J, Leypoldt L, Kamili A, Bokemeyer C, Weisel K, Kosch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994343"},{"title01":"Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone.","title02":"Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300401. Online ahead of print","author":"Parrondo RD, De Menezes R, Sledge H, Nayyar M, Yadav K, Bergsagel L, Fonseca R, Kapoor P, Buadi F, Gertz MA, Dispenzieri A, Roy V, Sher T, Binder M, Abdallah N, Chhabra S, Rajkumar VS, Gonsalves WI, Cook J, Dingli D, Lin Y, Fernandez A, Flott C, Yadav U, Warsame RM, Wiedmeier-Nutor EE, Kourelis T, Leung N, Siddiqui MA, Kumar S, Chanan-Khan AA, Ailawadhi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784017"},{"title01":"REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed\/refractory multiple myeloma outside of clinical trials.","title02":"REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed\/refractory multiple myeloma outside of clinical trials.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.289281. Online ahead of print","author":"Uttervall K, Kortum MK, Perrot A, Farmer SL, Cavo M, Kishore B, Jacquet C, Casanova M, Hansson M, Weisel K, Magen H, Liberatore C, Hansen CT, Gatt ME, Shragai T, Da Via MC, Alvarez TS, Streetly M, Raab MS, Manier S, Aegesen J, Albrecht C, Hu P, Smirnov P, Santra D, Rubio-Azpeitia E, Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784028"},{"title01":"Incidence and mortality of multiple myeloma: Global, regional and national estimates and projections from the Global Burden of Disease Study 2021.","title02":"Incidence and mortality of multiple myeloma: Global, regional and national estimates and projections from the Global Burden of Disease Study 2021.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70415. Online ahead of print","author":"Qu F, Hui M, Yang F, He Y, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796105"},{"title01":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","title02":"The shape-shifting plasma cell: Multiple myeloma with CKS1B amplification.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70376. Online ahead of print","author":"Amiot Q, Assadi-Gazvini C, Bugier S, Arnautou P, Maillot J, Malfuson JV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797264"},{"title01":"Enostosis 100 days post-transplant in multiple myeloma.","title02":"Enostosis 100 days post-transplant in multiple myeloma.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70412. Online ahead of print","author":"Browner C, Erber W, Cirillo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797418"},{"title01":"Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.","title02":"Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70428. Online ahead of print","author":"Aughey E, Estrada-Merly N, Akhtar OS, Dhakal B, Mohan M, Narra R, Pasquini MC, D'Souza A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797476"},{"title01":"Giant myeloma cells or crystal-storing histiocytes?","title02":"Giant myeloma cells or crystal-storing histiocytes?","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70422. Online ahead of print","author":"Chen H, Li L, Ma C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41808566"},{"title01":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","title02":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1559-1563. doi: 10.1182\/bloodadvances.2025018454","author":"Cedena MT, Puig N, Paiva B, de la Puerta JE, Perez-Montana A, Casanova M, Brena J, Garcia A, de Arriba F, Martinez-Chamorro C, Sirvent M, Blanchard MJ, Alonso R, Alvarez MA, Capote FJ, Garcia-Sanchez R, Perez JJ, Rodriguez-Otero P, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San-Miguel J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380099"},{"title01":"Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.","title02":"Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.","journal":"Blood","issue":"2026 March 5; 147(10):1070-1082. doi: 10.1182\/blood.2025029572","author":"Jelinek T, Zihala D, Zabaleta A, Kostopoulos IV, Soucek O, Venglar O, Moreno C, Fotiou D, Radova E, Tamariz-Amador LE, Theodorakakou F, Muronova L, Manubens A, Tsitsilonis O, Popkova T, Gonzalez C, Anilkumar Sithara A, Corrado F, Bidikian N, Guerrero C, Kapustova V, Bilek D, Hagner PR, Larrayoz M, Martinez Climent JA, Broskevicova L, Mihalyova J, Merz M, Sevcikova T, Ghobrial IM, San Miguel J, Dimopoulos MA, Rodriguez-Otero P, Radocha J, Kastritis E, Paiva B, Hajek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405507"},{"title01":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","title02":"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025030207. Online ahead of print","author":"Minnie S, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SR, Schmidt CR, Comstock ML, Lyons J, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770790"},{"title01":"TCR T cells targeting IgA- and IgG-expressing multiple myeloma.","title02":"TCR T cells targeting IgA- and IgG-expressing multiple myeloma.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025031897. Online ahead of print","author":"Douvlataniotis K, Titov A, Zeun J, Bilici M, Palashati H, Loh W, Rustad EH, Yang W, Tran TT, Lund-Johansen F, Bollineni RC, Kepple JD, Huth LP, Munthe LA, Boxaspen T, Schjesvold F, Waage A, Wagner DL, Bull KR, Hester J, Issa F, Giannakopoulou E, Olweus J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770814"},{"title01":"IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.","title02":"IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025031047. Online ahead of print","author":"Horns JM, Beder T, Kunstner A, Barz MJ, Bendig S, Bozzetti C, Chitadze G, Darzentas N, Iben K, Kotrova M, Martin-Subero JI, Mondal M, Neumann M, Fernandez Perez R, Stroh AS, Wessels W, Lenk L, Velten L, Boll B, Braitsch K, Bucklein VL, Duell J, Faul C, Fiedler W, Hanoun M, Janjetovic S, Klingler F, Knop S, Rollig C, Schwartz S, Spriewald BM, Steffen B, Wethmar K, Busch H, Gokbuget N, Baldus CD, Bastian L, Bruggemann M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824395"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 March; 40(3):491-501. doi: 10.1038\/s41375-025-02848-4","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","title02":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300086. Online ahead of print","author":"Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784015"},{"title01":"Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.","title02":"Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70397. Online ahead of print","author":"Cholack GA, Mwangi R, Vodicka P, Habermann TM, Hinder V, Robinson DP, Feldman AL, Witzig TE, Villasboas JC, Ansell SM, Link BK, Wang Y, Thompson CA, Slager SL, Maurer M, Novak AJ, Cerhan JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806244"},{"title01":"Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.","title02":"Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.","journal":"Br J Haematol","issue":"2026 March 12. doi: 10.1111\/bjh.70423. Online ahead of print","author":"De Re V, Lopci E, Brisotto G, Elia C, Vitullo A, Paduano V, De Zorzi M, Mussolin L, Quarello P, Bianchi S, Buffardi S, Garaventa A, Muggeo P, Pillon M, Sala A, Vinti L, d'Amore E, Mauz-Korholz C, Mascarin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41819087"},{"title01":"Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.","title02":"Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.","journal":"Br J Haematol","issue":"2026 March 5. doi: 10.1111\/bjh.70408. Online ahead of print","author":"Hwang YY, Au-Yeung R, Kwong YL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787739"},{"title01":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","title02":"From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70326. Online ahead of print","author":"Fu YC, Liu LP, Zhou YP, Yang MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787912"},{"title01":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","title02":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70401. Online ahead of print","author":"Rigolin GM, Soddu S, Dondolin R, Frustaci AM, Scortechini I, Mauro FR, Angotzi F, Motta M, Scarfo L, Mengarelli A, Giordano A, Martinelli S, Patti C, Sportoletti P, Sanna A, Maschio N, Riccioni R, Vigano CV, Tafuri A, Piciocchi A, Fazi P, Luminari S, Ferreri AJM, Gini G, Ghia P, Cuneo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806221"},{"title01":"Field-testing the MALT-IPI in a single center real-world cohort of patients with extranodal marginal zone lymphoma.","title02":"Field-testing the MALT-IPI in a single center real-world cohort of patients with extranodal marginal zone lymphoma.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025019076. Online ahead of print","author":"Sunder-Plassmann V, Kiesewetter B, Simonitsch-Klupp I, Brand R, Dolak W, Mayerhoefer M, Raderer M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774849"},{"title01":"Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed\/refractory mantle cell lymphoma.","title02":"Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed\/refractory mantle cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1457-1468. doi: 10.1182\/bloodadvances.2025017160","author":"Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269777"},{"title01":"Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.","title02":"Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.","journal":"Blood advances","issue":"2026 March 10; 10(5):1713-1721. doi: 10.1182\/bloodadvances.2025017752","author":"Luo Z, Li M, Primeaux BC, Shah R, Lin R, Iyer SP, Nastoupil LJ, Green MR, Westin JR, Flowers CR, Chihara D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201381"},{"title01":"Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","title02":"Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","journal":"Blood advances","issue":"2026 March 10; 10(5):1591-1602. doi: 10.1182\/bloodadvances.2025018079","author":"Merryman R, Rutherford SC, Ansell S, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman J, Zelenetz AD, Gutierrez M, Beguelin W, Casulo C, Cerhan J, Green M, Kahl B, Kridel R, Link B, Maurer MJ, Nadel B, Radtke AJ, Luttwak E, Salles G, Sehn L, Pasqualucci L, LaCasce AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337699"},{"title01":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","title02":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","journal":"Blood advances","issue":"2026 March 10; 10(5):1756-1772. doi: 10.1182\/bloodadvances.2025017643","author":"Kong X, Xu-Monette ZY, Xu Z, Hsi ED, Zhao X, Yan H, Nunns H, Au K, Visco C, Tzankov A, Dybkaer K, Yao S, Wu D, Wang C, Xu AM, Pan Z, Parsons BM, Chiu A, Tam W, Montes-Moreno S, Zhan F, Bernal-Mizrachi L, Zu Y, Zhang S, Moller MB, Chen W, Au Q, Merchant A, Bhagat G, Li Y, Young KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346287"},{"title01":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B-cell lymphoma.","title02":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1634-1645. doi: 10.1182\/bloodadvances.2025016858","author":"Yoon SE, Kang W, Cho J, Cho HJ, Chalita M, Oh HS, Hyun DW, Han S, Kim H, Sung H, Lee JY, Park B, Ryu KJ, Kim HY, Cho D, Kim WS, Kim SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364878"},{"title01":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","title02":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1733-1742. doi: 10.1182\/bloodadvances.2025016646","author":"Handunnetti SM, Khot A, Blombery P, Burbury K, Thompson PA, Ritchie D, Hicks RJ, Burke G, Koldej R, Bressel M, Di Iulio J, Westerman DA, Lade S, Roberts AW, Seymour JF, Tam CS, Anderson MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380113"},{"title01":"OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R\/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.","title02":"OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R\/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019367. Online ahead of print","author":"Santoro N, Mooyaart JE, Novak U, Protheroe R, Ayuk FA, Dreger P, van Meerten T, Paneesha S, Sanderson R, Ram R, Northend M, Forcade E, Huynh A, Yakoub-Agha I, Hoogenboom JD, Coelho MHM, Pagliuca S, Malard F, Kuball J, Sureda A, Bazarbachi A, Ruggeri A, Rocha V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779968"},{"title01":"Prognostic value of inflammation-based scores in patients with R\/R LBCL treated with CD3xCD20 bispecific T-cell engagers.","title02":"Prognostic value of inflammation-based scores in patients with R\/R LBCL treated with CD3xCD20 bispecific T-cell engagers.","journal":"Blood advances","issue":"2026 March 10; 10(5):1675-1686. doi: 10.1182\/bloodadvances.2025017766","author":"Magno G, Rejeski K, Rappa G, Stock S, Holzem A, Landwehr M, Seib M, Kutsch N, Mammadova J, Mayer S, Aumann S, Van Ham J, Ringelstein-Harlev S, Velazquez GF, Wurm-Kuczera R, Scholz JK, Greenbaum U, Raj SS, Shouval R, Muller F, Chapuy B, Schmid C, Beyar-Katz O, Vergote VKJ, Poeck H, Dong N, Holtick U, Ram R, Pabst T, Shumilov E, Lenz G, Iacoboni G, Barba P, Bucklein V, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124666"},{"title01":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","title02":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1722-1732. doi: 10.1182\/bloodadvances.2025016765","author":"Li N, Liu Y, Zhang L, Guo S, Wu Z, Xu Y, Yang M, Kong J, Che Y, Shao K, Yang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428986"},{"title01":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","title02":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","journal":"Blood advances","issue":"2026 March 10; 10(5):1670-1674. doi: 10.1182\/bloodadvances.2025018059","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 March 10; 10(5):1773-1782. doi: 10.1182\/bloodadvances.2025018057","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.","title02":"Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025019322. Online ahead of print","author":"Neumann MA, Schneider J, Szameitat M, Schommers P, Borchmann S, Hallek MJ, Borchmann P, Heger JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785308"},{"title01":"Proteogenomic features define subtypes of mantle cell lymphoma.","title02":"Proteogenomic features define subtypes of mantle cell lymphoma.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018701. Online ahead of print","author":"Yan Y, Chen W, Ge X, Sun J, Yu L, Garcia-Mansfield K, Zhang X, Yu Y, Xiong W, Zou D, An G, Jia Z, Pirrotte P, Li JJ, Yu Z, Hao M, Qiu L, Qi J, Wang L, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785305"},{"title01":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","title02":"Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.","journal":"Blood advances","issue":"2026 March 3. doi: 10.1182\/bloodadvances.2025018720. Online ahead of print","author":"Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774854"},{"title01":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","title02":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025017966. Online ahead of print","author":"Challenger A, McGale P, Probert J, Barrett A, Broggio J, Collins GP, Kayiparambil Harish K, Roden L, Royston D, Wang Z, Darby SC, Cutter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779974"},{"title01":"Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials.","title02":"Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials.","journal":"Blood advances","issue":"2026 March 10; 10(5):1497-1507. doi: 10.1182\/bloodadvances.2025016361","author":"Kho SJ, Diamond S, Lafeuille P, Schatz JH, Maura F, Aptekar J, Locke FL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201393"},{"title01":"Splitting from a lump: harmonizing ALCL classification.","title02":"Splitting from a lump: harmonizing ALCL classification.","journal":"Blood","issue":"2026 March 12; 147(11):1142-1143. doi: 10.1182\/blood.2025031931","author":"Ng SY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817557"},{"title01":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","title02":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","journal":"Blood","issue":"2026 March 5; 147(10):1058-1069. doi: 10.1182\/blood.2025029329","author":"Rhein S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, Serin N, Leisegang M, Timiliotis S, Ohlmeier L, Freund C, Willimsky G, Konietschke F, Kieback E, Tasian SK, Chapuy B, Keller U, Blankenstein T, Pezzutto A, Busse A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100732"},{"title01":"Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.","title02":"Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.","journal":"Blood","issue":"2026 March 13. doi: 10.1182\/blood.2025032050. Online ahead of print","author":"Oertel M, Dabaja BS, Gorlich D, Thomas BR, Sim V, Johnstone P, Hashmi A, Levis M, Ackerson B, Hague C, Weil CR, Plastaras J, Roos DE, Kirova Y, Fietkau R, Fang PQ, Ng AK, Bock F, Tseng YD, Linde P, Dunst J, Terezakis SA, Easwaran T, Peeken JC, Wittig A, Yoon HI, Tao R, Illidge TM, Kelsey CR, Ricardi U, Binkley MS, Campbell BA, Morris SL, Elsayad K, Storck M, Hoppe RT, Eich HT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824381"},{"title01":"Ready, set, GO? Treating older adults with AML.","title02":"Ready, set, GO? Treating older adults with AML.","journal":"Blood","issue":"2026 March 5; 147(10):1007-1008. doi: 10.1182\/blood.2025032119","author":"Jen WY, Ravandi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785006"},{"title01":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","title02":"BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031466. Online ahead of print","author":"Mimura K, Kaino A, Ochi Y, Chang YH, Seki M, Takeda J, Katayama S, Niizuma H, Sasahara Y, Mizoguchi Y, Shimomura M, Koyamada R, Ono R, Hasegawa D, Mitani K, Kubota H, Yoshihara S, Hiramoto N, Otsuki A, Okamura Y, Katsuoka F, Kinoshita K, Hasegawa M, Togo-Ohno M, Maeda H, Kakiuchi N, Takeuchi M, Sato-Otsubo A, Kato S, Watanabe K, Katayama K, Imoto S, Shiraishi Y, Koh K, Suenobu S, Hiyama E, Goyama S, Kikuchi A, Ogawa S, Kato M, Nannya Y, Takita J, Yoshida K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41790573"},{"title01":"RAG1\/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.","title02":"RAG1\/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.","journal":"Leukemia","issue":"2026 March 6. doi: 10.1038\/s41375-026-02896-4. Online ahead of print","author":"Lonardi S, Cancila V, Morello G, Varano G, Balzarini P, Pellegrini V, Albertini E, Giampaolo S, Pietrini I, Thanasi H, Sindaco P, Piazza F, Manni S, Lorenzini D, Pruneri G, Dei Tos AP, Ponzoni M, Facchetti F, Pizzi M, Lorenzi L, Tripodo C, Casola S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792441"},{"title01":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","title02":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","journal":"Lancet Oncol","issue":"2026 March; 27(3):361-371. doi: 10.1016\/S1470-2045(25)00678-3","author":"Pearson C, Jones DA, Baily G, Cherry R, Gray E, Hiom S, Rous B, Spencer K, Jose S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713471"},{"title01":"CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma.","title02":"CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma.","journal":"Lancet","issue":"2026 March 7; 407(10532):917-919. doi: 10.1016\/S0140-6736(26)00094-2","author":"Zhang S, Zhang H, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41794420"},{"title01":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","title02":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","journal":"Lancet","issue":"2026 March 7; 407(10532):963-975. doi: 10.1016\/S0140-6736(25)02435-3","author":"Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, Garcia-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692020"},{"title01":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","title02":"Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin\/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300086. Online ahead of print","author":"Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784015"},{"title01":"Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.","title02":"Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.289285. Online ahead of print","author":"Yang J, Villa D, Gerrie AS, Tonseth RP, Wilson DC, Benard F, Slack GW, Venner CP, Lo AC, Scott DW, Sehn LH, Savage KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784019"},{"title01":"Genetic and clinical characteristics of 54 pediatric lymphoma patients with variant mutation sites of UNC13D.","title02":"Genetic and clinical characteristics of 54 pediatric lymphoma patients with variant mutation sites of UNC13D.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.287782. Online ahead of print","author":"Duan Y, Gao H, Jin L, Yang J, Huang S, Zhang M, Li N, Yang X, Xu H, Wang T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784029"},{"title01":"Prognosis in marginal zone lymphoma: a comprehensive review.","title02":"Prognosis in marginal zone lymphoma: a comprehensive review.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300416. Online ahead of print","author":"Talami A, Nizzoli ME, Cappello E, Luminari S, Arcaini L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784035"},{"title01":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.","title02":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 March 1; 111(3):876-891. doi: 10.3324\/haematol.2025.287547","author":"Alhomoud M, Ibrahim R, Demetres M, Rejeski K, Scordo M, Shouval R, Tix T, Martinet J, Foley M, Gomez-Arteaga A, Shore T, Pagnini P, Aljurf M, Guzman ML, Formenti S, Yahalom J, Van Besien K, Imber BS, Chen Z, Yamshon S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637750"},{"title01":"The expanding spectrum of CAR-T related T-cell lymphomas.","title02":"The expanding spectrum of CAR-T related T-cell lymphomas.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300499. Online ahead of print","author":"Schonrade T, Braun T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816824"},{"title01":"Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma.","title02":"Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300488. Online ahead of print","author":"Noerenberg D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816814"},{"title01":"Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.","title02":"Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.","journal":"Haematologica","issue":"2026 March 1; 111(3):1007-1016. doi: 10.3324\/haematol.2025.287919","author":"Chung E, Wang L, Wellard C, Barraclough A, Campbell BA, Chong G, Ciaccio PD, Gregory GP, Hapgood G, Johnston AM, Tam CS, Opat S, Wood EM, McQuilten ZK, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994345"},{"title01":"Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.","title02":"Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.","journal":"Haematologica","issue":"2026 March 1; 111(3):1111-1115. doi: 10.3324\/haematol.2025.288699","author":"Yang J, Hayden AR, Villa D, Jiang A, Gerrie AS, Venner CP, Farinha P, Scott DW, Sehn LH, Savage KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035405"},{"title01":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","title02":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","journal":"Haematologica","issue":"2026 March 1; 111(3):1116-1119. doi: 10.3324\/haematol.2025.288780","author":"Senthil H, Streilein S, Whiteside T, Minuk L, Landego I, Kotb R, Menard C, Kansara R, Moltzan CJ, Johnston JB, Skrabek P, Yang L, Geirnaert M, Banerji V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063693"},{"title01":"Systematic echocardiogram surveillance to early detect and treat doxorubicin hydrochloride-induced cardiomyopathy in young adults and adults with classical Hodgkin lymphoma. Comment on: Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.","title02":"Systematic echocardiogram surveillance to early detect and treat doxorubicin hydrochloride-induced cardiomyopathy in young adults and adults with classical Hodgkin lymphoma. Comment on: Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300167. Online ahead of print","author":"Picardi M, Vincenzi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816839"},{"title01":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","title02":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289250. Online ahead of print","author":"Zhou B, Yuan Y, Cai Y, Zhou J, Shi L, Qin Y, Meng C, Zhang S, Yu S, Chen X, He X, Wu S, Li M, Yu X, Shi Y, Xing C, Chen C, Zhao M, Gao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816830"},{"title01":"To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.","title02":"To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300832. Online ahead of print","author":"Russler-Germain DA, Bartlett NL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816825"},{"title01":"Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed\/refractory primary mediastinal B-cell lymphoma.","title02":"Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed\/refractory primary mediastinal B-cell lymphoma.","journal":"Haematologica","issue":"2026 March 1; 111(3):1029-1033. doi: 10.3324\/haematol.2025.287672","author":"Santoro A, Improta CM, Sarina B, Mannina D, De Philippis C, Taurino D, Mariotti J, Balzarotti M, Bramanti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963380"},{"title01":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","title02":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","journal":"Haematologica","issue":"2026 March 1; 111(3):1120-1124. doi: 10.3324\/haematol.2025.288045","author":"Kiener TA, Schweighofer-Zwink G, Rendl G, Kern JM, Baskova L, Neureiter D, Melchardt T, Raderer M, Greil R, Pirich C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307123"},{"title01":"Unmasking the invisible: CAR T-cell therapy for intravascular large B-cell lymphoma.","title02":"Unmasking the invisible: CAR T-cell therapy for intravascular large B-cell lymphoma.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300761. Online ahead of print","author":"Avivi I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816813"},{"title01":"Renal dysfunction in symptomatic Waldenstrom macroglobulinaemia: A nationwide Italian multicentre study.","title02":"Renal dysfunction in symptomatic Waldenstrom macroglobulinaemia: A nationwide Italian multicentre study.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70424. Online ahead of print","author":"Danesin N, Autore F, Frustaci AM, Favrin G, Cencini E, Noto A, Dogliotti I, Olivieri J, Riva M, Ferrarini I, Barbui AM, Steffanoni S, Marino D, Puccini B, Stefani PM, Rizzi R, Merli M, Ferrari A, Luminari S, Visco C, Trentin L, Visentin A, Conconi A, Ferrero S, Varettoni M, Tedeschi A, Laurenti L, Piazza F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796393"},{"title01":"Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.","title02":"Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70417. Online ahead of print","author":"Nasibov T, Cunningham A, Sarpong L, Smyth E, O'Brien O, Quinn J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806113"},{"title01":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","title02":"Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70357. Online ahead of print","author":"O'Reilly MA, Wilson W, Maybury B, Kuhnl A, Roddie C, Uttenthal B, Johnson R, Alajangi R, Creasey T, Abdulgawad A, Arias CG, Iyengar S, Ferguson G, Panopoulou K, Delaney A, Pryce A, Rubio L, Jones C, Lambert J, Gupta S, Mathew A, Kasivisvanathan S, Awofisayo O, Hanmantgad S, Collins GP, Besley C, Seymour F, Sanderson R, Chaganti S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41796018"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 March 14. doi: 10.1111\/bjh.70426. Online ahead of print","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.","title02":"Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.","journal":"Br J Haematol","issue":"2026 March 3. doi: 10.1111\/bjh.70410. Online ahead of print","author":"Tuteja SK, Wlodaver A, Kirschmann D, Caparelli E, Yap KL, Schubert J, Zhong Y, Li MM, Leuer K, Gong S, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41773598"},{"title01":"Maneuvering ofCS toward precision medicine for AML?","title02":"Maneuvering ofCS toward precision medicine for AML?","journal":"Blood","issue":"2026 March 12; 147(11):1144-1145. doi: 10.1182\/blood.2025032403","author":"Carlsten M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817556"},{"title01":"Pharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia.","title02":"Pharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia.","journal":"Blood","issue":"2026 March 5; 147(10):1083-1097. doi: 10.1182\/blood.2025029875","author":"Zhang L, Kang H, Valerio M, Hoang DH, Pathak K, Garcia-Mansfield K, Lu X, Guo W, Fu YH, He X, Chen YC, Chen Z, Ghoda L, Buettner R, Li Z, Blackmon A, Li L, Zhang B, Pirrotte P, Marcucci G, Kuo YH, Nguyen LXT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397241"},{"title01":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","title02":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2026 March 12; 147(11):1147-1167. doi: 10.1182\/blood.2025031480","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang S, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw D, Kern W, Kim DDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein V, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon R, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Self-reinforcing IL-1b signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL.","title02":"Self-reinforcing IL-1b signaling accelerates the development and recurrence of TCF3::HLF-positive B-ALL.","journal":"Blood","issue":"2026 March 3. doi: 10.1182\/blood.2025031521. Online ahead of print","author":"Suzuki A, Shigehiro T, Hirakawa M, Hirano R, Tamai M, Akahane K, Okamoto K, Takayanagi H, Terashima Y, Ueha S, Kitami T, Takagi M, Keino D, Kawaguchi H, Kato K, Hino M, Inukai T, Yoshimura A, Ikawa T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774513"},{"title01":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","title02":"Myeloid\/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.","journal":"Blood","issue":"2026 March 4. doi: 10.1182\/blood.2025031016. Online ahead of print","author":"Vannucchi AM, Patel JL, Kiladjian JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779732"},{"title01":"The prevalence and clinical significance of clonal monocytosis.","title02":"The prevalence and clinical significance of clonal monocytosis.","journal":"Blood","issue":"2026 March 9. doi: 10.1182\/blood.2025031883. Online ahead of print","author":"Dunn WG, Sachs MC, Maggi M, Gu M, Quiros PM, Batta K, Andersen CL, Fabre MA, Chevassut TJ, Mohorianu I, Wiseman DH, Vassiliou GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41802133"},{"title01":"CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.","title02":"CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1048-1057. doi: 10.1182\/blood.2025031006","author":"Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew G, Dillon R, Gilkes A, Marquez Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne J, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills R, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237344"},{"title01":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","title02":"A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.","journal":"Blood","issue":"2026 March 5; 147(10):1058-1069. doi: 10.1182\/blood.2025029329","author":"Rhein S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, Serin N, Leisegang M, Timiliotis S, Ohlmeier L, Freund C, Willimsky G, Konietschke F, Kieback E, Tasian SK, Chapuy B, Keller U, Blankenstein T, Pezzutto A, Busse A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100732"},{"title01":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","title02":"Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.","journal":"Blood","issue":"2026 March 6. doi: 10.1182\/blood.2025031402. Online ahead of print","author":"Di Giacomo D, Polonen P, Bardelli V, Kimura S, Pierini V, Pagliaro L, Arniani S, Chang Y, Gao Q, Montefiori LE, Wu Y, Park CS, Wright WC, Vento F, Wei H, Matteucci C, Lei S, Rosikiewicz W, Nardelli C, Lema Fernandez AG, Ostergaard A, Backhaus EA, Baviskar P, Cerrano M, Leoncin M, Manabe A, Hirabayashi S, Takita J, Hasegawa D, Miyamoto S, Macchiarulo A, Xu J, Teachey DT, Roti G, Iacobucci I, La Starza R, Mecucci C, Mullighan CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791840"},{"title01":"MRD is a new therapeutic target in AML.","title02":"MRD is a new therapeutic target in AML.","journal":"Blood","issue":"2026 March 5; 147(10):1012-1013. doi: 10.1182\/blood.2025032278","author":"Recher C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785005"},{"title01":"CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.","title02":"CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2024027753. Online ahead of print","author":"Polcik L, Pethe A, Ashok D, Tissino E, Fernandez-Rego A, Pozzo F, Danner DJ, Holst M, Martines C, Hofmann K, Dimovski AJ, Kissel S, Harzschel A, Li L, Bittolo T, Andrieux G, Haslauer T, Hopner JP, Zaborsky N, Greil R, Miething C, Duque-Afonso J, Kohler N, Boerries M, Bomben R, Duyster J, Grosse R, Gaidano G, Zamo A, Zucchetto A, Carrasco YR, Efremov DG, Gattei V, Hartmann TN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41790574"},{"title01":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","title02":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):694-697. doi: 10.1038\/s41375-026-02870-0","author":"Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703025"},{"title01":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","title02":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):638-648. doi: 10.1038\/s41375-026-02884-8","author":"Gao J, Zhao X, Yin Q, Hu A, Qiu K, Blackburn L, Lei L, Xiong R, Bi C, Craig JW, Portell CA, Davila ML, Williams ME, Tao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41680300"},{"title01":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):708. doi: 10.1038\/s41375-026-02863-z","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41673334"},{"title01":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","title02":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):685-688. doi: 10.1038\/s41375-026-02872-y","author":"Yang ZZ, Kim HJ, Tang X, Novak JP, Bhardwaj V, Mukherjee P, Villasboas JC, Novak AJ, Mondello P, Ansell SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639205"},{"title01":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","title02":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","journal":"Leukemia","issue":"2026 March; 40(3):681-684. doi: 10.1038\/s41375-026-02861-1","author":"Nikkarinen A, Almlof J, Osterroos A, Ladenvall C, Amini RM, Hollander P, Ayoola Gustafsson K, Baliakas P, Glimelius I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639203"},{"title01":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","title02":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","journal":"Leukemia","issue":"2026 March; 40(3):666-670. doi: 10.1038\/s41375-025-02849-3","author":"Graf CM, Reese M, Vicente-Luque A, Monig N, Bruzeau C, Nadeu F, Latacz M, Bihler J, Meinel J, Cartolano M, Peifer M, Bea S, Campo E, Thelen M, Brockelmann PJ, Jachimowicz RD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588054"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):522-539. doi: 10.1038\/s41375-025-02844-8","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","title02":"Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.","journal":"Leukemia","issue":"2026 March 6. doi: 10.1038\/s41375-026-02869-7. Online ahead of print","author":"Grunenberg A, Schmelzle B, Gokeler J, Mund H, Viardot A, Dreyhaupt J, Nagel G, Reiser M, Gabrysiak T, Braulke F, Dunst J, Schlag R, Gaska T, Runde V, Kraemer D, Weber T, Mueller L, Johansson P, Ziske C, Hess G, Liersch R, Buske C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792439"},{"title01":"Validation of ICC hierarchical classification in secondary AML.","title02":"Validation of ICC hierarchical classification in secondary AML.","journal":"Blood advances","issue":"2026 March 5. doi: 10.1182\/bloodadvances.2025018188. Online ahead of print","author":"Attardi E, Cipriani M, Guarnera L, Savi A, Fabiani E, Mallegni F, Moretti F, Silvestrini G, Awada H, Durmaz A, Ferrari I, Maggioni G, Memoli M, Visconte V, Venditti A, Della Porta MG, Gurnari C, Piciocchi A, Maciejewski JP, Voso MT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785326"},{"title01":"Elevated lactate in AML bone marrow contributes to macrophage polarization via GPR81 signaling.","title02":"Elevated lactate in AML bone marrow contributes to macrophage polarization via GPR81 signaling.","journal":"Blood advances","issue":"2026 March 10; 10(5):1614-1629. doi: 10.1182\/bloodadvances.2025016400","author":"Soto CA, Lesch ML, Becker JL, Sharipol A, Khan A, Schafer XL, Li Z, Streeter AR, Becker MW, Munger JC, Frisch BJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364872"},{"title01":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","title02":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","journal":"Blood advances","issue":"2026 March 10; 10(5):1522-1536. doi: 10.1182\/bloodadvances.2025017243","author":"Kuehn HS, Gil Silva AA, Klangkalya N, Esteve-Sole A, Goel S, Niemela JE, Stoddard JL, Chong H, Williams K, Ip W, Framil Seoane M, Loganathan SK, Anantharachagan A, Garcia-Soidan A, Shaffren S, Bindernagel C, Mendez P, Miller RZ, Abolhassani H, Hoytema van Konijnenburg DP, Geerlinks AV, Cabanillas D, Zonneveld-Huijssoon E, Rutgers A, Tangye S, Ma C, Grey A, O'Young P, Aldave Becerra JC, Lyons JJ, White AA, Claiborne M, Doroudchi MA, Modena BD, Milner JD, Solanich X, Farela Neves J, Platt CD, Hammarstrom L, Routes JM, Verbsky J, Butte MJ, Lesmana H, Griffiths WJH, Kumararatne D, Hauck F, Allende LM, Rodriguez-Gallego C, Elfeky R, Rubin T, Boztug K, Fleisher TA, Rosenzweig SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380100"},{"title01":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","title02":"Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025019142. Online ahead of print","author":"Ben Hassine K, Gloor YS, Dupanloup I, Uppugunduri Satyanarayana CR, Mlakar V, Gonzales F, Gungor T, Ifversen M, Shaw PJ, Buechner J, Truong TH, Bittencourt H, Teague L, Toporski J, Sedlacek P, Poetschger U, Krajinovic M, Kalwak K, Balduzzi AC, Algeri M, Bader P, Peters C, Dalle JH, Ansari M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779961"},{"title01":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","title02":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","journal":"Blood advances","issue":"2026 March 10; 10(5):1537-1547. doi: 10.1182\/bloodadvances.2025018178","author":"Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, Derkach A, Geyer MB, Goldberg AD, Haque TZ, Thompson MC, Park JH, Tallman MS, Cai SF, Wang ES, Aldoss IT, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351513"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor-risk MDS\/AML.","journal":"Blood advances","issue":"2026 March 10; 10(5):1548-1558. doi: 10.1182\/bloodadvances.2025018631","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro R, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","title02":"Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.","journal":"Blood advances","issue":"2026 March 10; 10(5):1576-1586. doi: 10.1182\/bloodadvances.2025017837","author":"Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124669"},{"title01":"The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.","title02":"The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.","journal":"Blood","issue":"2026 March 12; 147(11):1229-1236. doi: 10.1182\/blood.2024028147","author":"Mujollari J, Estruch M, Khadgawat P, Choudhary S, Gustavsson T, Dagil R, Redlinger N, Loppke C, Vidal-Calvo EE, Nordmaj MA, Theander TG, Heidenreich O, Nguyen Y, Qin S, Tolboll Sorensen AL, Gronbaek K, Porse BT, Kircher B, Mueller J, Agerbaek MO, Salanti A, Theilgaard-Monch K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405498"},{"title01":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2026 March 12; 147(11):1168-1177. doi: 10.1182\/blood.2025031313","author":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2026 March 5; 147(10):1098-1110. doi: 10.1182\/blood.2025030816","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","title02":"Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.","journal":"Blood","issue":"2026 March 5. doi: 10.1182\/blood.2025031858. Online ahead of print","author":"Muffly LS, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle JR, Shizuru JA, Pang W, Artz AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41785374"},{"title01":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","title02":"A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial.","journal":"Blood","issue":"2026 March 11. doi: 10.1182\/blood.2025030972. Online ahead of print","author":"Gao L, Zhai X, Wang N, Liao N, Xiao P, Xu F, Yang M, Xu X, An Q, Luo J, Yang L, Yuan X, He Y, Zhuang Y, Wang H, Yang L, Zhang W, Liu YL, Li J, He H, Wang Y, Cheng C, Lu J, Jiang H, Ju X, Wang Q, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812214"},{"title01":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","title02":"Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.","journal":"Blood","issue":"2026 March 12; 147(11):1199-1214. doi: 10.1182\/blood.2024027700","author":"Feldman AL, Dasari S, Rimsza LM, Scott DW, Oishi N, Hu G, Farinha P, Amador C, Campo E, Chan WC, Cook JR, Delabie J, Fu K, Greiner TC, Hilton LK, Inghirami G, Iqbal J, Jaffe ES, Morin RD, Ondrejka SL, Ott G, Pittaluga S, Raess PW, Rosenwald A, Savage KJ, Slack GW, Slager SL, Song JY, Wright GW, Wang HW, Zeng Y, Yoshino T, Wu X, Wilcox RA, Wang X, Shi M, Satou A, Perry AM, Miranda RN, Medeiros LJ, Maurer MJ, Mou E, Ko YH, Karube K, Kahl BS, Jiang L, Jaye DL, Gru AA, de Leval L, Chen W, Chapman JR, Cerhan JR, Barrionuevo C, Ansell SM, Aljudi AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329859"},{"title01":"The Transposable Element-PARP Axis Underpins Synthetic Lethality and Immunogenic Vulnerability in Blood Cancer.","title02":"The Transposable Element-PARP Axis Underpins Synthetic Lethality and Immunogenic Vulnerability in Blood Cancer.","journal":"Blood","issue":"2026 March 10. doi: 10.1182\/blood.2025032216. Online ahead of print","author":"Zeisig BB, Karimi MM, So CWE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41812189"},{"title01":"Fixed-duration VenO vs FCR\/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.","title02":"Fixed-duration VenO vs FCR\/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.","journal":"Blood","issue":"2026 March 2. doi: 10.1182\/blood.2025030630. Online ahead of print","author":"Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Thadani-Mulero M, Cazares O, Huang W, Jiang Y, Clark E, Jin HY, Boyer M, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41770817"},{"title01":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia.","title02":"Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed\/refractory acute myeloid leukemia.","journal":"Blood","issue":"2026 March 3. doi: 10.1182\/blood.2025032299. Online ahead of print","author":"Becilli M, Merli P, Algeri M, Del Bufalo F, Pagliara D, Bertaina V, Agrati C, Rosignoli C, Cefalo MG, Boccieri E, Di Cecca S, Iaffaldano L, Lee Y, De Angelis B, Meshinchi S, Quintarelli C, Campana D, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41774512"},{"title01":"Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.","title02":"Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.","journal":"Haematologica","issue":"2026 March 1; 111(3):906-917. doi: 10.3324\/haematol.2025.288249","author":"Yuan M, Zhou L, Li W, Du X, Weng J, Yang L, Ma Y, Liu B, Liu Z, Wen Q, Zhao S, Zhang Y, Bai Q, Feng X, Han Y, Liu C, Meng L, Wang B, Ran X, Wang X, Zhang H, Zeng Y, Leng Q, Yu L, Li Z, Gale RP, Huang X, Jiang Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098110"},{"title01":"Monocytic transition in B-lymphoblastic leukaemia with a DUX4 rearrangement.","title02":"Monocytic transition in B-lymphoblastic leukaemia with a DUX4 rearrangement.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70407. Online ahead of print","author":"Li J, Lorsbach RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41793012"},{"title01":"Polycythaemic panmyelosis in chronic myeloid leukaemia.","title02":"Polycythaemic panmyelosis in chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70388. Online ahead of print","author":"Mason G, Hanamshet A, Kim S, Singh N, McIlroy K, Greenwood M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41793040"},{"title01":"Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.","title02":"Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 March 8. doi: 10.1111\/bjh.70409. Online ahead of print","author":"Claudiani S, Metelli S, Khan A, Hannah G, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Fernando F, Innes AJ, Apperley JF, Milojkovic D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41797306"},{"title01":"Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.","title02":"Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 March 6. doi: 10.1111\/bjh.70400. Online ahead of print","author":"Yamamoto C, Yamaguchi T, Honda S, Tominaga R, Yokoyama D, Furuki S, Noguchi A, Koyama S, Murahashi R, Nakashima H, Kawaguchi SI, Hyodo K, Toda Y, Umino K, Minakata D, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792981"},{"title01":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","title02":"An oncogenic, truncated FGFR1 variant cooperates with SPFQ\/NONO to regulate gene transcription in FGFR1-driven leukaemia.","journal":"Br J Haematol","issue":"2026 March 14. doi: 10.1111\/bjh.70426. Online ahead of print","author":"Cowell JK, Fang X, Mori SF, Hu T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41830421"},{"title01":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","title02":"Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70421. Online ahead of print","author":"McIlroy G, Carpenter B, Hough R, James B, Besley C, Nicholson E, Amrolia P, Mirci-Danicar O, Furness CL, Gibson B, Potter V, Pearce R, Lee J, Abamba C, Castleton A, Malladi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41813254"},{"title01":"Short and complex-Telomeres and genomes in CLL.","title02":"Short and complex-Telomeres and genomes in CLL.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70430. Online ahead of print","author":"Jebaraj BMC, Stilgenbauer S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814451"},{"title01":"Sweet’s syndrome in acute myeloid leukaemia.","title02":"Sweet’s syndrome in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 March 11. doi: 10.1111\/bjh.70389. Online ahead of print","author":"Mon HT, Han KH, Nicholson E, Aguilar-Duran S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814590"},{"title01":"Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.","title02":"Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.","journal":"Br J Haematol","issue":"2026 March 12. doi: 10.1111\/bjh.70418. Online ahead of print","author":"Costa A, Scalzulli E, Carmosino I, Bisegna ML, Lagana A, Ielo C, Cappelli L, Martelli M, Breccia M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41820245"},{"title01":"Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.","title02":"Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.","journal":"Br J Haematol","issue":"2026 March 12. doi: 10.1111\/bjh.70386. Online ahead of print","author":"Scott AP, Lo A, Xia Y, Thompson K, Bodimeade H, Fazlollahi A, Weber N, Curley C, Hunt S, Morris K, McNamara C, Perera N, Subramoniapillai E, Lane SW, Kennedy GA, Salvado O, Urriola J, McMahon KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41821185"},{"title01":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","title02":"Effect of Deferasirox Six Months after allo-HSCT on AML\/MDS Outcomes: a Propensity-Score Matched Study.","journal":"Blood advances","issue":"2026 March 11. doi: 10.1182\/bloodadvances.2025018894. Online ahead of print","author":"Buono R, Huynh A, Forcade E, Labussiere-Wallet H, Ceballos P, Cornillon J, Cabrera Q, D'Aveni M, Robin M, Devillier R, Raus N, Michallet M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41811968"},{"title01":"MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16.","title02":"MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16.","journal":"Blood advances","issue":"2026 March 13. doi: 10.1182\/bloodadvances.2025017325. Online ahead of print","author":"Wang L, Zhan Q, Luo J, Li J, He C, Zhu Y, Pei CX, Chen Y, Tang NN, Yin J, Su L Sr, Chen J, Xie M, Liu L, Luo XH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824794"},{"title01":"Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.","title02":"Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.","journal":"Blood advances","issue":"2026 March 10; 10(5):1687-1699. doi: 10.1182\/bloodadvances.2025018757","author":"Martino EA, Pitino A, Vigna E, Pasquale R, Ferrarini I, Moia R, Visentin A, Sanna A, Motta M, Moratti M, Sportoletti P, Chiarenza A, Maggi A, Zammit V, Merli M, Innocenti I, Giordano C, Nocilli L, Postorino M, Stelitano C, Ferrario A, Frustaci AM, Riva M, Pepe S, Ibatici A, Scardino S, Anticoli Borza P, Ballotta L, Mancuso S, Malaspina F, Mele A, Galimberti S, Catania G, Giordano A, Angeletti I, Schiattone L, Pennese E, Miccolis R, Fama A, Giordano G, Califano C, Bruzzese A, Caserta S, Farina G, Bulian P, Loseto G, Pocali B, Innao V, Galieni P, Fraticelli V, Vitale C, Romeo A, Rossi M, Scortechini I, Vozella F, Malandruccolo L, Varettoni M, Morello L, Pietrantuono G, Conte E, Cantelli M, Murru R, Caracciolo D, Derenzini E, Di Martina V, Marasca R, Del Principe MI, Figuera A, Angotzi F, Coscia M, Di Renzo N, Laurenti L, Amodio N, Musto P, Di Raimondo F, Liso A, Tedeschi A, Trentin L, Gaidano G, Mauro FR, Tripepi G, Morabito F, Gattei V, Gentile M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499776"},{"title01":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","title02":"Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years.","journal":"Blood advances","issue":"2026 March 4. doi: 10.1182\/bloodadvances.2025017966. Online ahead of print","author":"Challenger A, McGale P, Probert J, Barrett A, Broggio J, Collins GP, Kayiparambil Harish K, Roden L, Royston D, Wang Z, Darby SC, Cutter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41779974"},{"title01":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","title02":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","journal":"Blood advances","issue":"2026 March 10; 10(5):1481-1486. doi: 10.1182\/bloodadvances.2025018090","author":"Aquilanti E, Kageler L, Bozinov V, Meyerson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259746"},{"title01":"Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.","title02":"Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 March 10; 10(5):1700-1712. doi: 10.1182\/bloodadvances.2025017753","author":"Dreyzin A, Yates B, Shalabi H, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411486"},{"title01":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","title02":"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia\/lymphoma in HTLV-1 carriers.","journal":"Blood advances","issue":"2026 March 10; 10(5):1670-1674. doi: 10.1182\/bloodadvances.2025018059","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","title02":"A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.","journal":"Blood advances","issue":"2026 March 10; 10(5):1469-1472. doi: 10.1182\/bloodadvances.2025017795","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"Pediatric acute erythroid leukemia with NUP98::KDM5A fusion.","title02":"Pediatric acute erythroid leukemia with NUP98::KDM5A fusion.","journal":"Blood","issue":"2026 March 12; 147(11):1237. doi: 10.1182\/blood.2025032104","author":"Dermer K, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817552"},{"title01":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","title02":"Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):843-851. doi: 10.3324\/haematol.2025.287777","author":"Murphy T, Zhang B, Zhang T, King I, Capo-Chichi JM, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee KWL, Arruda A, Lu Z, Khalaf D, Rockwell C, Leber B, Sabloff M, Tierens A, Stockley TL, Chan SM, Ng SWK, Wang JCY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637740"},{"title01":"Intensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia.","title02":"Intensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300442. Online ahead of print","author":"Frisch A, Krayem B, Zuckerman T, Henig I, Yehudai-Ofir D, Glaubach N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784023"},{"title01":"Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood.","title02":"Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood.","journal":"Haematologica","issue":"2026 March 1; 111(3):1044-1048. doi: 10.3324\/haematol.2025.287942","author":"Chevillon F, Labrune E, Clappier E, Lapillonne H, Ballerini P, Lange VB, Fortin A, Itzykson R, Socie G, Buzyn A, Leverger G, Dalle JH, Dhedin N, Boissel N, De Latour RP, Salle B, Roux C, Poirot C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637728"},{"title01":"NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT\/beta-catenin pathway.","title02":"NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT\/beta-catenin pathway.","journal":"Haematologica","issue":"2026 March 1; 111(3):828-842. doi: 10.3324\/haematol.2025.287651","author":"Veltri G, Peloso A, Cani A, Mariotto E, Corallo D, Aveic S, Russo L, Cescon M, Santinon G, Frasson C, Simon K, Arrighi A, Iorio E, Minuzzo SA, Indraccolo S, Marmiroli S, Ntziachristos P, Biffi A, Pigazzi M, Buldini B, Bresolin S, Serafin V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035400"},{"title01":"Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response.","title02":"Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response.","journal":"Haematologica","issue":"2026 March 1; 111(3):1053-1060. doi: 10.3324\/haematol.2025.288054","author":"Barone PD, Dzedzik S, Kleinman AS, Chin CR, Meydan C, Valencia I, Sugita M, Guzman ML, Fein JA, Kaner JD, Desai P, Roboz GJ, Melnick AM, Mason CE, Patel SS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931876"},{"title01":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","title02":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","journal":"Haematologica","issue":"2026 March 1; 111(3):1130-1135. doi: 10.3324\/haematol.2025.288752","author":"Wei Q, Pemmaraju N, Wang SA, Hu S, DiNardo C, Issa GC, Bueso-Ramos CE, Xu J, Li S, Medeiros JL, Tang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262054"},{"title01":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/ refractory acute myeloid leukemia.","title02":"Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed\/ refractory acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):1075-1080. doi: 10.3324\/haematol.2025.288178","author":"Verdeyen K, Reuvekamp T, Van der Velden WJFM, Wouters BJ, Von dem Borne PA, Van Rhenen A, Lissenberg-Witte BI, Van Lammeren D, Van Sluis GL, De Jongh E, Fiets RB, Corsten MF, Van der Spek AC, Gerrits AM, Van Bladel ER, Tick LW, De Weerdt O, Van Zaane B, Cruijsen MJ, Posthuma EFM, Van Elssen CHMJ, Klein SK, Van de Loosdrecht AA, De Leeuw DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963393"},{"title01":"Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.","title02":"Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.","journal":"Haematologica","issue":"2026 March 1; 111(3):918-926. doi: 10.3324\/haematol.2025.288516","author":"Lokhorst DN, Smit Y, Van den Bemt BJF, Hermens RPMG, Nijziel MR, Jie AK, Daenen LGM, Klein SK, Posthuma EFM, Westerweel PE, Donker M, Hoogendoorn M, Bekker CL, Blijlevens NMA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41035410"},{"title01":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","title02":"Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.","journal":"Haematologica","issue":"2026 March 1; 111(3):1116-1119. doi: 10.3324\/haematol.2025.288780","author":"Senthil H, Streilein S, Whiteside T, Minuk L, Landego I, Kotb R, Menard C, Kansara R, Moltzan CJ, Johnston JB, Skrabek P, Yang L, Geirnaert M, Banerji V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063693"},{"title01":"Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia.","title02":"Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):1065-1069. doi: 10.3324\/haematol.2025.288131","author":"Duarte C, Abbot D, Bosma G, Kent A, Schwartz M, Collins C, Angelos MG, McMahon C, Gutman J, Pollyea DA, Amaya M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931864"},{"title01":"Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEGasparaginase hypersensitivity.","title02":"Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEGasparaginase hypersensitivity.","journal":"Haematologica","issue":"2026 March 1; 111(3):1039-1043. doi: 10.3324\/haematol.2025.287910","author":"Tang X, Zhao L, Li W, Liu S, Li X, Zhu L, Wang D, Chen S, Liu Z, Liu S, Wen F, Abla O, Wang Y, Mai H, Fu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931858"},{"title01":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):981-989. doi: 10.3324\/haematol.2025.287750","author":"Sanz J, Ferhat AT, Kulagin A, Kroger N, Rovira M, Lazzari L, Arat M, Montoro J, Versluis J, Remenyi P, Sica S, Blaise D, Saif MA, Vydra J, Fagioli F, Nur E, Giebel S, Peric Z, Brissot E, Nagler A, Piemontese S, Mohty M, Ciceri F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820728"},{"title01":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","title02":"Integrating killer cell immunoglobulin-like receptor highresolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 March 1; 111(3):971-980. doi: 10.3324\/haematol.2024.287061","author":"Schafer A, Buhler S, Farias TDJ, Kichula KM, Baldomero H, Sollet ZC, Ferrari-Lacraz S, Micheli B, Masouridi-Levrat S, Mesquita V, Kursteiner O, Nair G, Halter J, Gungor T, Schneidawind D, Chalandon Y, Passweg JR, Norman PJ, Villard J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637775"},{"title01":"Acute leukemia of ambiguous lineage: the known and the uncertain.","title02":"Acute leukemia of ambiguous lineage: the known and the uncertain.","journal":"Haematologica","issue":"2026 March 1; 111(3):813-827. doi: 10.3324\/haematol.2025.287793","author":"Sherban A, Wolach O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063702"},{"title01":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","title02":"A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns.","journal":"Haematologica","issue":"2026 March 1; 111(3):997-1006. doi: 10.3324\/haematol.2025.288006","author":"Yousuf M, Faldu P, Abdelmagid M, Aperna F, Fathima S, Alsugair AKA, Csizmar CM, Lasho TL, Mangaonkar AA, Reichard KK, He R, Pardanani A, Gangat N, Patnaik MM, Tefferi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098096"},{"title01":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","title02":"Selective DHCR7 inhibition versus AEBS modulation: Mechanistic implications for tamoxifen effects in AML.","journal":"Br J Haematol","issue":"2026 March 9. doi: 10.1111\/bjh.70420. Online ahead of print","author":"Poirot M, de Medina P, Silvente-Poirot S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41804099"},{"title01":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","title02":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","journal":"Br J Haematol","issue":"2026 March 10. doi: 10.1111\/bjh.70401. Online ahead of print","author":"Rigolin GM, Soddu S, Dondolin R, Frustaci AM, Scortechini I, Mauro FR, Angotzi F, Motta M, Scarfo L, Mengarelli A, Giordano A, Martinelli S, Patti C, Sportoletti P, Sanna A, Maschio N, Riccioni R, Vigano CV, Tafuri A, Piciocchi A, Fazi P, Luminari S, Ferreri AJM, Gini G, Ghia P, Cuneo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41806221"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 March; 40(3):594-608. doi: 10.1038\/s41375-025-02828-8","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):622-629. doi: 10.1038\/s41375-026-02874-w","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e133-e143. doi: 10.1016\/S2352-3026(25)00328-X","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","title02":"Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1\/2 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e157-e168. doi: 10.1016\/S2352-3026(25)00358-8","author":"Ruhnke L, Schliemann C, Mikesch JH, Stelljes M, Fransecky L, Steffen B, Kaufmann M, Burchert A, Rank A, Hanoun M, Hollein A, Kraus S, Schafer-Eckart K, Hanel M, Haake A, Fiebig F, Kramer M, Zukunft S, Kunadt D, Middeke JM, Sockel K, Schetelig J, Platzbecker U, von Bonin M, Rohnert MA, Oelschlagel U, Wagenfuhr L, Thiede C, Herold S, Poitz D, Stolzel F, Baldus CD, Serve H, Wermke M, Bornhauser M, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791831"},{"title01":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","title02":"Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e169-e180. doi: 10.1016\/S2352-3026(25)00361-8","author":"Oliva EN, Cottone F, Unni S, Correges A, Hansen JB, Marston XL, Cortes J, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41791832"},{"title01":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","title02":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","journal":"Lancet Haematol","issue":"2026 March; 13(3):e144-e156. doi: 10.1016\/S2352-3026(25)00357-6","author":"Gruber TA, Jeha S, Deyell RJ, Lewis V, Chang BH, Lowe EJ, Frediani J, Vezina C, Michon B, Richards M, Breese EH, Tran TH, Lacayo N, Bolen C, Desai S, Pauley JL, Huang M, Ashcraft E, Cheng C, Schultz KR, Stork L, Schlis K, Huynh VT, Gossai N, Messinger YH, Bittencourt H, Horton TM, Athale U, Stearns D, Schiff D, Gaynon PS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692013"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 March; 13(3):e181-e185. doi: 10.1016\/S2352-3026(25)00359-X","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.","title02":"Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.288334. Online ahead of print","author":"Oehler VG, Berman E, Huang IJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816837"},{"title01":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","title02":"NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.289250. Online ahead of print","author":"Zhou B, Yuan Y, Cai Y, Zhou J, Shi L, Qin Y, Meng C, Zhang S, Yu S, Chen X, He X, Wu S, Li M, Yu X, Shi Y, Xing C, Chen C, Zhao M, Gao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816830"},{"title01":"Shaping the future of older pa1ents with Philadelphia-nega1ve lymphoblas1c leukemia.","title02":"Shaping the future of older pa1ents with Philadelphia-nega1ve lymphoblas1c leukemia.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2026.300561. Online ahead of print","author":"Bassan R, Skert C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816828"},{"title01":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","title02":"Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.300176. Online ahead of print","author":"Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stolzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kroger N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784041"},{"title01":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","title02":"No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study.","journal":"Haematologica","issue":"2026 March 12. doi: 10.3324\/haematol.2025.300199. Online ahead of print","author":"Zadro Y, Lafaurie M, Sommet A, Lapeyre-Mestre M, Moulis G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41816826"},{"title01":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","title02":"Aberrant fucosylation of extracellular vesicles remodels the vascular microenvironment and promotes chemoresistance in myelodysplastic syndromes and acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 5. doi: 10.3324\/haematol.2025.288146. Online ahead of print","author":"Feng J, Wang K, Gou J, Wang Y, Hu B, Wei W, Ge J, Feng Y, Feng S, Solary E, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41784036"},{"title01":"Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed\/refractory acute myeloid leukemia: a real-world experience.","title02":"Clinical activity of venetoclax and azacitidine in children with de novo or secondary multiple relapsed\/refractory acute myeloid leukemia: a real-world experience.","journal":"Haematologica","issue":"2026 March 1; 111(3):852-860. doi: 10.3324\/haematol.2025.288246","author":"Arcourt A, Ilan U, Murillo L, Arad-Cohen N, Rubio A, Tasian SK, Baruchel A, Zwaan MC, Ducassou S, Goemans BF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098113"},{"title01":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","title02":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):775-777. doi: 10.3324\/haematol.2025.288928","author":"Sandhu M, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342189"},{"title01":"The sobering reality of fertility preservation in young female patients with acute leukemia.","title02":"The sobering reality of fertility preservation in young female patients with acute leukemia.","journal":"Haematologica","issue":"2026 March 1; 111(3):791-793. doi: 10.3324\/haematol.2025.288538","author":"Frisch A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40994349"},{"title01":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","title02":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):704-707. doi: 10.1038\/s41375-026-02888-4","author":"Wang C, Ge S, Gao J, Yang R, Guo X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703029"},{"title01":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2026 March 5. doi: 10.1038\/s41375-026-02909-2. Online ahead of print","author":"Setiawan T, Muhammad JA, Julianto NM, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41787068"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):522-539. doi: 10.1038\/s41375-025-02844-8","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","title02":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","journal":"Leukemia","issue":"2026 March; 40(3):553-561. doi: 10.1038\/s41375-025-02847-5","author":"Rea D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, Illes A, Angona Figueras A, Kiani A, Charbonnier A, Marinakis T, Stenke L, Steegmann JL, Saglio G, Hellmann A, Niederwieser D, Schuld P, Rosti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41555010"},{"title01":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","title02":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 March; 40(3):577-586. doi: 10.1038\/s41375-025-02855-5","author":"Ansuinelli M, Peragine N, De Propris MS, Puzzolo MC, Di Trani M, Elia L, Skert C, Cairoli R, Sica S, Rambaldi A, Tucci A, Cerrano M, Vallisa D, Cardinali V, Mule A, Chiaretti S, Guarini A, Foa R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571767"},{"title01":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","title02":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","journal":"Leukemia","issue":"2026 March; 40(3):562-576. doi: 10.1038\/s41375-026-02862-0","author":"Wang Y, Wang X, Li M, Song H, Liu C, Shi M, Tao X, Shen S, Li X, Fang H, Zhou Z, Zhang J, Han B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571768"},{"title01":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","title02":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","journal":"Leukemia","issue":"2026 March; 40(3):630-637. doi: 10.1038\/s41375-026-02873-x","author":"Nielsen CG, Als-Nielsen B, Albertsen BK, Davidsson OB, Dimitrijevic A, Hjalgrim H, Ifversen M, Lundgren L, Lynggaard LS, Olsen M, Overgaard UM, Rank CU, Rathe M, Rostgaard K, Schmiegelow K, Andres-Jensen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41667647"},{"title01":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Correction: Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 March; 40(3):708. doi: 10.1038\/s41375-026-02863-z","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41673334"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 March; 40(3):649-660. doi: 10.1038\/s41375-026-02886-6","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 March; 40(3):491-501. doi: 10.1038\/s41375-025-02848-4","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","title02":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","journal":"Leukemia","issue":"2026 March; 40(3):540-552. doi: 10.1038\/s41375-025-02856-4","author":"Camiolo G, Gonzalez Silvera D, Leah T, Schwaller J, Ottersbach K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545699"},{"title01":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","title02":"Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 March 6. doi: 10.1038\/s41375-026-02898-2. Online ahead of print","author":"Zhang L, Han Q, Xiang H, Lapalombella R, Eisfeld AK, Hanel WG, Brammer JE, Mims AS, Woyach JA, Song C, Ge Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41792440"},{"title01":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","title02":"Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02907-4. Online ahead of print","author":"Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803402"},{"title01":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","title02":"Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?","journal":"Leukemia","issue":"2026 March 9. doi: 10.1038\/s41375-026-02901-w. Online ahead of print","author":"Selimoglu-Buet D, Chevret S, Santini V, Thepot S, Morabito M, Ades L, Laplane L, Giagounidis A, Droin N, Lubbert M, Sapena R, Nimubona S, Torregrosa-Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Paul F, Patriarca A, Stamatoullas A, Gotze K, Chermat F, Platzbecker U, Fenaux P, Solary E, Itzykson R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41803403"},{"title01":"Immunophenotypic changes following menin inhibition in acute myeloid leukemia.","title02":"Immunophenotypic changes following menin inhibition in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 March 11. doi: 10.1038\/s41375-026-02905-6. Online ahead of print","author":"Loghavi S, Farhat A, Jamison TJ, El Hajjar G, Bataller A, Wang SA, Wang W, Tang G, Quesada AE, Bazinet A, Cuglievan B, DiNardo CD, Montalban-Bravo G, Takahashi K, Short NJ, Abbas HA, Kadia T, Ravandi F, Daver N, Jabbour E, Borthakur G, Andreeff M, Medeiros LJ, Kantarjian HM, Issa GC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814014"},{"title01":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","title02":"High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.","journal":"Leukemia","issue":"2026 March 11. doi: 10.1038\/s41375-026-02906-5. Online ahead of print","author":"Parker H, Carr L, Norris K, Nilsson-Takeuchi A, Stevens B, Amarasinghe H, Kadalayil L, Else M, Clifford R, Pettitt A, Munir T, Schuh A, Walewska R, Baird DM, Oscier DG, Pepper C, Bryant D, Gibson J, Strefford JC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814015"},{"title01":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2026 March 11. doi: 10.1038\/s41375-026-02911-8. Online ahead of print","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41814016"},{"title01":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","title02":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2026 March 12; 394(11):1084-1096. doi: 10.1056\/NEJMoa2515458","author":"Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindstrom V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Bottcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfo L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358601"},{"title01":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","title02":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","journal":"Leukemia","issue":"2026 March; 40(3):702-703. doi: 10.1038\/s41375-025-02837-7","author":"Zheng Y, Dong F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571770"},{"title01":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","title02":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","journal":"Leukemia","issue":"2026 March; 40(3):587-593. doi: 10.1038\/s41375-025-02852-8","author":"Oehler VG, Sala-Torra O, Gilderman N, Beppu L, Woolston DW, Namaganda P, Rynning J, Gonzalez IG, Towlerton A, Voutsinas J, Wu Q, Yeung CCS, Radich JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41577999"},{"title01":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","title02":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","journal":"Blood advances","issue":"2026 February 24; 10(4):1082-1093. doi: 10.1182\/bloodadvances.2025017908","author":"Schroeder JC, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733971"},{"title01":"Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.","title02":"Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.300331. Online ahead of print","author":"Chizzoniti D, Ciambelli F, Latargia ML, Canziani L, Godi C, Pavesi F, Zambrotta GMP, Lotesoriere I, Appio L, Bertolli V, Santamaria C, Ballardini F, Cecchetti C, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709740"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70374. Online ahead of print","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Non-ICANS neurological toxicities associated with BCMA-directed CAR T-cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis.","title02":"Non-ICANS neurological toxicities associated with BCMA-directed CAR T-cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70382. Online ahead of print","author":"Saini M, Deeksha FNU, Jandial A, Jain A, Prakash G, Khadwal A, Chakraborty R, Malhotra P, Singh C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705773"},{"title01":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","title02":"Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 17. doi: 10.1111\/bjh.70373. Online ahead of print","author":"Jamroziak K, Dytfeld D, Kubicki T, Dutka M, Wrobel T, Giannopoulos K, Konska A, Druzd-Sitek A, Tyczynska A, Olszewska-Szopa M, Morawska M, Szeremet A, Kopinska A, Wisniewski K, Czyz J, Helbig G, Gil L, Zaucha JM, Kruk-Kwapisz D, Walewski J, Gorecki T, Pula B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704058"},{"title01":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","title02":"Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70395. Online ahead of print","author":"Su M, Khan AM, Cowan AJ, Anderson LD Jr, Kaur G, Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733330"},{"title01":"Patients’, clinicians’ and research’s priorities on important outcomes in multiple myeloma: A mixed-methods study.","title02":"Patients’, clinicians’ and research’s priorities on important outcomes in multiple myeloma: A mixed-methods study.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70396. Online ahead of print","author":"Mainou M, Karagiannis T, Pagkalidou E, Liakos A, Malandrakis P, Hatjiharissi E, Chissan S, Mandala E, Van Oekelen O, Vlachaki E, Papaioannou M, Terpos E, Mohyuddin GR, Tsapas A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747758"},{"title01":"Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.","title02":"Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.","journal":"Blood advances","issue":"2026 February 24; 10(4):1324-1333. doi: 10.1182\/bloodadvances.2025017597","author":"Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733961"},{"title01":"Prognosis and patterns of progression in smoldering multiple myeloma.","title02":"Prognosis and patterns of progression in smoldering multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1344-1347. doi: 10.1182\/bloodadvances.2025018021","author":"Akhlaghi T, Maclachlan KH, Wiggins A, Usmani SZ, Derkach A, Hultcrantz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733947"},{"title01":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of multiple myeloma.","title02":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):953-959. doi: 10.1182\/bloodadvances.2025017676","author":"Chong PSY, Lim JSL, Tan TZ, Kong LR, de Mel S, Leow ACY, Yap EGS, Chng WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733965"},{"title01":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","title02":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300374. Online ahead of print","author":"Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742869"},{"title01":"Neutrophil extracellular traps, endothelial injury and use of abatacept for graft versus host disease prophylaxis.","title02":"Neutrophil extracellular traps, endothelial injury and use of abatacept for graft versus host disease prophylaxis.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2024.287235. Online ahead of print","author":"Ibrahimova A, Luebbering N, Strecker L, Langenberg L, Abdullah S, Lake KE, Wilhelm J, Lane A, Gloude N, Myers K, Dandoy C, Towe C, Khandelwal P, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709743"},{"title01":"Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial.","title02":"Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.300144. Online ahead of print","author":"Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Matos MGAD, Chopra Y, Bhat S, Im HJ, Gungor T, Lu MY, Stefanelli T, Peyrard S, Smith Y, Sinclair K, Diaz-de-Heredia C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709741"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70380. Online ahead of print","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70365. Online ahead of print","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 February 19. doi: 10.1111\/bjh.70392. Online ahead of print","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","title02":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70378. Online ahead of print","author":"Alberdi-Lema C, Garcia-Villaronga B, Linzodo-Lopez T, Carcelero E, Riu G, Monge-Escartin I, Suarez-Lledo M, Guardia L, Pedraza A, Sanz C, Charry P, Cid J, Lozano M, Carreras E, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721496"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70381. Online ahead of print","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70384. Online ahead of print","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 February 17. doi: 10.1111\/bjh.70379. Online ahead of print","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","title02":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025018455. Online ahead of print","author":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen PB, Mou E, Wallace DS, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami GG, Pongas GN, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl BS, Cerhan JR, Flowers CR, Feldman AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707114"},{"title01":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","title02":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","journal":"Blood advances","issue":"2026 February 27. doi: 10.1182\/bloodadvances.2025017456. Online ahead of print","author":"He Q, Sun X, Chen LV, Yang J, Gao Y, Wan L, Cai Y, Zhou X, Shen L, Jiang P, Liu J, Ding X, Li L, Tong Y, Qiu H, Huang C, Dong B, Zhou K, Yang Y, Wang P, Liang X, Zhang Y, Zhou BO, Zhang F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758999"},{"title01":"Intensity of conditioning but not measurable residual disease status impacts the outcomes of umbilical cord blood transplantation.","title02":"Intensity of conditioning but not measurable residual disease status impacts the outcomes of umbilical cord blood transplantation.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025018519. Online ahead of print","author":"Chan LKL, Nicholson E, Chan LY, Taussig DC, Potter MN, Ethell ME, Easdale S, Garnett C, Anthias C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747186"},{"title01":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","title02":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","journal":"Blood advances","issue":"2026 February 24; 10(4):1145-1152. doi: 10.1182\/bloodadvances.2025016648","author":"Farhadfar N, El Jurdi N, Baker KK, Ghosh S, Bat-Erdene M, Chen H, Sahu R, Weiss R, Mi J, Desatnik G, Williams LR, Tkaczyk ER, Lee SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191519"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2026 February 24; 10(4):1204-1216. doi: 10.1182\/bloodadvances.2024014831","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio L, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","title02":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 24; 10(4):1348-1360. doi: 10.1182\/bloodadvances.2025016938","author":"Ulschmid CM, Li X, Wang T, Logan BR, Pidala J, MacMillan ML, Kitko CL, Lee SJ, Spellman SR, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41498421"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018537. Online ahead of print","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda CJ, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz ML, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone RS, Jurgens EM, Miller KC, Rajeeve S, Giralt SA, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","title02":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018477. Online ahead of print","author":"Bhandari R, Meng Q, Hageman L, Francisco L, Ross ES, Balas N, Bosworth AK, Bhatia R, Landier W, Weisdorf DJ, Wong FL, Bhatia S, Armenian SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734391"},{"title01":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","title02":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","journal":"Blood advances","issue":"2026 February 24; 10(4):1260-1271. doi: 10.1182\/bloodadvances.2025018139","author":"Murdock HM, Kim HT, Maurer K, Kelkar A, Shapiro RM, Gooptu M, Romee R, Nageshwar PK, Garrity HM, Shimony S, Luskin MR, Winer ES, Vedula RS, Stahl M, Chen EC, Volpe V, Garcia JS, Wadleigh M, DeAngelo DJ, Stone RM, Wu CJ, Cutler CS, Koreth J, Ritz J, Antin JH, Ho VT, Nikiforow S, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733975"},{"title01":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","title02":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","journal":"Blood advances","issue":"2026 February 24; 10(4):1114-1125. doi: 10.1182\/bloodadvances.2025017680","author":"Ito S, Martin E, Panousis C, Rowe AM, Stras S, Roy J, Cofano EB, Ventura K, Parr K, Neupane B, Bellesis A, Toki A, Jing R, Jang J, Neves AT, Shlomchik MJ, Shlomchik WD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733935"},{"title01":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","title02":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025030823. Online ahead of print","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","title02":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","journal":"Blood","issue":"2026 February 19; 147(8):848-862. doi: 10.1182\/blood.2025029771","author":"Stewart J, Damania B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105850"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","journal":"Blood","issue":"2026 February 19; 147(8):821-833. doi: 10.1182\/blood.2025029611","author":"Boissel N, Chevret S, Huguet F, Leguay T, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Manz M, Cluzeau T, Turlure P, Rousselot P, de Prijck B, Grardel N, Bene MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah N, Lheritier V, Asnafi V, Clappier E, Dombret H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031545. Online ahead of print","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CTK, Villar-Prados A, Ji X, Jensen KP PhD, Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"Dysbiosis and gastrointestinal GVHD: to treat or not to treat.","title02":"Dysbiosis and gastrointestinal GVHD: to treat or not to treat.","journal":"Blood","issue":"2026 February 19; 147(8):809-810. doi: 10.1182\/blood.2025031542","author":"Waller EK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712295"},{"title01":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation.","title02":"Mucosal calprotectin is associated with severity of aGI-GVHD and poor outcomes after allogeneic stem cell transplantation.","journal":"Blood","issue":"2026 February 19; 147(8):886-896. doi: 10.1182\/blood.2025029402","author":"Gurer Kluge EE, Meedt E, Feicht J, Cao K, Hiergeist A, Mamilos A, Hirsch D, Hoepting M, Kattner AS, Matos C, Bulow S, Thiele Orberg E, Beckhove P, Kandulski A, Evert M, Hildner K, Kreutz M, Edinger M, Wolff D, Herr W, Poeck H, Gessner A, Weber D, Kehr B, Holler E, Ghimire S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032750"},{"title01":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","title02":"Hematopoietic Stem-Cell Gene Therapy for Cystinosis.","journal":"N Engl J Med","issue":"2026 February 19; 394(8):753-762. doi: 10.1056\/NEJMoa2506431","author":"Barshop BA, Ball ED, Benador N, Trauner D, Phillips S, Dohil R, Afshari NA, Roy S, Campo Fernandes B, Kohn D, Shayan K, Everett JK, Bushman FD, Midgley J, Liang H, Sawyers A, Gangoiti JA, Panchal M, Ahmed I, Cherqui S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707137"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02867-9. Online ahead of print","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 February 25; JCO2501591. doi: 10.1200\/JCO-25-01591. Online ahead of print","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"WBC Growth Factors: ASCO Guideline Update.","title02":"WBC Growth Factors: ASCO Guideline Update.","journal":"J Clin Oncol","issue":"2026 February 25; JCO2502938. doi: 10.1200\/JCO-25-02938. Online ahead of print","author":"Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740078"},{"title01":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","title02":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288962. Online ahead of print","author":"Matto N, Gandhi S, Rzepkowska M, Gerlevik S, Karimi MM, Kulasekararaj A, Douiri A, Miller A, Duran L, Cui H, Lewis J, Kordasti S, Lombardi G, Napolitani G, Mufti GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742894"},{"title01":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","title02":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.289302. Online ahead of print","author":"Bonifazi F, Roberto M, Stanghellini MTL, Chiusolo P, Polverelli N, Geromin A, Prezioso L, Algeri M, Mancini G, Prunotto G, Algarotti A, Nozzoli C, Malagola M, Mordini N, Fedele M, Santoro L, Zallio F, Castagna L, Picardi A, Busca A, Giaccone L, Skert C, Elice F, Facchini L, Mariotti J, Pierini A, Spina A, De Marchi R, Salvatore D, Martino M, Tumino M, Rambaldi A, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709738"},{"title01":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","title02":"Navigating through uncertainty-Experience from the UK national VEXAS MDT.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70365. Online ahead of print","author":"Pietsch D, Kulasekararaj A, Savic S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735226"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70384. Online ahead of print","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","title02":"Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70381. Online ahead of print","author":"Kawaguchi K, Miyamoto S, Yoshida N, Yamamoto S, Koike T, Okada S, Kajiwara M, Takahashi Y, Ishimura M, Sakaguchi H, Hama A, Cho Y, Sato M, Kato K, Okada K, Matsumoto K, Kato K, Hashii Y, Tabuchi K, Atsuta Y, Umeda K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41705788"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 February 19. doi: 10.1111\/bjh.70392. Online ahead of print","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","title02":"Avatrombopag for post-transplant thrombocytopenia following allogeneic haematopoietic stem cell transplantation: A single-centre retrospective study.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70378. Online ahead of print","author":"Alberdi-Lema C, Garcia-Villaronga B, Linzodo-Lopez T, Carcelero E, Riu G, Monge-Escartin I, Suarez-Lledo M, Guardia L, Pedraza A, Sanz C, Charry P, Cid J, Lozano M, Carreras E, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721496"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2026 February 24; 10(4):1204-1216. doi: 10.1182\/bloodadvances.2024014831","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio L, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733955"},{"title01":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","title02":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","journal":"Blood advances","issue":"2026 February 24; 10(4):1094-1105. doi: 10.1182\/bloodadvances.2025017838","author":"Murray J, Einhaus T, Radtke S, Bar KJ, Peterson CW, Kiem HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733968"},{"title01":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","title02":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","journal":"Blood advances","issue":"2026 February 24; 10(4):1260-1271. doi: 10.1182\/bloodadvances.2025018139","author":"Murdock HM, Kim HT, Maurer K, Kelkar A, Shapiro RM, Gooptu M, Romee R, Nageshwar PK, Garrity HM, Shimony S, Luskin MR, Winer ES, Vedula RS, Stahl M, Chen EC, Volpe V, Garcia JS, Wadleigh M, DeAngelo DJ, Stone RM, Wu CJ, Cutler CS, Koreth J, Ritz J, Antin JH, Ho VT, Nikiforow S, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733975"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2026 February 24; 10(4):1281-1292. doi: 10.1182\/bloodadvances.2025017433","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733973"},{"title01":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","title02":"VLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.","journal":"Blood advances","issue":"2026 February 27. doi: 10.1182\/bloodadvances.2025017456. Online ahead of print","author":"He Q, Sun X, Chen LV, Yang J, Gao Y, Wan L, Cai Y, Zhou X, Shen L, Jiang P, Liu J, Ding X, Li L, Tong Y, Qiu H, Huang C, Dong B, Zhou K, Yang Y, Wang P, Liang X, Zhang Y, Zhou BO, Zhang F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758999"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2026 February 24; 10(4):1293-1300. doi: 10.1182\/bloodadvances.2024015776","author":"Liu Q, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733938"},{"title01":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","title02":"Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 24; 10(4):1348-1360. doi: 10.1182\/bloodadvances.2025016938","author":"Ulschmid CM, Li X, Wang T, Logan BR, Pidala J, MacMillan ML, Kitko CL, Lee SJ, Spellman SR, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41498421"},{"title01":"Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.","title02":"Inflammatory Bowel Disease-induced Inflammation Augments Clonal Hematopoiesis of Indeterminate Potential through Ref-1.","journal":"Blood","issue":"2026 February 25. doi: 10.1182\/blood.2025032339. Online ahead of print","author":"Kumar R, Li L, Urbut S, Uddin MM, Niroula A, Kanumuri R, Ramdas B, Pasupuleti SK, Palam LR, Wang X, Padam KSR, Kelley MR, Natarajan P, Yu Z, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746260"},{"title01":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","title02":"How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025030823. Online ahead of print","author":"Shaffer BC, Lee SJ, Perales MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746780"},{"title01":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","title02":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031202. Online ahead of print","author":"Parfenova EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, Kiebish MA, Minden MD, Spagnuolo PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746867"},{"title01":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031545. Online ahead of print","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CTK, Villar-Prados A, Ji X, Jensen KP PhD, Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","title02":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2024027180. Online ahead of print","author":"Sharma R, Bhoopalan SV, Meyer R, Han L, Beesetti S, Liu N, Singh P, Palmer LE, Hansen BS, Khiami M, Larcher L, Begemann M, Corbacioglu S, Heller L, Jakob M, Ju Y, Sahoo SS, Gray N, Gheorghe G, Elbracht M, Khurana C, Kirschner M, Kurth I, Erlacher M, Brummendorf TH, Soulier J, Pruett-Miller SM, Beier F, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758987"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","journal":"Blood","issue":"2026 February 19; 147(8):821-833. doi: 10.1182\/blood.2025029611","author":"Boissel N, Chevret S, Huguet F, Leguay T, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Manz M, Cluzeau T, Turlure P, Rousselot P, de Prijck B, Grardel N, Bene MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah N, Lheritier V, Asnafi V, Clappier E, Dombret H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.","title02":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.","journal":"N Engl J Med","issue":"2026 February 26; 394(9):872-883. doi: 10.1056\/NEJMoa2508820","author":"Dumbrava EE, Shapiro GI, Parikh AR, Johnson ML, Tolcher AW, Thompson JA, El-Khoueiry AB, Vandross AL, Kummar S, Shepard DR, LeDuke K, Sheehan L, Alland L, Haque A, Jalota D, Fellous M, Schram AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740031"},{"title01":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","title02":"MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.","journal":"Lancet Oncol","issue":"2026 February 16. doi: 10.1016\/S1470-2045(25)00707-7. Online ahead of print","author":"Louis FM, van der Voort A, van Ramshorst MS, Daletzakis A, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJM, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Egeler MD, van de Poll-Franse LV, Mann RM, Sonke GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713473"},{"title01":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","title02":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288962. Online ahead of print","author":"Matto N, Gandhi S, Rzepkowska M, Gerlevik S, Karimi MM, Kulasekararaj A, Douiri A, Miller A, Duran L, Cui H, Lewis J, Kordasti S, Lombardi G, Napolitani G, Mufti GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742894"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2026 February 24; 10(4):1281-1292. doi: 10.1182\/bloodadvances.2025017433","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289157"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2026 February 24; 10(4):1293-1300. doi: 10.1182\/bloodadvances.2024015776","author":"Liu Q, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296017"},{"title01":"Regional brain age is decreased in children with sickle cell anemia.","title02":"Regional brain age is decreased in children with sickle cell anemia.","journal":"Blood advances","issue":"2026 February 24; 10(4):1035-1044. doi: 10.1182\/bloodadvances.2025017172","author":"Mirro AE, Power LC, Wang J, Germino-Watnick P, Roberts H, Cam Y, Guilliams KP, Fellah S, Chen Y, An H, Lee JM, Ford AL, Fields ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733950"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02886-6. Online ahead of print","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02883-9. Online ahead of print","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","title02":"Reframing-renaming(?)-myelodysplastic syndromes\/neoplasms and clonal hematopoiesis of indeterminate potential.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02865-x. Online ahead of print","author":"Lee NC, Miao R, Young NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703030"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 February 26. doi: 10.1038\/s41375-026-02892-8. Online ahead of print","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","title02":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288081. Online ahead of print","author":"Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XC, Lin CC, Chang H, Ko BS, Chou WC, Rollig C, Russell N, Dillon R, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742883"},{"title01":"The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.","title02":"The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2026.300553. Online ahead of print","author":"Chien KS, DeZern AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742893"},{"title01":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","title02":"Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.","journal":"Br J Haematol","issue":"2026 February 18. doi: 10.1111\/bjh.70384. Online ahead of print","author":"Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Cermak J, Langemeijer S, Hellstrom-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704134"},{"title01":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","title02":"High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens.","journal":"Blood advances","issue":"2026 February 24; 10(4):1114-1125. doi: 10.1182\/bloodadvances.2025017680","author":"Ito S, Martin E, Panousis C, Rowe AM, Stras S, Roy J, Cofano EB, Ventura K, Parr K, Neupane B, Bellesis A, Toki A, Jing R, Jang J, Neves AT, Shlomchik MJ, Shlomchik WD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170916"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 February 24; 10(4):939-950. doi: 10.1182\/bloodadvances.2025018408","author":"Boertjes EL, Grob T, Al Hinai A, Beverloo BHB, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska PL, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2026 February 24; 10(4):1126-1133. doi: 10.1182\/bloodadvances.2025017089","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733942"},{"title01":"Exposure to Agent Orange and Association with Myelodysplastic Syndromes.","title02":"Exposure to Agent Orange and Association with Myelodysplastic Syndromes.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025019262. Online ahead of print","author":"Sekeres MA, DeZern AE, Otterstatter M, Padron E, Al Baghdadi T, Foran JM, Komrokji RS, Abel GA, Saber W, Gore SD, Lee C, Bejar R, Liu JJ, Deeg HJ, Sherman S, Lindsley RC, Walter MJ, Gillis N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734386"},{"title01":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","title02":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","journal":"Blood","issue":"2026 February 19; 147(8):811-820. doi: 10.1182\/blood.2025029727","author":"Stahl M, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175364"},{"title01":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","title02":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2024027180. Online ahead of print","author":"Sharma R, Bhoopalan SV, Meyer R, Han L, Beesetti S, Liu N, Singh P, Palmer LE, Hansen BS, Khiami M, Larcher L, Begemann M, Corbacioglu S, Heller L, Jakob M, Ju Y, Sahoo SS, Gray N, Gheorghe G, Elbracht M, Khurana C, Kirschner M, Kurth I, Erlacher M, Brummendorf TH, Soulier J, Pruett-Miller SM, Beier F, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758987"},{"title01":"Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.","title02":"Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.","journal":"Leukemia","issue":"2026 February 20. doi: 10.1038\/s41375-026-02893-7. Online ahead of print","author":"Srisuwananukorn A, Loscocco GG, Dolezal JM, Kuykendall AT, Santi R, Zhang L, Singh AM, Guglielmelli P, Vannucchi AM, Salama ME, Pearson AT, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721088"},{"title01":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","title02":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02885-7. Online ahead of print","author":"Rolles B, Filho CMO, Fergusson N, Bewersdorf JP, Keating J, Perkins C, Schwede M, England J, Luskin MR, DeAngelo DJ, Shimony S, Faiz M, Hillerbrand AC, Kim C, Weeks LD, Waldman L, Wazir M, How J, Marneth AE, Liu Y, Aryee MJ, Rampal R, Tsai HK, Gotlib J, Gupta V, Stahl M, Mullally A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735484"},{"title01":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","title02":"Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.","journal":"Leukemia","issue":"2026 February 26. doi: 10.1038\/s41375-026-02892-8. Online ahead of print","author":"Jutzi JS, Crosse E, Kim CJ, van Gasteren B, Laurore C, Rolles B, Kramer F, Tishena A, Rocha AV, Wazir M, Weeks LD, How J, Stahl M, Luskin MR, Lindsley RC, Pozdnyakova O, Rai S, Graubert TA, Bradley RK, Mullally A, Marneth AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41748695"},{"title01":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","title02":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.289330. Online ahead of print","author":"Wang Y, Tang D, Cheng Z, Ding L, Zhang Y, Zhang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742887"},{"title01":"A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond.","title02":"A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond.","journal":"Blood advances","issue":"2026 February 24; 10(4):1250-1259. doi: 10.1182\/bloodadvances.2025017896","author":"Sonmez O, Oyur E, Yonal Hindilerden I, Hindilerden F, Sonmez M, Karismaz A, Atli Z, Soysal T, Eskazan AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733972"},{"title01":"Prime Time for The Use of Statins in MPNs: From Comorbidity Drugs to Disease-Modifying Partners.","title02":"Prime Time for The Use of Statins in MPNs: From Comorbidity Drugs to Disease-Modifying Partners.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2026019625. Online ahead of print","author":"Hasselbalch HC Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747195"},{"title01":"Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia.","title02":"Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia.","journal":"Blood advances","issue":"2026 February 27. doi: 10.1182\/bloodadvances.2025017575. Online ahead of print","author":"Gill H, Palandri F, Ross DM, Gothert JR, Cochrane T, Larsen SR, Halpern AB, Shortt J, Rossetti JM, Liang J, Marchetti M, Wilson AJ, Innes AJ, Hanna M, Vianelli N, Stevenson WS, Vannucchi AM, Kleppe M, Flynn J, Natsoulis G, Harrison CN, Rienhoff HY Jr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758981"},{"title01":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","title02":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","journal":"Blood","issue":"2026 February 26; 147(9):946-959. doi: 10.1182\/blood.2025028703","author":"Yan Y, Liu J, Zhao S, Li F, Yang L, Xu Z, Qin T, Zhu X, An W, Shi Z, Shen W, Zhang P, Huang G, Rampal RK, Xiao Z, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405487"},{"title01":"CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.","title02":"CD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.","journal":"Blood","issue":"2026 February 26; 147(9):907-909. doi: 10.1182\/blood.2025032444","author":"Johansson A, Lane SW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746641"},{"title01":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","title02":"Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.","journal":"Lancet Oncol","issue":"2026 February 16. doi: 10.1016\/S1470-2045(25)00678-3. Online ahead of print","author":"Pearson C, Jones DA, Baily G, Cherry R, Gray E, Hiom S, Rous B, Spencer K, Jose S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41713471"},{"title01":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","title02":"CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.","journal":"Leukemia","issue":"2026 February 19. doi: 10.1038\/s41375-026-02894-6. Online ahead of print","author":"Madiot C, Bellanger C, Dousset C, Decombis S, Thirouard L, Papin A, Baron E, Barc J, Le Bris Y, Gomez-Bougie P, Moreau-Aubry A, Tessoulin B, Pellat-Deceunynck C, Chiron D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714404"},{"title01":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","title02":"Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.","journal":"Leukemia","issue":"2026 February 19. doi: 10.1038\/s41375-026-02868-8. Online ahead of print","author":"Filip D, Litzmanova K, Michaelou A, Kledus F, Devan J, Boudny M, Hoferkova E, Sharma S, Seda V, Zeni PF, Borsky M, Matulova K, Kren L, Oppelt J, Blavet N, Hejret V, Urik M, Mareckova A, Rimsza LM, Kamaradova K, Belada D, Sykorova A, Mocikova H, Trneny M, Prouzova Z, Evans AG, Danilov A, Horn H, Ott G, Staber P, Mayer J, Friedberg JW, Janikova A, Mraz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714403"},{"title01":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","title02":"Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02870-0. Online ahead of print","author":"Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703025"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):476-485. doi: 10.1200\/JCO-25-02477","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):466-475. doi: 10.1200\/JCO-25-02380","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","title02":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):449-454. doi: 10.1200\/JCO-25-00203","author":"Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, Punnett A, Hodgson D, Keller FG, Drachtman RA, Lamble A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Hoppe BS, Song JY, Smith SM, Friedberg JW, Kelly KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512237"},{"title01":"Frontline therapy in primary mediastinal B-cell lymphoma: when salvage outcomes redefine the meaning of intensity. Comment on: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","title02":"Frontline therapy in primary mediastinal B-cell lymphoma: when salvage outcomes redefine the meaning of intensity. Comment on: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2026.000004. Online ahead of print","author":"Koca O, Kucukyurt S, Eskazan AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742899"},{"title01":"Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.","title02":"Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288473. Online ahead of print","author":"Kuchnio A, Yang D, Vloemans N, Cornelissen I, Amorim R, Perova T, Lowenstein C, Janssen L, Suls T, Bekkers M, Lasorsa E, Fontan L, Nemani N, Hojnacki T, Han C, Sukumaran S, Medeiros N, Srinivasan S, Wu B, Chen J, Feldkamp MD, Wu S, Habte H, McRee AJ, Daskalakis N, Krayer J, Holland C, Attar R, DeYoung PM, Singh S, Elsayed Y, Philippar U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742895"},{"title01":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","title02":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288996. Online ahead of print","author":"Tharmaseelan H, Sgonina LM, Buhnen I, Schnetzke U, Meissner J, Sellmayr M, Beverungen D, Hellmuth JC, Puthenparambil J, Zamrik T, Ferdinandus J, Shumilov E, Kerkhoff A, Melchardt T, Brockelmann PJ, Kobe C, Borchmann P, Von Tresckow B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742889"},{"title01":"Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?","title02":"Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.289210. Online ahead of print","author":"Dann EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742879"},{"title01":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","title02":"Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70390. Online ahead of print","author":"Ligia S, Assanto GM, Soriano T, Cappelli LV, Passucci M, Annechini G, D'Elia GM, Pulsoni A, Martelli M, Del Giudice I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721535"},{"title01":"Mycosis fungoides and Sezary syndrome.","title02":"Mycosis fungoides and Sezary syndrome.","journal":"Br J Haematol","issue":"2026 February 19. doi: 10.1111\/bjh.70392. Online ahead of print","author":"Martins F, Calvao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41711246"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70383. Online ahead of print","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70374. Online ahead of print","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","title02":"Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.","journal":"Br J Haematol","issue":"2026 February 17. doi: 10.1111\/bjh.70379. Online ahead of print","author":"Pouthier M, Garnier N, Leruste A, Rigaud C, Curtillet C, Ducassou S, Poiree M, Dourthe ME, Pochon C, Couec ML, Bonneau-Lagacherie J, Montravers F, Boudjemaa S, Jonca B, Haouy S, Leblanc T, Parker JL, Simonin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41704060"},{"title01":"Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r\/r lymphoma.","title02":"Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r\/r lymphoma.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70375. Online ahead of print","author":"Miles B, Mao D, Vardhanabhuti S, Bedognetti D, Filosto S, Shen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735224"},{"title01":"Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.","title02":"Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70402. Online ahead of print","author":"Argnani L, Stefoni V, Casadei B, Pelusi C, Preiato VL, Pagotto U, Bugane A, Pellegrini C, Broccoli A, Zinzani PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41744197"},{"title01":"Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).","title02":"Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).","journal":"Br J Haematol","issue":"2026 February 27. doi: 10.1111\/bjh.70406. Online ahead of print","author":"Liu Y, Zhang J, Wang L, Liang Z, Gong Y, Gao L, Zhang W, Lu X, Wang C, Yu L, Sun M, Zhuang Y, Miao Y, Ni H, Xie X, Xu J, Zhang Y, Zhao M, Xu M, Zhuang W, Gu W, Lin G, Hua H, Zhu J, Xu M, Jia T, Zhai L, Shan H, Shen Q, Fan L, Xia Y, Li J, Li B, Miao Y, Shi W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41757549"},{"title01":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","title02":"Long-term Health Outcomes in Older Blood or Marrow Transplantation Recipients: A Report from the BMTSS.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018477. Online ahead of print","author":"Bhandari R, Meng Q, Hageman L, Francisco L, Ross ES, Balas N, Bosworth AK, Bhatia R, Landier W, Weisdorf DJ, Wong FL, Bhatia S, Armenian SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734391"},{"title01":"Minimal Disease Detection by Immunoglobulin High-Throughput Sequencing in Pediatric Burkitt Lymphoma.","title02":"Minimal Disease Detection by Immunoglobulin High-Throughput Sequencing in Pediatric Burkitt Lymphoma.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025019436. Online ahead of print","author":"Craig SM, Okeson KR, Adlowitz DG, Baker C, Rock PJ, Burack R, Fries C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734384"},{"title01":"Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.","title02":"Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.","journal":"Blood advances","issue":"2026 February 24; 10(4):1194-1203. doi: 10.1182\/bloodadvances.2025017530","author":"Neuendorff NR, Pugh K, Juthani R, Soudant C, Mac Eochagain C, Torka P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733959"},{"title01":"Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.","title02":"Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.","journal":"Blood advances","issue":"2026 February 24; 10(4):1217-1232. doi: 10.1182\/bloodadvances.2024015689","author":"Ferrant J, Le Gallou S, Padonou F, Dubec-Fleury C, Leonard S, Papa I, Brottier C, Pangault C, Barthel A, Launay V, Manson G, Hoareau B, Deleurme L, Monvoisin C, Albaud B, Shipp MA, Van Acker N, Laurent C, Llamas Gutierrez F, Michaud HA, Bonnefoy N, Pecot T, Tarte K, Roussel M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733976"},{"title01":"Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed\/refractory mantle cell lymphoma in Chinese adults.","title02":"Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed\/refractory mantle cell lymphoma in Chinese adults.","journal":"Blood advances","issue":"2026 February 24; 10(4):1134-1144. doi: 10.1182\/bloodadvances.2024015763","author":"Xie Y, Zhou KS, Li LF, Liang AB, Mei H, Zou DH, Li WY, Jin J, Jin ZM, Jing HM, Yang HY, Chen T, Huang HQ, He PC, Cao JN, Xia Z, Gu YE, Zang YB, Zhou ZS, Tian ZZ, Zhu J, Song YQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811825"},{"title01":"Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.","title02":"Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1023-1034. doi: 10.1182\/bloodadvances.2025018137","author":"Darnell EP, Gallagher KME, Kanska J, Scarfo I, Balderrama-Gutierrez G, Berger TR, Budka J, Bozym DJ, Huang T, Shen R, Leick MB, Maus MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41686452"},{"title01":"A phase 1 study of blinatumomab\/lenalidomide in relapsed\/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.","title02":"A phase 1 study of blinatumomab\/lenalidomide in relapsed\/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.","journal":"Blood advances","issue":"2026 February 24; 10(4):1153-1162. doi: 10.1182\/bloodadvances.2025016845","author":"Tuscano JM, Othman T, Frankel P, Ruel C, Poh C, Herbert S, Maverakis E, Merleev AA, Luxardi G, Abedi M, Ranganathan R, Modi D, Zain J, Budde EL, Mei M, Rosenberg AS, Hoeg RT, Costello C, Foss FM, William BM, Holland HK, Sharon E, Streicher H, Danilov A, Newman E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213001"},{"title01":"MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.","title02":"MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1381-1394. doi: 10.1182\/bloodadvances.2025017760","author":"Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang J, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami G, Chen-Kiang S, Elemento O, Maddocks K, Leonard JP, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289154"},{"title01":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.","title02":"Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1372-1380. doi: 10.1182\/bloodadvances.2025018527","author":"Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Nizamuddin IA, Kahl BS, Danilov A, Argao C, Ruan J, Ryan CE, Merryman RW, Grover NS, Khan NB, Ouchveridze E, Tun AM, Ayyappan S, Mou E, Pongas GN, Lossos IS, Harris ZI, Munoz JL, Young P, Portell CA, Baidoun F, Alhaj Moustafa M, Reagan PM, Banaszak LG, Pophali PA, Velayati A, Greenwell IB, Gerber D, Jain P, Wang ML, Narkhede MS, Mehta A, Stack AC, Messmer MR, Bhansali RS, Barta SK, Moyo TK, Ghosh N, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380101"},{"title01":"Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.","title02":"Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025019303. Online ahead of print","author":"Kamdar M, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, Izutsu K, Morschhauser F, Lunning MA, Ribrag V, Lin Y, Bhatnagar R, Braun R, Montheard S, Abramson JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707107"},{"title01":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","title02":"Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study.","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025018455. Online ahead of print","author":"Ruan J, Chen Z, Larson MC, Bennani NN, Allen PB, Mou E, Wallace DS, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami GG, Pongas GN, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl BS, Cerhan JR, Flowers CR, Feldman AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707114"},{"title01":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2026 February 24; 10(4):1012-1022. doi: 10.1182\/bloodadvances.2025017165","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733951"},{"title01":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.","title02":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.","journal":"Blood","issue":"2026 February 17. doi: 10.1182\/blood.2025032307. Online ahead of print","author":"Dowling MR, Cliff ERS, Jeffrey A, Cashion C, Boyle S, Li J, Buss T, MacDonald R, Edelkina A, Scott HW MD, O'Leary N, Keir MW, Belbachir S, Westerman DA, Tam CS, Ho PJ, Harrison SJ, Barraclough A, Inam S, Blyth E, Henden AS, Vanguru V, Dickinson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701973"},{"title01":"A viral Achilles’ heel for EBV-positive lymphomas.","title02":"A viral Achilles’ heel for EBV-positive lymphomas.","journal":"Blood","issue":"2026 February 19; 147(8):804-806. doi: 10.1182\/blood.2025031851","author":"Yarchoan R, Tosato G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712297"},{"title01":"Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.","title02":"Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031181. Online ahead of print","author":"Yu C, Holloman M, Kim A, Chang Y, Meyer S, Holmes AB, Cai B, Mo T, Basso K, Dreval K, Morin RD, Bhagat G, Mullighan CG, Dalla-Favera R, Pasqualucci L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746257"},{"title01":"Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed\/Refractory B-NHL.","title02":"Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed\/Refractory B-NHL.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031309. Online ahead of print","author":"Marcoux P, Gava F, Tosolini M, Gravelle P, Schniederjohann C, Quertinmont S, Serrat N, Bouquet F, Herter S, Tarte K, Roussel M, Sesques P, Bret C, Rossi C, Aubert P, Morschhauser F, Cartron G, Huber W, Dietrich S, Ysebaert L, Brousset P, Bruch PM, Perez-Galan P, Bezombes C, Laurent C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746860"},{"title01":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","title02":"Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation.","journal":"Blood","issue":"2026 February 19; 147(8):848-862. doi: 10.1182\/blood.2025029771","author":"Stewart J, Damania B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105850"},{"title01":"CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.","title02":"CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031156. Online ahead of print","author":"Li X, Liu M, Shi Q, Du ZS, Fu D, Fang Y, Zhao LJ, Dai Y, Zhang MC, Zhang F, Zhao Y, Yi HM, He Y, Cheng S, Xu PP, Wang L, Chen J, Zhao W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758931"},{"title01":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","title02":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","journal":"N Engl J Med","issue":"2026 February 19; 394(8):739-752. doi: 10.1056\/NEJMoa2514663","author":"Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363801"},{"title01":"Biting the Tail of CAR-T for Relapsed Multiple Myeloma.","title02":"Biting the Tail of CAR-T for Relapsed Multiple Myeloma.","journal":"N Engl J Med","issue":"2026 February 19; 394(8):807-809. doi: 10.1056\/NEJMe2517627","author":"Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707143"},{"title01":"Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis.","title02":"Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02880-y. Online ahead of print","author":"Spataro F, Armentaro G, Di Gioia G, Meloni P, Rossi I, Williams M, Romiti GF, Talerico R, Villani R, Desantis V, Einsele H, Bencivenga L, Solimando AG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703031"},{"title01":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","title02":"The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02889-3. Online ahead of print","author":"Riedhammer C, Truger M, Lee H, Leypoldt LB, Meggendorfer M, Hutter S, Muller H, Mersi J, Kadel SK, Buchwald T, Kosch R, Helal M, Afrin N, Rosenwald A, Gerhard-Hartmann E, Brioli A, Kronke J, Haferlach T, Haferlach C, Weisel KC, Neri P, Einsele H, Kortum KM, Waldschmidt JM, Bahlis N, Weinhold N, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703032"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 February 27; JCO2501969. doi: 10.1200\/JCO-25-01969. Online ahead of print","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Mutual amplification of sensory nerve outgrowth and tumor progression in myeloma.","title02":"Mutual amplification of sensory nerve outgrowth and tumor progression in myeloma.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300309. Online ahead of print","author":"Nakagawa M, Hiasa M, Teramachi J, Harada T, Oda A, Nishino G, Matsuki S, Hanawa M, Bat-Erdene A, Taniguchi T, Taniguchi H, Tsuneyama K, Tominaga T, Tanaka E, Hiyama TY, Matsuoka KI, Katayama Y, Abe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742871"},{"title01":"Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.","title02":"Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025019231. Online ahead of print","author":"Tan CR, Usmani SZ, Derkach A, De Menezes Silva Corraes A, Parrondo RD, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Martinez-Lopez J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso AC, Lin Y, Martin TG, Mian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734378"},{"title01":"Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome.","title02":"Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018598. Online ahead of print","author":"Sester LS, Galeeva I, de Castilhos J, Borisov V, Gambihler A, Kilian M, Vonhoren D, Friedrich MJ, Poschet G, Steiger S, Chechenina A, Lettau K, Kohlberger CP, Prokoph N, Frenking JH, John L, Huhn S, Reichert P, Mai EK, Rippe K, Sauer S, Muller-Tidow C, Weinhold N, Platten M, Goldschmidt H, Raab MS, Stein-Thoeringer CK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734379"},{"title01":"Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma.","title02":"Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma.","journal":"Blood advances","issue":"2026 February 24. doi: 10.1182\/bloodadvances.2025018963. Online ahead of print","author":"Wood WA, Kumar SK, Semmel E, James S, Schroeder MA, Chung DJ, Rosenberg AS, Zonder JA, Rubinstein SM, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson LD, Derkach A, Geyer S, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734388"},{"title01":"Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma.","title02":"Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1405-1408. doi: 10.1182\/bloodadvances.2025018655","author":"Mian H, Arribas M, Fonseca R, Mutterback E, Shahid O, Gouda R, Pond GR, Visram A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733956"},{"title01":"Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed\/refractory multiple myeloma.","title02":"Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed\/refractory multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1395-1399. doi: 10.1182\/bloodadvances.2025017939","author":"Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733964"},{"title01":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","title02":"IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018537. Online ahead of print","author":"Maclachlan KH, Tan CR, Shekarkhand T, Rueda CJ, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz ML, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone RS, Jurgens EM, Miller KC, Rajeeve S, Giralt SA, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701976"},{"title01":"Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.","title02":"Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018974. Online ahead of print","author":"Di Palma-Grisi J, Biran N, Phull P, Vesole DH, Siegel DS, Parmar H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701974"},{"title01":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","title02":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","journal":"Blood advances","issue":"2026 February 24; 10(4):1400-1404. doi: 10.1182\/bloodadvances.2025018342","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S, Dhakal B, D'Souza A, Lin D, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","title02":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","journal":"Blood advances","issue":"2026 February 24; 10(4):1312-1323. doi: 10.1182\/bloodadvances.2025018133","author":"Fang B, Zhu Z, Chang Y, He X, Li S, Li M, Yan S, Zhu D, Li Z, Mao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385406"},{"title01":"Prognosis and patterns of progression in smoldering multiple myeloma.","title02":"Prognosis and patterns of progression in smoldering multiple myeloma.","journal":"Blood advances","issue":"2026 February 24; 10(4):1344-1347. doi: 10.1182\/bloodadvances.2025018021","author":"Akhlaghi T, Maclachlan KH, Wiggins A, Usmani SZ, Derkach A, Hultcrantz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380108"},{"title01":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.","title02":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.","journal":"Blood advances","issue":"2026 February 20. doi: 10.1182\/bloodadvances.2025019050. Online ahead of print","author":"Atrash S, Symanowski J, Robinson M, Flynn C, Norek S, Cox R, Plott M, Bumgarner K, Rhinehardt D, Begic X, Ndiaye AP, Robinson JD, Friend R, Paul BA, Varga C, Ferreri CJ, Pineda-Roman M, Foureau DM, Bhutani M, Voorhees PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719502"},{"title01":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.","title02":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.","journal":"Blood","issue":"2026 February 19; 147(8):834-847. doi: 10.1182\/blood.2025030027","author":"Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P, Testa JS, Ponticiello R, Brodeur S, Heidrich B, Packman K, Singh S, Attar R, Elsayed Y, Philippar U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100731"},{"title01":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","title02":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","journal":"Blood","issue":"2026 February 26; 147(9):932-945. doi: 10.1182\/blood.2025030083","author":"Fokkema C, Bertamini L, de Jong MME, Tahri S, Hofste Op Bruinink D, Kellermayer Z, Papazian N, den Hollander C, Vermeulen MPW, Stoetman ECG, van Beek G, Hoogenboezem R, van der Velden VHJ, Hulin C, Perrot A, Moreau P, Rowe M, Vieyra D, Carson R, van Duin M, Sanders MA, Broijl A, Sonneveld P, Cupedo T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411148"},{"title01":"At a crossroads: circulating tumor cells in myeloma.","title02":"At a crossroads: circulating tumor cells in myeloma.","journal":"Blood","issue":"2026 February 26; 147(9):906-907. doi: 10.1182\/blood.2025032333","author":"Alberge JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746637"},{"title01":"Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study.","title02":"Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025030120. Online ahead of print","author":"Orlowski RZ, Dimopoulos MA, Leleu X, Facon T, Ishida T, Hajek R, Spicka I, Romejko-Jarosinska J, Vorobyev VI, Besemer B, Kalayoglu Besisik S, Robak P, Jelinek T, Goldschmidt H, Martin T, Mohty M, Mace S, Kodas E, Tekle C, Shafer AT, Moreau P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758929"},{"title01":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","title02":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031663. Online ahead of print","author":"Wang Y, Liu S, Ghamlouch H, Gagler DC, Blaney P, Nabet B, Davies FE, Morgan GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758961"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02867-9. Online ahead of print","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","title02":"Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).","journal":"J Clin Oncol","issue":"2026 February 27; JCO2501969. doi: 10.1200\/JCO-25-01969. Online ahead of print","author":"Yan W, Du C, Lv R, Zou H, Zhang S, Yu T, Yan Y, Zhang Y, Peng S, Wang T, Deng S, Huang W, Yi S, Zou D, Cheng T, Wang J, Chang AH, Qiu L, An G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41759038"},{"title01":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","title02":"Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.","journal":"J Clin Oncol","issue":"2026 February 25; JCO2501591. doi: 10.1200\/JCO-25-01591. Online ahead of print","author":"Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, Page KM, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Lipsitt AE, Symons H, Bolanos-Meade J, Kharbanda S, Dvorak CC, Kapoor N, Doherty EE, Chavan RS, Broglie L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41740085"},{"title01":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","title02":"Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.289302. Online ahead of print","author":"Bonifazi F, Roberto M, Stanghellini MTL, Chiusolo P, Polverelli N, Geromin A, Prezioso L, Algeri M, Mancini G, Prunotto G, Algarotti A, Nozzoli C, Malagola M, Mordini N, Fedele M, Santoro L, Zallio F, Castagna L, Picardi A, Busca A, Giaccone L, Skert C, Elice F, Facchini L, Mariotti J, Pierini A, Spina A, De Marchi R, Salvatore D, Martino M, Tumino M, Rambaldi A, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709738"},{"title01":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","title02":"Phase I trial of autologous regulatory T cells for immune aplastic anemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288962. Online ahead of print","author":"Matto N, Gandhi S, Rzepkowska M, Gerlevik S, Karimi MM, Kulasekararaj A, Douiri A, Miller A, Duran L, Cui H, Lewis J, Kordasti S, Lombardi G, Napolitani G, Mufti GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742894"},{"title01":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","title02":"Anti-programmed cell death protein 1-based salvage therapy for relapsed\/refractory Hodgkin lymphoma: a multicenter real-world analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288996. Online ahead of print","author":"Tharmaseelan H, Sgonina LM, Buhnen I, Schnetzke U, Meissner J, Sellmayr M, Beverungen D, Hellmuth JC, Puthenparambil J, Zamrik T, Ferdinandus J, Shumilov E, Kerkhoff A, Melchardt T, Brockelmann PJ, Kobe C, Borchmann P, Von Tresckow B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742889"},{"title01":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","title02":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02883-9. Online ahead of print","author":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, Gitego N, Ma F, Aluri S, Pradhan K, Gordon-Mitchell S, Mantzaris I, Goldfinger M, Feldman E, Gritsman K, Shi Y, Hubner S, Qiu YH, Brown BD, Khasawneh A, Skwarska A, de Camargo Magalhaes ES, Verma A, Konopleva M, Tabe Y, Gavathiotis E, Colla S, Gollob J, Dey J, Kornblau SM, Koralov SB, Ito K, Shastri A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703028"},{"title01":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","title02":"The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02888-4. Online ahead of print","author":"Wang C, Ge S, Gao J, Yang R, Guo X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703029"},{"title01":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","title02":"Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.","journal":"Leukemia","issue":"2026 February 19. doi: 10.1038\/s41375-026-02875-9. Online ahead of print","author":"Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, Fabisch C, Nicolini FE, Olsson-Stromberg U, Zackova D, Lewandowski K, Ernst P, Castagnetti F, Hirschbuhl K, Zupan I, Voskanyan A, Golos A, Frietsch JJ, Gil J, Faber E, Krause SW, Parry A, Saussele S, Heibl S, Franke GN, Casado LF, Paczkowska E, Hebart H, Eder M, Anhut P, Trautmann-Grill K, Szczepanek E, Sudhoff T, Patkowska E, Kiani A, Ernst T, Apperley J, Mayer J, Hochhaus A, Pfirrmann M, Brioli A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41714405"},{"title01":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","title02":"Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 February 24. doi: 10.1038\/s41375-026-02867-9. Online ahead of print","author":"Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guerin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41735483"},{"title01":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","title02":"Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.","journal":"Leukemia","issue":"2026 February 17. doi: 10.1038\/s41375-026-02886-6. Online ahead of print","author":"Tiong IS, Hunter S, Kankanige Y, Mehta NN, Chisholm RA, Wu S, Li J, Casan J, Chan KL, Godley LA, Fox LC, Blombery P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41703027"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):476-485. doi: 10.1200\/JCO-25-02477","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","title02":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):435-439. doi: 10.1200\/JCO-25-02691","author":"Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363770"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):466-475. doi: 10.1200\/JCO-25-02380","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","title02":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","journal":"J Clin Oncol","issue":"2026 February 20; 44(6):440-444. doi: 10.1200\/JCO-25-02879","author":"Braunstein MJ, Williams ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557975"},{"title01":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","title02":"Clonal origin tracing and integrated biomarker analysis in a JAK2V617F-positive essential thrombocythemia patient progressing to T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.289330. Online ahead of print","author":"Wang Y, Tang D, Cheng Z, Ding L, Zhang Y, Zhang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742887"},{"title01":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","title02":"Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.288081. Online ahead of print","author":"Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XC, Lin CC, Chang H, Ko BS, Chou WC, Rollig C, Russell N, Dillon R, Hou HA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742883"},{"title01":"Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.","title02":"Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70405. Online ahead of print","author":"Groll AH, Cesaro S, Alten J, Attarbaschi A, Barbaric D, Ebrahimi-Fakhari D, Bodmer N, Conter V, Elitzur S, Moricke A, Schrappe M, Stary J, Zapotocka E, Zimmermann M, Lehrnbecher T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733132"},{"title01":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","title02":"Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 February 26. doi: 10.1111\/bjh.70380. Online ahead of print","author":"Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747740"},{"title01":"FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.","title02":"FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.","journal":"Blood advances","issue":"2026 February 24; 10(4):1179-1193. doi: 10.1182\/bloodadvances.2025018168","author":"Rohrbacher L, Nixdorf D, Stadler H, Brauchle B, Markl F, Gottschlich A, Hoffmann GV, Philipp N, Hanel G, Kirmaier ME, Marcinek A, Kazerani M, Richter D, Magno G, Goldstein RL, Theurich S, Straub T, Kobold S, Arvedson T, Bucklein V, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733953"},{"title01":"Interpreting Next-Generation Immunosequencing Results in Children and Young Adults with Acute Lymphoblastic Leukemia.","title02":"Interpreting Next-Generation Immunosequencing Results in Children and Young Adults with Acute Lymphoblastic Leukemia.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025018923. Online ahead of print","author":"Hamidi R, Kirsch IR, Schultz LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747190"},{"title01":"Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: when, how, who?","title02":"Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: when, how, who?","journal":"Blood advances","issue":"2026 February 24; 10(4):999-1011. doi: 10.1182\/bloodadvances.2025015936","author":"Datta S, Litzow MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115238"},{"title01":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","title02":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","journal":"Blood advances","issue":"2026 February 24; 10(4):1301-1311. doi: 10.1182\/bloodadvances.2024015408","author":"Lefeivre T, Grosu TI, Tudose C, Jones L, Leon TE, Wynne K, Oliviero G, Smith OP, Trinquand A, Mansour MR, Ryan CJ, Bond J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337688"},{"title01":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","title02":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.","journal":"Blood advances","issue":"2026 February 24; 10(4):1400-1404. doi: 10.1182\/bloodadvances.2025018342","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S, Dhakal B, D'Souza A, Lin D, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","title02":"Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.","journal":"Blood advances","issue":"2026 February 24; 10(4):1082-1093. doi: 10.1182\/bloodadvances.2025017908","author":"Schroeder JC, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289166"},{"title01":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2026 February 24; 10(4):1012-1022. doi: 10.1182\/bloodadvances.2025017165","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296002"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2026 February 24; 10(4):1204-1216. doi: 10.1182\/bloodadvances.2024014831","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio L, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Low Flow Cytometry Events in Detecting CNS Involvement in Pediatric BCP-ALL: NGS Validation and Prognostic Significance.","title02":"Low Flow Cytometry Events in Detecting CNS Involvement in Pediatric BCP-ALL: NGS Validation and Prognostic Significance.","journal":"Blood advances","issue":"2026 February 20. doi: 10.1182\/bloodadvances.2025018288. Online ahead of print","author":"Chou SW, Su YH, Lu MY, Chang HH, Yang YL, Du CJ, Yen HJ, Li MJ, Lee CY, Liew PT, Lin DT, Lin KH, Lin SW, Jou ST","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719456"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2026 February 24; 10(4):1126-1133. doi: 10.1182\/bloodadvances.2025017089","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346286"},{"title01":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","title02":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","journal":"Blood advances","issue":"2026 February 24; 10(4):1272-1277. doi: 10.1182\/bloodadvances.2025016618","author":"Mayerhofer C, Crompton E, Mayerhofer E, Kristiansen T, Fukushima T, Keyes S, Sharda A, Li D, Da Silva C, Shrestha D, Kiem A, Feuchtinger T, Scadden DT, Miller PG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351481"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 February 24; 10(4):939-950. doi: 10.1182\/bloodadvances.2025018408","author":"Boertjes EL, Grob T, Al Hinai A, Beverloo BHB, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska PL, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multi-site, retrospective cohort review.","title02":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multi-site, retrospective cohort review.","journal":"Blood advances","issue":"2026 February 17. doi: 10.1182\/bloodadvances.2025018604. Online ahead of print","author":"Rankin AW, Myers RM, Lamble AJ, Hsieh EM, Sankaran H, Chen L, Annesley C, DiNofia AM, Grupp SA, Pulsipher MA, Dolan JG, Bhojwani D, Gardner RA, Shah NN, Rheingold SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41701972"},{"title01":"CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?","title02":"CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?","journal":"Blood advances","issue":"2026 February 18. doi: 10.1182\/bloodadvances.2025018480. Online ahead of print","author":"Gava F, Yates B, Sun Z, Li G, O'Koren C, Adhikari B, Luger SM, Shalabi HN, Mattison RJ, Turkbey EB, Yuan CM, Paietta E, Wang HW, Mullighan CG, Silbert SK, Litzow MR, Shah NN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41707115"},{"title01":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","title02":"No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.","journal":"Blood advances","issue":"2026 February 24; 10(4):1260-1271. doi: 10.1182\/bloodadvances.2025018139","author":"Murdock HM, Kim HT, Maurer K, Kelkar A, Shapiro RM, Gooptu M, Romee R, Nageshwar PK, Garrity HM, Shimony S, Luskin MR, Winer ES, Vedula RS, Stahl M, Chen EC, Volpe V, Garcia JS, Wadleigh M, DeAngelo DJ, Stone RM, Wu CJ, Cutler CS, Koreth J, Ritz J, Antin JH, Ho VT, Nikiforow S, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41172235"},{"title01":"Anticoagulation, Recurrent Thrombosis and Major bleeding in antiphospholipid syndrome: UK multicentre observational study.","title02":"Anticoagulation, Recurrent Thrombosis and Major bleeding in antiphospholipid syndrome: UK multicentre observational study.","journal":"Blood advances","issue":"2026 February 20. doi: 10.1182\/bloodadvances.2025019447. Online ahead of print","author":"Crossette-Thambiah CK, Rajakaruna I, Odho Z, Doyle AJ, Breen KA, Laffan MA, J Arachchillage D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41719455"},{"title01":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","title02":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","journal":"Blood advances","issue":"2026 February 24; 10(4):987-998. doi: 10.1182\/bloodadvances.2025017083","author":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti A, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes W, Chyla B, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269778"},{"title01":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","title02":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","journal":"Blood","issue":"2026 February 19; 147(8):863-876. doi: 10.1182\/blood.2025028933","author":"Ling T, O'Brien C, St-Germain JR, Rondeau V, Shi M, Berman JM, Cepa A, Saez Raez P, Wunderlich M, Carter KM, Stillwell C, Sexton C, Culp-Hill R, Reisz JA, Adeel SA, Zeng AGX, Bansal S, Tsao E, Chen HT, Dick JE, Minden MD, Arruda A, Amaya ML, Tikhonova AN, Hope KJ, D'Alessandro A, Raught B, Jones CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237364"},{"title01":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","title02":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.","journal":"Blood","issue":"2026 February 19; 147(8):811-820. doi: 10.1182\/blood.2025029727","author":"Stahl M, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175364"},{"title01":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","title02":"Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031202. Online ahead of print","author":"Parfenova EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, Kiebish MA, Minden MD, Spagnuolo PA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41746867"},{"title01":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","title02":"Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2025031545. Online ahead of print","author":"Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CTK, Villar-Prados A, Ji X, Jensen KP PhD, Negrin RS, Meyer E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758930"},{"title01":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","title02":"Study of NSD2 using a dTAG system reveals their molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.","journal":"Blood","issue":"2026 February 26. doi: 10.1182\/blood.2025031663. Online ahead of print","author":"Wang Y, Liu S, Ghamlouch H, Gagler DC, Blaney P, Nabet B, Davies FE, Morgan GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758961"},{"title01":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","title02":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.","journal":"Blood","issue":"2026 February 19; 147(8):821-833. doi: 10.1182\/blood.2025029611","author":"Boissel N, Chevret S, Huguet F, Leguay T, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhedin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Manz M, Cluzeau T, Turlure P, Rousselot P, de Prijck B, Grardel N, Bene MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah N, Lheritier V, Asnafi V, Clappier E, Dombret H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135009"},{"title01":"Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals.","title02":"Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals.","journal":"Blood","issue":"2026 February 19; 147(8):897-901. doi: 10.1182\/blood.2024028042","author":"Attardi E, Gray N, Lewis S, Boals M, Shaker P, Kotmayer L, Sahoo SS, Li P, Andersen EF, Zhao J, Pizzo L, Oved JH, Jesudas R, Reiss UM, Sharma R, Christakopoulos GE, Bhoopalan SV, Takemoto CM, Kennedy A, Voso MT, Kang G, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41335385"},{"title01":"A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.","title02":"A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.","journal":"Blood","issue":"2026 February 24. doi: 10.1182\/blood.2024027853. Online ahead of print","author":"Himonas E, de Beauchamp L, Zerbst D, Desmares-Romain E, Sarnello D, Kalkman ER, Rattigan KM, James D, Shokry E, Copland M, Griessinger E, Recher C, Mansat-De Mas V, Vergez F, Sumpton D, Schimmer AD, Minden MD, Gottlieb E, Shanks E, Sarry JE, Helgason V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734389"},{"title01":"Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1\/BRM inhibitor.","title02":"Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1\/BRM inhibitor.","journal":"Blood","issue":"2026 February 24. doi: 10.1182\/blood.2025031486. Online ahead of print","author":"Fiskus W, Mill CP, Issa GC, Piel J, Collins MP, Hentemann M, Cuglievan B, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, Takahashi K, Hammond D, Senapati J, Loghavi S, Flores L, Su X, DiNardo CD, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41734382"},{"title01":"De novo CD19- B-ALL: awareness of a rare entity in initial diagnosis.","title02":"De novo CD19- B-ALL: awareness of a rare entity in initial diagnosis.","journal":"Blood","issue":"2026 February 19; 147(8):902. doi: 10.1182\/blood.2025031848","author":"Hagos T, Zhao C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712292"},{"title01":"Incremental changes to improve outcomes in ALL.","title02":"Incremental changes to improve outcomes in ALL.","journal":"Blood","issue":"2026 February 19; 147(8):801-802. doi: 10.1182\/blood.2025031878","author":"Litzow MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712294"},{"title01":"Glutathionylated leaky mitochondrial pores as target in AML.","title02":"Glutathionylated leaky mitochondrial pores as target in AML.","journal":"Blood","issue":"2026 February 19; 147(8):806-807. doi: 10.1182\/blood.2025032167","author":"Pereira-Martins D, Schuringa JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41712296"},{"title01":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","title02":"MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.","journal":"Blood","issue":"2026 February 27. doi: 10.1182\/blood.2024027180. Online ahead of print","author":"Sharma R, Bhoopalan SV, Meyer R, Han L, Beesetti S, Liu N, Singh P, Palmer LE, Hansen BS, Khiami M, Larcher L, Begemann M, Corbacioglu S, Heller L, Jakob M, Ju Y, Sahoo SS, Gray N, Gheorghe G, Elbracht M, Khurana C, Kirschner M, Kurth I, Erlacher M, Brummendorf TH, Soulier J, Pruett-Miller SM, Beier F, Wlodarski MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41758987"},{"title01":"Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL.","title02":"Persistence of PET Scan Positivity After Chemoimmunotherapy For DLBCL.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025019273. Online ahead of print","author":"Armitage JO, Lunning MA, Vose JM, Longo DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747191"},{"title01":"Real-World Outcomes and Toxicities of CAR-T in Relapsed\/Refractory Follicular Lymphoma: A Multicenter Cohort Study.","title02":"Real-World Outcomes and Toxicities of CAR-T in Relapsed\/Refractory Follicular Lymphoma: A Multicenter Cohort Study.","journal":"Blood advances","issue":"2026 February 26. doi: 10.1182\/bloodadvances.2025019115. Online ahead of print","author":"Sharp J, Strati P, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Reef D, Gorzewski AM, Wang JS, Shouse G, Reinert C, Teferra A, Toro Velez E, Pelcovits A, Ollila TA, Clark WB, Yazbeck V, Maakaron JE, Kamdar M, Fitzgerald LA, Danilov AV, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41747197"},{"title01":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","title02":"Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.","journal":"Leukemia","issue":"2026 February 25. doi: 10.1038\/s41375-026-02897-3. Online ahead of print","author":"Bohra A, Hassan R, Zanwar S, Jevremovic D, Olteanu H, Gonsalves WI, Otteson G, Horna P, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41741799"},{"title01":"Exploiting metabolic dependencies in acute myeloid leukemia: DHODH inhibition meets lipid and cholesterol metabolism.","title02":"Exploiting metabolic dependencies in acute myeloid leukemia: DHODH inhibition meets lipid and cholesterol metabolism.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2026.300677. Online ahead of print","author":"Cruz-Rodriguez N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742882"},{"title01":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","title02":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300374. Online ahead of print","author":"Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742869"},{"title01":"Platelet glycoprotein V autoantibodies and complement C3 are associated with thrombosis in systemic lupus erythematosus.","title02":"Platelet glycoprotein V autoantibodies and complement C3 are associated with thrombosis in systemic lupus erythematosus.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300094. Online ahead of print","author":"Bengtsson AA, Grenmyr E, Jonsen A, Kahn R, Semple JW, Porcelijn L, Kapur R, Linge CP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742868"},{"title01":"Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.","title02":"Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300427. Online ahead of print","author":"Baden D, Wolgast N, Ruhnke L, Metzeler K, Beder T, Pohlmann A, Steinhauser S, Muller-Nordhorn J, Katalinic A, Voso MT, Baldus CD, Fransecky L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742888"},{"title01":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","title02":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2026 February 26. doi: 10.3324\/haematol.2025.300417. Online ahead of print","author":"Mohetaer A, Hao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41742890"},{"title01":"Extracellular microvesicles from patients with antiphospholipid syndrome carry antigenic targets and promote endothelial cell activation in vitro.","title02":"Extracellular microvesicles from patients with antiphospholipid syndrome carry antigenic targets and promote endothelial cell activation in vitro.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.288860. Online ahead of print","author":"Capozzi A, Riitano G, Recalchi S, Longo A, Manganelli V, Mancuso S, Alessandri C, Misasi R, Garofalo T, Sorice M, Truglia S, Conti F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709746"},{"title01":"CML-like biology is a unifying feature of myeloid\/lymphoid neoplasms with tyrosine kinase fusions in lymphoid blast phase. Comment on: Multilineage involvement in ABL-class fusion-positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology.","title02":"CML-like biology is a unifying feature of myeloid\/lymphoid neoplasms with tyrosine kinase fusions in lymphoid blast phase. Comment on: Multilineage involvement in ABL-class fusion-positive pediatric B-cell acute lymphoblastic leukemia: CML-like biology.","journal":"Haematologica","issue":"2026 February 19. doi: 10.3324\/haematol.2025.300254. Online ahead of print","author":"Wang WJ, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41709742"},{"title01":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","title02":"An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL\/SLL.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70383. Online ahead of print","author":"Tian Z, Deng Z, Han F, Yu L, Jiang Y, Peng H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733051"},{"title01":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","title02":"Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.","journal":"Br J Haematol","issue":"2026 February 24. doi: 10.1111\/bjh.70393. Online ahead of print","author":"Eriksen JVN, de Pietri S, Rathe M, Hasle H, Enevold C, Nielsen CH, Schmigelow K, Moser C, Muller K, Weischendorff S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41733102"},{"title01":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","title02":"Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.","journal":"Br J Haematol","issue":"2026 February 20. doi: 10.1111\/bjh.70374. Online ahead of print","author":"Hsu CM, Hsu JF, Huang JF, Liu YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41721497"},{"title01":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):773-774. doi: 10.3324\/haematol.2025.288957","author":"Bethge W, Dreger P, German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy Drst, GWGFHSCTACTEVD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):771-772. doi: 10.3324\/haematol.2025.288731","author":"Deeren D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820855"},{"title01":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):773-774. doi: 10.3324\/haematol.2025.288957","author":"Bethge W, Dreger P, German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy Drst, GWGFHSCTACTEVD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):771-772. doi: 10.3324\/haematol.2025.288731","author":"Deeren D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820855"},{"title01":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: “Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):771-772. doi: 10.3324\/haematol.2025.288731","author":"Deeren D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820855"},{"title01":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","title02":"Response to Comment on: “Does size matter? Centerspecific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy”.","journal":"Haematologica","issue":"2026 February 1; 111(2):773-774. doi: 10.3324\/haematol.2025.288957","author":"Bethge W, Dreger P, German Registry For Hematopoietic Stem Cell Transplantation And Cell Therapy Drst, GWGFHSCTACTEVD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931877"},{"title01":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","title02":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019378. Online ahead of print","author":"Shimony S, Murdock HM, Keating JH, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg DS, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018770. Online ahead of print","author":"DeZern AE, Gillis N, Otterstatter M, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Xie Z, Zhang L, Moscinski LC, Kroft SH, Harrington AM, Foran JM, Komrokji RS, Starczynowski DT, Gore SD, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo NL, Walter MJ, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","title02":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 February; 40(2):360-372. doi: 10.1038\/s41375-025-02836-8","author":"Guy A, Mansier O, Decilap M, Catherineau A, Garcia G, Labrouche-Colomer S, Bats ML, Boyer F, Ianotto JC, Lippert E, Roy L, Tavitian S, Slama B, Girault S, Etienne G, Parry A, Saint-Lezer A, Denis G, Mediavilla C, Viallard JF, Legros L, Ranta D, Wemeau M, Nicolini FE, Lifermann F, Cambier N, Darnige L, Girodon F, Soret-Dulphy J, Cayssials E, Vacheret F, Sureau L, Paz DL, Ugo V, Kiladjian JJ, Thiebaut R, James C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436639"},{"title01":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","title02":"JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 February 2. doi: 10.1038\/s41375-025-02843-9. Online ahead of print","author":"Kealy D, Ellerington R, Bansal S, Medeiros JJF, Hawley CA, Zeng AGX, Lukaszonek J, West KA, Sinha AD, Caalim G, Gawne RT, Pope J, Ferreira BL, Blacknell NM, Drylie B, Chatzigerou J, Khoo HM, Wilkinson AC, Fielding AK, Wang G, Psaila B, Kent DG, Hitchcock IS, Holding AN, Mason AS, Gupta V, Dick JE, Bridge KS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41629621"},{"title01":"Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease.","title02":"Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300028. Online ahead of print","author":"Barbui T, Ghirardi A, Condorelli A, Sobas M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641637"},{"title01":"Hypoxia-inducible factors contribute to venous thrombosis in a mouse model of myeloproliferative neoplasms.","title02":"Hypoxia-inducible factors contribute to venous thrombosis in a mouse model of myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 February 10; 10(3):775-778. doi: 10.1182\/bloodadvances.2025016344","author":"Ghosh S, Miklosz J, Trebak F, Tourn J, Grover SP, Pawlinski R, Reeves BN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191539"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018770. Online ahead of print","author":"DeZern AE, Gillis N, Otterstatter M, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Xie Z, Zhang L, Moscinski LC, Kroft SH, Harrington AM, Foran JM, Komrokji RS, Starczynowski DT, Gore SD, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo NL, Walter MJ, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia.","title02":"Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018818. Online ahead of print","author":"Chowdhury SR, Sirotich E, Guyatt GH, Modi D, Cuker A, Breakey V, Grace RF, Pai M, Beck CE, Yan JW, Porter S, Kang M, Webert KE, O'Connor C, Pruitt B, DiRaimo J, Paynter D, Strachan G, St John M, Molnar L, Arnold DM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637560"},{"title01":"Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.","title02":"Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025018690. Online ahead of print","author":"Gunn E, Angulo PA, Badawy SM, Davini M, Elkus H, Hillier K, Kaicker S, Lebensburger J, Luke N, Scott KE, Nakano TA, Remiker AS, Rifkin-Zenenberg S, Schultz CL, Buissereth T, Carrier K, Durney J, Dekermanji A, Grace RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643186"},{"title01":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.","title02":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.","journal":"Blood","issue":"2026 February 12; 147(7):783-799. doi: 10.1182\/blood.2025029769","author":"Mei H, Xu M, Shu J, Tang L, Xie Q, Luo L, Wei Q, Jiang H, Ming Z, Hu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237341"},{"title01":"Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model.","title02":"Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model.","journal":"Blood","issue":"2026 February 3. doi: 10.1182\/blood.2025028563. Online ahead of print","author":"Hillier K, Zobeck M, MacMath D, Chumsky J, Kirk SE, O'Farrell C, Lucari B, Ngwerume F, Gaerlan S, Konde P, Wang KG, Lambert MP, Grace RF, Grimes AB, Kim TO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632829"},{"title01":"Stuck on you: Tregs, alphavbeta8, TGF-beta1, and platelets in ITP.","title02":"Stuck on you: Tregs, alphavbeta8, TGF-beta1, and platelets in ITP.","journal":"Blood","issue":"2026 February 12; 147(7):709-711. doi: 10.1182\/blood.2025031893","author":"Ragni MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678206"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025018774. Online ahead of print","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025017945. Online ahead of print","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"Informed shared decision-making or rigid eligibility and exclusion criteria for gene therapy for sickle cell disease?","title02":"Informed shared decision-making or rigid eligibility and exclusion criteria for gene therapy for sickle cell disease?","journal":"Blood advances","issue":"2026 February 10; 10(3):608-617. doi: 10.1182\/bloodadvances.2025017015","author":"Krishnamurti L, Olafimihan A, Hsu LL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092461"},{"title01":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","title02":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019378. Online ahead of print","author":"Shimony S, Murdock HM, Keating JH, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg DS, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","title02":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","journal":"Blood advances","issue":"2026 February 10; 10(3):887-900. doi: 10.1182\/bloodadvances.2025016812","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin NJ, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo L, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2026 February 10; 10(3):837-849. doi: 10.1182\/bloodadvances.2024015191","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","title02":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","journal":"Blood advances","issue":"2026 February 10; 10(3):759-773. doi: 10.1182\/bloodadvances.2025017705","author":"Tanaka-Yano M, Sugden WW, Wang D, Falchetti M, Badalamenti B, Cote P, Chin D, Goldstein J, George S, Rodrigues-Luiz GF, Lummertz da Rocha E, Li H, North TE, Gryder BE, Rowe RG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191516"},{"title01":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","title02":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","journal":"Blood advances","issue":"2026 February 10; 10(3):665-681. doi: 10.1182\/bloodadvances.2025017707","author":"Jullien M, Ferron E, Willem C, David G, Legrand N, Duquesne A, Bouzy S, Bastien M, Garnier A, Guillaume T, Le Bourgeois A, Vantyghem S, Peterlin P, Gagne K, Chevallier P, Retiere C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170906"},{"title01":"Antibiotic risk score for acute graft-versus-host disease.","title02":"Antibiotic risk score for acute graft-versus-host disease.","journal":"Blood advances","issue":"2026 February 10; 10(3):555-561. doi: 10.1182\/bloodadvances.2025018317","author":"Rashidi A, Gao F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160804"},{"title01":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","title02":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","journal":"Blood advances","issue":"2026 February 12. doi: 10.1182\/bloodadvances.2025018651. Online ahead of print","author":"Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, Astigarraga I, Lehrnbecher T, van den Bos C, Simonin M, Ahlmann M, Barkaoui M, Le Louet S, Chevallier A, Chalard F, Nguyen T, Holzhauer S, Beutel K, Haenicke H, Escherich G, Garcia-Obregon S Phd, Valero-Arrese L, Ruano D, Andres M, Habes D, Lacaille F, McLin V, Bomken S, Bishop H, Penn A, Naeije L, Kabbara N, Milne P, Helias-Rodzewicz Z, Kolenova A, Renard C, Marec-Berard P, Thalhammer J, Pagnier A, Salmon A, Aladjidi N, Olivier L, Saultier P, Blanc L, Gandemer V, Schneider P Sr, Hessissen L, Golan M, Elitzur S, Ben Arush M, Ashkenazi Lustig D, Dvir R, Raciborska A, Malas Z, Diallo S, Levy G, Efremova V, Munthe-Kaas MC, von Bahr Greenwood T, Felizzia GA Sr, Braier JL, Boudiaf H, Ben Fraj I, Svojgr K, Krenova Z, Bernard F, Adam C, Karaoli E, Kristensen IA, Dahl C, Trambusti I, Gaspari S, De Fusco C, Chiaravalli S, Corti PC, Todesco A, Papadakis V, Luz I, Costa V, Osipova DS, Lyudovskikh E, Maschan MA, Bronin G, Burcev E, Idbaih A, Larabi IA, Bellouard M, Alvarez JC, Novosad O, Collin M, Henter JI, Emile JF, Heritier S, Minkov M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678955"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.","title02":"Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.","journal":"Blood","issue":"2026 February 5; 147(6):613-632. doi: 10.1182\/blood.2024027948","author":"Turkalj S, Radtke FA, Stoilova B, Mecklenbrauck R, Groom AJ, Jakobsen NA, Lachowiez CA, Metzner M, Usukhbayar B, Salazar MA, Zeng Z, Loghavi S, Marvin-Peek J, Korber V, Ravandi F, Issa G, Kadia T, Symeonidou V, de Groot AP, Kantarjian H, Takahashi K, Konopleva M, DiNardo CD, Vyas P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191518"},{"title01":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","title02":"Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming.","journal":"Blood","issue":"2026 February 11. doi: 10.1182\/blood.2025031247. Online ahead of print","author":"Chen Y, Shen J, Lin Z, Ding Q, Zhang X, Zhang M, Yang H, Yao H, Liu S, Wan J, Liu S, Jia X, Wang X, Yu U, Hao S, Cao M, Jiang H, Guo B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671478"},{"title01":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","title02":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","journal":"Blood","issue":"2026 February 5; 147(6):662-674. doi: 10.1182\/blood.2025028918","author":"Semba Y, Yamauchi T, Bauer DE, Ogawa S, Akashi K, Maeda T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160778"},{"title01":"Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial.","title02":"Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial.","journal":"J Clin Oncol","issue":"2026 February; 44(4):261-273. doi: 10.1200\/JCO-25-02142","author":"Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, Rocha P, Hayashi H, Sakai T, Kim YJ, Hu H, Qian M, Singh J, Godard J, Tang M, Ahn MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41086386"},{"title01":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","title02":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","journal":"Haematologica","issue":"2026 February 1; 111(2):646-655. doi: 10.3324\/haematol.2024.287055","author":"Mei C, Xu G, Zheng C, Xie Y, Li M, Shao Y, Yao R, Tao S, Jiang W, Guo J, Zheng Z, Wang W, Zhou X, Ma L, Ye L, Luo Y, Yang C, Yu W, Xie W, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501398"},{"title01":"Increasing daily step counts improves physical fitness, reduces pain and arterial stiffness in sickle cell patients.","title02":"Increasing daily step counts improves physical fitness, reduces pain and arterial stiffness in sickle cell patients.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300290. Online ahead of print","author":"De Lima F, Diaw M, Nader E, Carin R, Ducray M, Coly MS, Charlot K, Marano M, Gallou-Guyot M, Diop S, Miyachi M, Yoshida T, Seck M, Samb A, Ranque B, Tripette J, Connes P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641647"},{"title01":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","title02":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):813-820. doi: 10.1182\/bloodadvances.2023012544","author":"Rangarajan HG, Mejias-Figueroa JA, Gehred A, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071946"},{"title01":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","title02":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","journal":"Blood advances","issue":"2026 February 10; 10(3):563-574. doi: 10.1182\/bloodadvances.2025017536","author":"Pincez T, Fernandes H, Leverger G, Barlogis V, Fahd M, Garnier N, Paillard C, Guitton C, Abou Chahla W, Pasquet M, Jeziorski E, Castelle M, Bayart S, Pellier I, Thomas C, Pagnier A, Benadiba J, Li Thiao Te V, Cheikh N, Lejeune J, Deparis M, Marie-Cardine A, Chastagner P, Desplantes C, Millot F, Vic P, Thouvenin S, Piguet C, Pluchart C, Leblanc T, Heritier S, Aladjidi N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092477"},{"title01":"Heme and hemozoin induce platelet cell death through UPR-induced apoptosis and ferroptosis in vivax malaria.","title02":"Heme and hemozoin induce platelet cell death through UPR-induced apoptosis and ferroptosis in vivax malaria.","journal":"Blood advances","issue":"2026 February 10; 10(3):575-592. doi: 10.1182\/bloodadvances.2024015623","author":"Gomes MT, Medeiros-de-Moraes IM, Vieira-de-Abreu A, de Azevedo-Quintanilha IG, Fontes TM, de Brito Carneiro A, Azambuja P, Tolley ND, Rowley JW, Carpinter BA, Ferreira MU, Goncalves RM, Rocha VN, Rosa Nascimento AL, Carvalho WA, Scopel KKG, Campbell RA, Bozza PT, Weyrich AS, Zimmerman GA, Lacerda MVG, Castro-Faria-Neto HC, Hottz ED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115249"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2026 February 10; 10(3):821-836. doi: 10.1182\/bloodadvances.2025017217","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy V, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","title02":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017942. Online ahead of print","author":"Gibson NM, Nguyen NTD, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel AA, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey C, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","title02":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018548. Online ahead of print","author":"Olivieri DJ, Othus M, Vo PT, Walter RB, Manjappa S, Basom R, Storb RF, Keel SB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Halofuginone Suppresses Hepcidin by a Heparan Sulfate-dependent Mechanism to Treat Iron Disorders in Mice.","title02":"Halofuginone Suppresses Hepcidin by a Heparan Sulfate-dependent Mechanism to Treat Iron Disorders in Mice.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025017943. Online ahead of print","author":"Leal S, Denardo A, Van Echten A, Jungnickel H, Nelson CB, Sandoval D, Salvador JA, Shin J, Chung A, Brush M, Bennett CP, Piermatteo A, Secrest P, Jung CL, Ganz T, Poli M, Gordts P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671472"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2026 February; 40(2):279-292. doi: 10.1038\/s41375-025-02839-5","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","title02":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","journal":"Leukemia","issue":"2026 February; 40(2):397-409. doi: 10.1038\/s41375-025-02831-z","author":"Santini V, Zeidan AM, Van Eygen K, Fenaux P, Germing U, Madanat YF, Raza A, Savona MR, Sekeres MA, Thepot S, Raddi MG, Boyer T, Sun L, Wan Y, Berry T, Xia Q, Huang F, Dougherty S, Navada S, Feller F, Komrokji RS, Platzbecker U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526614"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 9. doi: 10.1038\/s41375-026-02874-w. Online ahead of print","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","title02":"Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial.","journal":"Haematologica","issue":"2026 February 1; 111(2):646-655. doi: 10.3324\/haematol.2024.287055","author":"Mei C, Xu G, Zheng C, Xie Y, Li M, Shao Y, Yao R, Tao S, Jiang W, Guo J, Zheng Z, Wang W, Zhou X, Ma L, Ye L, Luo Y, Yang C, Yu W, Xie W, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501398"},{"title01":"Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?","title02":"Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?","journal":"Haematologica","issue":"2026 February 1; 111(2):451-453. doi: 10.3324\/haematol.2025.288157","author":"Mozessohn L, Buckstein R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568724"},{"title01":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","title02":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","journal":"Haematologica","issue":"2026 February 1; 111(2):518-534. doi: 10.3324\/haematol.2025.288080","author":"Yuen LD, Hasserjian RP, Fathi AT, Luskin MR, Winer ES, Dal Cin P, Kim AS, Lindsley RC, Tsai HK, Nardi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820841"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 February 1; 111(2):508-517. doi: 10.3324\/haematol.2025.287860","author":"Villalba M, Montoro J, Balaguer-Rosello A, Chorao P, Canto PA, Granados P, Gomez-Segui I, Solves P, Such E, Cervera J, Barrragan E, Santiago M, Gil-Orti JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","title02":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70358. Online ahead of print","author":"MacPhail A, Loke J, Houston BL, Dendle C, Henden AS, Weinkove R, Morrissey O, Neofytos D, Buetti N, Parker C, Slavin MA, Craddock C, Stanworth SJ, McQuilten Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41677362"},{"title01":"Decitabine-cedazuridine in patients with MDS and TP53 mutations.","title02":"Decitabine-cedazuridine in patients with MDS and TP53 mutations.","journal":"Blood advances","issue":"2026 February 10; 10(3):881-886. doi: 10.1182\/bloodadvances.2025017745","author":"Urrutia S, Sasaki K, Bataller A, Kantarjian H, Montalban-Bravo G, McCloskey J, Griffiths EA, Yee K, Zeidan A, Savona M, Oganesian A, Sano Y, Keer HN, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170912"},{"title01":"UBE2O as a key regulator of drug-induced erythropoiesis in the context of myelodysplastic syndromes.","title02":"UBE2O as a key regulator of drug-induced erythropoiesis in the context of myelodysplastic syndromes.","journal":"Blood advances","issue":"2026 February 10; 10(3):782-793. doi: 10.1182\/bloodadvances.2025017340","author":"Maffeo B, Panuzzo C, Savi A, Itri F, Piccioli S, Danzero AC, Maglione A, Marini S, Voso MT, Fava C, Bracco E, Pergolizzi B, Cilloni D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191526"},{"title01":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","title02":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","journal":"Blood advances","issue":"2026 February 10; 10(3):710-724. doi: 10.1182\/bloodadvances.2025017005","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AYH, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Thrombosis in Primary Myelofibrosis: The Influence of Cohort Composition and Disease Biology.","title02":"Thrombosis in Primary Myelofibrosis: The Influence of Cohort Composition and Disease Biology.","journal":"Blood advances","issue":"2026 February 12. doi: 10.1182\/bloodadvances.2026019668. Online ahead of print","author":"Barbui T, De Stefano V, Tefferi A, Vannucchi AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678834"},{"title01":"Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.","title02":"Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.","journal":"N Engl J Med","issue":"2026 February 12; 394(7):669-683. doi: 10.1056\/NEJMoa2514824","author":"Wang JJ, Schonborn L, Warkentin TE, Muller L, Thiele T, Ulm L, Volker U, Ameling S, Franzenburg S, Kaderali L, Tzvetkova A, Colella A, Chataway T, Tan CW, Armour B, Troelnikov A, Rutten L, McCluskey J, Zahn R, Gordon TP, Greinacher A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671482"},{"title01":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","title02":"Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study.","journal":"Blood advances","issue":"2026 February 10; 10(3):563-574. doi: 10.1182\/bloodadvances.2025017536","author":"Pincez T, Fernandes H, Leverger G, Barlogis V, Fahd M, Garnier N, Paillard C, Guitton C, Abou Chahla W, Pasquet M, Jeziorski E, Castelle M, Bayart S, Pellier I, Thomas C, Pagnier A, Benadiba J, Li Thiao Te V, Cheikh N, Lejeune J, Deparis M, Marie-Cardine A, Chastagner P, Desplantes C, Millot F, Vic P, Thouvenin S, Piguet C, Pluchart C, Leblanc T, Heritier S, Aladjidi N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092477"},{"title01":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","title02":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70367. Online ahead of print","author":"Pena M, Lazzari L, Martinez DF, Ciceri F, Balaguer-Rosello A, Sanz J, Pascual MJ, Benzaquen A, Pinana JL, Salas MQ, Nieto-Vazquez A, Espanol I, Huguet M, Bento L, Saez AJ, Barba P, Filaferro S, Carbonell Asins JA, Pena C, Mussetti A, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676905"},{"title01":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","title02":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70359. Online ahead of print","author":"Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693283"},{"title01":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","title02":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018667. Online ahead of print","author":"Stedema FG, Brink M, Huisman F, Van Rijn R, Sijs-Szabo A, Nijhof IS, Diepstra A, Vergote VKJ, van Gorkom G, Flinsenberg TWH, Huls GA, van Meerten T, Doorduijn J, Plattel WJ, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637634"},{"title01":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","title02":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017996. Online ahead of print","author":"Soares MV, Escamilla Gomez V, Azevedo RI, Pereira PNG, Caballero-Velazquez T, Mendes L, Alho AC, Garcia-Guerrero E, Garcia-Calderon CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Rodriguez-Gil A, Espada ELDS, Rodrigues A, Garcao A, Yaspo ML, Warnatz HJ, Lehrach HR, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P Sr, Caldas CMF, Ferreira R, Leite L, Martins C, Lourenco F, Moreno R, Campilho F, Cheyne CP, Garcia-Finana M, Campos AM, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Pinho Vaz C, Perez-Simon JAA, Lacerda JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637631"},{"title01":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","title02":"Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients.","journal":"Blood advances","issue":"2026 February 12. doi: 10.1182\/bloodadvances.2025018651. Online ahead of print","author":"Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, Astigarraga I, Lehrnbecher T, van den Bos C, Simonin M, Ahlmann M, Barkaoui M, Le Louet S, Chevallier A, Chalard F, Nguyen T, Holzhauer S, Beutel K, Haenicke H, Escherich G, Garcia-Obregon S Phd, Valero-Arrese L, Ruano D, Andres M, Habes D, Lacaille F, McLin V, Bomken S, Bishop H, Penn A, Naeije L, Kabbara N, Milne P, Helias-Rodzewicz Z, Kolenova A, Renard C, Marec-Berard P, Thalhammer J, Pagnier A, Salmon A, Aladjidi N, Olivier L, Saultier P, Blanc L, Gandemer V, Schneider P Sr, Hessissen L, Golan M, Elitzur S, Ben Arush M, Ashkenazi Lustig D, Dvir R, Raciborska A, Malas Z, Diallo S, Levy G, Efremova V, Munthe-Kaas MC, von Bahr Greenwood T, Felizzia GA Sr, Braier JL, Boudiaf H, Ben Fraj I, Svojgr K, Krenova Z, Bernard F, Adam C, Karaoli E, Kristensen IA, Dahl C, Trambusti I, Gaspari S, De Fusco C, Chiaravalli S, Corti PC, Todesco A, Papadakis V, Luz I, Costa V, Osipova DS, Lyudovskikh E, Maschan MA, Bronin G, Burcev E, Idbaih A, Larabi IA, Bellouard M, Alvarez JC, Novosad O, Collin M, Henter JI, Emile JF, Heritier S, Minkov M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678955"},{"title01":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","title02":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025019065. Online ahead of print","author":"Runaas L, Fank S, Palen K, Szabo A, Rein L, Ying G, Salzman N, Samanas L, Abedin SM, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters NR, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","title02":"The role of HLA transcription in unrelated hematopoietic cell transplantation.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025017945. Online ahead of print","author":"Morishima S, Shiina T, Azuma F, Tomori S, Doki N, Nishida T, Fukuda T, Eto T, Kataoka K, Hasegawa Y, Tanaka M, Ota S, Takada S, Katayama Y, Uchida N, Nakamae H, Kanda Y, Hiramoto N, Kanda J, Onizuka M, Ichinohe T, Atsuta Y, Morishima Y, Murata M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628351"},{"title01":"Antibiotic risk score for acute graft-versus-host disease.","title02":"Antibiotic risk score for acute graft-versus-host disease.","journal":"Blood advances","issue":"2026 February 10; 10(3):555-561. doi: 10.1182\/bloodadvances.2025018317","author":"Rashidi A, Gao F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160804"},{"title01":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","title02":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","journal":"Blood advances","issue":"2026 February 10; 10(3):665-681. doi: 10.1182\/bloodadvances.2025017707","author":"Jullien M, Ferron E, Willem C, David G, Legrand N, Duquesne A, Bouzy S, Bastien M, Garnier A, Guillaume T, Le Bourgeois A, Vantyghem S, Peterlin P, Gagne K, Chevallier P, Retiere C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170906"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2026 February 10; 10(3):837-849. doi: 10.1182\/bloodadvances.2024015191","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","title02":"Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.","journal":"Blood advances","issue":"2026 February 10; 10(3):887-900. doi: 10.1182\/bloodadvances.2025016812","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin NJ, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo L, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what’s next?","title02":"Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what’s next?","journal":"Blood","issue":"2026 February 5; 147(6):633-638. doi: 10.1182\/blood.2025030416","author":"Curtis DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411147"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","title02":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029546. Online ahead of print","author":"Diefenbach C, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen JB, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly KM, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1 and Th17-dependent GVHD within the Gastrointestinal Tract.","title02":"Targeting donor XCR1+ and CD11b+ dendritic cells prevents Th1 and Th17-dependent GVHD within the Gastrointestinal Tract.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029431. Online ahead of print","author":"Takahashi S, Inoue T, Ensbey KS, Legg SR, Sekiguchi T, Nelson EL, Nemychenkov NS, Joshi T, Minnie S, Yeh AC, Zhang P, Headley M, Paik J, Amory JK, Hill GR, Koyama M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662631"},{"title01":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","title02":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","journal":"Blood","issue":"2026 February 5; 147(6):662-674. doi: 10.1182\/blood.2025028918","author":"Semba Y, Yamauchi T, Bauer DE, Ogawa S, Akashi K, Maeda T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160778"},{"title01":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","title02":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","journal":"Blood","issue":"2026 February 12; 147(7):755-767. doi: 10.1182\/blood.2025030149","author":"Sorial MN, Malpica Castillo LE, Chiattone C, Julia E, Bachy E, Barta SK, Stuver R, Jacobsen E, Federico M, Jain H, Prince HM, Foss F, Zinzani PL, Okatani T, Kim WS, Verburgh E, Al-Mansour M, Cabrera ME, Bhagat G, Shen C, Jain S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41347825"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 February; 40(2):373-382. doi: 10.1038\/s41375-025-02854-6","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 February; 40(2):418-428. doi: 10.1038\/s41375-025-02851-9","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 February 3. doi: 10.1016\/S2352-3026(25)00328-X. Online ahead of print","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","title02":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","journal":"Lancet","issue":"2026 February 7; 407(10528):637-648. doi: 10.1016\/S0140-6736(25)02164-6","author":"Groarke EM, Turturice B, Patel BA, Quinn KA, Fike A, Grayson PC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41520673"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2026 February; 44(4):300-310. doi: 10.1200\/JCO-25-00889","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Lineage bias in hematopoietic stem cells: more niche or intrinsic factors?","title02":"Lineage bias in hematopoietic stem cells: more niche or intrinsic factors?","journal":"Haematologica","issue":"2026 February 1; 111(2):448-450. doi: 10.3324\/haematol.2025.288704","author":"Hayal TB, Wu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063708"},{"title01":"Elevated levels of Ube2g1 in hematopoietic stem cells lead to segmental aging of the hematopoietic system.","title02":"Elevated levels of Ube2g1 in hematopoietic stem cells lead to segmental aging of the hematopoietic system.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.288847. Online ahead of print","author":"Niemann J, Schuster T, Sakk V, Soller K, Brown A, Wiese S, Eiwen K, Hoenicka M, Liebold A, Oltmanns M, Reichel H, Mulaw MA, Geiger H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641641"},{"title01":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells.","title02":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells.","journal":"Haematologica","issue":"2026 February 1; 111(2):632-645. doi: 10.3324\/haematol.2025.287897","author":"Shamie I, Bliss-Moreau M, Lee JC, Mathieu R, Hoffman HM, Geng B, Lewis NE, Zhu YP, Croker BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671503"},{"title01":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","title02":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","journal":"Haematologica","issue":"2026 February 1; 111(2):546-557. doi: 10.3324\/haematol.2024.287157","author":"Bordat J, Kaphan E, Robin M, Xhaard A, De Fontbrune FS, Chevillon F, Socie G, De Latour RP, Michonneau D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874329"},{"title01":"CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.","title02":"CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.","journal":"Haematologica","issue":"2026 February 1; 111(2):457-469. doi: 10.3324\/haematol.2023.283896","author":"Wong CK, McDonald A, Buttigieg MM, Rauh MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905074"},{"title01":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","title02":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","journal":"Haematologica","issue":"2026 February 1; 111(2):493-507. doi: 10.3324\/haematol.2025.287740","author":"Naji NS, Pasca S, Chatzilygeroudi T, Toledano-Sanz P, Rimando J, An Y, Hemani Y, Perkins B, Zeng X, Talbot C Jr, Paun B, Abdulmalik A, Lossos C, Boronina TR, Sinanidis I, Tsakiroglou P, Fernandes P, Esteb C, Ambinder AJ, Cole RN, Xian R, Gojo I, Paul S, Levis MJ, DeZern AE, Luznik L, Karanika S, Resar LS, Jones RJ, Bunz F, Gondek L, Arvanitis M, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874324"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 February 1; 111(2):508-517. doi: 10.3324\/haematol.2025.287860","author":"Villalba M, Montoro J, Balaguer-Rosello A, Chorao P, Canto PA, Granados P, Gomez-Segui I, Solves P, Such E, Cervera J, Barrragan E, Santiago M, Gil-Orti JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","title02":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","journal":"Haematologica","issue":"2026 February 1; 111(2):620-631. doi: 10.3324\/haematol.2025.288279","author":"Gem H, Ebadi M, Sebastian G, Abasaeed R, Lloid M, Minot SS, Dean DR, Rashidi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905099"},{"title01":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","title02":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70367. Online ahead of print","author":"Pena M, Lazzari L, Martinez DF, Ciceri F, Balaguer-Rosello A, Sanz J, Pascual MJ, Benzaquen A, Pinana JL, Salas MQ, Nieto-Vazquez A, Espanol I, Huguet M, Bento L, Saez AJ, Barba P, Filaferro S, Carbonell Asins JA, Pena C, Mussetti A, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676905"},{"title01":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","title02":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017942. Online ahead of print","author":"Gibson NM, Nguyen NTD, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel AA, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey C, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","title02":"Phase I\/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017996. Online ahead of print","author":"Soares MV, Escamilla Gomez V, Azevedo RI, Pereira PNG, Caballero-Velazquez T, Mendes L, Alho AC, Garcia-Guerrero E, Garcia-Calderon CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Rodriguez-Gil A, Espada ELDS, Rodrigues A, Garcao A, Yaspo ML, Warnatz HJ, Lehrach HR, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P Sr, Caldas CMF, Ferreira R, Leite L, Martins C, Lourenco F, Moreno R, Campilho F, Cheyne CP, Garcia-Finana M, Campos AM, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Pinho Vaz C, Perez-Simon JAA, Lacerda JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637631"},{"title01":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","title02":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):813-820. doi: 10.1182\/bloodadvances.2023012544","author":"Rangarajan HG, Mejias-Figueroa JA, Gehred A, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071946"},{"title01":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","title02":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018548. Online ahead of print","author":"Olivieri DJ, Othus M, Vo PT, Walter RB, Manjappa S, Basom R, Storb RF, Keel SB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","title02":"TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025019065. Online ahead of print","author":"Runaas L, Fank S, Palen K, Szabo A, Rein L, Ying G, Salzman N, Samanas L, Abedin SM, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters NR, Peled JU, Johnson B, Kearl T, Drobyski WR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632629"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017189. Online ahead of print","author":"Utrero-Rico A, Kapoor U, Berrios BJ, Morales G, Levine JE, Prado-Acosta MP, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","title02":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006479. Online ahead of print","author":"O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670624"},{"title01":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","title02":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006469. Online ahead of print","author":"DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani AS, Aljurf M, Audino AN, Benitez L, Deeter A, Dworkin E, Hiltbrand OS, Isenalumhe LL, Li L, Miller-Chism CN, Mozessohn L, Ng AP, Pu JJ, Shafer D, Vargas Madueno F, Viny AD, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock WA, Wolfson JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670627"},{"title01":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","title02":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025017065. Online ahead of print","author":"Hagen MW, Setiawan NJ, Dexter SL, Woodruff KA, Gaerlan FLK, Billings TM, Orozco JJ, Termini CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671449"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2026 February 10; 10(3):821-836. doi: 10.1182\/bloodadvances.2025017217","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy V, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","title02":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","journal":"Haematologica","issue":"2026 February 1; 111(2):693-697. doi: 10.3324\/haematol.2025.287344","author":"Moore KLF, Rognvaldsson S, Szabo AG, Vaitekenaite V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH, Study Group NM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905090"},{"title01":"Dreaming of a better future: drug development in myeloma.","title02":"Dreaming of a better future: drug development in myeloma.","journal":"Blood advances","issue":"2026 February 10; 10(3):779-781. doi: 10.1182\/bloodadvances.2024015740","author":"Parikh R, Lonial S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269780"},{"title01":"Smoldering multiple myeloma in the United States: a population-based analysis.","title02":"Smoldering multiple myeloma in the United States: a population-based analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):661-664. doi: 10.1182\/bloodadvances.2025017817","author":"Wang SY, Wang R, Schoen M, Huber JH, Feuer EJ, Ruhl J, Neparidze N, Ma X, Davidoff AJ, Chang SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213002"},{"title01":"Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.","title02":"Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.","journal":"Blood advances","issue":"2026 February 10; 10(3):604-607. doi: 10.1182\/bloodadvances.2025018078","author":"Vieira Dos Santos J, Melnekoff DT, Aleman A, Mouhieddine TH, Montes de Oca R, Wang F, Rajeeve S, Bhalla S, Van Oekelen O, Upadhyaya B, Ghodke-Puranik Y, Leshchenko V, Kim-Schulze S, Rahman A, Afik S, Lewinsky H, Plaks V, Thibaud S, Cho HJ, Richter J, Rodriguez C, Sanchez L, Rossi A, Richard S, Chari A, Madduri D, Jagannath S, Parekh S, Lagana A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191534"},{"title01":"Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.","title02":"Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.","journal":"Blood","issue":"2026 February 3. doi: 10.1182\/blood.2025029358. Online ahead of print","author":"Du T, Fang T, Pillai SC, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632828"},{"title01":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","title02":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","journal":"Blood","issue":"2026 February 5; 147(6):650-661. doi: 10.1182\/blood.2025030061","author":"Bonolo de Campos C, He R, Pelino T, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybeng-Groot L, Moran MF, Tiedemann R, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191517"},{"title01":"PIKfyve blockade exposes lysosomal vulnerability in myeloma.","title02":"PIKfyve blockade exposes lysosomal vulnerability in myeloma.","journal":"Blood","issue":"2026 February 5; 147(6):605-607. doi: 10.1182\/blood.2025032023","author":"Fulciniti M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642608"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 February; 40(2):418-428. doi: 10.1038\/s41375-025-02851-9","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 February; 40(2):373-382. doi: 10.1038\/s41375-025-02854-6","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2026 February; 40(2):314-324. doi: 10.1038\/s41375-025-02823-z","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2026 February; 44(4):300-310. doi: 10.1200\/JCO-25-00889","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","title02":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.","journal":"J Clin Oncol","issue":"2026 February 11; JCO2502083. doi: 10.1200\/JCO-25-02083. Online ahead of print","author":"Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671533"},{"title01":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","title02":"Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.","journal":"J Clin Oncol","issue":"2026 February 11; JCO2502087. doi: 10.1200\/JCO-25-02087. Online ahead of print","author":"Faramand RG, Xie Z, Jain MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671523"},{"title01":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.","title02":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.","journal":"Haematologica","issue":"2026 February 1; 111(2):558-571. doi: 10.3324\/haematol.2025.287554","author":"Ma R, Zhu XY, Lu Y, Chen J, Xuan L, Yuan HL, Cao Y, Cao WJ, Fang XS, Miao KR, Hu XX, Yi H, Zhao YM, Wu YB, Yang T, Wang HT, Yin Y, Zhang ZM, Zhang XH, Xu LP, Wang Y, Liu KY, Huang XJ, Sun YQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671492"},{"title01":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","title02":"Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation.","journal":"Haematologica","issue":"2026 February 1; 111(2):546-557. doi: 10.3324\/haematol.2024.287157","author":"Bordat J, Kaphan E, Robin M, Xhaard A, De Fontbrune FS, Chevillon F, Socie G, De Latour RP, Michonneau D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874329"},{"title01":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","title02":"Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.","journal":"Haematologica","issue":"2026 February 1; 111(2):693-697. doi: 10.3324\/haematol.2025.287344","author":"Moore KLF, Rognvaldsson S, Szabo AG, Vaitekenaite V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH, Study Group NM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905090"},{"title01":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","title02":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","journal":"Haematologica","issue":"2026 February 1; 111(2):620-631. doi: 10.3324\/haematol.2025.288279","author":"Gem H, Ebadi M, Sebastian G, Abasaeed R, Lloid M, Minot SS, Dean DR, Rashidi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905099"},{"title01":"Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.","title02":"Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.","journal":"Blood advances","issue":"2026 February 10; 10(3):682-693. doi: 10.1182\/bloodadvances.2025015832","author":"Hall K, Lazaryan A, van der Laan M, Lee C, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota L, Nikai E, Ponomareva E, Koumas A, Waller EK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875591"},{"title01":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","title02":"Primary and secondary stroke prophylaxis in children with sickle cell anemia: a meta-analysis.","journal":"Blood advances","issue":"2026 February 10; 10(3):813-820. doi: 10.1182\/bloodadvances.2023012544","author":"Rangarajan HG, Mejias-Figueroa JA, Gehred A, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071946"},{"title01":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","title02":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006469. Online ahead of print","author":"DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani AS, Aljurf M, Audino AN, Benitez L, Deeter A, Dworkin E, Hiltbrand OS, Isenalumhe LL, Li L, Miller-Chism CN, Mozessohn L, Ng AP, Pu JJ, Shafer D, Vargas Madueno F, Viny AD, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock WA, Wolfson JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670627"},{"title01":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","title02":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006479. Online ahead of print","author":"O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670624"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017914. Online ahead of print","author":"Lewis KL, Assouline SE, Baker RI, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar MJ, Schuster SJ, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"Differential effects of GVHD therapies on intestinal epithelium.","title02":"Differential effects of GVHD therapies on intestinal epithelium.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017189. Online ahead of print","author":"Utrero-Rico A, Kapoor U, Berrios BJ, Morales G, Levine JE, Prado-Acosta MP, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643175"},{"title01":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","title02":"Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018548. Online ahead of print","author":"Olivieri DJ, Othus M, Vo PT, Walter RB, Manjappa S, Basom R, Storb RF, Keel SB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637641"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","title02":"Impact of Iron Overload on Hematopoietic Stem Cell Transplant in Children with Non-Malignant Hematological Disorders.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025017942. Online ahead of print","author":"Gibson NM, Nguyen NTD, Amaral S, Hsu J, Haney M, Heimbruch KE, Sabulski A, Zurawel AA, Davidow KA, Lind KT, Scanlon S, Alva H, Hall L, Bailey C, Olson TS, Kwiatkowski JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637630"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025018774. Online ahead of print","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","title02":"Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70361. Online ahead of print","author":"Poh C, Zain J, Godfrey J, Querfeld C, Puverel S, Chen L, Allen P, Herrera AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693089"},{"title01":"Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance.","title02":"Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029012. Online ahead of print","author":"Dorando HK, Andrews JM, Khatavkar OU, Borcherding N, Korshunova Y, Hakeman G, Panigassi RB, Vo PM, Tu RY, Tran D, Quinn CC, Schmidt JA, Aluri J, Harmon MT, Watkins MP, Frank A, Cooper MA, Musiek A, Mehta-Shah N, Payton JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662591"},{"title01":"Follicular lymphoma transformed to classic Hodgkin lymphoma.","title02":"Follicular lymphoma transformed to classic Hodgkin lymphoma.","journal":"Blood","issue":"2026 February 12; 147(7):800. doi: 10.1182\/blood.2025031906","author":"Yenwongfai LN, Francischetti IMB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678203"},{"title01":"The ticking clock of relapse in T-cell lymphomas.","title02":"The ticking clock of relapse in T-cell lymphomas.","journal":"Blood","issue":"2026 February 12; 147(7):707-708. doi: 10.1182\/blood.2025032024","author":"Jiang Q, Herling M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678205"},{"title01":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","title02":"Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.","journal":"Blood","issue":"2026 February 12; 147(7):755-767. doi: 10.1182\/blood.2025030149","author":"Sorial MN, Malpica Castillo LE, Chiattone C, Julia E, Bachy E, Barta SK, Stuver R, Jacobsen E, Federico M, Jain H, Prince HM, Foss F, Zinzani PL, Okatani T, Kim WS, Verburgh E, Al-Mansour M, Cabrera ME, Bhagat G, Shen C, Jain S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41347825"},{"title01":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","title02":"A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025029546. Online ahead of print","author":"Diefenbach C, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen JB, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly KM, Kahl BS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662628"},{"title01":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma – Authors’ reply.","title02":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma – Authors’ reply.","journal":"Lancet Oncol","issue":"2026 February; 27(2):e65. doi: 10.1016\/S1470-2045(26)00019-7","author":"Manier S, Lambert J, Hulin C, Macro M, Leleu X, Facon T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643703"},{"title01":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma.","title02":"Daratumumab-lenalidomide and the immunosuppressive budget in myeloma.","journal":"Lancet Oncol","issue":"2026 February; 27(2):e64. doi: 10.1016\/S1470-2045(25)00728-4","author":"Fu Y, Zhang J, Xu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643702"},{"title01":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","title02":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 February; 27(2):254-268. doi: 10.1016\/S1470-2045(25)00653-9","author":"Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martinez-Lopez J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41519141"},{"title01":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","title02":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","journal":"Leukemia","issue":"2026 February; 40(2):339-347. doi: 10.1038\/s41375-025-02834-w","author":"Grozinger M, Schlanke M, Grone J, Erdmann S, Hajiyianni M, Poos AM, Thierjung H, Mai EK, Sauer S, Kaudewitz D, Veelken K, Michel CS, Frenking JH, Sester LS, Weber TF, Sedaghat S, Wennmann M, Muller-Tidow C, Schlemmer HP, Delorme S, Raab MS, Goldschmidt H, Weinhold N, John L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430398"},{"title01":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","title02":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","journal":"Leukemia","issue":"2026 February; 40(2):440-443. doi: 10.1038\/s41375-025-02819-9","author":"Gustine JN, Scaringi JA, Bauer F, Cirstea DD, Branagan AR, Puliafito BR, Maus MV, Frigault MJ, Yee AJ, Mahmood U, Raje NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419604"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2026 February; 40(2):314-324. doi: 10.1038\/s41375-025-02823-z","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","title02":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","journal":"J Clin Oncol","issue":"2026 February; 44(4):321-334. doi: 10.1200\/JCO-25-00289","author":"Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380103"},{"title01":"EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway.","title02":"EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.288024. Online ahead of print","author":"Li Y, Wilson A, Chrisochoidou Y, Martin S, Bird S, Morales S, Leiro M, Kozik Z, Crump NT, Roumeliotis TI, Choudhary J, Pawlyn C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676914"},{"title01":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","title02":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300240. Online ahead of print","author":"Yu H, Zhang G, Gong B, Li S, Guo C, Liu Y, Gu R, Xu Y, An G, Wei H, Wang M, Rao Q, Liu W, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676912"},{"title01":"High-cholesterol diet fuels myeloma progression, dysregulates adipokine expression in vivo, and impairs treatment response ex vivo.","title02":"High-cholesterol diet fuels myeloma progression, dysregulates adipokine expression in vivo, and impairs treatment response ex vivo.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.288286. Online ahead of print","author":"Gamez B, Whipp DJ, Rao SR, Morris EV, Park YE, Kaya Z, Edwards CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676897"},{"title01":"Second primary malignancy in multiple myeloma: does a prior malignancy matter?","title02":"Second primary malignancy in multiple myeloma: does a prior malignancy matter?","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300320. Online ahead of print","author":"Visram A, Seow H, Chakraborty R, Pond G, Gayowsky A, Mohyuddin GR, Hadidi SA, Hansen DK, Sidana S, Gouda R, Garcia-Horton A, Fonseca R, Mian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641642"},{"title01":"Post-CAR-T lymphocytosis in multiple myeloma: too much of a good thing?","title02":"Post-CAR-T lymphocytosis in multiple myeloma: too much of a good thing?","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300428. Online ahead of print","author":"Chen G, Banerjee R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641636"},{"title01":"Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States.","title02":"Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States.","journal":"Haematologica","issue":"2026 February 1; 111(2):703-706. doi: 10.3324\/haematol.2025.287724","author":"Anuraj A, Rath D, Derkach A, Usmani SZ, Shah UA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40836775"},{"title01":"Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis.","title02":"Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis.","journal":"Haematologica","issue":"2026 February 1; 111(2):745-750. doi: 10.3324\/haematol.2025.288174","author":"Vandenboom H, Akhtar O, Szabo A, Narra R, Mohan M, D'Souza A, Pasquini M, Dhakal B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820831"},{"title01":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.","title02":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.","journal":"Haematologica","issue":"2026 February 1; 111(2):656-664. doi: 10.3324\/haematol.2025.288187","author":"Cani L, Scott SA, Roberts D, Joseph NS, Hofmeister CC, Gupta VA, Dhodapkar MV, Lonial S, Nooka AK, Kaufman JL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905083"},{"title01":"The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes – insights from a single-site study.","title02":"The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes – insights from a single-site study.","journal":"Haematologica","issue":"2026 February 1; 111(2):713-717. doi: 10.3324\/haematol.2025.287760","author":"Bauer MA, Farmer P, Su JL, Schootman M, Li C, Van Rhee F, Al Hadidi S, Schinke C, Shaughnessy JD, Zhan F, Ashby C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905079"},{"title01":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.","title02":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.","journal":"Haematologica","issue":"2026 February 1; 111(2):665-678. doi: 10.3324\/haematol.2025.288203","author":"Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Patel S, Suchindran S, Zhou X, Richardson PG, Cohen AD, Lowther DE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874339"},{"title01":"Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed\/refractory multiple myeloma: results from the French real-world EMMY study.","title02":"Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed\/refractory multiple myeloma: results from the French real-world EMMY study.","journal":"Haematologica","issue":"2026 February 1; 111(2):728-732. doi: 10.3324\/haematol.2025.287954","author":"Chalopin T, Hulin C, Royer B, Bastie JN, Bobin A, Merzoug KB, Macro M, Karlin L, Jacquet C, Mohty M, Frenzel L, Sonntag C, Fontan J, Rigaudeau S, Roussel M, Sanhes L, Chaoui D, Vincent L, Orfeuvre H, Bouketouche M, Garlantezec R, Decaux O, Perrot A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874328"},{"title01":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","title02":"Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.","journal":"Br J Haematol","issue":"2026 February 1. doi: 10.1111\/bjh.70356. Online ahead of print","author":"Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622574"},{"title01":"High-throughput monoclonal gammopathy community monitoring programme.","title02":"High-throughput monoclonal gammopathy community monitoring programme.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70366. Online ahead of print","author":"Agarwal G, Campbell L, Carty O, Larham J, Knight E, Moore S, Gooding S, Kothari J, Browning J, Evans J, Ferguson L, Vieira A, Swanborough L, Roberts P, Bateman E, Sadler R, Ramasamy K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41674337"},{"title01":"Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.","title02":"Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70352. Online ahead of print","author":"Rieu JB, Schavgoulidze A, Canali A, Largeaud L, Perrot A, Syrykh C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693048"},{"title01":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","title02":"Validation of the 2025 IMS\/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.","journal":"Br J Haematol","issue":"2026 February 15. doi: 10.1111\/bjh.70359. Online ahead of print","author":"Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41693283"},{"title01":"Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.","title02":"Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.","journal":"Blood advances","issue":"2026 February 10; 10(3):593-603. doi: 10.1182\/bloodadvances.2025017862","author":"Anderson DR, Gangaraju R, Sedhom WG, Hamulyak EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170879"},{"title01":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","title02":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","journal":"Blood","issue":"2026 February 12; 147(7):768-782. doi: 10.1182\/blood.2025030209","author":"Kawano G, Ikeda R, Ishihara D, Shima T, Sakoda T, Yamamoto S, Kochi Y, Semba Y, Ashitani S, Mori Y, Kato K, Maeda T, Miyamoto T, Soga T, Akashi K, Kikushige Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191529"},{"title01":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","title02":"PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.","journal":"Blood","issue":"2026 February 5; 147(6):650-661. doi: 10.1182\/blood.2025030061","author":"Bonolo de Campos C, He R, Pelino T, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybeng-Groot L, Moran MF, Tiedemann R, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191517"},{"title01":"Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.","title02":"Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.","journal":"Blood","issue":"2026 February 5. doi: 10.1182\/blood.2025031734. Online ahead of print","author":"Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu KS, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Odstrcil Bobillo S, Hilal T, Park JH, Valtis YK, Faramand RG, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine JP, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran M, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock WA, Schwartz MS, Byrd K, Yalniz FF, Bachanova V, Tracy SI, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai C, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643192"},{"title01":"MMF unlocks a new path to venetoclax sensitivity in AML.","title02":"MMF unlocks a new path to venetoclax sensitivity in AML.","journal":"Blood","issue":"2026 February 12; 147(7):708-709. doi: 10.1182\/blood.2025032116","author":"Nakada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41678204"},{"title01":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","title02":"The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.","journal":"Blood","issue":"2026 February 5; 147(6):662-674. doi: 10.1182\/blood.2025028918","author":"Semba Y, Yamauchi T, Bauer DE, Ogawa S, Akashi K, Maeda T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160778"},{"title01":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","title02":"Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.","journal":"Leukemia","issue":"2026 February 4. doi: 10.1038\/s41375-026-02872-y. Online ahead of print","author":"Yang ZZ, Kim HJ, Tang X, Novak JP, Bhardwaj V, Mukherjee P, Villasboas JC, Novak AJ, Mondello P, Ansell SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639205"},{"title01":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","title02":"Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.","journal":"Leukemia","issue":"2026 February 4. doi: 10.1038\/s41375-026-02861-1. Online ahead of print","author":"Nikkarinen A, Almlof J, Osterroos A, Ladenvall C, Amini RM, Hollander P, Ayoola Gustafsson K, Baliakas P, Glimelius I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41639203"},{"title01":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","title02":"Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.","journal":"Leukemia","issue":"2026 February 12. doi: 10.1038\/s41375-026-02884-8. Online ahead of print","author":"Gao J, Zhao X, Yin Q, Hu A, Qiu K, Blackburn L, Lei L, Xiong R, Bi C, Craig JW, Portell CA, Davila ML, Williams ME, Tao J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41680300"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2026 February; 40(2):314-324. doi: 10.1038\/s41375-025-02823-z","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","title02":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e86-e97. doi: 10.1016\/S2352-3026(25)00318-7","author":"Sorin M, Okde R, Goulet M, Ghaleb L, Pang R, Prosty C, Brailovski E, Assouline S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448213"},{"title01":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","title02":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e56-e57. doi: 10.1016\/S2352-3026(25)00342-4","author":"Karmali R, Gordon LI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448214"},{"title01":"Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sezary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.","title02":"Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sezary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e98-e109. doi: 10.1016\/S2352-3026(25)00322-9","author":"Stadler R, Quaglino P, Woei-A-Jin FJSH, Dummer R, Mitteldorf C, Papadavid E, Ortiz Romero PL, Guenova E, Abe R, Cowan R, Bagot M, Dalle S, Fujimura T, Gambichler T, Morris S, Wehkamp U, Terheyden P, Cozzio A, Dippel E, Alberti-Violetti S, Romejko-Jarosinska J, Wozniacka A, Gonzalez Barca E, Pujol Vallverdu R, Ramelyte E, Bechter O, Suzuki K, Knobler R, Danhauser-Riedl S, Scarisbrick J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651641"},{"title01":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","title02":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.","journal":"Lancet","issue":"2026 February 12. doi: 10.1016\/S0140-6736(25)02435-3. Online ahead of print","author":"Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, Garcia-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692020"},{"title01":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","title02":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):400-409. doi: 10.1200\/JCO-25-01712","author":"Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385760"},{"title01":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","title02":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):410-420. doi: 10.1200\/JCO-25-01587","author":"Krupka JA, Moutsopoulos I, Cutmore NH, Trethewey CS, Dayimu A, Goodhew R, Kaji F, Raso-Barnett L, Cheow H, Elzubeir L, Smith J, Kamil A, Barbara RR, Price J, Elston K, Kolodziejczyk A, Tarantino S, Mariscotti F, Barry P, Frost S, Demiris N, Thomas MG, Hassane D, Munugalavadla V, Nagumantry SK, Karanth MJ, Ahearne M, Shah N, Fox CP, Anand S, Hodson DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428995"},{"title01":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434.","title02":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):429. doi: 10.1200\/JCO-25-02779","author":"Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490480"},{"title01":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","title02":"Treosulfan\/fludarabine versus thiotepa\/busulfan\/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70367. Online ahead of print","author":"Pena M, Lazzari L, Martinez DF, Ciceri F, Balaguer-Rosello A, Sanz J, Pascual MJ, Benzaquen A, Pinana JL, Salas MQ, Nieto-Vazquez A, Espanol I, Huguet M, Bento L, Saez AJ, Barba P, Filaferro S, Carbonell Asins JA, Pena C, Mussetti A, Greco R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676905"},{"title01":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","title02":"Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.","journal":"Br J Haematol","issue":"2026 February 11. doi: 10.1111\/bjh.70363. Online ahead of print","author":"Wei C, Zhang Y, Zhao D, Zhang W, Zhou D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41668589"},{"title01":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","title02":"IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018667. Online ahead of print","author":"Stedema FG, Brink M, Huisman F, Van Rijn R, Sijs-Szabo A, Nijhof IS, Diepstra A, Vergote VKJ, van Gorkom G, Flinsenberg TWH, Huls GA, van Meerten T, Doorduijn J, Plattel WJ, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637634"},{"title01":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","title02":"Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.","journal":"Blood advances","issue":"2026 February 4. doi: 10.1182\/bloodadvances.2025018515. Online ahead of print","author":"Godtfredsen SJ, Bergstrom F, Harrysson S, Kragholm KH, El-Galaly TC, Smedby KE, Eloranta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41637561"},{"title01":"Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.","title02":"Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.","journal":"Blood advances","issue":"2026 February 10; 10(3):725-732. doi: 10.1182\/bloodadvances.2025017120","author":"Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens D, Romancik J, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Herr MM, Davis J, Jesme C, Pelcovits AR, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover N, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201962"},{"title01":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","title02":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","journal":"Blood advances","issue":"2026 February 10; 10(3):850-863. doi: 10.1182\/bloodadvances.2025016492","author":"Galtier J, Peanne R, Le Morvan V, Blondy T, Melane M, Bidon A, Chopin A, Prochazkova-Carlotti M, Poglio S, Merlio JP, Chevret E, Gros A, Pham-Ledard A, Beylot-Barry M, Bresson-Bepoldin L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358745"},{"title01":"Are CHOP-Plus Really CHOP-Minus Propositions in the Treatment of PTCL? A Comprehensive Assessment of the Strategy.","title02":"Are CHOP-Plus Really CHOP-Minus Propositions in the Treatment of PTCL? A Comprehensive Assessment of the Strategy.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018042. Online ahead of print","author":"Saleh N, O'Connor OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671456"},{"title01":"Long-term outcomes of 40Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.","title02":"Long-term outcomes of 40Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019130. Online ahead of print","author":"Yoon SE, Oh D, Ryu G, Cho J, Kim SJ, Kim WS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628317"},{"title01":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","title02":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","journal":"Blood advances","issue":"2026 February 10; 10(3):694-706. doi: 10.1182\/bloodadvances.2025015986","author":"Tam CS, Anderson MA, Simkovic M, Ghia P, Flinn IW, Laribi K, Opat S, Cull G, Munir T, Osterborg A, Tedeschi A, Wang M, Szeto A, Allewelt H, Salmi T, Li J, Xu L, Wu K, Vezan R, Shadman M, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829104"},{"title01":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","title02":"Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025018774. Online ahead of print","author":"Knorr F, Zimmermann M, Bader P, Lang P, Muller I, Basu O, Burkhardt B, Seidl J, Damm-Welk C, Pichler H, Attarbaschi A, Meissner B, Beier R, Woessmann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632689"},{"title01":"Exploring the Role of Blinatumomab in Pediatric B-Lymphoblastic Lymphoma (B-LLy).","title02":"Exploring the Role of Blinatumomab in Pediatric B-Lymphoblastic Lymphoma (B-LLy).","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025019473. Online ahead of print","author":"Devine KJ, Fries C, Wistinghausen B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643198"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017914. Online ahead of print","author":"Lewis KL, Assouline SE, Baker RI, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar MJ, Schuster SJ, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.","title02":"Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.","journal":"Blood advances","issue":"2026 February 10; 10(3):620-626. doi: 10.1182\/bloodadvances.2025017620","author":"Champagne JN, Villa D, Gerrie AS, Venner CP, Slack GW, Farinha P, Craig JW, Hilton LK, Savage KJ, Scott DW, Sehn LH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170907"},{"title01":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","title02":"MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.","journal":"Blood","issue":"2026 February 9. doi: 10.1182\/blood.2025031089. Online ahead of print","author":"Heger JM, Mattlener J, Kaul H, Ferdinandus J, Schneider J, Schleifenbaum JK, Schneider G, Schaub V, Haenel M, Hellmuth JC, Dierlamm J, Martin S, Mathas S, Meissner J, Pegtel DM, Zijlstra JM, Ossowski A, Becker K, Hallek MJ, von Tresckow B, Borchmann P, Borchmann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41662627"},{"title01":"Stable, thus in critical condition: m6A-methylated fusion transcripts in B-cell acute lymphoblastic leukemia.","title02":"Stable, thus in critical condition: m6A-methylated fusion transcripts in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300292. Online ahead of print","author":"De Kesel J, Ntziachristos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676904"},{"title01":"Genomic proximity mapping: a promising next generation cytogenomic assay for comprehensive assessment of acute myeloid leukemia.","title02":"Genomic proximity mapping: a promising next generation cytogenomic assay for comprehensive assessment of acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2026.000003. Online ahead of print","author":"Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676907"},{"title01":"A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixed-phenotype acute leukemia.","title02":"A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixed-phenotype acute leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300161. Online ahead of print","author":"Zhang Y, Fan Y, Xu M, Xue S, Tang X, Qiu H, Miao M, Chen S, Zhou H, Zhang J, Yang X, Xu Y, Zhang X, Wu D, Chen J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676908"},{"title01":"Body mass index during and early after therapy for pediatric acute lymphoblastic leukemia is associated with obesity in survivors.","title02":"Body mass index during and early after therapy for pediatric acute lymphoblastic leukemia is associated with obesity in survivors.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.288529. Online ahead of print","author":"Suwannaying K, Zhou GC, Lertvivatpong N, Neupane A, Petrykey K, Yoshida T, Baedke JL, Rujkijyanont P, Wilson CL, Dixon SB, Delaney A, Sapkota Y, Kaste SC, Armstrong GT, Pui CH, Hudson MM, Srivastava D, Ness KK, Inaba H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676909"},{"title01":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","title02":"Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300240. Online ahead of print","author":"Yu H, Zhang G, Gong B, Li S, Guo C, Liu Y, Gu R, Xu Y, An G, Wei H, Wang M, Rao Q, Liu W, Wang J, Qiu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676912"},{"title01":"Intrinsic cellular resistance to BCR::ABL1 inhibitors.","title02":"Intrinsic cellular resistance to BCR::ABL1 inhibitors.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.287814. Online ahead of print","author":"Cruz-Rodriguez N, Torres-Llanos Y, Deininger MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676916"},{"title01":"FLT3-ITD measurable residual disease from the QuANTUM-First trial.","title02":"FLT3-ITD measurable residual disease from the QuANTUM-First trial.","journal":"Blood advances","issue":"2026 February 10; 10(3):917-928. doi: 10.1182\/bloodadvances.2025016444","author":"Levis MJ, Erba HP, Montesinos P, Kim HJ, Vrhovac R, Patkowska E, Zak P, Wang PN, Connolly Rohrbach JE, Chang KCN, Liu L, Mostafa Kamel Y, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052406"},{"title01":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","title02":"Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.","journal":"Blood advances","issue":"2026 February 10; 10(3):665-681. doi: 10.1182\/bloodadvances.2025017707","author":"Jullien M, Ferron E, Willem C, David G, Legrand N, Duquesne A, Bouzy S, Bastien M, Garnier A, Guillaume T, Le Bourgeois A, Vantyghem S, Peterlin P, Gagne K, Chevallier P, Retiere C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170906"},{"title01":"Metformin induces ferroptosis associated with lipidomic remodeling in AML.","title02":"Metformin induces ferroptosis associated with lipidomic remodeling in AML.","journal":"Blood advances","issue":"2026 February 10; 10(3):733-747. doi: 10.1182\/bloodadvances.2025016155","author":"Sternadt D, Pereira-Martins DA, Chatzikyriakou P, Albuquerque-Simoes L, Yang M, Silveira DRA, Wierenga ATJ, Weinhauser I, Hogeling SM, Oudejans LL, Casares Alaez P, Sarry JE, Frezza C, Huls GA, Quek L, Schuringa JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41172231"},{"title01":"Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study.","title02":"Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study.","journal":"Blood advances","issue":"2026 February 10; 10(3):642-653. doi: 10.1182\/bloodadvances.2025016509","author":"Pastoret C, Yang J, Feith DJ, Roussel M, Moignet A, Dighe S, Solga MD, Marchand T, Visser G, Gasparini VR, Teramo A, Zambello R, Loughran TP Jr, Lamy T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191533"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2026 February 10; 10(3):837-849. doi: 10.1182\/bloodadvances.2024015191","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","title02":"Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.","journal":"Blood advances","issue":"2026 February 10; 10(3):710-724. doi: 10.1182\/bloodadvances.2025017005","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AYH, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Reassessing IgRT in CLL: evidence still unconvincing.","title02":"Reassessing IgRT in CLL: evidence still unconvincing.","journal":"Blood advances","issue":"2026 February 10; 10(3):533-534. doi: 10.1182\/bloodadvances.2025018312","author":"Lesan V, Munteanu C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150822"},{"title01":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","title02":"CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018600. Online ahead of print","author":"Xu J, McCoy M, Martinez Z, Sussman JH, Gao D, Vincent TL, Wang H, Ma C, Elghawy O, Chen GM, Yang AG, Polonen P, Natan K, Shraim R, Newman H, Hofmann TJ, Scoma S, DiNofia AM, Hunger SP, Yang JJ, Mullighan CG, Bernt KM, Hexner EO, Grupp SA, Watanabe K, June CH, Tan K, Teachey DT, Diorio C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671457"},{"title01":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","title02":"A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History Study.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025018770. Online ahead of print","author":"DeZern AE, Gillis N, Otterstatter M, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Xie Z, Zhang L, Moscinski LC, Kroft SH, Harrington AM, Foran JM, Komrokji RS, Starczynowski DT, Gore SD, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo NL, Walter MJ, Sekeres MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671442"},{"title01":"Conventional Therapy vs HMA or LDAC +\/- Venetoclax in Older Adults With AML: Systematic Review and Meta-analysis.","title02":"Conventional Therapy vs HMA or LDAC +\/- Venetoclax in Older Adults With AML: Systematic Review and Meta-analysis.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2025016877. Online ahead of print","author":"Ibrahim S, Burgos-Mansilla B, Roldan Y, Oliveros MJ, Bhogal G, Bravo-Soto G, Bagherianlemraski M, Movahed H, Gutierrez-Arias R, Mulazzani F, Taj TK, Hadeiy SK, Qureshi M, Chowdhury SR, Couban R, Artz AS, Fletcher L, Gilberto L, Mattison RJ, Sekeres MA, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41671437"},{"title01":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","title02":"ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006469. Online ahead of print","author":"DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani AS, Aljurf M, Audino AN, Benitez L, Deeter A, Dworkin E, Hiltbrand OS, Isenalumhe LL, Li L, Miller-Chism CN, Mozessohn L, Ng AP, Pu JJ, Shafer D, Vargas Madueno F, Viny AD, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock WA, Wolfson JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670627"},{"title01":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","title02":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL.","journal":"Blood advances","issue":"2026 February 11. doi: 10.1182\/bloodadvances.2021006479. Online ahead of print","author":"O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin B, Henry M, Jaffe A, Jamy O, Kebriaei P, Mehrtens I, Shah NN, Wilde L, Young P, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Gupta S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41670624"},{"title01":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","title02":"CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025019378. Online ahead of print","author":"Shimony S, Murdock HM, Keating JH, Tsai HK, Sasi A, Gibson CJ, Faderl S, Wagner A, Dronamraju N, Lin TL, Prebet T, Cortes JE, Uy GL, Lancet JE, Reilly CR, Neuberg DS, Stone RM, Lindsley RC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628350"},{"title01":"Germ line LCP1 mutations cause immunodeficiency with neutropenia, monocytopenia, lymphopenia, and defective cytokinesis.","title02":"Germ line LCP1 mutations cause immunodeficiency with neutropenia, monocytopenia, lymphopenia, and defective cytokinesis.","journal":"Blood advances","issue":"2026 February 10; 10(3):627-641. doi: 10.1182\/bloodadvances.2025016507","author":"van Bergen T, Bosch DA, Bellanne-Chantelot C, Mulet-Lazaro R, Bledsoe JR, Chen L, de Looper HWJ, van Dijk C, Ter Borg MND, Bindels EMJ, Hoogenboezem RM, Roovers O, Olofsen PA, Bartels M, van Montfrans J, Breed P, Salzer E, Holierhoek MG, Nelken B, Beaupain B, Fleming MD, Shimamura A, Raaijmakers MHGP, Donadieu J, Newburger PE, Touw IP, Aalbers AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056520"},{"title01":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","title02":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL: analysis across clinical studies.","journal":"Blood advances","issue":"2026 February 10; 10(3):694-706. doi: 10.1182\/bloodadvances.2025015986","author":"Tam CS, Anderson MA, Simkovic M, Ghia P, Flinn IW, Laribi K, Opat S, Cull G, Munir T, Osterborg A, Tedeschi A, Wang M, Szeto A, Allewelt H, Salmi T, Li J, Xu L, Wu K, Vezan R, Shadman M, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829104"},{"title01":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","title02":"Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018688. Online ahead of print","author":"Chiu SK, Furlong E, Fox A, McKinnon EJ, Sanchez-Ovando S, Mclean-Tooke A, Oommen J, Yeoh DK, Cheung LC, Gottardo NG, Kotecha RS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628313"},{"title01":"Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.","title02":"Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.","journal":"Blood advances","issue":"2026 February 3. doi: 10.1182\/bloodadvances.2025019153. Online ahead of print","author":"Zeidner JF, Jain J, Welkie RL, Huang Y, Swords R, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH Jr, Baer MR, Duong VH, Blum W, Arellano ML, Stock WA, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran E, Handa S, Heerema NA, Chen TL, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate UM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41632633"},{"title01":"TP53-aberrated CLL: is BTK inhibitor monotherapy enough?","title02":"TP53-aberrated CLL: is BTK inhibitor monotherapy enough?","journal":"Blood advances","issue":"2026 February 10; 10(3):707-709. doi: 10.1182\/bloodadvances.2025017954","author":"Niemann CU","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41615766"},{"title01":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","title02":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter’s transformation.","journal":"Blood advances","issue":"2026 February 5. doi: 10.1182\/bloodadvances.2025017914. Online ahead of print","author":"Lewis KL, Assouline SE, Baker RI, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar MJ, Schuster SJ, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41643182"},{"title01":"Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow Cytometry.","title02":"Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow Cytometry.","journal":"Blood advances","issue":"2026 February 6. doi: 10.1182\/bloodadvances.2025018607. Online ahead of print","author":"Li S, Short NJ, Wang W, Ling J, Qiu L, Xu J, Wang WJ, Jia F, Tang G, Karrar O, Maroun MM, Medeiros LJJ, Ravandi F, Wang SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41649796"},{"title01":"Clonal cacophony of AML relapse.","title02":"Clonal cacophony of AML relapse.","journal":"Blood","issue":"2026 February 5; 147(6):603-604. doi: 10.1182\/blood.2025032092","author":"Wang ES","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642609"},{"title01":"Inclusion as innovation: broadening trial criteria in AML.","title02":"Inclusion as innovation: broadening trial criteria in AML.","journal":"Blood","issue":"2026 February 5; 147(6):604-605. doi: 10.1182\/blood.2025031718","author":"Kennedy VE, Muffly L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642607"},{"title01":"Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials.","title02":"Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials.","journal":"Blood","issue":"2026 February 5; 147(6):639-649. doi: 10.1182\/blood.2025030741","author":"Hantel A, Wang Y, Cronin A, Khan I, Abraham I, Eisfeld AK, Patel AA, Stock W, Monick S, Walsh TP, Gallagher E, Luskin MR, Avila Rodriguez AM, Galvez C, Doukas P, Altman JK, Burkart M, Erra A, Zia M, Larson ML, Dave A, Tsai SB, Aleen A, Raptis N, Lathan CS, Uno H, DeAngelo DJ, Abel GA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100728"},{"title01":"TP53 loss traps AML in XPO7-NPAT nuclear transport fraud.","title02":"TP53 loss traps AML in XPO7-NPAT nuclear transport fraud.","journal":"Blood","issue":"2026 February 5; 147(6):607-609. doi: 10.1182\/blood.2025032009","author":"Skwarska A, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41642606"},{"title01":"Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.","title02":"Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.","journal":"Blood","issue":"2026 February 12; 147(7):725-738. doi: 10.1182\/blood.2025031243","author":"Schroeder B, Yuan C, Wang HW, Mohindroo C, Zhou H, Raffeld M, Xi L, Arons E, Feurtado J, James-Echenique L, Calvo KR, Maric I, Kreitman RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060318"},{"title01":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","title02":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT.","journal":"Blood","issue":"2026 February 4. doi: 10.1182\/blood.2025031053. Online ahead of print","author":"Mushtaq MU, DiPersio JF, Azzi J, Cooper BW, Koehne G, Koura D, Maakaron JE, Magenau JM, McClune B, Rimando JC, Shah NN, Suh HC, Beuka K, Sturrock J, Nikam MH, Berglund E, Hu J, Keschner Y, Etchin J, Lydeard JR, Vasquez MD, O'Donnell D, Mundelboim G, Thosar S, Canesin G, Xavier-Ferrucio J, Hyzy SL, Lloyd DM, Spink K, Hummel D, Lee-Sundlov MM, Scherer J, Lin MI, Whangbo JS, Muffly LS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41636724"},{"title01":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","title02":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e74-e85. doi: 10.1016\/S2352-3026(25)00323-0","author":"Heitmann JS, Maringer Y, Jung S, Wacker M, Hackenbruch C, Polster M, Marconato M, Nelde A, Bauer J, Zwick M, Baur AS, Metzger A, Krolla C, Andrieux G, Kohler N, Boerries M, Denk M, Zieschang L, Kammer C, Hoenisch-Gravel N, Richter M, Oezbek MT, Wirths S, Dengler A, Dubbelaar ML, Pumptow M, Martus P, Bruggemann M, Rammensee HG, Salih HR, Walz JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41547362"},{"title01":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","title02":"Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 February 3. doi: 10.1016\/S2352-3026(25)00328-X. Online ahead of print","author":"Ortiz-Maldonado V, Martinez-Cibrian N, Alserawan L, Espanol-Rego M, Navarro-Velazquez S, Albiol N, Oliver-Caldes A, Triguero A, Herrero-Garcia M, Gutierrez-Herrero S, Benitez-Ribas D, Paciello ML, Torrent A, Delgado-Serrano J, Sanchez-Castanon M, Calderon H, Mata JJ, Sanchez-Salinas A, Saez-Penataro J, Sans-Pola C, Calvo-Orteu M, Lopez-Corral L, Kwon M, Rifon J, Charry P, Alonso-Fernandez RA, Huguet M, Blazquez-Goni C, Sanchez-Pina JM, Sanchez R, Rosa-Rosa JM, Martinez-Lopez J, Blanquer M, Ribera JM, Urbano-Ispizua A, Bachiller M, Palau L, Olesti E, Calvo G, Martin-Martin L, Orfao A, Gonzalez-Navarro EA, Domenech G, Varea S, Juan M, Delgado J, Esteve J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651004"},{"title01":"Jorge Cortes: building a network of leukaemia expertise in Latin America.","title02":"Jorge Cortes: building a network of leukaemia expertise in Latin America.","journal":"Lancet Haematol","issue":"2026 February; 13(2):e61. doi: 10.1016\/S2352-3026(26)00003-7","author":"Wilkinson E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41651639"},{"title01":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","title02":"Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1\/2 study.","journal":"Lancet Haematol","issue":"2026 February 12. doi: 10.1016\/S2352-3026(25)00357-6. Online ahead of print","author":"Gruber TA, Jeha S, Deyell RJ, Lewis V, Chang BH, Lowe EJ, Frediani J, Vezina C, Michon B, Richards M, Breese EH, Tran TH, Lacayo N, Bolen C, Desai S, Pauley JL, Huang M, Ashcraft E, Cheng C, Schultz KR, Stork L, Schlis K, Huynh VT, Gossai N, Messinger YH, Bittencourt H, Horton TM, Athale U, Stearns D, Schiff D, Gaynon PS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41692013"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2026 February; 44(4):300-310. doi: 10.1200\/JCO-25-00889","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","title02":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","journal":"J Clin Oncol","issue":"2026 February 10; 44(5):370-374. doi: 10.1200\/JCO-25-01806","author":"Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, Stary J, Ferster A, Brethon B, Locatelli F, Schrappe M, Scholte-van Houtem PE, Valsecchi MG, Huitema ADR, Pieters R, van der Sluis IM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505662"},{"title01":"The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells.","title02":"The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells.","journal":"Haematologica","issue":"2026 February 1; 111(2):481-492. doi: 10.3324\/haematol.2025.287352","author":"Gil KB, Borg J, Pereira RM, Inguva-Sheth A, Araujo G, Rahkola J, Showers W, Grier A, D'Alessandro A, Smith C, McMahon C, Pollyea DA, Gillen AE, Amaya ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534505"},{"title01":"Interleukin signaling mitigates the inhibitory effects of combined Src\/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia.","title02":"Interleukin signaling mitigates the inhibitory effects of combined Src\/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.288829. Online ahead of print","author":"Naeemikia F, Reynolds J, Dong C, Pritchard JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641639"},{"title01":"Successful re-exposure to high-dose methotrexate after severely delayed methotrexate elimination and renal toxicity in children with acute lymphoblastic leukemia.","title02":"Successful re-exposure to high-dose methotrexate after severely delayed methotrexate elimination and renal toxicity in children with acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.300277. Online ahead of print","author":"Barzilai-Birenboim S, Arad-Cohen N, Bardi E, Heldrup J, Kovacs G, Mateos M, Moericke A, Oosterom N, Sonnenberg S, Steinhauer F, Vaitkeviciene GE, Van der Sluis IM, Weinreb SM, Zapotocka E, Zucker D, Schmiegelow K, Mikkelsen TS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641640"},{"title01":"Beating the STATs: targeting the metabolome in acute myeloid leukemia.","title02":"Beating the STATs: targeting the metabolome in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):439-441. doi: 10.3324\/haematol.2025.288349","author":"Nachmias B, Wolach O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905076"},{"title01":"Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.","title02":"Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):718-723. doi: 10.3324\/haematol.2025.287794","author":"Ahn JS, Park JH, Lee C, Song IC, Kim MY, Sohn SK, Yhim HY, Park Y, Kim I, Shin HJ, Park SK, Kim SH, Cheong JW, Lee HS, Lee H, Bae SH, Choi Y, Lee HG, Do YR, Han JJ, Kim MK, Park S, Kim HJ, Kim HJ, Working Party KA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605710"},{"title01":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","title02":"Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 February 1; 111(2):508-517. doi: 10.3324\/haematol.2025.287860","author":"Villalba M, Montoro J, Balaguer-Rosello A, Chorao P, Canto PA, Granados P, Gomez-Segui I, Solves P, Such E, Cervera J, Barrragan E, Santiago M, Gil-Orti JV, Lamas B, Bataller A, Louro A, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905088"},{"title01":"The glutaminase activity of ASNS fuels glutamine metabolism in leukemia.","title02":"The glutaminase activity of ASNS fuels glutamine metabolism in leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):679-686. doi: 10.3324\/haematol.2024.287099","author":"Chan WK, Tan L, Martinez SA, Du D, Horvath TD, Pontikos M, Rusling LA, Chiu Y, Tran BQ, Rempe SB, Sukharev S, Weinstein JN, Lorenzi PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931860"},{"title01":"Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.","title02":"Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells.","journal":"Haematologica","issue":"2026 February 1; 111(2):583-596. doi: 10.3324\/haematol.2025.287934","author":"Holl NJ, Fearnow A, Christodoulou I, Vorri SC, Rahnama R, Choe J, Ghosal A, Ng WI, Vyas V, Song HW, Varadhan R, Bonifant CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931866"},{"title01":"CCRL2 and who? An important driver in TP53-mutant myeloid leukemias.","title02":"CCRL2 and who? An important driver in TP53-mutant myeloid leukemias.","journal":"Haematologica","issue":"2026 February 1; 111(2):442-443. doi: 10.3324\/haematol.2025.288631","author":"Arnold O, Saygin C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931868"},{"title01":"IGLV3-21(R110)-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.","title02":"IGLV3-21(R110)-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):572-582. doi: 10.3324\/haematol.2025.287697","author":"Fischer C, Chen SS, Nimmerfroh J, Eugster A, Stucheli S, Schultheiss C, Widmer C, Heim D, Kasenda B, Passweg J, Kobold S, Egli L, Coianiz N, Chijioke O, Chiorazzi N, Follo M, Laubli H, Peipp M, Binder M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931870"},{"title01":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","title02":"Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.","journal":"Haematologica","issue":"2026 February 1; 111(2):518-534. doi: 10.3324\/haematol.2025.288080","author":"Yuen LD, Hasserjian RP, Fathi AT, Luskin MR, Winer ES, Dal Cin P, Kim AS, Lindsley RC, Tsai HK, Nardi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820841"},{"title01":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey.","title02":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey.","journal":"Haematologica","issue":"2026 February 1; 111(2):597-608. doi: 10.3324\/haematol.2025.287772","author":"Lang F, Pemberton-Whiteley Z, Clements J, Ruiz C, Rea D, Machado L, Takahashi N, Moon SH, Grigg A, Borowczak C, Schuld P, Frank P, Constantinescu C, Boquimpani C, Cortes JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637752"},{"title01":"Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study.","title02":"Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study.","journal":"Haematologica","issue":"2026 February 1; 111(2):764-767. doi: 10.3324\/haematol.2025.288776","author":"Jung BK, Weissmann S, Schock C, Meggendorfer M, Haferlach T, Dicker F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41098098"},{"title01":"Advancing quality of life research in chronic myeloid leukemia: where do we stand?","title02":"Advancing quality of life research in chronic myeloid leukemia: where do we stand?","journal":"Haematologica","issue":"2026 February 1; 111(2):446-447. doi: 10.3324\/haematol.2025.288391","author":"Lipton JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637736"},{"title01":"Impact of insertion\/deletion mutations affecting the ABL1 gene in Ph-positive leukemias.","title02":"Impact of insertion\/deletion mutations affecting the ABL1 gene in Ph-positive leukemias.","journal":"Haematologica","issue":"2026 February 12. doi: 10.3324\/haematol.2025.300345. Online ahead of print","author":"Lucini C, Lion T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41676918"},{"title01":"Modern treatment of acute promyelocytic leukemia.","title02":"Modern treatment of acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):437-438. doi: 10.3324\/haematol.2025.289382","author":"Russell N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622919"},{"title01":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","title02":"Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.","journal":"Br J Haematol","issue":"2026 February 12. doi: 10.1111\/bjh.70358. Online ahead of print","author":"MacPhail A, Loke J, Houston BL, Dendle C, Henden AS, Weinkove R, Morrissey O, Neofytos D, Buetti N, Parker C, Slavin MA, Craddock C, Stanworth SJ, McQuilten Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41677362"},{"title01":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children’s Cancer Group trial (JCCG AML-12).","title02":"Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children’s Cancer Group trial (JCCG AML-12).","journal":"Br J Haematol","issue":"2026 February 3. doi: 10.1111\/bjh.70355. Online ahead of print","author":"Komori T, Kawai T, Okuno Y, Tsujimoto S, Kato S, Kamitori T, Saida S, Ikeda J, Ohki K, Kato M, Tomizawa D, Taga T, Takita J, Horibe K, Adachi S, Hayashi Y, Ito S, Shiba N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41631723"},{"title01":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","title02":"Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.","journal":"Br J Haematol","issue":"2026 February 1. doi: 10.1111\/bjh.70349. Online ahead of print","author":"Bidet A, Laharanne E, Dos Santos M, De Grande AC, Leguay T, Pigneux A, Frison E, Achard S, Dupont-Moufakkir S, Klein E, Dumas PY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622767"},{"title01":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","title02":"Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 February 1. doi: 10.1111\/bjh.70351. Online ahead of print","author":"Monaghan L, Bunschoten RP, Bittencourt-Silvestre J, Park T, Gannon S, Pirvan PA, Hoose A, Wheadon H, Liskamp RMJ, Huang X, Jorgensen HG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41622589"},{"title01":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","title02":"Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease.","journal":"Blood advances","issue":"2026 February 2. doi: 10.1182\/bloodadvances.2025018349. Online ahead of print","author":"Hakkarainen M, Sicre de Fontbrune F, Kaaja I, Douglas SPM, Dalle JH, Risitano AM, Kulasekararaj AG, Alsultan A, Cutler CS, Ho VT, Hellstrom-Lindberg ES, Mielke S, Myhre AE, Rihani R, Abu Shanap M, Hashem H, Shimamura A, Rowe RG, Auer F, Beier F, Desnica L, Hough RE Professor, Jafri SRA, Ayas MF, Jardine L, Fernandez-Mellid E, Corrales Insa I, Richardson DS, Ozbek NY, Zaniewska-Tekieli A, Gozdzik J, Ryhanen SJ, Niinimaki R, Jahnukainen K, Salmenniemi U, Kilpivaara O, Wartiovaara-Kautto U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628318"},{"title01":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","title02":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","journal":"Leukemia","issue":"2026 February; 40(2):454-458. doi: 10.1038\/s41375-025-02797-y","author":"Agathangelidis A, Iatrou A, Pechlivanis N, Karakatsoulis G, Zaragoza-Infante L, Galigalidou C, Maity PC, Ranghetti P, Almeida J, Fuentes-Herrero B, Navarro A, Alcoceba M, Rabbani L, Thorvaldsdottir B, Scarfo L, Orfao A, Psomopoulos F, Jumaa H, Rosenquist R, Chatzidimitriou A, Ghia P, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501505"},{"title01":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","title02":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):435-439. doi: 10.1038\/s41375-025-02825-x","author":"Haaksma LH, Palmieri R, Reuvekamp T, Tettero JM, Ngai LL, Bachas C, Kelder A, Scholten WJ, Gradowska P, Arena V, Joao Simione A, Maurillo L, Venditti A, Lowenberg B, Ossenkoppele GJ, de Leeuw DC, Ikoma-Colturato MRV, Buccisano F, Cloos J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372597"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2026 February; 40(2):279-292. doi: 10.1038\/s41375-025-02839-5","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","title02":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):444-448. doi: 10.1038\/s41375-025-02835-9","author":"Fedenko A, Czapinska H, Kramer A, Stolzel F, Bochtler T, Bochtler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419603"},{"title01":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","title02":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","journal":"Leukemia","issue":"2026 February; 40(2):293-303. doi: 10.1038\/s41375-025-02816-y","author":"Ho TC, LaMere MW, Kawano H, Byun DK, LaMere EA, Chiu YC, Chen C, Wang LJ, Wang J, Ramdas B, Dokholyan NV, Calvi LM, Liesveld JL, Jordan CT, Singh RK, Kapur R, Becker MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419607"},{"title01":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2026 February; 40(2):304-313. doi: 10.1038\/s41375-025-02842-w","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419608"},{"title01":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","title02":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):325-338. doi: 10.1038\/s41375-025-02829-7","author":"Dinh TTT, Lordo MR, Zhang AY, Goda C, Shilo N, Altynova E, Ruesch M, Kronen P, Broughton M, Jeremy E, Sellers VL, Zhang X, Larkin KT, Collins PL, Dorrance AM, Freud AG, Oakes CC, Mundy-Bosse BL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430399"},{"title01":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","title02":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):348-359. doi: 10.1038\/s41375-025-02832-y","author":"Yang Y, Liu X, Wei J, Qin J, Tan Q, Ji J, Guo F, Zheng Y, Bi F, Liu M, Wang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436638"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 February; 40(2):373-382. doi: 10.1038\/s41375-025-02854-6","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","title02":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","journal":"Leukemia","issue":"2026 February; 40(2):449-453. doi: 10.1038\/s41375-025-02846-6","author":"Ayoub M, Hitier C, Dehgane L, Mallet E, Tannoury M, Nemazanyy I, Roos-Weil D, Maloum K, Ringshausen I, Chapiro E, Nguyen-Khac F, Garnier D, Lagouge M, Lerner LK, Susin SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501504"},{"title01":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","title02":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):265-278. doi: 10.1038\/s41375-025-02817-x","author":"Struckman NE, Koutsoumpli G, de Jong RCM, van der Lee DI, Remst DFG, Smith SI, Honders MW, Hagedoorn RS, de Ru AH, Matsuda M, Ishikawa F, Tak T, Valk PJM, Heemskerk MHM, van Veelen PA, Falkenburg JHF, Griffioen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41388195"},{"title01":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","title02":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February; 40(2):383-396. doi: 10.1038\/s41375-025-02845-7","author":"Gonzales F, Schneider C, Alexe G, Lin S, Khalid D, Alvarez M, Basanthakumar A, Ellegast JM, Merickel L, Salhotra S, Taillon A, Giaimo M, Wunderlich M, Ansari M, Perry JA, Degar B, Pikman Y, Stegmaier K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41507381"},{"title01":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","title02":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","journal":"Leukemia","issue":"2026 February; 40(2):410-417. doi: 10.1038\/s41375-025-02859-1","author":"Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Mohle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuss A, Gothert JR, Ernst T, Abu-Samra M, Hoffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526617"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study.","journal":"Leukemia","issue":"2026 February; 40(2):418-428. doi: 10.1038\/s41375-025-02851-9","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","title02":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.","journal":"Leukemia","issue":"2026 February 9. doi: 10.1038\/s41375-026-02874-w. Online ahead of print","author":"Mecklenbrauck R, Villaverde Ramiro A, Strang E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernandez-Sanchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Onate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Dohner K, Haferlach T, Mills KI, Dohner H, Castellani G, Ossenkoppele GJ, Hernandez-Rivas JM, Bullinger L, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41663622"},{"title01":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","title02":"Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.","journal":"Leukemia","issue":"2026 February 10. doi: 10.1038\/s41375-026-02873-x. Online ahead of print","author":"Nielsen CG, Als-Nielsen B, Albertsen BK, Davidsson OB, Dimitrijevic A, Hjalgrim H, Ifversen M, Lundgren L, Lynggaard LS, Olsen M, Overgaard UM, Rank CU, Rathe M, Rostgaard K, Schmiegelow K, Andres-Jensen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41667647"},{"title01":"Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia.","title02":"Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.289170. Online ahead of print","author":"Fan L, Gao L, Zhang W, Yang L, Liu H, Wang H, Xiao P, Liao N, Zhuang Y, Xu X, Luo J, He Y, Zhang Y, Han X, Hu Y, Li J, He H, Wang Y, Cheng C, Zhai X, Ju X, Wang N, Lu J, Jiang H, Ribeiro RC, Hu S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641646"},{"title01":"FLAG-IDA-Venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.","title02":"FLAG-IDA-Venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.","journal":"Haematologica","issue":"2026 February 5. doi: 10.3324\/haematol.2025.288866. Online ahead of print","author":"Krayem B, Frisch A, Yehudai-Ofir D, Henig I, Glaubach N, Zuckerman T, Haran A, Nachmias B, Aumann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41641653"},{"title01":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","title02":"C-C motif chemokine receptor-like 2 promotes the interferon-gamma signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.","journal":"Haematologica","issue":"2026 February 1; 111(2):493-507. doi: 10.3324\/haematol.2025.287740","author":"Naji NS, Pasca S, Chatzilygeroudi T, Toledano-Sanz P, Rimando J, An Y, Hemani Y, Perkins B, Zeng X, Talbot C Jr, Paun B, Abdulmalik A, Lossos C, Boronina TR, Sinanidis I, Tsakiroglou P, Fernandes P, Esteb C, Ambinder AJ, Cole RN, Xian R, Gojo I, Paul S, Levis MJ, DeZern AE, Luznik L, Karanika S, Resar LS, Jones RJ, Bunz F, Gondek L, Arvanitis M, Karantanos T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874324"},{"title01":"The immunophenotypic and genetic characterization of pediatric T-lymphoblastic leukemia with a mature immunophenotype.","title02":"The immunophenotypic and genetic characterization of pediatric T-lymphoblastic leukemia with a mature immunophenotype.","journal":"Haematologica","issue":"2026 February 1; 111(2):751-755. doi: 10.3324\/haematol.2025.288233","author":"Khanlari M, Wang W, Tizro P, Eldomery MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874330"},{"title01":"Beyond somatic mutations: the role of next-generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia.","title02":"Beyond somatic mutations: the role of next-generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia.","journal":"Haematologica","issue":"2026 February 1; 111(2):454-456. doi: 10.3324\/haematol.2025.288448","author":"Loghavi S, Ravandi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874334"}]